



---

# CPDD 76th Annual Scientific Meeting Program

---

**June 14-19, 2014**

**Caribe Hilton  
San Juan, Puerto Rico**





**Accreditation Statement:**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Temple University School of Medicine and The College on Problems of Drug Dependence. Temple University School of Medicine is accredited by the ACCME to sponsor Continuing Medical Education for physicians.

**Certification Statement:**

Temple University School of Medicine designates this live activity for a maximum of 21.00 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Policy:**

It is the policy of the Temple University School of Medicine, The Albert J. Finestone, M.D., Office for Continuing Medical Education that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Temple University School of Medicine, Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.

**Target Audience:**

Physicians, Residents/Fellows, Physician Assistants, Nurses, Medical Students

**Objectives:**

Upon completion of this course, participants should be able to:

1. Critically evaluate current treatments for drug dependence
2. Be informed of the latest findings in epidemiology, prevention and advances in treatment of drug abuse and dependence
3. Select appropriate therapeutic approaches to dealing with issues of dependence to a variety of abused substances

## QUALIFYING SYMPOSIA AND WORKSHOPS FOR CME CREDIT

### Sunday, June 15

SI: (2:30-4:30PM)	Stress and Relapse to Drug Use: From Animal Models to Clinical Trials	2 credits
SII: (2:30-4:30PM)	Up in Smoke: Cannabis and Tobacco, Linked at the Hip and Double Trouble	2 credits
SIV: (5:00-6:00PM)	Translational is Behavioral Research in Addiction	1 credit
SV: (5:00-6:00PM)	DSM-5 Substance-Related and Addictive Disorders: Rationale and Controversies	1 credit
WII: (7:00-9:00PM)	Integration of Addiction Care into Medical Settings: The State of Science	2 credits
WIII: (7:00-9:00PM)	Go/No-Go Decisions in Medication Development: Why Some Compounds Should NOT Go Forward and How Do We Identify Them?	2 credits

### Monday, June 16

SVI: (10:00AM-12:00PM)	Acute and Chronic Stimulant Effects on Motivation and Behavioral Control	2 credits
SVII: (10:00AM-12:00PM)	Neuropeptidergic Targets for CNS Disorders	2 credits
SVIII: (2:00-4:00PM)	The Effects, Use Patterns and Youth Perception of Electronic Cigarettes	2 credits
SIX: (2:00-4:00PM)	Novel Approaches to Examining the Intertwining Epidemics of HIV and Drug Abuse: From Decision-Making to Viral Load	2 credits
WVI: (7:00-9:00PM)	Knowledge Translation in Addiction Sciences: Why and How to Share Research Knowledge Beyond the Academic Community	2 credits
WVII: (7:00-9:00PM)	High Risk and Understudied: Assessing Abuse Liability in Opioid-Dependent Subjects	2 credits
WVIII: (7:00-9:00PM)	Eating Disorders, Addictions and Substance Use Disorders: Research, Clinical and Treatment Aspects	2 credits

**Tuesday, June 17**

SX: (10:00AM-12:00PM)	CB2 Functions in the Brain and the Periphery	2 credits
SXI: (10:00AM-12:00PM)	Trajectories of Heroin Use: Insights from Longitudinal Studies	2 credits
WXI: (7:00-9:00PM)	Improving the Writing of Emerging Investigators in Addiction Science: Innovative Training, Evaluation Methods, and Resources	2 credits
WXIII: (7:00-9:00PM)	Addiction Treatment Research vs. Usual Care: What are the Foreseeable Risks?	2 credits

**Wednesday, June 18**

SXII: (10:00AM-12:00PM)	Bill Woolverton's Greatest Hits: Drugs, Choices, and Consequences	2 credits
SXIII: (2:30-4:30PM)	Environmental and Physiological Factors Predisposing Susceptibility to Drug Abuse	2 credits

**Thursday, June 19**

SXIV: (10:00AM-12:00PM)	Medications for Drug Addictions: Sex Differences in Outcomes in Animal and Human Laboratory Studies and in Clinical Trials	2 credits
SXV: (10:00AM-12:00PM)	Demystifying Medicinal Chemistry and Drug Design	2 credits

Registration for CME credit is \$100. The fee includes 1.00-21.00 credits maximum.

## Faculty Disclosures:

It is the policy of Temple University School of Medicine, Office for Continuing Medical Education to insure balance, independence, objectivity, and scientific rigor in all its individually sponsored educational programs. All faculty, program planning committee members, and Temple University School of Medicine Continuing Medical Education staff participating in any Temple University sponsored programs are expected to disclose to the program audience **ANY** real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. **ALL** faculty for the **CPDD 76<sup>th</sup> Annual Meeting** being held **June 14-19, 2014** have provided disclosure information. Listed below are those faculty who have identified a relationship with a commercial company. Such disclosure should not be construed as a conflict of interest, but, rather as a disclosure of a current or previous financial arrangement. All other faculty have indicated they do not have a financial relationship to disclose.

Marc Auriacombe	<i>Grant/Research Support:</i>	RBK Pharma, Ferrer Int, Lundbeck, Mundipharma, DA Pharma
Sudie Back	<i>Grant/Research Support:</i>	NIDA, Dept. of Defense
Robert L. Balster	<i>Consultant:</i>	Inflexxion, Newton, MA
Warren K. Bickel	<i>Grant/Research Support:</i>	NIH/NIDA (R01DA024080), NIH/NIDA (R01DA030241), NIH/NIMHD (R01MD007054), NIH/NCI (U19CA157345), NIH/NIDA (R01DA036017), Virginia Youth Tobacco Projects, NIH/NIDA (R01DA034755), NIH/NIAAA (R01AA021529), NIH (DP&DE024068), Medical University of South Carolina
	<i>Consultant:</i>	General Genetics Corporation, ProPhase, LLC, AstraZeneca Pharmaceuticals, LP, ADial Pharmaceuticals, LLC, Vermont Center on Behavior and Health
	<i>Other:</i>	Principal of HealthSim, LLC, a software development company
Laura Bohn	<i>Grant/Research Support:</i>	Eli Lilly & Co.
	<i>Consultant:</i>	Mencuro Therapeutics, Inc.
	<i>Stockholder:</i>	Mencuro Therapeutics, Inc.
Kathleen T. Brady	<i>Consultant:</i>	Embra Pharmaceuticals, Ovation Pharmaceuticals
Timothy D. Brewerton	<i>Other: Book Royalties</i>	Springer Publishing Co.
Michael R. Bruchas	<i>Grant/Research Support:</i>	NIH – NIDA, Directors Award NIH
Sandra D. Comer	<i>Grant/Research Support:</i>	Rechitt Benckiser
	<i>Consultant:</i>	AstraZeneca, Salix, Pfizer, Guidepoint Global

Wilson M. Compton	<i>Stockholder:</i>	Pfizer, General Electric (less than \$10,000 stock holdings in each)
Andrew Coop	<i>Grant/Research Support:</i>	National Institutes of Health
Jonathan Foulds	<i>Grant/Research Support:</i> <i>Consultant:</i>	Pfizer, Inc. Pfizer, Inc., GSK
Kevin Freeman	<i>Grant/Research Support:</i>	NIDA
Christine Grella	<i>Grant/Research Support:</i> <i>Consultant:</i>	NIDA Chestnut Health Systems
Margaret Haney	<i>Consultant:</i>	Insys Pharmaceuticals
Colleen A. Hanlon	<i>Grant/Research Support:</i>	National Institute of Health Career Development Award
Andrea G. Hohmann	<i>Grant/Research Support:</i> <i>Consultant:</i>  <i>Stockholder:</i> <i>Other:</i>	National Institutes of Health, NIDA Speaker for Cannabidiol Scientific Exchange (travel expenses paid) Pfizer Pharmaceuticals G.W. Pharmaceuticals provided Sativex but no financial support for pilot double blind placebo controlled crossover trial I published with Mary Lynch on which I was collaborator
Sally L. Huskinson	<i>Grant/Research Support:</i>	R01-DA-027666 to KBF from the National Institute on Drug Abuse
Iliyan Ivanov	<i>Other: DSUB member</i>	Lundbeck
Kathleen M. Kantak	<i>Grant/Research Support:</i>	DA 011716
Marc J. Kaufman	<i>Grant/Research Support:</i>	PhotoThera, Inc.
Frances Kay-Lambkin	<i>Grant/Research Support:</i>  <i>Consultant:</i>	Research fellowship – National Health and Medical Research Council (AUST) Cobalt Therapeutics, LLC
Therese K. Killeen	<i>Consultant:</i>	Rosewood Institute for Eating Disorder Training and Education
Naama Levy-Cooperman	<i>Consultant:</i>	Consultant to pharmaceutical companies and biotech.
Aron Lichtman	<i>Scientific Advisory Board:</i>	Abide Therapeutics
Bertha Madras	<i>Consultant:</i>	RiverMend Health, National Football League
John Mantsch	<i>Consultant:</i> <i>Stockholder:</i> <i>Other: Co-founder</i>	Promentis Pharmaceuticals Promentis Pharmaceuticals Promentis Pharmaceuticals

F. Joseph McClernon	<i>Grant/Research Support:</i>	Consultant on a Pfizer, Inc. investigator initiated GRAND award to Marcus Munafo
Sherry McKee	<i>Grant/Research Support:</i>	Investigator initiated grant support, Pfizer
Yann Mineur	<i>Grant/Research Support:</i>	NIMH, NIDA
F. Gerard Moeller	<i>Consultant:</i>	Boehringer Ingelheim
Michael A. Nader	<i>Grant/Research Support:</i>	NIH/NIDA (DA017763)
Thomas E. Prisinzano	<i>Grant/Research Support:</i> <i>Consultant</i>	NIDA (DA018151), NIGMS (GM008545) National Institutes of Health
Paula Riggs	<i>Grant/Research Support:</i>	NIDA
Andrew Saxon	<i>Speakers' Bureau</i> <i>Other:</i>	Reckitt Benckiser UpToDate, Inc.
Steven Shoptaw	<i>Grant/Research Support:</i> <i>Consultant:</i>	MediciNova, Inc. Pfizer, Inc.
Rajita Sinha	<i>Grant/Research Support:</i> <i>Scientific AdvisoryBoard:</i>	NIH Embra Neurotherapeutics, LLC
Eric C. Strain	<i>Consultant:</i>	DemeRx, Jazz, Zogenix, Reckitt-Benckiser, The Oak Group
Sharon L. Walsh	<i>Consultant:</i>  <i>Speaker/Chair:</i> <i>Development of Teaching Materials</i>	Sun Pharma, AstraZeneca, Equinox Group, Jazz Pharmaceuticals, MedSignals, Inc., Camurus PCM Scientific PCM Scientific
Laurie Zawertailo	<i>Grant/Research Support:</i>  <i>Stockholder:</i>	Current unrestricted grant funding from Pfizer Canada and Pfizer International GlaxoSmithKline

The planning committee and staff of the Office for Continuing Medical Education have provided disclosure information and indicated they do not have any financial relationships to disclose. All conflicts have been resolved.





## BOARD OF DIRECTORS

Frank Vocci, Jr., PhD, President	Toby Eisenstein, PhD
Richard De La Garza, II, PhD, Past-President	Margaret Haney, PhD
Eric Strain, M.D., President-Elect	Carl L. Hart, PhD
Theodore J. Cicero, PhD, Treasurer	Stephen T. Higgins, PhD
Michael T. Bardo, PhD	Marc J. Kaufman, PhD
Alan J. Budney, PhD	Mary Jeanne Kreek, MD
Andrew Coop, PhD	A. Thomas McLellan, PhD
Linda B. Cottler, PhD, MPH	Gregory M. Miller, PhD
Linda P. Dwoskin, PhD	Charles O'Keefe, M.B.A.
Linda A. Dykstra, PhD	Roger D. Spealman, PhD

## EXECUTIVE OFFICER

Martin W. Adler, PhD

## DIRECTOR, EXECUTIVE OFFICE

Ellen B. Geller, MA

## SCIENTIFIC PROGRAM COMMITTEE

Elise Weerts, PhD, Chair  
Martin W. Adler, PhD, *ex officio*  
Ellen B. Geller, MA, *ex officio*  
Mary E. Abood, PhD  
Linda B. Cottler, PhD, MPH  
Kelly Dunn, PhD  
Linda P. Dwoskin, PhD  
William E. Fantegrossi, PhD  
Deborah S. Hasin, PhD  
Michael Kuhar, PhD  
Wendy Lynch, PhD  
F. Gerald Moeller, MD  
William W. Stoops, PhD  
George E. Woody, MD

## PRE-MEETING SATELLITES

*7<sup>th</sup> Meeting of the International Women's and Children's and Gender Group*

Chaired by Wendee Wechsberg

**San Cristobal B/C/D**

June 13

*The 2014 NIDA International Forum: Building International Collaborative Research on Drug Abuse*

Chaired by Steven Gust

**San Geronimo A/C**

June 13 and June 14

*Preconference Workshop—AAAP's PCSS-MAT Buprenorphine Waiver Training (supported in part by SAMHSA)*

**Las Olas**

June 14

(8:00 AM – 5:30 PM)

*The International Study Group Investigating Drugs as Reinforcers (ISGIDAR)*

Chaired by Morgan Drake

**San Cristobal E/G**

June 14

*13<sup>th</sup> Annual Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment (CSAT) Pre-Conference Session*

Chaired by Suzan Swanton

**San Cristobal A/D**

June 14

## CPDD REGISTRATION

<b>Saturday, June 14</b>	<b>Peacock Alley</b>	<b>1:30 PM - 5:30 PM</b>
<b>Sunday, June 15</b>	<b>Peacock Alley</b>	<b>7:30 AM - 5:00 PM</b>
<b>Mon, Tues, Wed (16/17/18)</b>	<b>Conference Room 3</b>	<b>7:30 AM - 5:00 PM</b>
<b>Thursday, June 19</b>	<b>Conference Room 3</b>	<b>7:30 AM - 3:00 PM</b>

## OPENING RECEPTION Pool Area (Cash Bar)

**Saturday, June 14**

**7:00 PM - 9:00 PM**  
*(Pre-registrants can pick up badges only)*

**Plenary Session**

**SAN GERONIMO  
8:00 - 11:00 AM**

- 8:00 *Welcome*  
CPDD President Frank Vocci, Jr.
- 8:10 *In Memoriam*
- 8:20 *Report from the National Institute on Drug Abuse*  
Nora D. Volkow, NIDA/NIAAA, Bethesda, MD
- 8:40 *Report from the National Institute on Alcohol Abuse and Alcoholism*  
George F. Koob, The Scripps Research Institute, La Jolla, CA
- 9:00 *Presentation of the CPDD/NIDA Media Award to Charles Evans, Jr.*  
Introduction by Bertha Madras
- 9:15 *Presentation of the Martin and Toby Adler Distinguished Service Award to David Shurtleff*  
Introduction by Frank Vocci, Jr.
- 9:25 *Presentation of the Joseph Cochin Young Investigator Award to C. Debra Furr-Holden*  
Introduction by James Anthony
- 9:35 *Presentation of the Mentorship Award to Michael Bardo*  
Introduction by Janet Neisewander
- 9:45 *Presentation of the Nathan B. Eddy Award to Nora D. Volkow*  
Introduction by Anna Rose Childress
- 10:00 *Nathan B. Eddy Award Lecture: Fronto-striatal circuitry in addiction*  
Nora D. Volkow, NIDA Bethesda, MD

**Film Screening:  
Addiction Incorporated**

**AUDITORIUM  
11:15 - 12:00 PM**

**Town Hall Industry/Academia Forum**

**SAN CRISTOBAL  
11:15 - 1:15 PM**

**PHARMACOTHERAPY RESEARCH - OPPORTUNITIES,  
CHALLENGES AND SUCCESSES IN THE CROSS-TALK OF  
INDUSTRY, ACADEMIA, AND GOVERNMENT**

Chair: Beatriz Rocha

*Challenges and unique advantages of using academic medical centers in conducting pharmacotherapy research*

Charles P. O'Brien, University of Pennsylvania, Philadelphia, PA

*Perspective of a government funding source*

David McCann, National Institutes of Health, Bethesda, MD

*Experience in collaborating with the private sector and smaller firms*

Linda P. Dvoskin, University of Kentucky, Lexington, KY

*Pharma perspective and experience in collaborating with academia*

Beatrice Setnik, INC Research., Durham, NC

*Challenges on collaborations between industry and academic institutions (Part 1)*

Jean M. Bidlack, University of Rochester, Rochester, NY

*Challenges on collaborations between industry and academic institutions (Part 2)*

Margaret Haney, Columbia University, New York, NY

**CPDD Travel Awards Luncheon**  
(By Invitation Only)

**LAS OLAS**  
**11:45 - 1:00 PM**

**President's Lecture**

**BALLROOM B**  
**1:15 - 2:15 PM**

*The Harrison Act at 100. Past, present and future science behind the search for new opioid analgesics*

Andrew Coop, University of Maryland

**Symposium I**

**SAN CRISTOBAL**  
**2:30 - 4:30 PM**

**STRESS AND RELAPSE TO DRUG USE:  
FROM ANIMAL MODELS TO CLINICAL TRIALS**

Chairs: John R. Mantsch and Yavin Shaham

- 2:30 *Neurobiological mechanisms that contribute to stress-related cocaine use: Results of preclinical animal studies*  
John R. Mantsch, Marquette University, Milwaukee, WI
- 2:55 *Stress-induced reinstatement of drug seeking—19 years of progress*  
Yavin Shaham, Intramural Research Program/NIDA, Baltimore, MD
- 3:20 *Stress mechanisms increasing addiction relapse risk in humans: Potential for new addiction therapeutics*  
Rajita Sinha, Yale University School of Medicine, New Haven, CT
- 3:45 *The neurokinin 1 receptor as a treatment target in addiction and other stress-related disorders*  
Markus Heilig, NIAAA/NIDA, Bethesda, MD
- 4:10 *Stress and substance use disorders: The role of early life trauma*  
Sudie E. Back, Medical University of South Carolina, Charleston, SC

**Symposium II**

**BALLROOM B**  
**2:30 - 4:30 PM**

**UP IN SMOKE: CANNABIS AND TOBACCO,  
LINKED AT THE HIP AND DOUBLE TROUBLE**

Chairs: Alan J. Budney and Frances Kay-Lambkin

- 2:30 *Genetic pathways to cannabis and tobacco co-use and misuse*  
Lauren Few, Washington University School of Medicine, Saint Louis, MO
- 2:55 *Effect of tobacco use on marijuana withdrawal and relapse in the human laboratory*  
Margaret Haney, Columbia University, New York, NY
- 3:20 *Tobacco use among those with cannabis use disorders: Clinical approaches to co-occurring use*  
Dustin C. Lee, Geisel School of Medicine at Dartmouth, Lebanon, NH

- 3:45 *The interaction between cannabis use, tobacco use and psychiatric disorders: Implications for treatment*  
Frances Kay-Lambkin, University of New South Wales, New South Wales, NSW, Australia
- 4:10 *DISCUSSANT: Implications of co-use for adolescents, with focus on how rising national trends in marijuana use and marijuana legislation may moderate these concerns*  
Paula D. Riggs, University of Colorado School of Medicine, Aurora, CO

## **Oral Communications 1**

**BALLROOM C**  
**2:30 - 4:30 PM**

### **HIV/HCV: DRUGS/INFECTION INTERSECTION**

Chairs: Don C. Des Jarlais and Jeffrey Samet

- 2:30 *Knowledge about the transmission of HIV and HCV: A comparison between injection drug users and non-injection drug users*  
P. Wheeler, N. E. Whitehead, L. Hearn, W. W. Latimer, Clinical and Health Psychology, University of Florida, Gainesville, FL
- 2:45 *Hepatitis C virus incidence among HIV+ men who have sex with men: The role of non-injection drug use*  
H. Hagan<sup>1</sup>, J. Neurer<sup>1</sup>, A. E. Jordan<sup>1</sup>, D. C. Des Jarlais<sup>2</sup>, J. Wu<sup>3</sup>, K. Dombrowski<sup>4</sup>, B. Khan<sup>5</sup>, S. Braithwaite<sup>6</sup>, J. Kessler<sup>6</sup>, <sup>1</sup>New York University, New York, NY, <sup>2</sup>Beth Israel Medical Center, New York, NY, <sup>3</sup>New York University School of Medicine, New York, NY, <sup>4</sup>University of Nebraska, Lincoln, NE, <sup>5</sup>John Jay College of Criminal Justice, New York, NY, <sup>6</sup>New York University, New York, NY
- 3:00 *HCV genotype distribution among injection drug users in Taiwan*  
Y. Lan<sup>1</sup>, Y. Yang<sup>1</sup>, T. Chi<sup>1</sup>, K. Chen<sup>1</sup>, R. Wang<sup>2</sup>, Y. Chiang<sup>3</sup>, C. Huang<sup>3</sup>, I. Ho<sup>3</sup>, Y. Hser<sup>4,1</sup>, <sup>1</sup>Department of Health Risk Management, China Medical University, Taichung, Taiwan, <sup>2</sup>Department of Public Health, China Medical University, Taichung, Taiwan, <sup>3</sup>Center for Drug Abuse and Addiction, China Medical University Hospital, Taichung, Taiwan, <sup>4</sup>Integrated Substance Abuse Program, UCLA, Los Angeles, CA
- 3:15 *The impact of HIV testing policies and practices on HCV testing*  
J. A. Frimpong, T. D'Aunno, D. M. Wutchiett, L. R. Metsch, Columbia University, New York, NY
- 3:30 *Hepatitis C virus testing and treatment among HIV-infected people who inject drugs in St. Petersburg, Russia*  
J. Samet<sup>1,2</sup>, E. Krupitsky<sup>3,4</sup>, L. A. Wulach<sup>2</sup>, C. E. Chaisson<sup>1</sup>, J. Tsui<sup>1,2</sup>, <sup>1</sup>Boston University, Boston, MA, <sup>2</sup>Boston Medical Center, Boston, MA, <sup>3</sup>First St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation, <sup>4</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation
- 3:45 *Impact of 20 years harm reduction policy on HIV and HCV among opioid users not in treatment*  
C. M. Denis, M. Fatseas, V. Beltran, J. Daulouede, M. Auriacombe, Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France
- 4:00 *Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: The HITS-C study*  
L. Maher<sup>1</sup>, B. White<sup>1</sup>, G. Dore<sup>1</sup>, A. Lloyd<sup>1</sup>, W. Rawlinson<sup>2</sup>, <sup>1</sup>University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>Prince of Wales Hospital, Sydney, NSW, Australia

4:15 *Does effective combined prevention reduce racial/ethnic and sex disparities in HIV infection among PWID*

D. C. Des Jarlais<sup>1</sup>, K. Arasteh<sup>1</sup>, C. McKnight<sup>1</sup>, J. P. Feelemyer<sup>1</sup>, H. L. Cooper<sup>2</sup>, H. Hagan<sup>3</sup>, D. Perlman<sup>1</sup>, <sup>1</sup>Beth Israel Medical Center, New York, NY, <sup>2</sup>Emory University, Atlanta, GA, <sup>3</sup>New York University, New York, NY

## **Symposium III**

**BALLROOM A**

**2:30 - 3:30 PM**

### **NEW BUPRENORPHINE FORMULATIONS AND DRUG COMBINATIONS IN CLINICAL DEVELOPMENT**

Chairs: David McCann and Bob Walsh

2:30 *The development of buprenorphine (Probuphine®) subdermal implants*

Frank Vocci, Jr.<sup>1</sup>, Behshad Sheldon<sup>2</sup>, <sup>1</sup>Friends Research Institute, Inc., Baltimore, MD, <sup>2</sup>Braeburn Pharmaceuticals, Inc, Princeton, NJ

2:50 *CAM2038: Long-acting buprenorphine injection formulations in clinical development*

Fredrik Tiberg, Camurus AB, Lund, Sweden

3:10 *Development of the opioid modulator ALKS 5416: A sublingual co-formulation of buprenorphine and ALKS 33*

Elliot Ehrich, Alkermes, Inc., Cambridge, MA

## **Oral Communications 2**

**BALLROOM A**

**3:45 - 4:45 PM**

### **BREAKING THE ICE: METHAMPHETAMINE TREATMENT TARGETS**

Chairs: William W. Stoops and Walter Ling

3:45 *Preclinical evaluation of JPC-141 as a novel treatment for methamphetamine abuse*

J. R. Nickell<sup>1</sup>, E. D. Denehy<sup>2</sup>, J. P. Culver<sup>1</sup>, P. A. Crooks<sup>3</sup>, M. T. Bardo<sup>2</sup>, L. P. Dwoskin<sup>1</sup>, <sup>1</sup>Pharmaceutical Sciences, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY, <sup>3</sup>University of Arkansas, Fayetteville, AR

4:00 *Preclinical efficacy of an anti-methamphetamine vaccine with an E6020 adjuvant*

R. Arora<sup>1,2</sup>, T. A. Kosten<sup>3</sup>, R. S. Bennett<sup>1,2</sup>, B. M. Kinsey<sup>2</sup>, F. M. Orson<sup>1,2</sup>, T. R. Kosten<sup>1,2</sup>, <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>MEDVAMC, Houston, TX, <sup>3</sup>University of Houston, Houston, TX

4:15 *Influence of bupropion, naltrexone and bupropion+naltrexone on methamphetamine self-administration in humans*

W. W. Stoops<sup>1,2</sup>, E. Pike<sup>2</sup>, L. R. Hays<sup>3</sup>, P. E. Glaser<sup>3</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY

4:30 *Sustained-release methylphenidate for the treatment of methamphetamine dependence*

W. Ling, M. P. Hillhouse, J. Jenkins, J. Hernandez, M. Olaer, S. Reed, L. Mooney, M. Torrington, D. Dickerson, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA

## **Symposium IV**

**SAN CRISTOBAL  
5:00 - 6:00 PM**

### **HOW TRANSLATIONAL IS BEHAVIORAL RESEARCH IN ADDICTION?**

Chairs: F. Gerard Moeller and Kathryn A. Cunningham

- 5:00 *What needs to be translated in addiction research?*  
Steven Grant, National Institute on Drug Abuse, NHS, HHS, Bethesda, MD
- 5:20 *Cue reactivity in cocaine-dependent subjects, Relationship to impulsivity and 5-HT<sub>2C</sub> receptor genotype*  
F. Gerard Moeller, Virginia Commonwealth University Institute for Drug and Alcohol, Richmond, VA
- 5:40 *5-HT<sub>2C</sub> receptor function, impulsivity and cocaine cue reactivity in rodents*  
Kathryn Cunningham, University of Texas Medical Branch, Galveston, TX

## **Symposium V**

**BALLROOM B  
5:00 - 6:00 PM**

### **DSM-5 SUBSTANCE-RELATED AND ADDICTIVE DISORDERS: RATIONALE AND CONTROVERSIES**

Chairs: Deborah S. Hasin and Wilson Compton

- 5:00 *Combining abuse and dependence into a single disorder*  
Deborah S. Hasin, Columbia University, New York, NY
- 5:20 *Cannabis, caffeine-related disorders, craving, and legal problems in DSM-5*  
Wilson Compton, National Institute on Drug Abuse, NHS, HHS, Bethesda, MD
- 5:40 *Gambling disorder, Internet gaming disorder and other behavioral addictions in DSM-5*  
Marc Auriacombe, University of Bordeaux, Bordeaux, France

## **Oral Communications 3**

**BALLROOM C  
5:00 - 6:00 PM**

### **BUZZ KILL: NEW DATA ON COMBINED ALCOHOL AND STIMULANTS**

Chairs: Erin E. Bonar and Steven E. Meredith

- 5:00 *Effects of chronic alcohol consumption on cocaine self-administration in rhesus monkeys*  
P. W. Czoty, Physiology & Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC
- 5:15 *Energy drink use by adolescents and emerging adults seeking care in the emergency department: Alcohol, drugs, and other risk behaviors*  
E. E. Bonar, R. M. Cunningham, S. Polshkova, S. T. Chermack, F. C. Blow, M. A. Walton, University of Michigan, Ann Arbor, MI
- 5:30 *Caffeine increases the reinforcing effects of alcohol in some social drinkers*  
S. E. Meredith, D. Evatt, E. C. Strain, R. R. Griffiths, The Johns Hopkins University School of Medicine, Baltimore, MD



- 5:45 *Modafinil and naltrexone for the treatment of comorbid cocaine and alcohol dependence*  
K. M. Kampman, H. M. Pettinati, K. G. Lynch, J. G. Plebani, J. Lachewitz, K. Feeney,  
L. Rodriguez, C. P. O'Brien, Psychiatry, University of Pennsylvania, Philadelphia, PA

## **Oral Communications 4**

**BALLROOM A**  
**5:00 - 6:00 PM**

### **THE GAIN IN PAIN STAYS MAINLY ON THE WANE**

Chairs: Matthew J. Worley and Judith I. Tsui

- 5:00 *Hepatitis C virus infection, HIV and pain sensitivity in opioid-dependent patients*  
J. Tsui<sup>1</sup>, D. M. Cheng<sup>2</sup>, M. C. Lira<sup>1</sup>, M. R. Winter<sup>2</sup>, D. Alford<sup>1</sup>, J. Mao<sup>3</sup>, R. R. Edwards<sup>3</sup>,  
J. Samet<sup>1,2</sup>, <sup>1</sup>Boston Medical Center; Boston University School of Medicine, Boston, MA,  
<sup>2</sup>Boston University School of Public Health, Boston, MA, <sup>3</sup>Harvard Medical School,  
Boston, MA
- 5:15 *Pain sensitivity and tolerance among individuals on opioid maintenance: Long-term effects*  
A. Wachholtz, G. Gonzalez, Psychiatry, University of Massachusetts Medical School,  
Worcester, MA
- 5:30 *Chronic pain volatility predicts outcomes of buprenorphine-naloxone for prescription opioid dependence*  
M. Worley<sup>1</sup>, K. Heinzerling<sup>1</sup>, S. Shoptaw<sup>1</sup>, W. Ling<sup>2</sup>, <sup>1</sup>Department of Family Medicine,  
University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Integrated Substance Abuse  
Programs, University of California, Los Angeles, Los Angeles, CA
- 5:45 *Cognitive behavioral therapy improves treatment outcome for prescription opioid users in primary-care based buprenorphine/naloxone treatment*  
C. J. Cutter, B. A. Moore, D. Barry, L. E. Fiellin, R. S. Schottenfeld, D. Fiellin, P. O'Connor,  
Yale University School of Medicine, New Haven, CT

## **Workshop I**

**BALLROOM A**  
**6:00 - 7:45 PM**

### **THE EPIDEMIOLOGY OF NONMEDICAL USE OF PRESCRIPTION OPIOIDS AND OPIOID USE DISORDERS IN THE USA: RECENT TRENDS, LONGITUDINAL PATTERNS, AND TRANSITIONS TO HEROIN AND INJECTION DRUG USE**

Chairs: Silvia S. Martins and Sean E. McCabe

- Recent trends in nonmedical prescription opioid use and prescription opioid use disorder in the USA among adolescents and young adults*  
Silvia S. Martins, Columbia University, New York, NY
- Longitudinal patterns of medical use, medical misuse, and nonmedical use of prescription opioids among adolescents in the United States*  
Sean E. McCabe, University of Michigan, Ann Arbor, MI
- Risk of transition to heroin among non-opioid dependent illicit pharmaceutical opioid users*  
Robert Carlson, Wright State University, Dayton, OH
- Injection drug use and other risk behaviors among rural prescription opioid users*  
Jennifer R. Havens, University of Kentucky School of Medicine, Lexington, KY

---

**Sunday, June 15, 2014**

---

*An epidemiologic investigation of the overlap between prescription opioid dependence and alcohol use disorders in the U.S*

Howard Chilcoat, Purdue Pharma, Stamford, CT

## **Workshop II**

**BALLROOM B**

**7:00 - 9:00 PM**

### **INTEGRATION OF ADDICTION CARE INTO MEDICAL SETTINGS: THE STATE OF THE SCIENCE**

Chairs: Richard Saitz and Jeffrey Samet

*Drug use among primary care patients with a positive screen for alcohol misuse*

Kimberly Hepner, RAND Corporation, Santa Monica, CA

*Health outcomes associated with decreases in illicit drug use in primary care*

Tae Woo Park, Boston University, Boston, MA

*Variability in primary care opioid prescribing practices*

Jane M. Liebschutz, Boston Medical Center/Boston University, Boston, MA

*Models of SBIRT for opioid dependence in emergency department patients*

Gail D'Onofrio, Yale University School of Medicine, New Haven, CT

*Discussant: Integration of addiction care into medical settings: The state of the science*

Richard Saitz, Boston University School of Public Health, Boston, MA

## **Workshop III**

**BALLROOM C**

**7:00 - 9:00 PM**

### **GO/NO-GO DECISIONS IN MEDICATION DEVELOPMENT: WHY SOME COMPOUNDS SHOULD NOT GO FORWARD AND HOW DO WE IDENTIFY THEM?**

Chair: Jane B. Acri

*Introduction and early stage toxicity testing in drug development: Examples of how predictions of toxicity are evaluated and can be used to guide SAR*

Jane B. Acri, NIDA/NIH/DHHS, Bethesda, MD

*Cardiovascular safety interaction testing and how it may kill a promising target*

Nathan Appel, NIDA/NIH/DHHS, Bethesda, MD

*Assessing anhedonia in drug development using intracranial self-stimulation: What it might predict and does it matter?*

David A. White, NIDA/NIH/DHHS, Bethesda, MD

## **Workshop IV**

**SAN CRISTOBAL  
7:00 - 9:00 PM**

**THE 20TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP (WILL INCLUDE PRESENTATIONS BY JUNIOR AND SENIOR INVESTIGATORS OF DATA FROM ONGOING STUDIES THAT INVOLVE CM)**

Chairs: Steven Meredith and Kelly E. Dunn

*Some reflections on 20 years of research on the use of financial incentives to promote behavior change*

Stephen Higgins, University of Vermont, Burlington, VT

## **Workshop V**

**BALLROOM A  
8:15 - 10:00 PM**

**EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS FOR MINORITIES AND UNDER-REPRESENTED MINORITIES (CO-SPONSORED BY CPDD INTERNATIONAL PROGRAMS COMMITTEE)**

Chairs: J. C. Anthony and Jan Copeland

*Just-in-time adaptive interventions delivered via smartphones*

Susan A. Murphy, The University of Michigan, Ann Arbor, MI

*The challenge of effective and culturally sensitive research methodologies: Australian Aboriginal and Torres Strait Islander communities*

Jan Copeland, UNSW Medicine University of New South Wales, Sydney, NSW, Australia

*The challenge of effective and culturally sensitive research methodologies in the United States: Lessons learned from the Collaborative Psychiatric Epidemiology Surveys and Other Health Disparities Research Projects*

Margarita Alegria, Cambridge Health Alliance & Harvard Medical School, Somerville, MA

## Poster Session I (Breakfast)

GRAN SALON  
LOS ROSALES  
8:00 - 10:00 AM

Odd-numbered posters manned first hour;  
Even-numbered, second hour

Set-up time begins Sunday 1:00 PM  
Must be removed by Monday 12:00 Noon

### STIMULANTS - HUMANS I

- 1 *Caffeine withdrawal in college students: Differences by gender and beverage type*  
D. Pomm, D. Svikis, P. Dillon, D. Dick, K. Kendler, Virginia Commonwealth University, Richmond, VA
- 2 *Coffee and energy drink use in college freshmen: Is trouble brewing?*  
D. Svikis<sup>1</sup>, P. Dillon<sup>1</sup>, L. Thacker<sup>1</sup>, S. Meredith<sup>2</sup>, K. M. Polak<sup>1</sup>, D. Dick<sup>1</sup>, S. Kornstein<sup>1</sup>, K. Kendler<sup>1</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Johns Hopkins School of Medicine, Baltimore, MD
- 3 *Understanding the buzz about energy drink use in college students*  
P. Dillon, D. Svikis, D. Pomm, L. Thacker, K. Kendler, D. Dick, Virginia Commonwealth University, Richmond, VA
- 4 *Risk factors for consumption of energy drinks, alcohol and both among a sample of youth from 10 U.S. metropolitan areas*  
S. R. Khan, S. O. Lasopa, L. Cottler, C. W. Striley, Epidemiology, University of Florida, Gainesville, FL
- 5 *Energy drink consumption and other drug use in male and female eighth, tenth, and twelfth graders*  
K. M. Polak, P. Dillon, S. Girma, R. Koch, D. Svikis, Virginia Commonwealth University, Richmond, VA
- 6 *Basal neuroendocrine status and cocaine craving measurements in active cocaine-dependent volunteers at admission and after 8 weeks of abstinence*  
E. A. Ducat, B. M. Ray, J. Jackson, E. Butelman, M. Kreek, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY
- 7 *CRF versus AVP in human stress responsivity: Initial studies*  
B. M. Ray, E. A. Ducat, B. Reed, J. Altschuler, M. Kreek, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY
- 8 *Oxidative stress, BDNF and severity of crack cocaine use in early withdrawal*  
A. O. Sordi, F. Pechansky, F. Kessler, L. von Diemen, Psychiatry - Addiction, Center for Drug and Alcohol Research (CPAD), Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil, Porto Alegre, Brazil
- 9 *BDNF levels of crack users are associated with clinical outcome during inpatient treatment*  
L. von Diemen<sup>1</sup>, F. Kapczinski<sup>2</sup>, A. O. Sordi<sup>1</sup>, F. H. Kessler<sup>1</sup>, J. Narvaez<sup>1</sup>, F. P. Pechansky<sup>1</sup>, <sup>1</sup>Center for Drug and Alcohol Research, Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, <sup>2</sup>Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT), Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

- 10 *Prevalence of mild traumatic brain injury in cocaine-dependent research volunteers*  
D. Ramesh<sup>1</sup>, L. A. Keyser-Marcus<sup>1</sup>, J. Schmitz<sup>3</sup>, S. D. Lane<sup>3</sup>, J. H. Marwitz<sup>2</sup>, J. S. Kreutzer<sup>2</sup>, F. Moeller<sup>1</sup>, <sup>1</sup>Institute of Drug & Alcohol Studies, VCU, Richmond, VA, <sup>2</sup>Physical Medicine & Rehabilitation, VCU, Richmond, VA, <sup>3</sup>Psychiatry & Behavioral Sciences, UT-Houston, Houston, TX
- 11 *Distinctive types of executive dysfunction on cocaine dependence and ADHD compared to healthy controls*  
P. D. Goncalves, M. Ometto, T. Chain, B. Santos, M. Silva, M. Louza, M. Cavallet, S. Caetano, A. Malbergier, S. Nicastrì, A. Andrade, G. Busatto, P. J. Cunha, Institute & Department of Psychiatry, School of Medicine, University of São Paulo, Sao Paulo, Brazil
- 12 *Cocaine images impact inhibitory control: A within- and between-subjects comparison*  
E. Pike<sup>1,2</sup>, W. W. Stoops<sup>1,2</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Psychology, University of Kentucky, Lexington, KY, <sup>2</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY
- 13 *Inhibitory control in patients with cocaine abuse is equally disrupted by generic and personally salient cocaine images*  
G. J. DiGirolamo<sup>1,2</sup>, D. Smelson<sup>2</sup>, N. Guevremont<sup>2</sup>, G. Gonzalez<sup>2</sup>, <sup>1</sup>Psychology, College of the Holy Cross, Worcester, MA, <sup>2</sup>Psychiatry, University of Massachusetts, Medical School, Worcester, MA
- 14 *Predicting the effects of d-amphetamine using measures of sensation seeking and impulsivity*  
A. M. Harvanko<sup>1,2</sup>, C. Martin<sup>2,3</sup>, R. J. Charnigo<sup>4</sup>, J. S. Fogel<sup>1,2</sup>, J. A. Lile<sup>2</sup>, T. H. Kelly<sup>1,2,3</sup>, <sup>1</sup>Psychology, University of Kentucky, Lexington, KY, <sup>2</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY, <sup>4</sup>Biostatistics, University of Kentucky, Lexington, KY
- 15 *Influence of sensation seeking on d-amphetamine reinforcement*  
M. E. Patrick<sup>1</sup>, A. C. Meyer<sup>2</sup>, S. T. Higgins<sup>1,2</sup>, S. C. Sigmon<sup>1,2</sup>, <sup>1</sup>Psychology, University of Vermont, Burlington, VT, <sup>2</sup>Psychiatry, University of Vermont, Burlington, VT
- 16 *Low striatal dopamine D2/3 receptor availability predicts steeper delay discounting in methamphetamine abusers*  
M. E. Ballard<sup>1</sup>, J. R. Monterosso<sup>3</sup>, A. C. Dean<sup>1</sup>, M. A. Mandelkern<sup>4,5</sup>, E. London<sup>1,2</sup>, <sup>1</sup>Psychiatry & Biobehavioral Neuroscience, University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Molecular & Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, <sup>3</sup>Psychology, University of Southern California, Los Angeles, CA, <sup>4</sup>Nuclear Medicine Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, <sup>5</sup>Physics, University of California, Irvine, Irvine, CA
- 17 *The paradoxical effect of transcranial direct current stimulation on methamphetamine craving*  
H. Ekhtiari<sup>1,2</sup>, A. Shahbabaie<sup>1</sup>, B. Zamanian<sup>2</sup>, M. Ebrahimipour<sup>1</sup>, M. Golesorkhi<sup>1</sup>, F. Keshvari<sup>1</sup>, V. Nejati<sup>1</sup>, <sup>1</sup>Translational Neuroscience Program, Institute for Cognitive Science Studies, Tehran, Islamic Republic of Iran, <sup>2</sup>Iranian National Center for Addiction Studies, Tehran, Islamic Republic of Iran
- 18 *Dependence on amphetamines increases Parkinson's disease: Effect of gender*  
G. R. Hanson, A. E. Fleckenstein, K. Curtin, University of Utah, Salt Lake City, UT
- 19 *Cardiovascular safety of ibudilast treatment with intravenous methamphetamine administration*  
D. DeYoung<sup>1</sup>, K. G. Heinzerling<sup>1</sup>, A. Swanson<sup>2</sup>, J. Tsuang<sup>3</sup>, B. Furst<sup>3</sup>, Y. Yi<sup>4</sup>, Y. Wu<sup>4</sup>, S. Shoptaw<sup>1</sup>, <sup>1</sup>Family Medicine, UCLA, Los Angeles, CA, <sup>2</sup>Psychiatry, Stanford University, Stanford, CA, <sup>3</sup>Psychiatry, Harbor-UCLA Medical Center, Torrance, CA, <sup>4</sup>Statistics, UCLA, Los Angeles, CA

- 20 *Influence of buspirone on the cardiovascular and subject-rated effects of methamphetamine*  
C. R. Rush<sup>1,2,3</sup>, E. Pike<sup>2</sup>, W. W. Stoops<sup>1,2</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY
- 21 *Cognitive and cardiovascular effects of carvedilol in recently abstinent, cocaine-dependent patients*  
M. J. Mancino<sup>1</sup>, S. Shervani<sup>1</sup>, J. D. Thostenson<sup>1</sup>, J. B. Guise<sup>1</sup>, J. McGaugh<sup>1</sup>, T. R. Kosten<sup>2</sup>, A. Oliveto<sup>1</sup>, <sup>1</sup>Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, <sup>2</sup>Psychiatry, Baylor College of Medicine and Michael E DeBakey VA Medical Center, Houston, TX

**ADOLESCENT DRUG ABUSE I**

- 22 *Teens' vulnerability to substance use disorder: Excess reward or deficient inhibition?*  
T. J. Crowley<sup>1</sup>, M. S. Dalwani<sup>1</sup>, S. K. Mikulich-Gilbertson<sup>1</sup>, S. Young<sup>1</sup>, S. K. McWilliams<sup>1</sup>, K. M. Raymond<sup>1</sup>, M. Roark<sup>1</sup>, M. T. Banich<sup>2</sup>, <sup>1</sup>University of Colorado, Denver, CO, <sup>2</sup>University of Colorado, Boulder, CO
- 23 *Buffering effects of moral identity on the links between peer relationship quality and problem behaviors*  
C. Streit, G. Carlo, S. E. Killoren, M. E. Len-Rios, L. Cooper, A. Deutsch, A. N. Davis, University of Missouri, Columbia, MO
- 24 *Longitudinal trajectories of disinhibitory personality and behavioral constructs across early to middle adolescence*  
V. Brown, A. Collado, J. Felton, J. M. Shadur, L. MacPherson, C. W. Lejuez, Psychology, University of Maryland, College Park, College Park, MD
- 25 *Substance use trajectories from early adolescence through the college years*  
K. J. Derefinko<sup>1</sup>, R. J. Charnigo<sup>1</sup>, R. Milich<sup>1</sup>, D. R. Lynam<sup>2</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>Purdue University, West Lafayette, IN
- 26 *Personality traits and sex under the influence of alcohol during adolescence*  
M. Orgiles, A. Morales, M. T. Gonzalez, A. Guillen, J. P. Espada, Miguel Hernandez University, Alicante, Spain
- 27 *Perceived drinking risk and adolescent alcohol use over time: A dual latent growth curve analysis*  
J. M. Shadur, J. W. Felton, L. MacPherson, C. W. Lejuez, Psychology, University of Maryland, College Park, MD
- 28 *Adolescent attachment and substance use: Concurrent and prospective links*  
J. D. Jones, N. Bounoua, L. Pandes-Carter, C. W. Lejuez, J. Cassidy, University of Maryland, College Park, College Park, MD
- 29 *Beyond an adolescent's first occasion of using prescription pain relievers extra-medically: Associations with sex and with alcohol involvement*  
M. A. Parker, J. C. Anthony, Michigan State University, East Lansing, MI
- 30 *Initiation of nonmedical prescription opioid use and development of opioid dependence among young adults*  
P. Mateu-Gelabert, H. Guarino, Institute for Infectious Disease Research, NDRI, Inc., New York, NY
- 31 *Effects of family relationships quality on drug use: Mediating effects of moral conviction*  
A. N. Davis, G. Carlo, C. Streit, University of Missouri, Columbia, MO

- 32 *WITHDRAWN*
- 33 *Substance use trajectories among drug-using youth presenting to an urban ED*  
M. A. Walton<sup>1</sup>, J. E. Goldstick<sup>1</sup>, Q. Epstein-Ngo<sup>1</sup>, F. C. Blow<sup>1</sup>, M. Zimmerman<sup>1</sup>, B. M. Booth<sup>2</sup>, R. M. Cunningham<sup>1</sup>, <sup>1</sup>Departments of Psychiatry, Emergency Medicine, or School of Public Health, University of Michigan, Ann Arbor, MI, <sup>2</sup>University of Arkansas for Medical Sciences, Little Rock, AR
- 34 *Understanding the service needs of assault-injured, drug-using youth presenting for care in an urban emergency department*  
L. S. Massey<sup>2</sup>, K. Bohnert<sup>2</sup>, M. A. Walton<sup>2</sup>, M. Ranney<sup>4</sup>, E. E. Bonar<sup>2</sup>, F. C. Blow<sup>2</sup>, M. Zimmerman<sup>1</sup>, B. M. Booth<sup>3</sup>, R. M. Cunningham<sup>1</sup>, <sup>1</sup>Injury Center, University of Michigan, Ann Arbor, MI, <sup>2</sup>Department of Psychiatry, University of Michigan, Ann Arbor, MI, <sup>3</sup>University of Arkansas, Little Rock, AR, <sup>4</sup>Brown University, Providence, RI
- 35 *Drug-using ED assault-injured youth: 2-year prospective study of violent injury and mortality*  
R. Cunningham<sup>3</sup>, P. Carter<sup>3</sup>, M. Zimmerman<sup>3</sup>, F. C. Blow<sup>2</sup>, B. M. Booth<sup>1</sup>, M. A. Walton<sup>2</sup>, <sup>1</sup>Univ of Arkansas, Little Rock, AR, <sup>2</sup>Department of Psychiatry, Univ of Michigan, Ann Arbor, MI, <sup>3</sup>Injury Center, Univ of Michigan, Ann Arbor, MI
- 36 *The effect of neighborhood context on the relationship between substance misuse and weapons aggression in urban adolescents*  
J. E. Goldstick<sup>1</sup>, R. Lipton<sup>1</sup>, P. Carter<sup>1</sup>, M. Newton<sup>1</sup>, S. A. Stoddard<sup>2</sup>, M. A. Walton<sup>3</sup>, T. Reischl<sup>2</sup>, M. Zimmerman<sup>2</sup>, R. Cunningham<sup>1,2</sup>, <sup>1</sup>Emergency Medicine, University of Michigan, Ann Arbor, MI, <sup>2</sup>Health Behavior and Health Education, University of Michigan, Ann Arbor, MI, <sup>3</sup>Psychiatry, University of Michigan, Ann Arbor, MI
- 37 *Exploring the effects of alcohol and marijuana use on experience of teen dating violence among high school students in Maryland*  
E. Parker<sup>1</sup>, C. Bradshaw<sup>1,2</sup>, K. Debnam<sup>1</sup>, A. J. Milam<sup>1,3</sup>, C. D. Furr-Holden<sup>1</sup>, <sup>1</sup>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Curry School of Education, University of Virginia, Charlottesville, VA, <sup>3</sup>School of Medicine, Wayne State University, Detroit, MI
- 38 *Can a brief intervention be effective for adolescents with a severe-end drug problem?*  
K. Winters, S. Lee, Psychiatry, University of Minnesota Medical School, Minneapolis, MN
- 39 *Parent tobacco use, monitoring, and impulsive decision making: Predictors of post treatment youth substance use*  
V. Noel, C. Stanger, A. J. Budney, Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH
- 40 *Maternal impulsivity as a predictor of adolescent smoking status*  
A. Herrick<sup>1</sup>, S. Fields<sup>1</sup>, B. Reynolds<sup>2</sup>, P. Pirie<sup>3</sup>, <sup>1</sup>Psychology, Texas A&M University, College Station, TX, <sup>2</sup>Behavioral Science, University of Kentucky College of Medicine, Lexington, KY, <sup>3</sup>Ohio State University, Columbus, OH
- 41 *Increasing the value of an alternative monetary reinforcer reduces cigarette choice in adolescents*  
R. Cassidy, J. W. Tidey, C. W. Kahler, T. B. Wray, S. M. Colby, Center for Alcohol and Addiction Studies, Brown University, Providence, RI

### NICOTINE I

- 42 *Prenatal intravenous nicotine exposure enhances methamphetamine sensitization and alters BDNF levels in adult rat offspring*  
R. T. Lacy<sup>1</sup>, A. J. Morgan<sup>2</sup>, R. W. Brown<sup>3</sup>, M. K. Perna<sup>3</sup>, S. B. Harrod<sup>2</sup>, <sup>1</sup>Psychology, Davidson College, Davidson, NC, <sup>2</sup>Psychology, University of S. Carolina, Columbia, SC, <sup>3</sup>Psychology, E. Tennessee State University, Johnson City, TN

- 43 *Nicotine and stress: A role for the glutamate system*  
H. Philogene, C. S. Tallarida, S. Rawls, Center for Substance Abuse Research (CSAR), Temple University School of Medicine, Philadelphia, PA
- 44 *Opioid system located downstream of  $\alpha 7$  nicotinic acetylcholine receptor participates in the development of physical dependence on nicotine in mice*  
S. Kishioka, N. Kiguchi, Y. Kobayashi, F. Saika, C. Yamamoto, Pharmacology, Wakayama Medical University, Wakayama, Japan
- 45 *Effects of extended release tramadol on cigarette smoking during opioid withdrawal*  
M. R. Lofwall<sup>1,3,2</sup>, S. Babalonis<sup>1,3</sup>, L. Bennett<sup>4</sup>, P. A. Nuzzo<sup>3</sup>, S. L. Walsh<sup>1,3,2</sup>, <sup>1</sup>Behavioral Science, University of Kentucky College of Medicine (UK COM), Lexington, KY, <sup>2</sup>Psychiatry, UK COM, Lexington, KY, <sup>3</sup>Center on Drug and Alcohol Research, UK COM, Lexington, KY, <sup>4</sup>Anesthesiology, UK COM, Lexington, KY
- 46 *Effects of anatabine at relevant human nicotinic receptor subtypes in vitro and on craving and C-reactive protein in heavy smokers*  
R. K. Lanier, A. E. Cohen, J. L. Loeschner, K. D. Gibson, M. Varga, C. Wright IV, Rock Creek Pharmaceuticals, Inc., Gloucester, MA
- 47 *Modeling potential mechanisms of differential treatment effects in osmotic-release methylphenidate for smoking cessation*  
S. X. Luo<sup>1</sup>, M. M. Wall<sup>1</sup>, L. S. Covey<sup>1</sup>, M. Hu<sup>1</sup>, F. R. Levin<sup>1</sup>, E. V. Nunes<sup>1</sup>, T. Winhusen<sup>2</sup>, <sup>1</sup>Psychiatry, Columbia University, New York, NY, <sup>2</sup>Psychiatry, University of Cincinnati, Cincinnati, OH
- 48 *Executive functioning and emotion dysregulation in ADHD and non-ADHD cigarette smokers*  
J. Mitchell<sup>1</sup>, P. Dennis<sup>2</sup>, J. Beckham<sup>2</sup>, S. H. Kollins<sup>1</sup>, <sup>1</sup>Psychiatry & Behavioral Sciences, Duke University Medical Center, Durham, NC, <sup>2</sup>Durham Veterans Affairs Medical Center, Durham, NC
- 49 *Delay discounting predicts preference reversals by cigarette smokers*  
K. N. Tormohlen, A. K. Matusiewicz, A. Tyson, R. Yi, Center for Addictions, Personality and Emotion Research, Department of Psychology, University of Maryland, College Park, MD
- 50 *Examination of a recommended algorithm for eliminating nonsystematic delay discounting data*  
T. J. White<sup>1,2</sup>, R. Redner<sup>1,2</sup>, J. M. Skelly<sup>1,3</sup>, S. T. Higgins<sup>1,2,4</sup>, <sup>1</sup>Vermont Center on Behavior & Health, University of Vermont, Burlington, VT, <sup>2</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>3</sup>Medical Biostatistics, University of Vermont, Burlington, VT, <sup>4</sup>Psychology, University of Vermont, Burlington, VT
- 51 *Influence of nicotine replacement therapy on heart rate variability and relapse*  
S. R. Vorel, M. Mahoney, A. Bisaga, Psychiatry, Columbia University/New York State Psychiatric Institute, New York, NY
- 52 *Online attentional re-training for smoking*  
R. Wiers<sup>1</sup>, I. Elfeddali<sup>2</sup>, T. W. Pronk<sup>1</sup>, C. Bolman<sup>3</sup>, H. De Vries<sup>2</sup>, <sup>1</sup>Addiction Development and Psychopathology (ADAPT) Lab, Psychology, University of Amsterdam, Amsterdam, Netherlands, <sup>2</sup>Maastricht University, Maastricht, Netherlands, <sup>3</sup>Open University, Heerlen, Netherlands
- 53 *Psychedelic-facilitated smoking cessation: An online survey*  
A. P. Garcia-Romeu, R. R. Griffiths, M. W. Johnson, Johns Hopkins School of Medicine, Baltimore, MD
- 54 *A novel behavioral activation intervention for smoking cessation; Mechanisms of change*  
C. Kopetz<sup>1</sup>, L. MacPherson<sup>2</sup>, A. Mitchell<sup>2</sup>, A. Houston-Ludlam<sup>2</sup>, R. W. Wiers<sup>3</sup>, H. Larsen<sup>3</sup>, <sup>1</sup>Psychology, Wayne State University, Detroit, MI, <sup>2</sup>Psychology, University of Maryland, College Park, MD, <sup>3</sup>Psychology, University of Amsterdam, Amsterdam, Netherlands



- 55 *Task persistence as a target for tobacco dependence treatment*  
M. L. Steinberg<sup>1</sup>, E. E. Epstein<sup>2</sup>, N. F. Stahl<sup>1</sup>, T. D. Budsock<sup>1</sup>, J. M. Williams<sup>1</sup>, <sup>1</sup>Psychiatry, Rutgers University, New Brunswick, NJ, <sup>2</sup>Center of Alcohol Studies, Rutgers University, Piscataway, NJ
- 56 *CEASE quit smoking: A successful CBPR trial*  
P. Sheikhattari<sup>1,2</sup>, F. A. Wagner<sup>1,2</sup>, <sup>1</sup>Prevention Sciences Research Center, Morgan State University, Baltimore, MD, <sup>2</sup>School of Community Health and Policy, Morgan State University, Baltimore, MD
- 57 *CM of smoking abstinence vs. CM with shaping for smoking cessation among treatment-seeking patients*  
R. Secades-Villa, C. López-Núñez, I. Pericot-Valverde, F. Alonso-Pérez, O. Garcia-Rodriguez, Department of Psychology, University of Oviedo, Oviedo, Spain
- 58 *Hookah use among college students: Prevalence, mental health and drug use*  
A. Grinberg<sup>1</sup>, C. L. Hart<sup>2,3</sup>, J. Shapiro<sup>4</sup>, D. Keith<sup>3</sup>, F. Taha<sup>1</sup>, M. P. McNeil<sup>3</sup>, R. Goodwin<sup>1,4</sup>, <sup>1</sup>The Graduate Center (CUNY) at Queens College, Queens, NY, <sup>2</sup>New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY, <sup>3</sup>Columbia University, New York, NY, <sup>4</sup>Mailman School of Public Health, Columbia University, New York, NY

### THC AND CANNABINOIDS

- 59 *Does marijuana increase risk for dating violence victimization or perpetration?: Results of a meta-analysis*  
E. F. Rothman<sup>1</sup>, R. M. Johnson<sup>3</sup>, K. Pettoruto<sup>1</sup>, M. Lavalley<sup>2</sup>, <sup>1</sup>Community Health Sciences, Boston University School of Public Health, Boston, MA, <sup>2</sup>Biostatistics, Boston University School of Public Health, Boston, MA, <sup>3</sup>Johns Hopkins University, Baltimore, MD
- 60 *Monitoring marijuana use and risk perceptions with Google Trends data*  
P. Cavazos-Rehg, M. Krauss, E. Spitznagel, S. Buckner-Petty, R. Grucza, L. Bierut, Washington University School of Medicine, St. Louis, MO
- 61 *Does health status influence attitudes about and use of medical marijuana? Findings from a general population survey in California*  
C. E. Grella<sup>1</sup>, S. Cochran<sup>2</sup>, V. Mays<sup>3</sup>, <sup>1</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, CA, <sup>2</sup>Public Health, University of California, Los Angeles, CA, <sup>3</sup>Psychology, University of California, Los Angeles, CA
- 62 *Medical marijuana: Stepping stone or protective effect?*  
S. Lankenau<sup>1</sup>, E. Iverson<sup>2</sup>, <sup>1</sup>Drexel University, Philadelphia, PA, <sup>2</sup>Children's Hospital Los Angeles, Los Angeles, CA
- 63 *Recent cannabis use among adolescent and young adult immigrants in the Netherlands: The roles of acculturation strategy and linguistic acculturation*  
M. Delforterie<sup>1,2</sup>, H. Creemers<sup>1,2</sup>, A. Huizink<sup>1</sup>, <sup>1</sup>Faculty of Psychology & EMGO, VU University, Amsterdam, Netherlands, <sup>2</sup>Child Development and Education, University of Amsterdam, Amsterdam, Netherlands
- 64 *Racial/ethnic differences in attentional bias and cue reactivity among individuals with marijuana use disorders*  
L. M. Ruglass, R. Melara, Psychology, The City College of New York, New York, NY
- 65 *Neighborhood environment and marijuana use in urban young adults*  
C. M. Furr-Holden, M. H. Lee, A. J. Milam, A. Duncan, P. J. Leaf, N. Ialongo, Mental Health, Johns Hopkins School of Public Health, Baltimore, MD

- 66 *Specialist 'cannabis only' clinics in NSW, Australia: Client and treatment characteristics and associations with treatment-seeking behavior*  
J. Copeland, D. J. Allsop, National Cannabis Prevention and Information Centre, UNSW, Sydney, NSW, Australia
- 67 *Evaluation of guanfacine administration on cognition in volunteers with cannabis-use disorder*  
C. D. Verrico<sup>1,2</sup>, D. G. Thompson-Lake<sup>1,2</sup>, T. Iqbal<sup>1,2</sup>, J. Mahoney<sup>1,2</sup>, T. R. Kosten<sup>1,2</sup>, T. F. Newton<sup>1,2</sup>, R. De La Garza, II<sup>1,2</sup>, <sup>1</sup>Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, <sup>2</sup>Michael E. DeBakey VA Medical Center, Houston, TX
- 68 *I-cut — an integrative group cessation intervention for co-smokers of tobacco and cannabis: Feasibility study*  
J. Becker, M. P. Schaub, Swiss Research Institute for Public Health and Addiction, Zurich, Switzerland
- 69 *Psychometric evaluation of the Marijuana Reduction Strategy Self-Efficacy Scale with a community sample of marijuana users*  
A. K. Davis, N. Cross, K. Laruitsen, H. Rosenberg, L. Ashrafioun, Psychology, Bowling Green State University, Bowling Green, OH
- 70 *WITHDRAWN*
- 71 *Daily marijuana use and craving in the academic setting: A study using ecological momentary assessment*  
K. T. Phillips, M. M. Phillips, T. L. Lalonde, University of Northern Colorado, Greeley, CO
- 72 *Initial validation of a marijuana purchase task*  
E. Aston<sup>1</sup>, J. MacKillop<sup>3,1</sup>, R. Cassidy<sup>1</sup>, J. Metrik<sup>2,1</sup>, <sup>1</sup>Center for Alcohol and Addiction Studies, Brown University, Providence, RI, <sup>2</sup>Providence VA Medical Center, Providence, RI, <sup>3</sup>Department of Psychology, University of Georgia, Athens, GA
- 73 *Family environment as a mediator of relations between familial risk and impulsivity*  
S. R. Ryan, C. W. Mathias, A. Acheson, D. M. Dougherty, Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX
- 74 *Marijuana use and its relationship to impulsivity measured via delay discounting*  
M. S. Sferra, S. Thamotharan, S. Fields, Psychology, Texas A&M University, College Station, TX
- 75 *Measurement of attentional bias and stress in chronic marijuana users*  
S. Liu<sup>1</sup>, N. Dias<sup>2</sup>, N. Rathnayaka<sup>2</sup>, J. H. Yoon<sup>2,1</sup>, J. Schmitz<sup>2</sup>, S. D. Lane<sup>2</sup>, <sup>1</sup>Psychiatry, Baylor College of Medicine, Houston, TX, <sup>2</sup>Psychiatry & Behavioral Sciences, UTHSC-Houston, Houston, TX
- 76 *Marijuana use and FAAH genotype predict sleep quality in adolescents and emerging adults*  
K. E. Maple, N. E. Wright, K. M. Lisdahl, Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI
- 77 *THC ( $\Delta^9$ -tetrahydrocannabinol) elicits persistent changes in expression of genes implicated in adolescent neurodevelopment*  
B. K. Madras<sup>1</sup>, J. Zimmer<sup>1</sup>, L. M. Ogawa<sup>1</sup>, G. M. Miller<sup>1</sup>, S. V. Westmoreland<sup>1</sup>, E. Vallender<sup>1</sup>, Y. L. Hurd<sup>2</sup>, <sup>1</sup>Psychiatry, Harvard Medical School-NEPRC, Southborough, MA, <sup>2</sup>Mount Sinai Hospital, New York, NY
- 78 *A study on neurotoxicity and dependence mechanisms of JWH-081 and JWH-210*  
H. Cha, K. Lee, M. Song, Y. Kim, J. Shin, H. Kim, W. Seong, H. Kang, Pharmacological Research Division, NIFDS/MFDS, Chungwon-gun, Chungbuk, Republic of Korea

- 79 *Conditioned taste avoidance induced by  $\Delta$ -9-tetrahydrocannabinol in the Fischer and Lewis rat strains*

A. G. Wakeford, A. L. Riley, Psychology, American University, Washington, DC

### CLUB DRUGS

- 80 *Role of glycogen synthase kinase-3 $\beta$  in ketamine self-administration, cue and drug-induced reinstatement*  
X. Huang, K. Huang, W. Zheng, X. Li, W. Zhou, Y. Liu, Ningbo University School of Medicine, Ningbo, China
- 81 *Substantial enantiomer-specific differences in the neurochemical and behavioral actions of the synthetic cathinone mephedrone*  
R. A. Gregg<sup>1</sup>, M. H. Baumann<sup>2</sup>, A. Vouga<sup>1</sup>, C. Tallarida<sup>1</sup>, S. Rawls<sup>1</sup>, <sup>1</sup>Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, <sup>2</sup>Medicinal Chemistry Section, NIDA Intramural Research Program, Baltimore, MD
- 82 *Striatal dopamine dynamics in mice following acute and repeated toluene exposure*  
A. Apawu<sup>2</sup>, T. Mathews<sup>2</sup>, S. Bowen<sup>1</sup>, <sup>1</sup>Psychology, Wayne State University, Detroit, MI, <sup>2</sup>Chemistry, Wayne State University, Detroit, MI
- 83 *Survey study of challenging experiences after ingesting psilocybin mushrooms: Demographics and phenomenology*  
T. M. Carbonaro<sup>1</sup>, F. S. Barrett<sup>1</sup>, M. P. Bradstreet<sup>1</sup>, M. W. Johnson<sup>1</sup>, K. A. MacLean<sup>1</sup>, R. Jesse<sup>1,3</sup>, R. R. Griffiths<sup>1,2</sup>, <sup>1</sup>Psychiatry, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Neurosciences, Johns Hopkins University, Baltimore, MD, <sup>3</sup>Council on Spiritual Practices, Baltimore, MD
- 84 *The Challenging Experience Questionnaire: Characterization of acute adverse reactions to psilocybin*  
F. S. Barrett<sup>1</sup>, M. P. Bradstreet<sup>1</sup>, J. S. Leoutsakos<sup>1</sup>, M. W. Johnson<sup>1</sup>, K. A. MacLean<sup>1</sup>, R. Jesse<sup>1,3</sup>, R. R. Griffiths<sup>1,2</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, <sup>2</sup>Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD, <sup>3</sup>Council on Spiritual Practices, San Francisco, CA
- 85 *Longitudinal patterns of ecstasy and other drug use among young adults*  
A. M. Arria, B. A. Bugbee, K. M. Caldeira, K. B. Vincent, K. E. O'Grady, Center on Young Adult Health and Development, Dept. of Behavioral and Community Health, University of Maryland School of Public Health, College Park, MD
- 86 *K2 use at college entry and experimentation over college career*  
K. L. Egan, C. K. Suerken, B. A. Reboussin, E. L. Sutfin, K. G. Wagoner, B. Debinski, J. Spangler, M. Wolfson, Wake Forest School of Medicine, Winston-Salem, NC
- 87 *Synthetic cannabinoid use and awareness in a drug abuse treatment clinic*  
E. Disney, K. B. Stoller, R. Vandrey, Johns Hopkins University School of Medicine, Baltimore, MD
- 88 *Synthetic cannabinoid use among treatment seeking substance users*  
M. A. Kelly, J. J. Mariani, A. Glass, M. Pavlicova, A. Radin, F. R. Levin, Psychiatry, Substance Abuse, Columbia/New York State Psychiatric Institute, New York, NY

### CHEMISTRY AND PHARMACOKINETICS

- 89 *Structure-activity relationship studies on the tetrahydroisoquinoline-based orexin 1 receptor antagonists: The 1-benzyl position*  
Y. Zhang, D. A. Perrey, D. L. Harris, N. A. German, A. M. Decker, B. P. Gilmour, B. F. Thomas, Research Triangle Institute, Research Triangle Park, NC

- 90 *Targeting the serotonin (5-HT) 5-HT<sub>2C</sub> receptor: Rational design of small molecule allosteric modulators to treat psychostimulant use disorders*  
C. Wild, C. Ding, G. Zhang, N. Anastasio, J. Moncrief, T. Carbonaro, R. Fox, S. Stutz, R. Hartley, T. Smith, K. Cunningham, J. Zhou, Center for Addiction Research / Pharmacology, Univ of Texas Medical Branch, Galveston, TX
- 91 *Chemical modifications to alter monoamine releasing activity of phenmetrazine analogs as potential treatments of stimulant addiction*  
O. A. Namjoshi<sup>1</sup>, A. M. Decker<sup>1</sup>, A. Landavazo<sup>1</sup>, J. S. Partilla<sup>2</sup>, M. H. Baumann<sup>2</sup>, R. B. Rothman<sup>2</sup>, B. E. Blough<sup>1</sup>, <sup>1</sup>Drug Discovery, RTI International, Research Triangle Park, NC, <sup>2</sup>Medicinal Chemistry Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD
- 92 *Plasma butyrylcholinesterase enzyme functional activity in cocaine addicts*  
D. A. Gorelick<sup>1,2</sup>, J. R. Cashman<sup>3</sup>, J. R. Schroeder<sup>1</sup>, <sup>1</sup>Intramural Resesarch Program, National Institute on Drug Abuse, NIH, Baltimore, MD, <sup>2</sup>Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD, <sup>3</sup>Human BioMolecular Research Institute, San Diego, CA
- 93 *Acetazolamide, a new adherence marker for clinical trials?*  
A. Hampson<sup>1</sup>, S. Babalonis<sup>2</sup>, M. R. Lofwall<sup>2</sup>, P. A. Nuzzo<sup>2</sup>, S. L. Walsh<sup>2</sup>, <sup>1</sup>Div. Pharmacotherapies, National Institute on Drug Abuse, NHS, HHS, Rockville, MD, <sup>2</sup>Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 94 *Quinine: A potential tracer for monitoring medication adherence*  
S. Babalonis<sup>1,2</sup>, A. Hampson<sup>4</sup>, M. R. Lofwall<sup>1,2,3</sup>, P. A. Nuzzo<sup>2</sup>, S. L. Walsh<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, University of Kentucky (UK), Lexington, KY, <sup>2</sup>Center on Drug and Alcohol Research, UK, Lexington, KY, <sup>3</sup>Psychiatry, UK, Lexington, KY, <sup>4</sup>National Institute on Drug Abuse, Rockville, MD
- 95 *Safety and pharmacokinetics of oxycodone DETERx administered intranasally in recreational opioid users*  
E. A. Kopecky<sup>1</sup>, A. B. Fleming<sup>1</sup>, P. K. Noonan<sup>2</sup>, <sup>1</sup>Collegium Pharmaceutical, Inc., Canton, MA, <sup>2</sup>PK Noonan Pharmaceutical Consulting, LLC, Williamsburg, VA
- 96 *Pharmacokinetic-pharmacodynamic analyses in the assessment of abuse-deterrent opioid formulations*  
M. Shram<sup>1</sup>, S. Colucci<sup>2</sup>, S. Harris<sup>2</sup>, P. J. Perrino<sup>2</sup>, K. A. Schoedel<sup>1</sup>, N. Levy-Cooperman<sup>1</sup>, S. L. Walsh<sup>3</sup>, <sup>1</sup>Altreos Research Partners Inc., Toronto, ON, Canada, <sup>2</sup>Purdue Pharma LP, Stamford, CT, <sup>3</sup>Department Behavioral Science, University of Kentucky, Lexington, KY

### BEHAVIOR

- 97 *Aerobic exercise decreases speedball self-administration in female rats*  
J. C. Strickland, R. T. Lacy, M. K. Brophy, M. A. Witte, M. A. Smith, Davidson College, Davidson, KY
- 98 *Modulation of behavioral effects of polydrug (cocaine/heroin) mixtures by alpha-2 agonists*  
R. D. Spealman<sup>1</sup>, J. Bergman<sup>2</sup>, <sup>1</sup>Behavioral Biology-NERPRC, Harvard Medical School, Southborough, MA, <sup>2</sup>Preclinical Pharmacology, McLean Hospital-Harvard Medical School, Belmont, MA
- 99 *A novel 5HT<sub>2C</sub>-specific agonist/5HT<sub>2A-2B</sub> antagonist attenuates psychomotor behaviors induced by methamphetamine, oxycodone, and their combination*  
D. Morgan<sup>1</sup>, C. E. Canal<sup>2</sup>, P. C. Orza<sup>1</sup>, J. L. Rose<sup>1</sup>, M. S. Kim<sup>2</sup>, R. G. Booth<sup>2</sup>, <sup>1</sup>Psychiatry, University of Florida, Gainesville, FL, <sup>2</sup>Center for Drug Discovery, Northeastern University, Boston, MA

- 100 *Chronic, but not acute, low doses of pramipexole increased risk-taking behavior in rats*  
S. E. Tedford<sup>1,3</sup>, N. A. Holtz<sup>1,3</sup>, A. L. Persons<sup>1,3</sup>, C. Napier<sup>1,2,3</sup>, <sup>1</sup>Pharmacology, RUSH University, Chicago, IL, <sup>2</sup>Psychiatry, RUSH University, Chicago, IL, <sup>3</sup>Center for Compulsive Behavior and Addiction, RUSH University, Chicago, IL
- 101 *Choice self-administration in the HIV-1 transgenic rats: A perspective on compulsive behavior*  
C. F. Mactutus, S. B. Harrod, S. J. Bertrand, A. J. Morgan, M. N. Cranston, R. M. Booze, Psychology, University of South Carolina, Columbia, SC
- 102 *HIV-1 transgenic rats exhibit attenuated cocaine-mediated increase in synaptosomal [3H] dopamine uptake in striatum following cocaine self-administration*  
J. Zhu<sup>1</sup>, B. J. Bertrand<sup>2</sup>, S. B. Harrod<sup>2</sup>, C. F. Mactutus<sup>2</sup>, R. M. Booze<sup>2</sup>, <sup>1</sup>Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, <sup>2</sup>Psychology, University of South Carolina, Columbia, SC
- 103 *Is high fructose corn syrup addictive? Studies of operant intraoral self-administration in rats*  
F. Leri, A. Levy, Psychology, University of Guelph, Guelph, ON, Canada
- 104 *The role of nociceptin in responding for palatable rewards*  
I. A. Mendez, N. T. Maidment, N. P. Murphy, Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA
- 105 *Characterization of the discriminative stimulus effects of the NOP agonist Ro 64-6198 in non-human primates*  
P. A. Saccone, K. A. Zelenock, A. Lindsey, M. E. Zaks, J. H. Woods, Pharmacology, University of Michigan Medical School, Ann Arbor, MI
- 106 *Characterization of morphine discriminative stimulus properties in C57BL/6 mice*  
D. M. Walentiny, L. S. Harris, Department of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA
- 107 *Evaluation of intravenous self-administration of ALKS 33 in rats trained to self-administer morphine*  
M. Sgro<sup>1</sup>, D. Modlin<sup>1</sup>, M. Todenkopf<sup>2</sup>, D. Deaver<sup>2</sup>, M. Kallman<sup>1</sup>, <sup>1</sup>Covance Laboratories, Greenfield, IN, <sup>2</sup>Alkermes, Waltham, MA
- 108 *Oxycodone-induced conditioned place preference and locomotor activity in adult female C57BL/6J mice*  
D. T. Collins, M. Kreek, Y. Zhang, The Laboratory of the Biology of Addictive Disease, The Rockefeller University, New York, NY
- 109 *Effect of opioid withdrawal on delay discounting of food in rhesus monkeys*  
D. R. Maguire, L. R. Gerak, C. P. France, Pharmacology, UTHSCSA, San Antonio, TX
- 110 *Morphine and interleukin-1 receptor antagonist prevent the development of stress-enhanced fear learning*  
M. Jones, C. Lebonville, D. Lysle, Psychology, UNC Chapel Hill, Chapel Hill, NC
- 111 *Oxytocin effects on human aggressive responding*  
J. L. Alcorn, N. Dias, N. Rathnayaka, J. Schmitz, C. Green, S. D. Lane, Department of Psychiatry & Behavioral Sciences, School of Medicine, Program in Neuroscience, Graduate School of Biomedical Sciences University of Texas Health Science Center –Houston, Houston, TX
- 112 *Cocaine dependence and childhood maltreatment are associated with altered configurations of personality traits*  
L. K. Brents, S. Tripathi, J. Young, G. James, C. D. Kilts, Helen L. Porter and James T. Dyke Brain Imaging Research Center, Psychiatric Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR

- 113 *Relationship between alexithymia and dopamine D2-type receptor availability: Methamphetamine-dependent subjects differ from healthy controls*  
K. Okita<sup>1</sup>, D. Ghahremani<sup>2</sup>, D. Payer<sup>3</sup>, M. Mandelkern<sup>4,5</sup>, E. London<sup>1,2,4</sup>, <sup>1</sup>Laboratory of Molecular Neuroimaging, University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Department of Psychiatry and Biobehavioral Neuroscience, University of California, Los Angeles, Los Angeles, CA, <sup>3</sup>Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>4</sup>Nuclear Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, <sup>5</sup>Physics Department, University of California, Irvine, Irvine, CA
- 114 *Varenicline improves information processing speed and verbal memory in methamphetamine-dependent participants*  
A. Kalechstein<sup>1,2</sup>, J. Mahoney<sup>1,2</sup>, C. D. Verrico<sup>1,2</sup>, T. Iqbal<sup>1,2</sup>, R. De La Garza, II<sup>1,2</sup>, <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Michael E. DeBakey VA Medical Center, Houston, TX
- 115 *Total recall?: Researchers' perceptions of the consent process*  
K. L. Dugosh, D. Festinger, Treatment Research Institute, Philadelphia, PA

**OPIOIDS I**

- 116 *Gene variants of the opioid system - Relationship to heroin self-exposure, addiction, and treatment*  
M. Randesi<sup>1</sup>, O. Levrant<sup>1</sup>, E. Butelman<sup>1</sup>, V. Yuferov<sup>1</sup>, J. Ott<sup>2</sup>, P. Blanken<sup>3</sup>, W. van den Brink<sup>3</sup>, J. M. van Ree<sup>3</sup>, M. Kreek<sup>1</sup>, <sup>1</sup>Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY, <sup>2</sup>Institute of Psychology, Chinese Academy of Sciences, Beijing, China, <sup>3</sup>Central Committee on the Treatment of Heroin Addicts (CCBH), Utrecht, Netherlands
- 117 *Cognitive-behavioral therapy and educational counseling for chronic pain and opioid dependence*  
D. T. Barry<sup>1,2</sup>, C. J. Cutter<sup>1,2</sup>, M. Beitel<sup>1,2</sup>, C. Liang<sup>2</sup>, R. S. Schottenfeld<sup>1</sup>, <sup>1</sup>Psychiatry, Yale School of Medicine, New Haven, CT, <sup>2</sup>APT Foundation Pain Treatment Services, New Haven, CT
- 118 *Repeated exposure produces tolerance to some of the abuse-related subjective effects of oral tramadol in humans*  
B. L. Bolin<sup>1</sup>, C. R. Rush<sup>1,2</sup>, P. Glaser<sup>2</sup>, W. W. Stoops<sup>1</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, College of Medicine, Lexington, KY, <sup>2</sup>Psychiatry, University of Kentucky, College of Medicine, Lexington, KY
- 119 *Comparison of impulsivity and decision making in ketamine, opioid and non-drug users*  
H. Zeng<sup>1</sup>, X. Zheng<sup>2</sup>, H. Ye<sup>1</sup>, <sup>1</sup>The Research Center of Psychology and Brain Science, Guangzhou University, Guangzhou, China, <sup>2</sup>School of Psychology, South China Normal University, Guangzhou, China
- 120 *Effects of yohimbine and hydrocortisone pretreatment on opioid seeking, stress biomarkers, and learning in heroin-dependent volunteers*  
M. K. Greenwald, L. H. Lundahl, V. Diwadkar, Wayne State University, Detroit, MI
- 121 *WITHDRAWN*
- 122 *Real-time stress, craving and mood differences in polydrug-using methadone treatment responders and nonresponders*  
M. A. Furnari, M. L. Jobes, K. A. Phillips, D. H. Epstein, K. L. Preston, NIDA Intramural Research Program, Baltimore, MD
- 123 *Junkie habitus: Beyond disease and moral defect*  
C. Gelpi-Acosta, Postdoctoral Fellow, NIDA Behavioral Science Training in Drug Abuse Research, National Development and Research Institute, New York City, NY

- 124 *Increasing incidence of hospital admissions for opioid poisonings in adolescents and young adults: 2000-2009*  
D. R. Camenga, J. R. Gaither, J. Leventhal, S. Ryan, Yale School of Medicine, New Haven, CT
- 125 *Opioid deaths or polydrug/multi-cause deaths?*  
J. G. Erensen, J. D. Haddox, Health Policy, Purdue Pharma L.P., Stamford, CT
- 126 *Comparison of the risk of opioid overdose among patients prescribed immediate-release and extended-release opioid analgesics*  
P. Coplan, A. DeVaugh-Geiss, A. Kadakia, G. Stiles, Risk Management and Epidemiology, Purdue Pharma, Stamford, CT
- 127 *Risk factors associated with overdose among patients seeking treatment for opioid dependence*  
E. L. Winstanley<sup>1</sup>, A. Clark<sup>2</sup>, <sup>1</sup>Psychiatry & Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, <sup>2</sup>Nursing, University of Cincinnati, Cincinnati, OH
- 128 *Detection of opioid overdoses and poisonings in electronic medical records as compared to medical chart reviews*  
S. Janoff<sup>1</sup>, P. Coplan<sup>2</sup>, N. Perrin<sup>1</sup>, C. Campbell<sup>3</sup>, E. Shuster<sup>3</sup>, T. Ray<sup>3</sup>, M. Roberts<sup>1</sup>, H. Chilcoat<sup>2</sup>, C. Green<sup>1</sup>, <sup>1</sup>Kaiser Permanente, Portland, OR, <sup>2</sup>Purdue Pharma, Stamford, CT, <sup>3</sup>Kaiser Permanente, Oakland, CA
- 129 *Opioid overdose risk perception and naloxone acceptability among patients maintained on chronically prescribed opioids at the Cincinnati VA*  
C. M. Wilder<sup>1,2</sup>, S. C. Miller<sup>2,1</sup>, E. Tiffany<sup>1</sup>, T. Winhusen<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, <sup>2</sup>Substance Dependence Program - Mental Health, Cincinnati VA Medical Center, Cincinnati, OH
- 130 *Is opioid dose a strong predictor of the risk of opioid overdose?: Important confounding factors that change the dose-overdose relationship*  
A. DeVaugh-Geiss, P. Coplan, A. Kadakia, H. Chilcoat, Purdue Pharma LP, Stamford, CT
- 131 *Brief guide to prevent overdose fatality for prescription opioid abusers: A harm reduction initiative*  
L. E. Sandstrom<sup>1</sup>, P. Coplan<sup>1</sup>, H. Chilcoat<sup>1</sup>, F. W. Brason<sup>2</sup>, C. Leukefeld<sup>3</sup>, L. A. Morris<sup>4</sup>, <sup>1</sup>Purdue Pharma, Stamford, CT, <sup>2</sup>Project Lazarus, Moravian Falls, NC, <sup>3</sup>University of Kentucky, Lexington, KY, <sup>4</sup>Louis A Morris & Assoc., Dix Hills, NY
- 132 *Overdose education and naloxone rescue kits for family members of opioid users: Characteristics, motivations and naloxone use*  
S. Bagley<sup>1</sup>, J. Peterson<sup>2</sup>, D. M. Cheng<sup>3</sup>, C. Jose<sup>1</sup>, P. G. O'Connor<sup>4</sup>, A. Y. Walley<sup>1</sup>, <sup>1</sup>Boston University Medical Center/Boston Medical Center, Boston, MA, <sup>2</sup>Learn to Cope, Raynham, MA, <sup>3</sup>Boston University School of Public Health, Boston, MA, <sup>4</sup>Yale University School of Medicine, New Haven, CT
- 133 *Mortality among patients accessing pharmacological treatment for opioid dependence in California, 2006-2010*  
L. Li<sup>1</sup>, E. Evans<sup>1</sup>, D. Y. Huang<sup>1</sup>, D. Urada<sup>1</sup>, L. Liu<sup>2</sup>, Y. Hser<sup>1</sup>, B. Nosyk<sup>3,4</sup>, <sup>1</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>2</sup>Feinberg School of Medicine, Northwestern University, Evanston, IL, <sup>3</sup>British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, <sup>4</sup>Simon Fraser University, Vancouver, BC, Canada
- 134 *Comparison between former opiate addicts on methadone maintenance treatment and medication free for  $\geq 10$  years*  
E. Peles, A. Sason, O. Tene, Y. Domany, S. Schreiber, M. Adelson, Adelson Clinic for Drug Abuse Treatment & Research, Psychiatry, Tel-Aviv Medical Center, Tel-Aviv University, Tel-Aviv, Israel

- 135 *Characterizing interpregnancy intervals of opioid-maintained women*  
C. L. Bergeria<sup>1</sup>, D. Hand<sup>2</sup>, M. Meyer<sup>3</sup>, S. T. Higgins<sup>1,2</sup>, S. C. Sigmon<sup>1,2</sup>, S. H. Heil<sup>1,2</sup>,  
<sup>1</sup>Psychology, University of Vermont, Burlington, VT, <sup>2</sup>Psychiatry, University of Vermont,  
Burlington, VT, <sup>3</sup>Obstetrics & Gynecology, University of Vermont College of Medicine,  
Burlington, VT
- 136 *Characteristics and quality of life of opioid-dependent pregnant women in Austria*  
V. Metz<sup>1,2</sup>, S. D. Comer<sup>1</sup>, J. Wuerzl<sup>2</sup>, A. Pribasnik<sup>2</sup>, G. Fischer<sup>2</sup>, <sup>1</sup>Psychiatry, NYSPI &  
Columbia University, New York, NY, <sup>2</sup>Medical University of Vienna, Vienna, Austria
- 137 *Stigma management for women in recovery*  
A. Gunn, <sup>1</sup>University of Chicago, Chicago, IL, <sup>2</sup>National Development Research Institutes,  
Inc, New York, NY
- 138 *Examining the association between methadone maintenance treatment and body mass index*  
S. C. Sigmon<sup>1</sup>, J. Fenn<sup>2</sup>, <sup>1</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>2</sup>Nursing,  
University of Vermont, Burlington, VT
- 139 *Risk-taking behavior over 36-month follow-up treatment in outpatient opioid maintenance  
treatment program*  
J. Daulouède<sup>1,2</sup>, C. M. Denis<sup>1</sup>, M. Fatseas<sup>1</sup>, V. Beltran<sup>1,2</sup>, M. Auriacombe<sup>1,2</sup>, <sup>1</sup>Addiction  
Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, <sup>2</sup>Addiction Treatment  
Center, Bizia, Bayonne, France
- 140 *Area-level attributes and program resources as predictors of methadone dosage patterns*  
D. Wutchiett, J. A. Frimpong, T. D'Aunno, Columbia University, New York, NY
- 141 *Change of suicidality among heroin users: 1 month after methadone maintenance treatment*  
S. Wang<sup>1</sup>, C. Huang<sup>2</sup>, N. Y. Wang<sup>2</sup>, C. Chan<sup>4</sup>, Y. Liu<sup>1</sup>, C. Chen<sup>3</sup>, I. Ho<sup>2</sup>, <sup>1</sup>Center for  
Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan, <sup>2</sup>China  
Medical University and Hospital, Taichung, Taiwan, <sup>3</sup>National Yang Ming University, Taipei,  
Taiwan, <sup>4</sup>Taoyuan Mental Hospital, Taoyuan, Taiwan
- 142 *Trends in racial/ethnic differences in heroin use and heroin risk behaviors among nonmedical  
users of prescription opioids from 2002 to 2011*  
S. S. Martins<sup>1</sup>, J. Santaella<sup>1</sup>, B. D. Marshall<sup>2</sup>, A. Maldonado<sup>1</sup>, M. Cerdá<sup>1</sup>, <sup>1</sup>Epidemiology,  
Columbia University, New York, NY, <sup>2</sup>Epidemiology, Brown University, Providence, RI
- 143 *Predictors of retention in methadone maintenance treatment differ by gender*  
A. R. Levine, L. H. Lundahl, D. M. Ledgerwood, M. K. Greenwald, Wayne State University,  
Detroit, MI
- 144 *The meaning of work: Perceptions among persons with maintenance treatment for opioid  
addiction who are employed*  
M. Augutis<sup>1</sup>, D. Rosenberg<sup>2</sup>, H. Hillborg<sup>3</sup>, <sup>1</sup>Research and Development, Sundsvall Hospital,  
Sundsvall, Sweden, <sup>2</sup>Department of Social Work, Umeå University, Umeå, Sweden,  
<sup>3</sup>Research and Development, Sundsvall Hospital, Sundsvall, Sweden

**HIV/HCV I**

- 145 *Perceptions of genetic testing and genomic medicine among urban drug users*  
D. Perlman<sup>1</sup>, C. Gelpi-Acosta<sup>2</sup>, S. R. Friedman<sup>2</sup>, A. E. Jordan<sup>3</sup>, H. Hagan<sup>3</sup>, <sup>1</sup>Beth Israel  
Medical Center, New York, NY, <sup>2</sup>NDRI, Inc., New York, NY, <sup>3</sup>New York University, New  
York, NY
- 146 *The effect of high stress on T-cell protein expression in chronic drug users: HIV implications*  
N. Boukli, S. Lopez, M. Rodriguez, E. Rios, Microbiology and Immunology, Universidad  
Central Del Caribe, Bayamon



- 147 *Effects of HIV infection and cocaine dependence on neurocognitive impairment*  
S. Towe<sup>1</sup>, K. Robertson<sup>2</sup>, L. J. King<sup>1</sup>, C. S. Meade<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Duke University, Durham, NC, <sup>2</sup>Department of Neurology, University of North Carolina, Chapel Hill, NC
- 148 *The impact of prescription opioids on CD4 count in HIV: A longitudinal analysis*  
E. J. Edelman<sup>1</sup>, K. S. Gordon<sup>2</sup>, W. Becker<sup>2,1</sup>, J. R. Gaither<sup>1</sup>, A. J. Gordon<sup>3</sup>, J. Samet<sup>4</sup>, A. Justice<sup>2,1</sup>, D. Fiellin<sup>1</sup>, <sup>1</sup>Yale, New Haven, CT, <sup>2</sup>VA CT, West Haven, CT, <sup>3</sup>VA Pittsburgh and University of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Boston University, Boston, MA
- 149 *Cerebrospinal fluid kynurenic acid and depressive symptoms in HIV-infected individuals*  
N. Tanizaki<sup>1</sup>, A. Franke<sup>2</sup>, X. Li<sup>2</sup>, N. Holmes<sup>1</sup>, V. Douet<sup>1</sup>, L. Chang<sup>1</sup>, <sup>1</sup>Medicine, University of Hawaii at Manoa, Honolulu, HI, <sup>2</sup>University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI
- 150 *Formal and informal organizational activities of people who inject drugs*  
S. R. Friedman, E. R. Pouget, M. Sandoval, Y. Jones, National Development and Research Institutes, New York, NY
- 151 *Trends in care for persons who inject drugs in San Francisco*  
P. O. Coffin<sup>1,2</sup>, H. Jin<sup>1</sup>, E. Hurliaux<sup>1</sup>, H. Raymond<sup>1,2</sup>, <sup>1</sup>San Francisco Department of Public Health, San Francisco, CA, <sup>2</sup>UCSF, San Francisco, CA
- 152 *The causal effect of opioid substitution treatment on highly active antiretroviral treatment adherence*  
B. Nosyk<sup>1,2</sup>, J. Min<sup>1</sup>, G. Colley<sup>1</sup>, V. Lima<sup>1,3</sup>, B. Yip<sup>1</sup>, M. Milloy<sup>1</sup>, E. Wood<sup>1,3</sup>, J. Montaner<sup>1,3</sup>, <sup>1</sup>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, <sup>2</sup>Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada, <sup>3</sup>Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
- 153 *Neighborhood disorder, HIV treatment access and ARV diversion: A mediation study of drug-involved HIV-positive individuals in South Florida*  
C. L. O'Grady, H. Surratt, Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL
- 154 *Who in the world buys ARVs on the black market? The impact of drug use and ARV diversion on adherence*  
K. Tsuyuki, H. Surratt, M. A. Levi Minzi, C. L. O'Grady, Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL
- 155 *Non-medical use of prescription drugs among HIV-positive individuals taking antiretroviral therapy*  
H. Newville<sup>1</sup>, J. Roley<sup>2</sup>, J. Sorensen<sup>2</sup>, <sup>1</sup>St. Luke's-Roosevelt Hospital, New York, NY, <sup>2</sup>University of California, San Francisco, San Francisco, CA
- 156 *Hepatitis C infection among Hispanics in California*  
D. G. Fisher, G. L. Reynolds, E. Erlyana, C. Cummins, Center for Behavioral Research and Services, California State University, Long Beach, Long Beach, CA
- 157 *Primary drug use types and intervention-related self-monitoring in HIV patients*  
E. Aharonovich<sup>1,2</sup>, D. S. Hasin<sup>1,2</sup>, <sup>1</sup>Psychiatry, Columbia University Medical Center, New York, NY, <sup>2</sup>The New York State Psychiatric Institute, New York, NY
- 158 *Comparative efficacy of a computer-based HIV testing video intervention in sites of varying HIV prevalence*  
I. D. Aronson<sup>1</sup>, S. Rajan<sup>3</sup>, L. A. Marsch<sup>2</sup>, J. Koken<sup>1</sup>, T. Bania<sup>3</sup>, <sup>1</sup>NDRI, New York, NY, <sup>2</sup>Dartmouth, Lebanon, NH, <sup>3</sup>Columbia, New York, NY

- 159 *Drug use and response to alcohol intervention among HIV+ men and women*  
J. C. Elliott<sup>1</sup>, E. Aharonovich<sup>1,2</sup>, D. S. Hasin<sup>1,2</sup>, <sup>1</sup>Columbia University Medical Center, New York, NY, <sup>2</sup>New York State Psychiatric Institute, New York, NY
- 160 *Understanding drug use and the HIV cascade of care in San Juan, Puerto Rico*  
D. Hernández<sup>1</sup>, Y. Fernández<sup>1</sup>, F. Torres Cardona<sup>2</sup>, P. Castellon<sup>1</sup>, J. Vargas Vidot<sup>2</sup>, S. Miranda de Leon<sup>3</sup>, D. Feaster<sup>4</sup>, B. Schackman<sup>5</sup>, A. Rodriguez<sup>4</sup>, J. Santana<sup>6</sup>, L. Metsch<sup>1</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>Iniciativa Comunitaria de Investigación, San Juan, <sup>3</sup>Puerto Rico Department of Health, San Juan, <sup>4</sup>University of Miami, Miami, FL, <sup>5</sup>Cornell University, New York, NY, <sup>6</sup>University of Puerto Rico, Rio Piedras
- 161 *Immediate impact of Hurricane Sandy on people who inject drugs in New York City*  
E. R. Pouget, M. Sandoval, G. K. Nikolopoulos, S. R. Friedman, Institute for Infectious Disease Research, National Development and Research Institutes, Inc., New York, NY
- 162 *Support, traumatization, and employment differences in drug court outcomes*  
D. Morse<sup>1</sup>, C. Cerulli<sup>1</sup>, S. Bandyopadhyay<sup>2</sup>, J. J. Guido<sup>2</sup>, H. Yang<sup>2</sup>, J. L. Wilson<sup>1</sup>, F. Taxman<sup>3</sup>, <sup>1</sup>Psychiatry, University of Rochester School of Medicine, Rochester, NY, <sup>2</sup>Biostatistics, University of Rochester School of Medicine, Rochester, NY, <sup>3</sup>Criminology, Law & Society, George Mason University, Fairfax, VA

## **Symposium VI**

**SAN CRISTOBAL  
10:00 - 12:00 PM**

### **ACUTE AND CHRONIC STIMULANT EFFECTS ON MOTIVATION AND BEHAVIORAL CONTROL**

Chairs: Scott H. Kollins and Iliyan Ivanov

- 10:00 *Chronic effects of methylphenidate on reward signaling and behavior in animal models of ADHD*  
Peter Thanos, Stony Brook University, Stony Brook, NY
- 10:25 *Methylphenidate and brain activity in a reward/conflict paradigm: The role of the insula in motivation and interference control: A human fMRI study*  
Iliyan Ivanov, Icahn School of Medicine at Mount Sinai, New York, NY
- 10:50 *ADHD, smoking and stimulant medication: Preliminary results of a neuroimaging study of smokers with and without ADHD*  
F. Joseph McClernon, Duke University Medical Center, Durham, NC
- 11:15 *Moderators of alcohol and substance use outcomes from stimulant medication and ADHD*  
Steve Lee, UCLA, Los Angeles, CA
- 11:40 *DISCUSSANT:*  
Nora D. Volkow, National Institute on Drug Abuse, Bethesda, MD

## **Symposium VII**

**BALLROOM B  
10:00 - 12:00 PM**

### **NEUROPEPTIDERGIC TARGETS FOR CNS DISORDERS**

Chairs: Ivy Carroll and Scott P. Runyon

- 10:00 *Nociceptin/orphanin FQ opioid receptor functional selectivity, signaling and behavior*  
Michael Bruchas, Washington University School of Medicine, St. Louis, MO

- 10:25 *Evaluation of ligand bias at the kappa opioid receptor: Spanning compound development to effects in neurons*  
Laura Bohn, The Scripps Research Institute, Jupiter, FL
- 10:50 *Identification of neuropeptide S antagonists as pharmacotherapies for substance abuse*  
Scott P. Runyon, Research Triangle Institute, Research Triangle Park, NC
- 11:15 *Neoclerodane diterpenes as novel treatments for drug abuse*  
Thomas E. Prisinzano, University of Kansas, Lawrence, KS
- 11:40 *DISCUSSANT: Summary and analysis of neuropeptidergic targets for CNS disorders*  
Ivy Carroll, Research Triangle Institute, Research Triangle Park, NC

### Oral Communications 5

**BALLROOM C**  
**10:00 - 12:00 PM**

#### PRISONERS OF ADDICTION: A GLOBAL VIEW

Chairs: David S. Festinger and Sarah Larney

- 10:00 *Historical representation of drug related issues in a sample of Puerto Rican print media*  
G. D. Vega, S. Rivera, L. M. Torres, C. E. Albizu, University of Puerto Rico, San Juan
- 10:15 *Residential mobility and housing instability among justice-involved African-American opioid abusers*  
A. Wooditch, F. Taxman, A. Murphy, Criminology, Law & Society, George Mason University, Fairfax, VA
- 10:30 *Risk factors of psychosis among amphetamine users: A prospective study of clients in the Swedish criminal justice system*  
J. G. Bramness<sup>1</sup>, E. B. Rognli<sup>1</sup>, J. Berge<sup>2</sup>, A. C. Håkansson<sup>2</sup>, <sup>1</sup>Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway, <sup>2</sup>Department of Clinical Sciences Lund, Lund University, Lund, Sweden
- 10:45 *Substance use, mental health and incarceration among Mexican-American young adult men with a history of gang membership*  
A. Cepeda<sup>1</sup>, A. Valdez<sup>1,2</sup>, K. M. Nowotny<sup>3</sup>, <sup>1</sup>School of Social Work, University of Southern California, Los Angeles, CA, <sup>2</sup>Sociology, University of Southern California, Los Angeles, CA, <sup>3</sup>Sociology, University of Colorado Boulder, Boulder, CO
- 11:00 *Heroin and prescription opioid users: Characterization in a Canadian federal context*  
B. Brands<sup>1,2,3</sup>, T. Thornton<sup>1</sup>, M. Ternes<sup>4</sup>, M. Cheverie<sup>4</sup>, K. Thibault<sup>4</sup>, A. Moser<sup>4</sup>, <sup>1</sup>Health Canada, Ottawa, ON, Canada, <sup>2</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>3</sup>University of Toronto, Toronto, ON, Canada, <sup>4</sup>Correctional Services Canada, Ottawa, ON, Canada
- 11:15 *Post-incarceration factors and relapse to opioid injection in St. Petersburg, Russia*  
J. A. Cepeda<sup>1</sup>, A. Lyubimova<sup>2</sup>, O. Levina<sup>2</sup>, R. Heimer<sup>1</sup>, <sup>1</sup>Epidemiology of Microbial Diseases, Yale University, New Haven, CT, <sup>2</sup>NGO Stellit, St. Petersburg, Russian Federation
- 11:30 *Opioid substitution therapy as a strategy to reduce deaths in prison: Retrospective cohort study*  
S. Larney<sup>1,2</sup>, N. Gisev<sup>1</sup>, M. Farrell<sup>1</sup>, T. Dobbins<sup>3</sup>, L. Burns<sup>1</sup>, A. Gibson<sup>4</sup>, J. Kimber<sup>1</sup>, L. Degenhardt<sup>1,5</sup>, <sup>1</sup>University of NSW, Sydney, NSW, Australia, <sup>2</sup>Brown University, Providence, RI, <sup>3</sup>University of Sydney, Sydney, NSW, Australia, <sup>4</sup>University of Western Sydney, Sydney, NSW, Australia, <sup>5</sup>University of Melbourne, Melbourne, NSW, Australia

- 11:45 *The impact of opioid substitution therapy on mortality post-release from prison*  
L. Degenhardt<sup>1,2</sup>, S. Larney<sup>1,3</sup>, J. Kimber<sup>1</sup>, N. Gisev<sup>1</sup>, M. Farrell<sup>1</sup>, T. Dobbins<sup>4</sup>,  
D. J. Weatherburn<sup>5</sup>, A. Gibson<sup>6</sup>, R. Mattick<sup>1</sup>, T. Butler<sup>7</sup>, L. Burns<sup>1</sup>, <sup>1</sup>National Drug and  
Alcohol Research Centre, University of NSW, Sydney, NSW, Australia, <sup>2</sup>School of Population  
and Global Health, University of Melbourne, Melbourne, VIC, Australia, <sup>3</sup>Alpert Medical  
School, Brown University, Providence, RI, <sup>4</sup>Sydney School of Public Health, University of  
Sydney, Sydney, NSW, Australia, <sup>5</sup>New South Wales Bureau of Crime Statistics and Research  
(BOCSAR), Sydney, NSW, Australia, <sup>6</sup>University of Western Sydney, Sydney, NSW,  
Australia, <sup>7</sup>Kirby Institute, University of New South Wales, Sydney, NSW, Australia

## Oral Communications 6

**BALLROOM A**  
**10:00 - 12:00 PM**

### SEX, DRUGS AND RANDOMIZED TRIALS

Chairs: Teresa Franklin and MacKenzie R. Peltier

- 10:00 *Influence of sex on gray matter volume differences between smokers and nonsmokers*  
T. R. Franklin, R. Wetherill, K. Jagannathan, B. Johnson, J. Mumma, N. Hager, H. Rao,  
A. Childress, University of Pennsylvania, Philadelphia, PA
- 10:15 *Sex differences in impulsivity and brain volumes in methamphetamine users*  
S. Kogachi, L. Chang, C. Jiang, D. Alicata, T. Ernst, University of Hawaii, Honolulu, HI
- 10:30 *Exploring gender in response to provocative stimuli in limbic regions of interest among cocaine users*  
M. R. Peltier<sup>1,2</sup>, M. Canterbury<sup>2</sup>, C. A. Hanlon<sup>2</sup>, <sup>1</sup>Louisiana State University, Baton  
Rouge, LA, <sup>2</sup>Medical University of South Carolina, Charleston, SC
- 10:45 *Delay discounting in current, ex, and non-smokers: Interactions with gender*  
A. Quisenberry, C. Franck, M. N. Koffarnus, W. K. Bickel, Virginia Tech Carilion Research  
Institute, Roanoke, VA
- 11:00 *Sex differences in cognitive and motor impulsivity among users of different classes of drugs in protracted abstinence*  
M. J. Wilson<sup>1</sup>, G. Vasilev<sup>2</sup>, F. Moeller<sup>3</sup>, J. Vassileva<sup>1</sup>, <sup>1</sup>Psychiatry, University of Illinois at  
Chicago, Chicago, IL, <sup>2</sup>Bulgarian Addictions Institute, Sofia, Bulgaria, <sup>3</sup>Psychiatry, Virginia  
Commonwealth University, Richmond, VA
- 11:15 *Gender differences in use of alternative tobacco products among daily and nondaily smokers*  
A. M. Allen<sup>1</sup>, C. Mathur<sup>2</sup>, T. S. Scheuermann<sup>3</sup>, N. Nollen<sup>3</sup>, D. Hatsukami<sup>4</sup>, J. Ahluwalia<sup>3</sup>,  
<sup>1</sup>Family Medicine & Community Health, University of Minnesota, Minneapolis, MN,  
<sup>2</sup>Internal Medicine, University of Minnesota, Minneapolis, MN, <sup>3</sup>Preventive Medicine &  
Public Health, University of Kansas, Kansas City, KS, <sup>4</sup>Psychiatry, University of Minnesota,  
Minneapolis, MN
- 11:30 *Evidence of gender-specific telescoping effects in chronic, regular heroin users*  
J. J. Stoltman, E. A. Woodcock, L. Lundahl, M. K. Greenwald, Psychiatry, Wayne State  
University, Detroit, MI
- 11:45 *Sex differences in depressive-like effects of kappa opioid receptor activation in rats*  
J. Mays, D. Puttick, S. Russell, E. Chartoff, Psychiatry, Harvard Medical School,  
Belmont, MA

**Policy Forum  
(Brown Bag Lunch)**

**BALLROOM B  
12:15 - 1:45 PM**

Chairs: William L. Dewey and Martin Y. Iguchi

*Introduction:*

William L. Dewey, VCU, Richmond, VA

*Update from Capitol Hill*

Ed Long, VanScoyoc Associates, Washington, DC

*Panel on the Affordable Care Act: Implications for the substance abuse field*

*Substance abuse treatment under the ACA: So simple, so complex*

Andrew Kessler, Slingshot Solutions, Annandale, VA

*The Affordable Care Act: A watershed moment for substance use disorders*

A. Thomas McLellan, Treatment Research Center, Philadelphia, PA

**Symposium VIII**

**BALLROOM A  
2:00 - 4:00 PM**

**THE EFFECTS, USE PATTERNS AND YOUTH PERCEPTION OF  
ELECTRONIC CIGARETTES**

Chairs: Robert Balster and Thomas Eissenberg

- 2:00 *Acute effects of electronic cigarettes in adults: Nicotine delivery and abuse liability*  
Thomas Eissenberg, Virginia Commonwealth University Institute for Drug and Alcohol,  
Richmond, VA
- 2:25 *Results from a large survey of electronic cigarette users*  
Jonathan Foulds, Penn State University, Hershey, PA
- 2:50 *Perceptions about electronic cigarettes among adolescents and young adults*  
Suchitra Krishnan-Sarin, Yale University, New Haven, CT
- 3:15 *Trajectories of electronic cigarette use among young adults*  
Erin L. Sutfin, Wake Forest University, Winston-Salem, NC
- 3:40 *DISCUSSANT:*  
Warren K. Bickel, Virginia Tech University, Roanoke, VA

**Symposium IX**

**BALLROOM B  
2:00 - 4:00 PM**

**NOVEL APPROACHES TO EXAMINING THE INTERTWINING  
EPIDEMICS OF HIV AND DRUG ABUSE: FROM DECISION-  
MAKING TO VIRAL LOAD**

Chairs: Matthew W. Johnson and Steven Shoptaw

- 2:00 *Effects of acute alcohol, cocaine, and methamphetamine on the delay discounting of sexual  
consequences among drug users*  
Matthew W. Johnson, Johns Hopkins University, Baltimore, MD
- 2:25 *Do laboratory-based measures of risk taking correlate with real-life HIV risk behavior in  
cocaine users?*  
Christina S. Meade, Duke University Medical Center, Durham, NC

- 2:50 *Using crowdsourcing technology to examine HIV risk, drug use, and sexual decision-making among men who have sex with men*  
Evan S. Herrmann, Johns Hopkins University, Baltimore, MD
- 3:15 *Partner stimulant use is independently associated with detectable HIV viral load among HIV-positive men in same-sex relationships*  
Adam W. Carrico, University of California, San Francisco, San Francisco, CA
- 3:40 *DISCUSSANT: Novel approaches to examining the intertwining epidemics of HIV and drug abuse: Summary and future directions*  
Steven Shoptaw, University of California, Los Angeles, Los Angeles, CA

### Oral Communications 7

**BALLROOM C**  
**2:00 - 4:00 PM**

#### WHAT'S THE BUZZ ON ALCOHOL?

Chairs: Kelly E. Dunn and Elise Weerts

- 2:00 *Drinking during the first two weeks of a clinical trial significantly predicts drinking at the end of the trial*  
K. E. Dunn, E. C. Strain, Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD
- 2:15 *Comparison of baclofen vs. naltrexone treatment during abstinence on reinstatement of alcohol self-administration in baboons*  
E. Weerts, B. J. Kaminski, Johns Hopkins University School of Medicine, Baltimore, MD
- 2:30 *Do medications impact treatment outcomes? XR-NTX in county-funded treatment*  
D. A. Crevecoeur-MacPhail<sup>1</sup>, S. J. Cousins<sup>1</sup>, J. Barger<sup>2</sup>, D. Bennett<sup>1</sup>, E. Vasquez<sup>1</sup>, W. Sugita<sup>2</sup>, R. Rawson<sup>1</sup>, <sup>1</sup>Psychiatry, UCLA Integrated Substance Abuse Programs, Los Angeles, CA, <sup>2</sup>Department of Public Health, Substance Abuse Prevention and Control, Alhambra, CA
- 2:45 *Does the efficacy of medications for substance abuse treatment decrease over time?*  
E. M. Klemperer, J. Hughes, Psychiatry, University of Vermont, Burlington, VT
- 3:00 *Deconstructing clozapine further: Toward medication for alcohol use disorder in schizophrenia*  
A. I. Green, J. Y. Khokhar, Psychiatry, Dartmouth College, Lebanon, NH
- 3:15 *Alcohol drinking and related behaviors in hypothalamic-specific POMC-deficient mice*  
Y. Zhou<sup>1</sup>, M. Rubinstein<sup>2</sup>, M. J. Low<sup>3</sup>, M. Kreek<sup>1</sup>, <sup>1</sup>Rockefeller Univ, NY, NY, <sup>2</sup>Univ Buenos Aires, Buenos Aires, Argentina, <sup>3</sup>Univ Michigan, Ann Arbor, MI
- 3:30 *The involvement of the CNR1 gene in impulsivity and stress response in alcohol-related behaviors*  
M. Niculescu<sup>1</sup>, K. J. Cerullo<sup>1</sup>, K. Hess<sup>1</sup>, R. E. Rupslaukyte<sup>1</sup>, B. Stoothoff<sup>1</sup>, N. Enman<sup>1</sup>, K. Hesterberg<sup>2</sup>, L. Manza<sup>1</sup>, K. E. Hutchison<sup>2</sup>, <sup>1</sup>Psychology, Lebanon Valley College, Annville, PA, <sup>2</sup>Psychology and Neuroscience, University of Colorado, Boulder, CO
- 3:45 *Alcohol dependence, gender, and cortisol response predict amygdala response pattern to fMRI stress task*  
N. E. Wright<sup>1</sup>, C. B. Padula<sup>4</sup>, K. E. Maple<sup>1</sup>, R. Anthenelli<sup>2</sup>, E. Nelson<sup>3</sup>, K. M. Lisdahl<sup>1</sup>, <sup>1</sup>Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI, <sup>2</sup>University of California San Diego, San Diego, CA, <sup>3</sup>University of Cincinnati, Cincinnati, OH, <sup>4</sup>VA Palo Alto Health Care System, Palo Alto, CA

**Oral Communications 8****SAN CRISTOBAL  
2:00 - 4:00 PM****SAY NO TO BLOW: COCAINE TREATMENT TARGETS**

Chairs: Jun-Xu Li and Wilfrid N. Raby

- 2:00 *Positive allosteric modulators of the serotonin 2C receptor as novel therapeutics for cocaine use disorder*  
R. Hartley, G. Zhang, J. Moncrief, C. Ding, N. C. Anastasio, R. G. Fox, S. J. Stutz, C. Wild, J. Zhou, K. Cunningham, Ctr Addiction Res, UTMB, Galveston, TX
- 2:15 *Bi-directional effects of presynaptic and postsynaptic adenosine A<sub>2A</sub> receptor antagonism on cocaine seeking*  
C. E. O'Neill, S. C. Levis, D. Schreiner, R. K. Bachtell, Center for Neuroscience, University of Colorado, Boulder, CO
- 2:30 *The trace-amine-associated receptor 1 agonist RO5263397 attenuates abuse-related effects of cocaine in rats*  
J. Li<sup>1</sup>, D. A. Thorn<sup>1</sup>, L. Jing<sup>1</sup>, Y. Zhang<sup>2</sup>, <sup>1</sup>Pharmacology and Toxicology, University at Buffalo, Buffalo, NY, <sup>2</sup>Research Triangle Institute, Research Triangle Park, NC
- 2:45 *Carvedilol treatment reduces cocaine use in methadone-maintained cocaine users*  
M. Sofuoglu<sup>1,2</sup>, T. Babuscio<sup>2</sup>, K. M. Carroll<sup>2,1</sup>, <sup>1</sup>Psychiatry, VA CT Healthcare System, West Haven, CT, <sup>2</sup>Psychiatry, Yale University, New Haven, CT
- 3:00 *Evaluation of lisdexamfetamine alone and lisdexamfetamine + modafinil for cocaine use disorder*  
A. Brewer<sup>1</sup>, D. G. Thompson-Lake<sup>2</sup>, J. J. Mahoney<sup>2</sup>, T. F. Newton<sup>2</sup>, R. De La Garza, II<sup>1,2</sup>, <sup>1</sup>Pharmacology, Baylor College of Medicine, Houston, TX, <sup>2</sup>Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX
- 3:15 *A multi-site, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence*  
T. Winhusen<sup>1</sup>, D. Lewis<sup>1</sup>, G. Sharma<sup>2</sup>, S. Sparenborg<sup>3</sup>, <sup>1</sup>University of Cincinnati, Cincinnati, OH, <sup>2</sup>EMMES Corp., Rockville, MD, <sup>3</sup>NIDA, Bethesda, MD
- 3:30 *Prognostic relevance of dopamine beta-hydroxylase levels on disulfiram treatment at higher doses of cocaine dependence in methadone-stabilized patients: A secondary analysis*  
R. Nahata<sup>1</sup>, M. J. Mancino<sup>1</sup>, H. Hendrickson<sup>3</sup>, L. Song<sup>3</sup>, J. D. Thostenson<sup>2</sup>, A. Oliveto<sup>1</sup>, <sup>1</sup>Psychiatry, UAMS, Little Rock, AR, <sup>2</sup>Biostatistics Faculty Support, UAMS, Little Rock, AR, <sup>3</sup>College of Pharmacy, Bioanalytical, UAMS, Little Rock, AR
- 3:45 *Absence of stress dysregulation predicts cocaine and mood outcomes in a study of mirtazapine for depressed cocaine-dependent patients*  
W. N. Raby<sup>1,2</sup>, D. Bryon<sup>1</sup>, A. Glass<sup>3</sup>, M. Pavlikova<sup>3</sup>, E. V. Nunes<sup>1</sup>, H. D. Kleber<sup>1</sup>, <sup>1</sup>Division on Substance Abuse, Department of Psychiatry, Columbia University, New York City, NY, <sup>2</sup>Division on Substance Abuse, Department of Psychiatry, Albert Einstein College of Medicine, New York City, NY, <sup>3</sup>Division of Biostatistics, Department of Public Health, Columbia University, New York City, NY

---

**Monday, June 16, 2014**

---

**MARIAN W. FISCHMAN  
MEMORIAL AWARD LECTURE**

**BALLROOM B  
4:15 - 5:15 PM**

*Presentation of the Marian W. Fischman Award to Amy H. Newman*

Introduction by Michael Nader

*Lecture: What's a nice girl like you doing in a field like this?*  
Amy H. Newman

**Pre- and Post-Doctoral Trainees  
Networking Event**

**LAS OLAS  
5:15 - 6:45 PM**

**Workshop VI**

**BALLROOM A  
7:00 - 9:00 PM**

**KNOWLEDGE TRANSLATION IN ADDICTION SCIENCES:  
WHY AND HOW TO SHARE RESEARCH KNOWLEDGE BEYOND  
THE ACADEMIC COMMUNITY**

Chairs: Doris Payer and Marc J. Kaufman

*Introduction to knowledge translation in addiction sciences: Why and how*

Doris Payer, Center for Addiction and Mental Health, Toronto, ON, Canada

*Incorporating the Knowledge Translation Cycle in addictions treatment: Lessons from a  
nicotine- dependence clinic within an addictions hospital*

Laurie Zawertailo, Centre for Addiction and Mental Health, Toronto, ON, Canada

*Speaking to the media: Experiences and coaching for addiction researchers*

Bertha K. Madras, Harvard Medical School, Southborough, MA

*Social media and non-traditional strategies for drug-abuse science communication*

Michael A. Taffe, The Scripps Research Institute, La Jolla, CA

*Using academic research to inform public policy*

Jane C. Maxwell, University of Texas School of Social Work, Austin, TX

*Public outreach initiatives by CPDD: Past and future*

Marc J. Kaufman, McLean Hospital, Belmont, MA

**Workshop VII**

**BALLROOM B  
7:00 - 9:00 PM**

**HIGH RISK AND UNDERSTUDIED: ASSESSING ABUSE LIABILITY  
IN OPIOID-DEPENDENT SUBJECTS**

Chairs: Sandra Comer and Kerri Schoedel

*Evaluating abuse potential in the context of opioid dependence: Critical methodological  
considerations*

Sharon L. Walsh, University of Kentucky College of Pharmacy, Lexington, KY



*The assessment of tramadol's pharmacological profile as an example of abuse liability testing in humans*

Eric C. Strain, Johns Hopkins University School of Medicine, Baltimore, MD

*The use of opioid-dependent subjects to test abuse potential of agonist/antagonist ADFs: Contrast with recreational users*

Naama Levy-Cooperman, Altreos Research Partners, Inc., Toronto, ON, Canada

*Discussant: Role of agonist efficacy in abuse liability testing among opioid-dependent participants*

Sandra Comer, Columbia University and NYSPI, New York, NY

### Workshop VIII

**BALLROOM C**

**7:00 - 9:00 PM**

#### **EATING DISORDERS, ADDICTIONS AND SUBSTANCE USE DISORDERS: RESEARCH, CLINICAL AND TREATMENT ASPECTS**

Chairs: Timothy Brewerton and Therese Killeen

*Eating disorders, addictions and substance use disorders: Research, clinical and treatment aspects I*

Timothy Brewerton, Medical University of South Carolina, Mt. Pleasant, SC

*Eating disorders, addictions and substance use disorders: Research, clinical and treatment aspects II*

A Matthews, The EMMES Corporation, Rockville, MD

*Eating disorders, addictions and substance use disorders: Research, clinical and treatment aspects III*

Therese Killeen, Medical University of South Carolina, Charleston, SC

### Workshop IX

**AUDITORIUM**

**7:00 - 9:00 PM**

#### **ADVANCES IN ADOLESCENT RECOVERY RESEARCH**

Chairs: Michael L. Dennis and John F. Kelly

*The role of 12-step mutual-help organizations in youth recovery: Benefits, moderators, and mechanisms*

John F. Kelly, Massachusetts General Hospital, Boston, MA

*Recovery schools as an aftercare pathway*

Ken Winters, University of Minnesota, Minneapolis, MN

*Using smartphones to manage adolescent recovery*

Michael L. Dennis, Chestnut Health Systems, Normal, IL

*Long-term trajectories of adolescent recovery and the factors that predict them*

Sandra A. Brown, University of California San Diego, La Jolla, CA

*Developing more recovery oriented systems of care for adolescents*

Westley Clark, SAMHSA Center for Substance Abuse Treatment, Rockville, MD

Chair: Steven W. Gust

**BASIC SCIENCE**

100. *Human pharmacology of mephedrone: A dose-finding pilot study*  
M. Farré<sup>1,2</sup>, E. Papaseit<sup>1,2</sup>, C. Pérez-Mañá<sup>1,2</sup>, M. Pujadas<sup>1</sup>, F. Fonseca<sup>1</sup>, M. Torrens<sup>1,2</sup>, R. de la Torre<sup>1,3</sup>. <sup>1</sup>Hospital del Mar Medical Research Institute-IMIM and Drug Addiction Unit, Parc de Salut Mar, Spain; <sup>2</sup>Universidad Autónoma de Barcelona, Spain; <sup>3</sup>Universidad Pompeu Fabra, Spain
101. *Brain perfusion and neurocognitive performance during cocaine withdrawal in patients with suicidal and depressive symptoms*  
C. Ibañez<sup>1</sup>, T. Massardo<sup>1</sup>, J. Véliz<sup>1</sup>, J. Pallavicini<sup>1</sup>, R. Jaimovich<sup>2</sup>, R. Fernández<sup>1</sup>, P. Flores<sup>2</sup>, M. Servat<sup>1</sup>, R. Chandía<sup>1</sup>, J. Pereira<sup>2</sup>. <sup>1</sup>Universidad de Chile, Chile; <sup>2</sup>Pontificia Universidad Católica de Chile, Chile
102. *Pharmacology and anti-addiction effects of Mesyl Sal B: A potent and long-acting analogue of Salvinorin A*  
B.M. Kivell<sup>1</sup>, B. Simonson<sup>1</sup>, A.S. Morani<sup>1</sup>, N. Kumar<sup>1</sup>, D. Simpson<sup>2</sup>, T.E. Prisinzano<sup>2</sup>. <sup>1</sup>School of Biological Science, Centre for Biodiscovery, Victoria University of Wellington, New Zealand; <sup>2</sup>Department of Medicinal Chemistry, University of Kansas, United States
103. *Neurochemical and behavioral profile of a rat model of depression and methamphetamine addiction comorbidity*  
J. Kucerova<sup>1,2</sup>, P. Amchova<sup>1,2</sup>, Z. Babinska<sup>1,2</sup>, T. Havlickova<sup>3</sup>, P. Jerabek<sup>3</sup>, P. Kacer<sup>4</sup>, M. Sustkova<sup>3</sup>, A. Sulcova<sup>1</sup>. <sup>1</sup>Central European Institute of Technology, Masaryk University, Czech Republic; <sup>2</sup>Department of Pharmacology, Masaryk University, Czech Republic; <sup>3</sup>Department of Pharmacology, Charles University, Czech Republic; <sup>4</sup>Institute of Chemical Technology, Czech Republic
104. *Role of deep brain stimulation of medial prefrontal cortex on heroin-seeking behavior in rats*  
H. Liu, J. Chen, H. Zhu, A. Sun, M. Lai, W. Chen, F. Zhang, W. Zhou. Ningbo Addiction Research and Treatment Center, China

105. *Molecular diversity of HIV-1 among drug users in Kenya*  
M.O. Oyaró<sup>1</sup>, N. Padayachee<sup>2,3</sup>, K. Hiramén<sup>2,3</sup>, T. Ndung'u<sup>2,3</sup>, K. Gounder<sup>2,3</sup>, J. Wylie<sup>4</sup>.  
<sup>1</sup>Immunology Unit, Department of Human Pathology, University of Nairobi, Kenya; <sup>2</sup>HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, South Africa; <sup>3</sup>KwaZulu-Natal Research Institute for Tuberculosis and HIV, South Africa; <sup>4</sup>Medical Microbiology Department, University of Manitoba, Canada
106. *Effect of nalbuphine on motor activity in opiate-dependent rats*  
R. Raghav<sup>1</sup>, R. Jain<sup>1</sup>, T.S. Roy<sup>2</sup>, A. Dhawan<sup>1</sup>, P. Kumar<sup>1</sup>. <sup>1</sup>National Drug Dependence Treatment Centre, India; <sup>2</sup>Department of Anatomy, All India Institute of Medical Sciences, India
107. *Xylazine as a drug of abuse: Toxic effects to endothelial cells in combination with cocaine and heroin*  
L.A. Silva-Torres<sup>1,2</sup>, C. Vélez<sup>3</sup>, J. Vargas-Vidot<sup>4</sup>, J.G. Ortiz<sup>1</sup>, B. Zayas<sup>1,3</sup>.  
<sup>1</sup>Pharmacology and Toxicology Department, School of Medicine, Medical Science Campus, University of Puerto Rico, United States; <sup>2</sup>Puerto Rico Institute of Forensic Science, United States; <sup>3</sup>School of Environmental Affairs, Universidad Metropolitana, United States; <sup>4</sup>Iniciativa Comunitaria, United States
108. *A transgenerational ripple: How a puff during early development led to a global huff in microRNA profiles as well as grand-offspring addictive behavior in *Caenorhabditis elegans**  
F. Taki, X. Pan, B. Zhang. East Carolina University, United States
109. *Chronic administration of ketamine mimics the perturbed sense of body ownership associated with schizophrenia*  
J. Tang<sup>1</sup>, H.L. Morgan<sup>2</sup>, Y. Liao<sup>1</sup>, P.R. Corlett<sup>3</sup>, D. Wang<sup>1</sup>, H. Li<sup>1</sup>, Y. Tang<sup>4</sup>, J. Chen<sup>1</sup>, T. Liu<sup>1</sup>, W. Hao<sup>1</sup>, P.C. Fletcher<sup>2</sup>, X. Chen<sup>1,5</sup>. <sup>1</sup>Institute of Mental Health, the Second Xiangya Hospital, Central South University, China; <sup>2</sup>Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, United Kingdom; <sup>3</sup>Department of Psychiatry, Ribicoff Research Facility, Yale University, Connecticut Mental Health Center, United States; <sup>4</sup>Department of Psychiatry, The First Affiliated Hospital, China Medical University, China; <sup>5</sup>The State Key Laboratory of Medical Genetics, Central South University, China
110. *Unique and common neurocognitive effects of opiate and stimulant dependence persist with protracted abstinence*  
J. Vassileva<sup>1</sup>, F.G. Moeller<sup>2</sup>, K. Bozgunov<sup>3</sup>, M. Wilson<sup>1</sup>, G. Vasilev<sup>3</sup>. <sup>1</sup>University of Illinois at Chicago, United States; <sup>2</sup>Virginia Commonwealth University, United States; <sup>3</sup>Bulgarian Addictions Institute, Bulgaria

111. *Alpha-1 adrenergic receptor modulation of ventral tegmental area dopamine neurons: Role in cocaine sensitization*  
M.C. Velásquez-Martínez<sup>1,2</sup>, B. Santos-Vera<sup>1</sup>, R. Vázquez-Torres<sup>1</sup>, C.A. Jiménez-Rivera<sup>1</sup>. <sup>1</sup>Department of Physiology, Medical Sciences Campus, University of Puerto Rico, United States; <sup>2</sup>Department de Ciencias Básicas, Escuela de Medicina, Universidad Industrial de Santander, Colombia
112. *Dorsal raphe serotonergic projections play a critical role in cocaine escalation*  
M.M.M. Verheij<sup>1,2</sup>, C. Contet<sup>2</sup>, P. Karel<sup>1</sup>, J. Latour<sup>1</sup>, R.H.A. van der Doelen<sup>3</sup>, T. Kozicz<sup>3</sup>, J.R. Homberg<sup>1</sup>, G.F. Koob<sup>2</sup>. <sup>1</sup>Department of Cognitive Neuroscience, Radboud University Nijmegen Medical Centre, The Netherlands; <sup>2</sup>Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, United States; <sup>3</sup>Department of Cellular Animal Physiology, Radboud University Nijmegen, The Netherlands
113. *Acute combined low/high bursts stimulation of the lateral habenula attenuates cue-induced heroin-seeking in rats*  
F. Zhang, S. Yang, H. Zhu, H. Liu, J. Gu, W. Zhou. Laboratory of Behavioral Neuroscience, Ningbo Addiction Research and Treatment Center, School of Medicine, Ningbo University, China
114. *Neuroimaging of adolescent drug users: Magnetic resonance spectroscopy metabolites variance in the anterior cingulate cortex reflects individual differences in personality traits*  
G. Zoccatelli<sup>1,2</sup>, F. Alessandrini<sup>1</sup>, C. Rimondo<sup>2</sup>, G. Serpelloni<sup>2,3</sup>. <sup>1</sup>University Hospital of Verona, Italy; <sup>2</sup>Addiction Department, ULSS 20 Verona, Italy; <sup>3</sup>Antidrug Policies Department, Presidency of the Council of Ministers, Italy
115. *Characterization of the effects of  $\alpha 4\beta 2^*$  nACh receptor partial agonist cytisine in the two-choice serial reaction time task*  
E.E. Zvartau, G.S. Makshakov, O.A. Dravolina, A.Y. Beshpalov, E.S. Kayukova, M.V. Dorofeikova. Valdman Institute of Pharmacology, First Pavlov State Medical University, Russia

## EPIDEMIOLOGY

200. *Access to services for women with addiction in Eastern Europe*  
A.O. Abagiu<sup>1</sup>, P. Dolezalova<sup>2</sup>, Z. Alexandercikova<sup>3</sup>, J.K. Csorba<sup>4</sup>, V. Bogdanova<sup>5</sup>, B. Habrat<sup>6</sup>, A. Ivancic<sup>7</sup>, A. Kastelici<sup>8</sup>. <sup>1</sup>National Institute for Infectious Diseases Prof. Dr. Matei Bals, ARENA OST Center, Romania; <sup>2</sup>Clinic of Addictology, Medical Faculty, Charles University, Czech Republic; <sup>3</sup>Center for Treatment of Drug Dependencies, Slovakia; <sup>4</sup>Drug Outpatient and Prevention Center, Nyiro Gyula Hospital, Hungary; <sup>5</sup>National Center for Addictions, Drug Demand Reduction Department, Bulgaria; <sup>6</sup>Institute of Psychiatry and Neurology, Poland; <sup>7</sup>Center for Addiction Treatment, Croatia; <sup>8</sup>Center for Treatment of Drug Addiction, University Psychiatric Hospital, Slovenia

201. *Effect of cigarette smoking on blood sugar*  
R.I. Aqrawi. Research Department, Ministry of Health–Kurdistan, Iraq
202. *Prevalence of cigarette smoking or other form of tobacco use among university students*  
F. Bautista-Pérez. Research Department, Universidad Evangélica de El Salvador, El Salvador
203. *Risk of tobacco dependence for early and late alcohol first users in Peru*  
A. Burela<sup>1</sup>, J. Beltran<sup>1</sup>, M. Piazza<sup>1,2</sup>, F. Fiestas<sup>1</sup>. <sup>1</sup>National Institute of Health, Peru; <sup>2</sup>Universidad Peruana Cayetano Heredia, Peru
204. *Monitoring drug use through the Internet*  
L. Burns, J. Van Buskirk, A. Roxburgh. National Drug and Alcohol Research Centre, University of New South Wales, Australia
205. *Tobacco use and exposure to secondhand smoke in Mexican pregnant women*  
O. Campollo<sup>1</sup>, F. Hernandez<sup>2</sup>, E. Angulo<sup>3</sup>, A. Guzman<sup>2</sup>, A. Munguía<sup>1</sup>, M. García<sup>1</sup>, J.K. Cunningham<sup>4</sup>. <sup>1</sup>Center of Studies on Alcohol and Addictions, CUCS, Universidad de Guadalajara, Hospital Civil de Guadalajara, Mexico; <sup>2</sup>Obstetrics Department, Antiguo Hospital Civil de Guadalajara, Mexico; <sup>3</sup>Neonatology Department, Antiguo Hospital Civil de Guadalajara, Mexico; <sup>4</sup>Department of Family and Community Medicine, The University of Arizona, United States
206. *Trend of accident-related health care expenditures in patients receiving treatment for opioid abuse or dependence in Taiwan*  
Y-J. Chang<sup>1</sup>, C-Y. Peng<sup>2</sup>, C-H. Muo<sup>3</sup>. <sup>1</sup>National Taiwan Normal University, Taiwan; <sup>2</sup>University of California, Los Angeles, United States; <sup>3</sup>China Medical University Hospital, Taiwan
207. *Recent cannabis use among adolescent immigrants in The Netherlands—role of acculturation*  
M.J. Delforterie<sup>1,2</sup>, H.E. Creemers<sup>1,2</sup>, A.C. Huizink<sup>1</sup>. <sup>1</sup>Institute for Health and Care Research (EMGO), Vrije Universiteit (VU University), The Netherlands; <sup>2</sup>Research Institute of Child Development and Education, University of Amsterdam, The Netherlands
208. *Patterns of use of marijuana among university students in Bolivia, Colombia, Ecuador, and Peru*  
M. Demarco<sup>1</sup>, M. Hynes<sup>2</sup>, J.C. Araneda<sup>3</sup>, F. Cumsille<sup>1</sup>. <sup>1</sup>Inter-American Observatory on Drugs, Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), United States; <sup>2</sup>Latin American Network of Researchers on Drugs (REDLA), CICAD, OAS, United States; <sup>3</sup>Global Synthetics Monitoring: Analyses, Reporting and Trends (SMART) Programme–Latin America, United Nations Office on Drugs and Crime, Chile

209. *Secondhand smoke exposure among working women in a developing country: The Jordanian case*  
O. El-Shahawy<sup>1,2</sup>, L. Haddad<sup>3</sup>. <sup>1</sup>School of Medicine, Virginia Commonwealth University, United States; <sup>2</sup>General Medical Management, Ain Shams University, Egypt; <sup>3</sup>School of Nursing, Virginia Commonwealth University, United States
210. *Increased emergency department visits associated with tramadol abuse are correlated with opioid-related overdose death in the United States*  
F. Fang<sup>1</sup>, Y. Wang<sup>2</sup>, J. Wu<sup>1</sup>. <sup>1</sup>University of North Carolina, United States; <sup>2</sup>Capital Medical University, China
211. *Male and female differences in the prevalence of ever use of illegal drugs in Peru*  
F. Fiestas<sup>1</sup>, J. Beltran<sup>1</sup>, A. Burela<sup>1</sup>, M. Piazza<sup>1,2</sup>. <sup>1</sup>Instituto Nacional de Salud, Peru; <sup>2</sup>Universidad Peruana Cayetano Heredia, Peru
212. *Measuring altruistic and solidaristic orientations toward others among people who inject drugs*  
S.R. Friedman<sup>1</sup>, E.R. Pouget<sup>1</sup>, M. Sandoval<sup>1</sup>, Y. Jones<sup>1</sup>, G. Nikolopoulos<sup>2</sup>, P. Mateu-Gelabert<sup>1</sup>. <sup>1</sup>Institute for Infectious Disease Research, National Development and Research Institutes, Inc., United States; <sup>2</sup>Transmission Reduction Intervention Project, Greece
213. *Urinary cannabis detection and mortality in a cohort of patients admitted for hospital detoxification*  
D. Fuster<sup>1</sup>, A. Sanvisens<sup>1</sup>, P. Zuluaga<sup>1</sup>, J. Tor<sup>1</sup>, I. Rivas<sup>2</sup>, R. Muga<sup>1</sup>. <sup>1</sup>Internal Medicine Service, Hospital Germans Trias i Pujol, Spain; <sup>2</sup>Municipal Centre for Substance Abuse Treatment, Centro Delta, IMSP, Spain
214. *A successful strategy for estimating the consumption of needles and syringes by Czech injecting drug users*  
R. Gabrhelík, J. Vacek, J. Mišta. Department of Addictology, Charles University in Prague, Czech Republic
215. *A complex image of social influences on adolescents' illicit substance use*  
A. Gardikiotis<sup>1,2</sup>, D.W. Crano<sup>2</sup>. <sup>1</sup>Aristotle University of Thessaloniki, Greece; <sup>2</sup>Claremont Graduate University, United States
216. *Follow-up of crack users after hospital discharge based on probabilistic record linkage methodology*  
V.M. Gonçalves<sup>1,2,3</sup>, R.S. Pedroso<sup>1,2</sup>, A.M. dos Santos<sup>3</sup>, F. Pechansky<sup>1,2</sup>. <sup>1</sup>Center for Drug and Alcohol Research, Universidade Federal do Rio Grande do Sul, Brazil; <sup>2</sup>Hospital de Clinicas de Porto Alegre–Prof. Álvaro Alvim, Brazil; <sup>3</sup>Informatics Department, Ministry of Health, Brazil

217. *Prevalence and psychosocial correlates of Internet addiction among university students: A cross-sectional study*  
S.H. Hassaan<sup>1,2</sup>, K.A. Elbeh<sup>1</sup>. <sup>1</sup>Department of Psychiatry, Assiut University, Egypt; <sup>2</sup>Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
218. *A needs assessment study for the community of Cité Beau-Vallon, Mauritius*  
M. Hennequin. Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
219. *Betel quid chewing, cigarette smoking, and alcohol consumption associate differently with metabolic biomarkers*  
Y-W. Hsu<sup>1</sup>, H-Y. Li<sup>2</sup>, J-N. Wei<sup>1</sup>. <sup>1</sup>Chia Nan University of Pharmacy and Science, Taiwan; <sup>2</sup>Department of Internal Medicine, National Taiwan University, Taiwan
220. *Online peer influence on Facebook, substance use attitudes, and offline behaviors among university students*  
M.A. Jules<sup>1</sup>, D.M. Maynard<sup>1</sup>, N. Coulson<sup>2</sup>. <sup>1</sup>University of the West Indies, Barbados; <sup>2</sup>University of Nottingham, United Kingdom
221. *Illicit drug use in Hunan Province, China: A profile of Chinese drug users in the general population*  
Y. Liao<sup>1</sup>, J. Tang<sup>1</sup>, J. Wang<sup>2</sup>, T. Liu<sup>1</sup>, W. Hao<sup>1</sup>, X. Chen<sup>1</sup>. <sup>1</sup>Mental Health Institute, the Second Xiangya Hospital of Central South University, China; <sup>2</sup>Children's National Medical Center, George Washington University, United States
222. *Prevalence of khat use among Ethiopian HIV patients newly enrolled in care: Preliminary results*  
A. Lifson<sup>1</sup>, S. Workneh<sup>2</sup>, H. Tekle<sup>2</sup>, B. Dame<sup>2</sup>, L. Bezabih<sup>2</sup>, K. Winters<sup>1</sup>, L. Slater<sup>3</sup>, T. Shenie<sup>2</sup>. <sup>1</sup>University of Minnesota, United States; <sup>2</sup>Ethiopian National Alliance of State and Territorial AIDS Directors, Ethiopia; <sup>3</sup>Global Program National Alliance of State and Territorial AIDS Directors, United States
223. *Smoking behavior among college students of Bolivia*  
R.G. Lopez. School of Psychology, Universidad Mayor de San Andres, Bolivia
224. *Effects of immigration to the United States on alcohol, tobacco, and cannabis use among Colombian adolescents*  
C. Lopez-Quintero, M. De La Rosa. The Center for Research on United States Latino HIV/AIDS and Drug Abuse, Florida International University, United States
225. *Brazilian crack cocaine users: Preliminary results from a nationwide survey*  
M. Malta<sup>1</sup>, N. Bertoni<sup>2</sup>, F.I. Bastos<sup>2</sup>. <sup>1</sup>Social Science Department, Sergio Arouca School of Public Health, Oswaldo Cruz Foundation, Brazil; <sup>2</sup>Institute of Scientific and Technological Communication and Information in Health, Oswaldo Cruz Foundation, Brazil

226. *Development of the Multidimensional Attitudes Scale (2013) for measuring attitudes toward persons who abuse drugs in Latin America and the Caribbean*  
P.M. Martin<sup>1</sup>, R. Basden<sup>2</sup>, A. McKay<sup>3</sup>, A.D. Gallassi<sup>4</sup>, P.J. Concha<sup>5</sup>, C.A.D. Rivera<sup>6</sup>, S.A.A. Haughton<sup>7</sup>, T.D.J. Aleman Rivera<sup>8</sup>, R.F.P. Olano<sup>9</sup>, I.R. Bakari<sup>10</sup>, R. Mann<sup>11</sup>, B. Brands<sup>11</sup>, H. Hamilton<sup>11</sup>, A. Kenti<sup>11</sup>, G. Wright<sup>12</sup>, I. Padilla<sup>12</sup>. <sup>1</sup>University of Guyana, Guyana; <sup>2</sup>University of the West Indies–Bahamas Campus, Bahamas; <sup>3</sup>University of Belize, Belize; <sup>4</sup>University of Brasilia, Brazil; <sup>5</sup>University of Concepcion, Chile; <sup>6</sup>Council for Control of Narcotic and Psychotropic Substances, Ecuador; <sup>7</sup>University of the West Indies–Mona Campus, Jamaica; <sup>8</sup>National Autonomous University of Nicaragua, Nicaragua; <sup>9</sup>Universidad Peruana Cayetano Heredia, Peru; <sup>10</sup>University of the Southern Caribbean, Trinidad and Tobago; <sup>11</sup>Center for Addiction and Mental Health, Canada; <sup>12</sup>Inter-American Observatory on Drugs, Inter-American Drug Abuse Control Commission, United States
227. *Pattern of drug abuse among street children in Dhaka City*  
J.H.B. Masud. Diabetic Association of Bangladesh, Bangladesh
228. *Heroin production in Colombia: A time-bomb for a drug injection-driven HIV epidemic in Colombia?*  
P. Mateu-Gelabert<sup>1</sup>, D. Berbesi<sup>2</sup>, I.E.M. Motta<sup>3,4</sup>, H. Guarino<sup>1</sup>, S. Harris<sup>1</sup>. <sup>1</sup>National Development and Research Institutes, Inc., United States; <sup>2</sup>CES University, Colombia; <sup>3</sup>Pan American Health Organization, Columbia; <sup>4</sup>Colombian Ministry of Health, Colombia
229. *Barriers to accessing opioid substitution therapy among drug injectors in Ukraine*  
A. Mazhnaya<sup>1</sup>, M.J. Bojko<sup>2</sup>, J. Makarenko<sup>3</sup>, R. Marcus<sup>2</sup>, S. Dvoryak<sup>3</sup>, Z. Islam<sup>1</sup>, F.L. Altice<sup>2</sup>. <sup>1</sup>ICF International HIV/AIDS Alliance, Ukraine; <sup>2</sup>School of Medicine AIDS Program, Yale University, United States; <sup>3</sup>Ukrainian Institute for Public Health Policy, Ukraine
230. *Application of outreach strategies to international collaborative research*  
C.B. McCoy, V. McCoy, J. McCoy-Bengoa, D.C. McBride, R. Achi, S. Lai, M. Zhao, J.M. Shultz. Department of Public Health, University of Miami, United States
231. *Female cocaine users are at excess risk of becoming cocaine dependent soon after onset of cocaine use: Estimates for the United States, 2002–2011*  
A.M. Mohammed, J.C. Anthony. Research Training in Drug Dependence Epidemiology Program, Michigan State University, United States
232. *Epidemiological and social factors of drug problems and other addictive behaviors in Spain*  
A.J. Molina Fernández<sup>1</sup>, F. Rueda<sup>1</sup>, M.J. Fernández-Serrano<sup>2</sup>, E. Rueda<sup>1</sup>, B. Aragonés<sup>1</sup>, C. Mora<sup>1</sup>. <sup>1</sup>Universidad Complutense de Madrid, Spain; <sup>2</sup>University of Jaen, Spain



233. *Disease outcomes in non-injecting cocaine-dependent patients seeking drug treatment in Barcelona, Spain*  
R. Muga<sup>1,2</sup>, M. Torrens<sup>2,3</sup>, P. Zuluaga<sup>1,2</sup>, D. Fuster<sup>1</sup>, F. Fonseca<sup>2,3</sup>, F. Bolao<sup>4,5</sup>, M. Pineda<sup>1</sup>, I. Rivas<sup>6</sup>, J. Tor<sup>1,2</sup>, A. Sanvisens<sup>1</sup>. <sup>1</sup>Hospital Universitari Germans Trias i Pujol, Spain; <sup>2</sup>Universitat Autònoma de Barcelona, Spain; <sup>3</sup>Parc de Salut Mar, Spain; <sup>4</sup>Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain; <sup>5</sup>Universitat de Barcelona, Spain; <sup>6</sup>Municipal Center for Substance Abuse Treatment (Centro Delta) IMSP, Spain
234. *Cannabis use and criminal behavioral tendencies in young people: A study of Kaduna State, Nigeria*  
M.O. Onoja<sup>1</sup>, A. Okoh<sup>2</sup>, J.A. Ocheh<sup>1</sup>. <sup>1</sup>National Primary Health Care Development Agency, Nigeria; <sup>2</sup>University of Jos–Plateau State, Nigeria
235. *Herbal incenses, seizure latency, and anxiety*  
J.G. Ortiz<sup>1</sup>, E.A. Suárez-Zayas<sup>2</sup>, J.A. Peña Jiménez<sup>3</sup>. <sup>1</sup>Department of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, United States; <sup>2</sup>Universidad Metropolitana–Cupey, United States; <sup>3</sup>University of Puerto Rico–Río Piedras, United States
236. *Psychiatric symptoms in a sample of young, sexual minority Brazilian ecstasy and LSD users*  
F. Pechansky<sup>1</sup>, L.S. Remy<sup>1</sup>, F. Kessler<sup>1</sup>, L. Guimarães<sup>1</sup>, H.L. Surratt<sup>2</sup>, S. Kurtz<sup>2</sup>. <sup>1</sup>Center for Drug and Alcohol Research, Hospital of Clinics of Porto Alegre, Federal University of Rio Grande do Sul, Brazil; <sup>2</sup>Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, United States
237. *Association between highly active antiretroviral therapy nonadherence and tobacco use in women living with human immunodeficiency virus in public hospital in Lima, Peru*  
R.F. Pena-Olano<sup>1</sup>, H. Maldonado-Ruiz<sup>1</sup>, J.C. Bazo<sup>1</sup>, J. Echevarría<sup>1,2,3</sup>, E. Gotuzzo<sup>1,2,3</sup>. <sup>1</sup>Cayetano Heredia University, Peru; <sup>2</sup>Cayetano Heredia National Hospital, Peru; <sup>3</sup>Institute of Tropical Medicine “Alexander Von Humboldt”, Peru
238. *Sex-related variation in patterns of tobacco dependence, alcohol, and drug abuse in the world mental health study in Peru*  
M. Piazza<sup>1,2</sup>, F. Fiestas<sup>1</sup>, A. Burela<sup>1</sup>, J. Beltran<sup>1</sup>. <sup>1</sup>National Institute of Health, Peru; <sup>2</sup>Universidad Peruana Cayetano Heredia, Peru
239. *Tobacco chewing practice and oral health status of truck drivers of Karachi*  
A. Qureshi, A. Younus, N. Dawani. Department of Community Dentistry, Dr. Ishratulebad Khan Institute of Oral Health Sciences, Dow University of Health Sciences, Pakistan

240. *Prevalence and correlates of neck injection among people who inject drugs in Tijuana, Mexico*  
C. Rafful<sup>1,2</sup>, K. Wagner<sup>1</sup>, P. Gonzalez-Zuniga<sup>1</sup>, G. Rangel<sup>1</sup>, S. Verdugo<sup>1</sup>, S.A. Strathdee<sup>1</sup>. <sup>1</sup>University of California, San Diego, United States; <sup>2</sup>San Diego State University, United States
241. *Prevalence of prohibited drug use in the Philippines*  
L.S.Ramiro. Department of Clinical Epidemiology, University of the Philippines, Philippines
242. *Energy drink consumption and its association with substance abuse among college students in St. Petersburg, Russia*  
M. Rusakova<sup>1,2</sup>, V. Odinkova<sup>2</sup>, P. Dillon<sup>3</sup>, D. Svikis<sup>3</sup>. <sup>1</sup>St. Petersburg State University, Russia; <sup>2</sup>NGO Stellit, Russia; <sup>3</sup>Addiction and Women's Health: Advancing Research and Evaluation Program, Virginia Commonwealth University, United States
243. *Temperament and Lesch typology in the context of alcohol and heroin dependence*  
B. Salem<sup>1,2,3</sup>, O. Lesch<sup>3</sup>. <sup>1</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, United States; <sup>2</sup>Amal Hospital, Saudi Arabia; <sup>3</sup>Department of Psychiatry and Psychotherapy, Vienna Medical University, Austria
244. *Association of intimate partner violence with cigarette smoking before and during pregnancy, 2004–2008 births*  
S. Salimi<sup>1</sup>, M. Terplan<sup>2</sup>, M. Chisolm<sup>3</sup>, D. Cheng<sup>4</sup>. <sup>1</sup>Department of Medicine, School of Medicine, University of Maryland, United States; <sup>2</sup>Department of Obstetrics, Gynecology and Reproductive Sciences and Department of Epidemiology and Public Health, School of Medicine, University of Maryland, United States; <sup>3</sup>Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, United States; <sup>4</sup>Maternal and Child Health Bureau, Maryland Department of Health and Mental Hygiene, United States
245. *Methorphan in street heroin: Issues and challenges of the identification of a chiral compound in cases of opiate overdose in Italy*  
G. Serpelloni<sup>1</sup>, C. Rimondo<sup>2</sup>, C. Seri<sup>2,3</sup>, M. Cavallini<sup>2</sup>, S. Strano Rossi<sup>4</sup>, F. Bortolotti<sup>3</sup>, R. Gottardo<sup>3</sup>, G. Musile<sup>3</sup>, F. Tagliaro<sup>3</sup>. <sup>1</sup>Department for Antidrug Policies, Presidency of the Council of Ministers, Italy; <sup>2</sup>National Early Warning System, Department for Antidrug Policies, Presidency of the Council of Ministers, Italy; <sup>3</sup>Department of Public Health and Community Medicine, Unit of Forensic Medicine, University of Verona, Italy; <sup>4</sup>Institute of Legal Medicine, Catholic University of Sacred Heart, Italy
246. *Khat chewing and oral health status: A cross-sectional study on patients attending dental hospital in Jazan region*  
K.A. Sheikh<sup>1</sup>, M. El-Setouhy<sup>1</sup>, R. Alsanosy<sup>1</sup>, A.M. Al-Zailai<sup>2</sup>. <sup>1</sup>Medical Research Center, Jazan University, Saudi Arabia; <sup>2</sup>Jazan Dental Center, Jazan Province, Saudi Arabia

247. *Do females and males behave differently on the road under the influence of alcohol and other drugs?*  
T. Sousa<sup>1</sup>, G. Pasa<sup>1</sup>, J. Lunnen<sup>2</sup>, F. Pechansky<sup>2</sup>. <sup>1</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil; <sup>2</sup>Johns Hopkins International Injury Research Unit, Bloomberg School of Public Health, Johns Hopkins University, United States
248. *Early evaluation of the experiences and opinions of pharmacists towards the Ontario Narcotics Monitoring System*  
B. Sproule<sup>1,2</sup>, K. Liu<sup>1,2</sup>, J. Chundamala<sup>1</sup>. <sup>1</sup>Centre for Addiction and Mental Health, Canada; <sup>2</sup>University of Toronto, Canada
249. *HIV risk-taking behaviors and psychological status among methadone patients using benzodiazepine in Jakarta*  
H. Susami<sup>1</sup>, D. Utami<sup>2</sup>, R. Sarasvita<sup>3</sup>, A. Nurhidayat<sup>4</sup>, M. Chawarski<sup>5</sup>, G. Woody<sup>6</sup>, D. Metzger<sup>6</sup>. <sup>1</sup>Special Working Group on HIV/AIDS, Faculty of Medicine, University of Indonesia, Indonesia; <sup>2</sup>The Indonesian National Narcotics Board, Indonesia; <sup>3</sup>Drug Abuse Division, Ministry of Health of Indonesia, Indonesia; <sup>4</sup>Drug Dependence Hospital RSKO–Jakarta, Indonesia; <sup>5</sup>Department of Psychiatry, Yale University, United States; <sup>6</sup>Department of Psychiatry, University of Pennsylvania, United States
250. *Socio-demographic and clinical characteristics of crack cocaine consumer pregnant and puerperal women*  
C.M. Szobot<sup>1</sup>, V. Mardini<sup>1</sup>, G. Bocchese da Cunha<sup>2</sup>, S.H.D.A. Martins-Costa<sup>1</sup>, F. Guarienti<sup>1</sup>, L. Manna<sup>3</sup>, T.G. Pianca<sup>1</sup>, F. Pechansky<sup>1</sup>, L.A.P. Rohde<sup>1</sup>, F. Kapczinski<sup>1</sup>, K. Cereser<sup>1</sup>, M. L. Zavaschi<sup>1</sup>. <sup>1</sup>Federal University of Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Brazil; <sup>2</sup>Hospital Materno Infantil Presidente Vargas, Brazil; <sup>3</sup>Lutheran University, Brazil
251. *Substance-related knowledge and attitudes among adolescents in Kosovo*  
Z. Tahiri, I. Mecini, V. Hashani. Main Family Medicine Center, Kosovo
252. *Police bribery and access to methadone maintenance therapy within the context of drug policy reform in Tijuana, Mexico*  
D. Werb<sup>1</sup>, K. Wagner<sup>1</sup>, L. Beletsky<sup>1</sup>, P. Gonzalez-Zuniga<sup>1</sup>, G. Rangel<sup>1,2</sup>, M.E. Medina-Mora<sup>3</sup>, S. Strathdee<sup>1</sup>. <sup>1</sup>Division of Global Public Health, University of California, San Diego, United States; <sup>2</sup>El Colegio de la Frontera del Norte, Mexico; <sup>3</sup>Instituto Nacional de Psiquiatría Ramón de la Fuente, Mexico
253. *Female opioid users may be at excess risk of becoming dependent soon after extra medical prescription pain reliever use in adolescence but not in young adulthood: Estimates for the United States, 2002–2011*  
H-H. Yeh, J.C. Anthony. Department of Epidemiology and Biostatistics, Michigan State University, United States

254. *Detecting a signal in the noise: Results of a pilot project to monitor the global spread of new drugs by monitoring media*  
M.M Young<sup>1</sup>, C. Dubeau<sup>1</sup>, K. Diedrich<sup>1</sup>, O. Corazza<sup>2</sup>. <sup>1</sup>Canadian Centre on Substance Abuse, Canada; <sup>2</sup>Department of Postgraduate Medicine, School of Life and Medical Sciences, University of Hertfordshire, United Kingdom
255. *Viral hepatitis C and HIV in the Czech prison system: Prevalence, risk factors, and responses*  
T. Zabransky<sup>1</sup>, B. Janikova<sup>1</sup>, K. Grohmannova<sup>1</sup>, M. Krejdllova<sup>2</sup>. <sup>1</sup>Department of Addictology, Charles University, Czech Republic; <sup>2</sup>Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University, Czech Republic
256. *Social networks, spatial distance, and HIV risk among people who inject drugs in Malaysia*  
A. Zelenev<sup>1</sup>, E. Long<sup>2</sup>, A. Bazazi<sup>3</sup>, F.L. Altice<sup>1</sup>. <sup>1</sup>School of Medicine, Yale University, United States; <sup>2</sup>School of Management, University of California, Los Angeles, United States; <sup>3</sup>School of Public Health, Yale University, United States

## **OTHER**

300. *Lifetime substance use and medical costs among Baltimore medicare recipients*  
P. Alexandre, S. Wang, W.E. Eaton. Johns Hopkins University, United States
301. *Developing international information literacy competency standards for the addictions field*  
N. Bryant. James Branch Cabell Library, Virginia Commonwealth University, United States
302. *Analysis of policies affecting prevention and treatment of drug abuse in Burma (Myanmar)*  
N.P.E. Kham, R.L. Balster. Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
303. *The Hubert H. Humphrey Fellowship Program at Virginia Commonwealth University*  
J.R. Koch, R.L. Balster, A. Breland, L.D. Hedges. Virginia Commonwealth University, United States
304. *Virginia Commonwealth University Hubert H. Humphrey Fellowship in Substance Abuse Prevention, Treatment, and Policy: One-year follow-up assessment*  
O. Leonchuk<sup>1</sup>, J.R. Koch<sup>2</sup>, R.L. Balster<sup>2</sup>, A. Breland<sup>2</sup>. <sup>1</sup>North Carolina State University, United States; <sup>2</sup>Virginia Commonwealth University, United States
305. *Physical and economic risk environments for HIV in compulsory drug addiction treatment centers: A study in Yunnan, China*  
J. Meng<sup>1</sup>, S. Burris<sup>2</sup>. <sup>1</sup>Faculty of Law, Shantou University, China; <sup>2</sup>James E. Beasley School of Law, Temple University, United States

306. *International Society of Addiction Journal Editors (ISAJE)*  
R. Pates. ISAJE, United Kingdom

### PREVENTION

400. *Attitudes toward drug use mediated by social context and perception of drug effects among adolescents in Tijuana*  
N. Amador<sup>1</sup>, C. Rafful<sup>2,3</sup>, J. Villatoro<sup>1</sup>, M.E. Medina-Mora<sup>1</sup>. <sup>1</sup>Mexican National Institute of Psychiatry, Mexico; <sup>2</sup>University of California, San Diego, United States; <sup>3</sup>San Diego State University, United States
401. *Risk reduction in antidrug abuse campaign*  
R. Ariel<sup>1</sup>, V. Colondam<sup>1</sup>, R. Rokhim<sup>2</sup>, P.B. Hartanto<sup>2</sup>. <sup>1</sup>YCAB Foundation, Indonesia; <sup>2</sup>Universitas Indonesia, Indonesia
402. *Drug-using Tajikistan male migrants in Moscow: HIV risk behaviors, risk environment, and prevention needs*  
M. Bahromov<sup>1</sup>, S. Weine<sup>2</sup>, J. Jonbekov<sup>1</sup>, J. Levy<sup>2</sup>. <sup>1</sup>PRISMA Research Center, Tajikistan; <sup>2</sup>University of Illinois at Chicago, United States
403. *Recruiting for a Short Message Service smoking cessation intervention in Peru: Pilot study results*  
D. Blitchtein, K. Zevallos, R. Samolski, M. Ybarra, J.C. Anthony. Research Training in Drug Dependence Epidemiology Program, Michigan State University, United States
404. *Parents' self-fulfilling prophecy may influence children's substance use*  
W.D. Crano, C.S. Lamb. Claremont Graduate University, United States
405. *Barriers to entry into medical care and antiretroviral therapy adherence among HIV-positive substance users in San Salvador, El Salvador*  
J. Dickson-Gomez<sup>1</sup>, G. Bodnar<sup>2</sup>, W. Cuellar<sup>2</sup>, M.O. Zuniga<sup>2</sup>, V. Navas<sup>2</sup>, K. Johnson<sup>1</sup>. <sup>1</sup>Medical College of Wisconsin, United States; <sup>2</sup>Fundación Antidrogas de El Salvador, El Salvador
406. *Use trajectories of amphetamine-type stimulants in Shanghai, China*  
J. Du<sup>1</sup>, D. Huang<sup>2</sup>, M. Zhao<sup>1</sup>, Y-I. Hser<sup>2</sup>. <sup>1</sup>Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, China; <sup>2</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, United States
407. *Alcohol, drug abuse, and HIV infection among street children living in Kivulu slum in Kampala, Uganda*  
D. Elipu<sup>1</sup>, H. Nakatudde<sup>1</sup>, J. Kintu<sup>1</sup>, M. Aweko<sup>1</sup>, J. Akellot<sup>1</sup>, B. Ayikoru<sup>2</sup>. <sup>1</sup>Prevention of Alcohol, Drug Abuse, and HIV/AIDS Among Youth in Uganda, Uganda; <sup>2</sup>Ministry of Gender, Labour and Social Development, Uganda

408. *Uncomfortably numb: Substance use-associated elder mistreatment*  
D.V. Flores<sup>1,2,3</sup>, J. Burnett<sup>1,2,3</sup>, J. Booker<sup>2,4</sup>, C.B. Dyer<sup>1,2,3</sup>. <sup>1</sup>University of Texas Medical School at Houston, University of Texas Health, United States; <sup>2</sup>Texas Elder Abuse and Mistreatment Institute, United States; <sup>3</sup>Harris Health System, United States; <sup>4</sup>Adult Protective Services, United States
409. *Identifying undiagnosed HIV infections among crack users in the metropolitan area of San Salvador*  
L.R. Glasman<sup>1</sup>, J. Dickson Gomez<sup>1</sup>, J. Lechuga<sup>2</sup>, G. Bodnar<sup>3</sup>, L. Rivas de Mendoza<sup>4</sup>, M.O. Zuniga<sup>3</sup>. <sup>1</sup>Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, United States; <sup>2</sup>Department of Psychology, University of Texas at El Paso, United States; <sup>3</sup>Fundación Antidrogas de El Salvador, El Salvador; <sup>4</sup>Universidad Centroamericana “José Simeón Cañas,” El Salvador
410. *Study attrition among HIV-infected Russian risky drinkers*  
T. Kiriazova<sup>1,2,3</sup>, D.M. Cheng<sup>1</sup>, S.M. Coleman<sup>1</sup>, E. Blokhina<sup>4</sup>, E. Krupitsky<sup>4,5</sup>, M.C. Lira<sup>2</sup>, C. Briden<sup>2</sup>, A. Raj<sup>6</sup>, J.H. Samet<sup>1,2</sup>. <sup>1</sup>Boston University, United States; <sup>2</sup>Boston Medical Center, United States; <sup>3</sup>Future Without AIDS Foundation, Ukraine; <sup>4</sup>First St. Petersburg Pavlov State Medical University, Russia; <sup>5</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; <sup>6</sup>University of California, San Diego, United States
411. *Prevalence of pretreatment drug use among patients in a voluntary substance abuse treatment center in Malaysia*  
A. Krishnan<sup>1</sup>, S.E. Brown<sup>1</sup>, F. Khan<sup>1</sup>, M. Ghani<sup>1</sup>, A. Kamarulzaman<sup>2</sup>, F.L. Altice<sup>1</sup>. <sup>1</sup>Yale University, United States; <sup>2</sup>Centre of Excellence for Research in AIDS, University of Malaya, Malaysia
412. *Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: The hepatitis C incidence and transmission study*  
L. Maher<sup>1</sup>, B. White<sup>1</sup>, G.J. Dore<sup>1</sup>, A. Lloyd<sup>2</sup>, W. Rawlinson<sup>3</sup>. <sup>1</sup>The Kirby Institute, University of New South Wales (UNSW), Australia; <sup>2</sup>Inflammation and Infection Research Centre, School of Medical Sciences, UNSW, Australia; <sup>3</sup>Virology Division, SEALS Microbiology, Prince of Wales Hospital, Australia
413. *A review of substance abuse and related harms among indigenous women in Canada: Prevention, resilience, and treatment*  
D. Morisano<sup>1,2</sup>, R. Linklater<sup>1</sup>, S. Cunning<sup>1</sup>. <sup>1</sup>Centre for Addiction and Mental Health, Canada; <sup>2</sup>University of Toronto, Canada
414. *Personality disorders among patients with substance use disorders in a treatment facility in Lagos*  
C.C. Okonkwo, A. Bamisile, O.F. Ajiroto. Federal Neuropsychiatric Hospital, Nigeria

415. *Structural factors related to drug use and HIV vulnerability among men who have sex with men in the Mexico/Guatemala border region*  
E.R. Orellana<sup>1</sup>, C. Fernandez-Casanueva<sup>2</sup>, S. Morales-Miranda<sup>3</sup>, V.J. Mercer<sup>4</sup>, K.C. Brouwer<sup>4</sup>. <sup>1</sup>School of Social Work, Portland State University, United States; <sup>2</sup>Centro de Investigaciones y Estudios Superiores en Antropología Social, Mexico; <sup>3</sup>Universidad del Valle de Guatemala, Guatemala; <sup>4</sup>Division of Global Public Health, University of California, San Diego, United States
416. *Prevalence of illicit drug use among patients of community health centers in East Los Angeles and Tijuana*  
M. Rico<sup>1</sup>, M. Vahidi<sup>1</sup>, J. Scholtz<sup>1</sup>, M. Garcia<sup>1</sup>, G. Natera<sup>2</sup>, R. Andersen<sup>3</sup>, I. Bojorquez<sup>4</sup>, J. Yacenda<sup>1</sup>, M. Arroyo<sup>2</sup>, M. González<sup>5</sup>, L. Gelberg<sup>1,3</sup>. <sup>1</sup>Department of Family Medicine, University of California, Los Angeles, United States; <sup>2</sup>National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico; <sup>3</sup>School of Public Health, University of California, Los Angeles, United States; <sup>4</sup>Department of Population Studies, El Colegio de la Frontera Norte, Mexico; <sup>5</sup>Intersectoral Operations in Public Health, National Commission Against Addictions, Mexico
417. *Evaluation of the impact of the CHOICE program on truancy reduction among eighth graders in Chernihiv, Ukraine*  
V. Ryabukha. Chernihiv Region Charitable Organization “Aratta,” Ukraine
418. *Contraceptive practices and reproductive health needs among female sex workers who inject drugs in two Mexican-United States border cities*  
A. Servin. University of California, San Diego, United States
419. *A stepped-wedge randomized cluster trial assessing reductions in HIV risk and amphetamine-type stimulant use among women engaged in sex work in Cambodia*  
E. Stein<sup>1</sup>, J. Evans<sup>1</sup>, A. Carrico<sup>1</sup>, M. Sokunny<sup>2</sup>, C. Srean<sup>2</sup>, A. Weissman<sup>2</sup>, S. Ngak<sup>2</sup>, C. Sophal<sup>3</sup>, N. Yuthea<sup>4</sup>, L. Maher<sup>5</sup>, K. Page<sup>1</sup>. <sup>1</sup>University of California, San Francisco, United States; <sup>2</sup>FHI 360, Cambodia; <sup>3</sup>Royal Cambodian Government, Ministry of Health, Cambodia; <sup>4</sup>National Authority to Combat Drugs, Cambodia; <sup>5</sup>The Kirby Institute for Health and Immunity, University of New South Wales, Australia
420. *Results of the international ADHD in substance use disorder prevalence study*  
G. van de Glind<sup>1,2</sup>, W. van den Brink<sup>1</sup>, International Collaboration on ADHD and Substance Abuse (ICASA) Research Group<sup>2</sup>, F.R. Levin<sup>3</sup>. <sup>1</sup>University of Amsterdam, Netherlands; <sup>2</sup>ICASA, The Netherlands; <sup>3</sup>Columbia University, United States
421. *Factors associated with energy drinks among university students*  
F. Williams. Northern Caribbean University, Jamaica
422. *Factors associated with quality of life of Nicaraguan drug users in rehabilitation*  
P.I. Zeledon. Centre for Demographic Health Research, UNAN-León, Nicaragua

### TREATMENT

500. *A comparative study of retention rates for two dispensing regimens for buprenorphine for subjects with opioid dependence at a tertiary care substance use disorder treatment centre*  
Y.P.S. Balhara. Department of Psychiatry, National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, India
501. *The feasibility of implementing screening, brief intervention and referral to treatment in Peru*  
J. Beltran-Puerta<sup>1</sup>, J.P. Terashima<sup>1</sup>, K.A. Hoffman<sup>2</sup>, M. Calderón<sup>1</sup>, L. García<sup>1</sup>, F. Fiestas<sup>1</sup>, J. Muench<sup>2</sup>. <sup>1</sup>Peruvian National Institute of Health, Peru; <sup>2</sup>Oregon Health and Science University, United States
502. *Implantable and oral naltrexone for preventing relapse in opiate addicts: A psychometric evaluation*  
E. Blokhina<sup>1</sup>, E. Krupitsky<sup>1</sup>, N. Bushara<sup>1</sup>, T. Yaroslavtseva<sup>1</sup>, A. Tiurina<sup>1</sup>, V. Palatkin<sup>1</sup>, E. Verbitskaya<sup>1</sup>, E. Zvartau<sup>1</sup>, G. Woody<sup>2,3</sup>. <sup>1</sup>Valdman Institute of Pharmacology, First Pavlov State Medical University of St. Petersburg, Russia; <sup>2</sup>Department of Psychiatry, University of Pennsylvania, United States; <sup>3</sup>Treatment Research Institute, United States
503. *Effects of maternal opioid maintenance therapy on neonatal outcomes: Methadone versus buprenorphine*  
L. Brandt<sup>1</sup>, S. Fischberger<sup>2</sup>, C. Aschauer<sup>2</sup>, R. Jagsch<sup>3</sup>, G. Fischer<sup>1,2</sup>. <sup>1</sup>Center for Public Health, Medical University of Vienna, Austria; <sup>2</sup>Department for Psychiatry and Psychotherapy, Medical University of Vienna, Austria; <sup>3</sup>Department of Applied Psychology, Health, Development, Enhancement and Intervention, University of Vienna, Austria
504. *Problem cases and treatment denial: A qualitative study in institutional directors and supervisors in Buenos Aires*  
J. Capece, M. Fanton. Programación Para la Prevención de la Drogadicción y lucha contra el Narcotráfico, Argentina
505. *Screening and brief intervention for substance-using and delinquent adolescents from Cape Town, South Africa*  
T. Carney<sup>1</sup>, B. Myers<sup>1,2</sup>, J. Louw<sup>3</sup>, H. Carrara<sup>4</sup>. <sup>1</sup>Alcohol and Drug Abuse Research Unit, Medical Research Council, South Africa; <sup>2</sup>Department of Psychiatry and Mental Health, University of Cape Town, South Africa; <sup>3</sup>Department of Psychology, University of Cape Town, South Africa; <sup>4</sup>Department of Public Health and Family Medicine, University of Cape Town, South Africa



506. *HIV transmission risk behaviors among patients of opioid maintenance treatment programs in Ukraine*  
V. Chtenguelov<sup>1</sup>, S. Dvoriak<sup>2</sup>, G. Prib<sup>3</sup>. <sup>1</sup>Department of Social Work and Applied Psychology, Academy of Labor, Social Relations and Tourism, Ukraine; <sup>2</sup>Ukrainian Institute on Public Health Policy, Ukraine; <sup>3</sup>Department of Psychology, Institute of Professional Training for Public Employment Service of Ukraine, Ukraine
507. *Comparison of expenditures in usual psychiatric care between Madrid and Boston hospital systems*  
B. Cook<sup>1</sup>, E. Baca-Garcia<sup>2</sup>, M. Alegría<sup>2</sup>. <sup>1</sup>Center for Multicultural Mental Health Research, Cambridge Health Alliance, Department of Psychiatry, Harvard Medical School, United States; <sup>2</sup>Fundación Jimenez Diaz, Spain
508. *Specialist “cannabis only” treatment clinics in New South Wales, Australia: Client and treatment characteristics and associations with treatment-seeking behavior*  
J. Copeland, D. Allsop. National Cannabis Prevention and Information Centre, University of New South Wales, Australia
509. *Performance measurement as a tool for improving substance abuse treatment in Brazil*  
F. De Conto<sup>1,2</sup>, J.R. Koch<sup>2</sup>. <sup>1</sup>Florianopolis Department of Health and University Hospital, Brazil; <sup>2</sup>Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
510. *The impact of opioid substitution therapy on mortality post-release from prison*  
L. Degenhardt<sup>1,2</sup>, S. Larney<sup>1,3</sup>, J. Kimber<sup>1</sup>, N. Gisev<sup>1</sup>, M. Farrell<sup>1</sup>, T. Dobbins<sup>4</sup>, D.J. Weatherburn<sup>5</sup>, A. Gibson<sup>6</sup>, R. Mattick<sup>1</sup>, T. Butler<sup>7</sup>, L. Burns<sup>1</sup>. <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>2</sup>School of Population and Global Health, University of Melbourne, Australia; <sup>3</sup>Alpert Medical School, Brown University, United States; <sup>4</sup>Cancer Epidemiology and Services Research, Sydney School of Public Health, Sydney Medical School, University of Sydney, Australia; <sup>5</sup>New South Wales Bureau of Crime Statistics and Research, Australia; <sup>6</sup>University of Western Sydney, Australia; <sup>7</sup>The Kirby Institute, University of New South Wales, Australia
511. *The helping horse: How equine-assisted learning contributes to the well-being of First Nations youth in treatment for volatile substance misuse*  
C. Dell. University of Saskatchewan, Canada; University of Regina, Canada; University of Calgary, Canada; White Buffalo Youth Inhalant Treatment Program, Canada; Cartier Equine Learning Centre, Canada; Youth Solvent Addiction Committee, Canada; Canadian Centre on Substance Abuse, Canada; National Native Addictions Partnership Foundation, Canada; Saskatoon Community Youth Art Program, Canada

512. *A pilot implementation project of an integrated treatment for opioid addiction in Vietnam*  
C. Denis<sup>1</sup>, D. Metzger<sup>1</sup>, G. Viretto<sup>2</sup>, V. Trias<sup>2</sup>, M. Auriacombe<sup>3</sup>, G. Raguin<sup>2</sup>, S. Mai-Thi-Hoai<sup>4</sup>, G. Le-Truong<sup>4</sup>, J-P. Daulouède<sup>2,3,5</sup>, C. O'Brien<sup>1</sup>. <sup>1</sup>Center for Studies of Addiction, University of Pennsylvania, United States; <sup>2</sup>ESTHER, France; <sup>3</sup>University Bordeaux Segalen, France; <sup>4</sup>Ho Chi Minh City AIDS Committee, Vietnam; <sup>5</sup>Bizia Addiction Clinic, France
513. *Treatment of women with substance use disorder at high risk of stigmatization*  
P. Dolezalova. Clinic of Addictology, Charles University, Czech Republic
514. *Methadone treatment and antiretroviral therapy adherence among Kiev people who inject drugs*  
S. Dvoriak<sup>1</sup>, A. Karachevsk<sup>2</sup>, G. Woody<sup>3,4</sup>. <sup>1</sup>Ukrainian Institute of Public Health Policy, Ukraine; <sup>2</sup>Department of Psychiatry and Drug Abuse, O.O. Bogomolets National Medical University, Ukraine; <sup>3</sup>Perelman School of Medicine, University of Pennsylvania, United States; <sup>4</sup>Treatment Research Institute, United States
515. *A trend analysis on substance abuse treatment market in Iran using newspaper advertisements*  
H. Ekhtiari<sup>1,2</sup>, S. Rezaee<sup>1,3</sup>, S. Esmizadeh<sup>4</sup>, A. Deylamizadeh<sup>4</sup>. <sup>1</sup>Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Iran; <sup>2</sup>Translational Neuroscience Program, Institute for Cognitive Science Studies, Iran; <sup>3</sup>Cultural Studies Department, Faculty of Social Sciences and Communication, Allameh Tabatabai University, Iran; <sup>4</sup>Rebirth Charity Organization, Iran
516. *Transitional effect of community-based addiction recovery meetings in Quezon City, Philippines*  
L.R. Estacio, Jr.<sup>1</sup>, M. Oda<sup>2</sup>, J.M.D. Estacio<sup>3</sup>. <sup>1</sup>University of the Philippines-Manila, Philippines; <sup>2</sup>Asia-Pacific Addiction Research Institute, Philippines; <sup>3</sup>Addictus-Philippines Inc., Philippines
517. *Crack cocaine users show low adherence rates in Brazilian public outpatient treatment*  
S. Faller, A.R. Stolf, F. Pechansky, F. Kessler. Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil
518. *“Pasta base” cocaine and psychosocial deterioration: A comparative study in a local sample of drug users*  
M. Fanton<sup>1</sup>, M. Ricciardi<sup>2</sup>, R. Aldezabal<sup>2</sup>, S. Azzollini<sup>3</sup>. <sup>1</sup>Programación Para la Prevención de la Drogadicción y la Lucha contra el Narcotráfico, Argentina; <sup>2</sup>Ministerio de Desarrollo Social, Gobierno de la Ciudad de Buenos Aires, Argentina; <sup>3</sup>Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina

519. *Safety reporting in randomized clinical trials for behavioral interventions in Mexico*  
J. Fernández-Mondragón<sup>1</sup>, V. Horigian<sup>2</sup>, J. Graue-Moreno<sup>1</sup>, E. Alonso<sup>2</sup>, R. Verdeja<sup>2</sup>, L. Bucay-Harari<sup>1</sup>, A. De La Fuente Martín<sup>2</sup>, C. Berlanga-Cisneros<sup>3</sup>, R. Marín-Navarrete<sup>1</sup>.  
<sup>1</sup>Clinical Trials Unit on Addiction and Mental Health, Ramón de la Fuente Muñiz National Institute of Psychiatry, Mexico; <sup>2</sup>Florida Node Alliance, University of Miami, United States; <sup>3</sup>Direction of Clinical Research, Ramón de la Fuente Muñiz National Institute of Psychiatry, Mexico
520. *The level of anxiety among methamphetamine users at Drug Dependence Hospital RSKO-Jakarta*  
F. Firdaus<sup>1</sup>, M. Fadhillah<sup>1</sup>, L. Hendarmin<sup>1</sup>, A. Zaki<sup>1</sup>, A. Nurhidayat<sup>2</sup>. <sup>1</sup>UIN Syarif Hidayatullah University, Indonesia; <sup>2</sup>Drug Dependence Hospital RSKO–Jakarta, Indonesia
521. *Impact of comorbid psychiatric disorders on engagement in treatment after referral by an addiction liaison psychiatry unit*  
F. Fonseca<sup>1,2</sup>, J. León<sup>1</sup>, M. Llobet<sup>1</sup>, P. Rossi<sup>1,2</sup>, D. Martínez-Sanvisens<sup>1,2</sup>, C. Tamarit<sup>1,2</sup>, M. Farré<sup>1,2,3</sup>, M. Torrens<sup>1,2,3</sup>. <sup>1</sup>Institut de Neuropsiquiatria i Addiccions, IMIM, Parc de Salut Mar, Spain; <sup>2</sup>Institut Hospital Del Mar d'Investigacions Mèdiques, IMIM, Parc de Salut Mar, Spain; <sup>3</sup>Facultad de Medicina, Universidad Autónoma de Barcelona, Spain
522. *Baseline depressive symptoms and contingency management outcomes in smokers*  
O. Garcia-Rodriguez, S. Weidberg, V. Martínez-Loredo, J.R. Fernández-Hermida, R. Secades-Villa. Department of Psychology, University of Oviedo, Spain
523. *TREATNET: Quality standards for drug dependence treatment and care services*  
G. Gerra, A. Busse, E. Saenz. Drug Prevention and Health Branch, Prevention, Treatment and Rehabilitation Section, United Nations Office on Drugs and Crime, Austria
524. *Cytokines during acute abstinence of crack cocaine: The role of early life stress*  
R. Grassi-Oliveira, M.L. Levandowski, T.W. Viola, J.C. Pezzi, L.E. Wearick, M.E. Bauer, A.L. Teixeira, E. Brietzke. Centre of Studies and Research in Traumatic Stress, Pontifical Catholic University of Rio Grande do Sul, Brazil
525. *Predictors of receiving treatment for drug or alcohol problems among youth*  
E. Haan<sup>1</sup>, Y. Quevedo<sup>2,3</sup>, R. de Cerqueira Campos<sup>4</sup>, T. Mmolawa<sup>5</sup>, P. Alexandre<sup>6</sup>.  
<sup>1</sup>Public Health Department, Ministry of Social Affairs, Estonia; <sup>2</sup>East Psychiatry Department, University of Chile, Chile; <sup>3</sup> Instituto Médico Schilkrut, Chile; <sup>4</sup>Department of Health, Brazil; <sup>5</sup>Department of Defense, Botswana; <sup>6</sup>Johns Hopkins University, United States

526. *Impact of substance abuse comorbidity on length of hospital stay for the treatment of psychosis in Egypt*  
W. Hassan<sup>1,2</sup>, W.A. Alhaleem<sup>1</sup>. <sup>1</sup>Institute of Psychiatry, Ain Shams University, Egypt; <sup>2</sup>Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
527. *The gains of monetary cost and productivity with methadone maintenance treatment: One-year follow-up*  
C.Y. Hsiao<sup>1,2</sup>, K.C. Chen<sup>1,2,3</sup>, L-T. Lee<sup>1,2</sup>, H.C. Tsai<sup>1,3</sup>, W.H. Chang<sup>1,3</sup>, I.H. Lee<sup>1,2</sup>, P.S. Chen<sup>1,2</sup>, R-B. Lu<sup>1,2,4</sup>, Y.K. Yang<sup>1,2</sup>. <sup>1</sup>Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Taiwan; <sup>2</sup>Addiction Research Center, National Cheng Kung University, Taiwan; <sup>3</sup>Department of Psychiatry, National Cheng Kung University Hospital, Dou-Liou Branch, Taiwan; <sup>4</sup>Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Taiwan
528. *Retention and dropout of opioid substitution therapy program in Ukraine*  
Z. Islam, S. Filippovych, T. Prokhorova, A. Shost. International HIV/AIDS Alliance, Ukraine
529. *International collaboration between academic institutions: University Sains Malaysia and Yale School of Medicine*  
B.V. Kasinather<sup>1</sup>, A. Desrosiers<sup>2</sup>, R. Schottenfeld<sup>2</sup>, M. Chawarski<sup>2</sup>. <sup>1</sup>Centre for Drug Research, Universiti Sains Malaysia, Malaysia; <sup>2</sup>School of Medicine, Yale University, United States
530. *Preliminary evidence of injecting drug reduction from a woman-focused random controlled trial in Republic of Georgia*  
I. Kirtadze<sup>1</sup>, D. Otiashvili<sup>1</sup>, K. O'Grady<sup>2</sup>, H. Jones<sup>3</sup>, W. Zule<sup>4</sup>, E. Krupitsky<sup>5</sup>, W. Wechsberg<sup>4</sup>. <sup>1</sup>Addiction Research Center, Alternative Georgia, Georgia; <sup>2</sup>Department of Psychology, University of Maryland, College Park, United States; <sup>3</sup>University of North Carolina (UNC) Horizons, Department of Obstetrics and Gynecology, UNC at Chapel Hill, United States; <sup>4</sup>RTI International, United States; <sup>5</sup>Department of Addictions, Bekhterev Research Psychoneurological Institute, Russia
531. *Development of an educational intervention to support primary care of alcohol problems among drug users*  
J. Klimas<sup>1,2</sup>, K. Lally<sup>1</sup>, L. Murphy<sup>1</sup>, L. Crowley<sup>1</sup>, R. Anderson<sup>3</sup>, D. Meagher<sup>1</sup>, B.P. Smyth<sup>4</sup>, G. Bury<sup>2</sup>, W. Cullen<sup>1</sup>. <sup>1</sup>Centre for Interventions in Infection, Immunity and Inflammation and Graduate Entry Medical School, Faculty of Education and Health Sciences, University of Limerick, Ireland; <sup>2</sup>University College Dublin School of Medicine and Medical Science, Coombe Healthcare Centre, Ireland; <sup>3</sup>The Charlemont Clinic, Ireland; <sup>4</sup>Addiction Services, Health Services Executive, Ireland

532. *Pharmacogenetics of treatment of opioid dependence with oral naltrexone and long-acting naltrexone implant*  
E. Krupitsky<sup>1</sup>, A. Kibitov<sup>2</sup>, E. Zvartau<sup>3</sup>, E. Blokhina<sup>3</sup>, E. Verbitskaya<sup>3</sup>, V. Palatkin<sup>3</sup>, D. Nielsen<sup>4</sup>, T. Kosten<sup>4</sup>, G. Woody<sup>5</sup>. <sup>1</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; <sup>2</sup>National Research Centre on Addictions, Russia; <sup>3</sup>St. Petersburg State Pavlov Medical University, Russia; <sup>4</sup>Baylor College of Medicine, United States; <sup>5</sup>University of Pennsylvania, United States
533. *Psychopathology among methadone patients at Drug Dependence Hospital RSKO–Jakarta*  
M. Kurniawan<sup>1,2</sup>, A. Nurhidayat<sup>1,3</sup>, M. Fadhilah<sup>2</sup>, A. Rahayu<sup>2</sup>, A. Zaki<sup>2</sup>. <sup>1</sup>Institute of Mental Health, Addiction and Neuroscience, Indonesia; <sup>2</sup>UIN Syarif Hidayatullah University, Indonesia; <sup>3</sup>Drug Dependence Hospital RSKO–Jakarta, Indonesia
534. *Specialized women’s track in methadone maintenance treatment clinic in Israel: Program description, client characteristics, and preliminary outcomes*  
M. Lawental<sup>1</sup>, H. Taylor<sup>2</sup>, M. Blumenfeld<sup>2</sup>, O. Zaslavsky<sup>3</sup>, T. Araten-Bergman<sup>1</sup>. <sup>1</sup>School of Social Work, University of Haifa, Israel; <sup>2</sup>Haifa Drug Abuse Treatment Center, Israel; <sup>3</sup>School of Nursing, University of Haifa, Israel
535. *Implementation of drug and HIV risk counseling in methadone maintenance treatment programs in Taiwan*  
T. Szu-Hsien Lee<sup>1</sup>, M. Chawarski<sup>2</sup>, C-Y. Peng<sup>1</sup>, C-C. Hung<sup>3</sup>, D. Metzger<sup>4</sup>. <sup>1</sup>Department of Health Promotion and Education, National Taiwan Normal University, Taiwan; <sup>2</sup>School of Medicine, Yale University, United States; <sup>3</sup>Taichung Veterans General Hospital, Taiwan; <sup>4</sup>University of Pennsylvania, United States
536. *The association between levels of plasma oxytocin and craving among heroin users*  
S-H. Lin<sup>1,2</sup>, P.S. Chen<sup>1,2</sup>, L-T. Lee<sup>1,2,3</sup>, S-Y. Lee<sup>1,2</sup>, H-C. Tsai<sup>1,3</sup>, K.C. Chen<sup>1,2,3</sup>, I.H. Lee<sup>1,2</sup>, R-B. Lu<sup>1,2,4</sup>, Y.K. Yang<sup>1,2,4</sup>. <sup>1</sup>Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Taiwan; <sup>2</sup>Addiction Research Center, National Cheng Kung University, Taiwan; <sup>3</sup>Department of Psychiatry, National Cheng Kung University Hospital, Dou-Liou Branch, Taiwan; <sup>4</sup>Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Taiwan
537. *Physiological and subjective responses after psychosocial stress among Uyghur heroin users in Xinjiang, China*  
S. Liu<sup>1</sup>, A. Abudula<sup>2</sup>, A.Yashen<sup>2</sup>, L. Zhang<sup>1</sup>, Y. Cheng<sup>3</sup>, G. Song<sup>3</sup>, G. Yang<sup>4</sup>. <sup>1</sup>Shanghai University of Traditional Chinese Medicine, China; <sup>2</sup>Addiction Treatment and Rehabilitation Center, Xinjiang Medical University, China; <sup>3</sup>Xinjiang Medical University, China; <sup>4</sup>Ningbo Addiction Research and Treatment Center, China

538. *How increased information changed the attitude toward self-help groups in Russia for the last 5 years*  
B. Lobodov<sup>1</sup>, L. Rod<sup>2</sup>, E. Chernyckii<sup>2</sup>, P. Strogonov<sup>2</sup>. <sup>1</sup>Medical Center “Semya,” Russia; <sup>2</sup>Voronezh State Regional Narcological Dispanser, Russia
539. *Stigma and health care utilization among Russian HIV-infected drug users*  
K. Lunze<sup>1,2</sup>, D. Lioznov<sup>3</sup>, D. Cheng<sup>1</sup>, L. Forman<sup>1</sup>, L. Wulach<sup>2</sup>, A. Raj<sup>4</sup>, E. Krupitsky<sup>3</sup>, J.H Samet<sup>1,2</sup>. <sup>1</sup>Boston University, United States; <sup>2</sup>Boston Medical Center, United States; <sup>3</sup>First St. Petersburg Pavlov State Medical University, Russia; <sup>4</sup>University of California, San Diego, United States
540. *Effectiveness and factors affecting drug use behavior among patients in methadone maintenance treatment program in Hai Phong and Ho Chi Minh City, Vietnam*  
M.T.N. Mac<sup>1</sup>, T.T.M. Nguyen<sup>1</sup>, L.T. Nguyen<sup>1</sup>, H. Tran<sup>2</sup>, K. Soonthorndraha<sup>3</sup>. <sup>1</sup>Vietnam Authority of HIV/AIDS Control, Ministry of Health, Vietnam; <sup>2</sup>Partners in Health Research, Vietnam; <sup>3</sup>Institute for Population and Social Research, Mahidol University, Thailand
541. *A multisite randomized controlled trial of motivational enhancement treatment in outpatient addiction care centers in Mexico*  
R. Marín-Navarrete<sup>1</sup>, V.E. Horigian<sup>2</sup>, J. Fernández-Mondragón<sup>1</sup>, R.E. Verdeja<sup>2</sup>, E. Alonso<sup>2</sup>, L. Templos-Nuñez<sup>1</sup>, A. Eliosa-Hernández<sup>1</sup>, D. Feaster<sup>2</sup>, R. Sánchez-Huesca<sup>3</sup>, A. de la Fuente-Martín<sup>1</sup>, C. Lima-Rodríguez<sup>4</sup>, C. Berlanga-Cisneros<sup>1</sup>, M.E. Medina-Mora<sup>1</sup>. <sup>1</sup>Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico; <sup>2</sup>Florida Node Alliance, University of Miami, United States; <sup>3</sup>Centros de Integración Juvenil, Mexico; <sup>4</sup>Consejo Estatal Contra las Adicciones Puebla, Mexico
542. *Continued methadone maintenance treatment among women: The first study on barriers*  
Z.A. Mehrjerdi<sup>1</sup>, A. Kiakojouri<sup>2</sup>, K. Dolan<sup>1</sup>, L. Arshad<sup>3</sup>, F. Rezaee<sup>4</sup>, H. Naranjiha<sup>5</sup>. <sup>1</sup>Program of International Research and Training, National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>2</sup>Peyman Opiate and Methamphetamine Use Treatment Clinic, Iran; <sup>3</sup>Mikhak Female-Specific Drop in Center, Iran; <sup>4</sup>Sarzamin Khorshid Female-Specific Drop in Center, Iran; <sup>5</sup>Darius Institute, University of Social Welfare and Rehabilitation Sciences, Iran
543. *Correlates of perceived need for drug treatment among women from disadvantaged communities in Cape Town, South Africa, enrolled into a randomized field experiment*  
B. Myers<sup>1,2</sup>, T.L. Kline<sup>3</sup>, I.A. Doherty<sup>3</sup>, T. Carney<sup>1</sup>, W.M. Wechsberg<sup>3,4,5,6</sup>. <sup>1</sup>Alcohol and Drug Abuse Research Unit, South African Medical Research Council, South Africa; <sup>2</sup>Department of Psychiatry and Mental Health, University of Cape Town, South Africa; <sup>3</sup>RTI International, United States; <sup>4</sup>Gillings Global School of Public Health, University of North Carolina, United States; <sup>5</sup>Psychology in the Public Interest, North Carolina State University, United States; <sup>6</sup>Psychiatry and Behavioral Sciences, Duke University School of Medicine, United States

544. *Pilot implementation of Screening, Brief Intervention, Referral, and Treatment at Tirana University Hospital “Mother Theresa” Center and private clinics in Albania*  
E. Ngjelina<sup>1,2</sup>, L. Cathers<sup>2</sup>, C. Wagner<sup>2</sup>. <sup>1</sup>Center for Development and Social Initiatives, Albania; <sup>2</sup>Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
545. *Treatment-seeking codeine users: A different kettle of fish?*  
S. Nielsen<sup>1,2</sup>, B. Murnion<sup>2</sup>, A. Dunlop<sup>3,4</sup>, L. Degenhardt<sup>1,5</sup>, A. Demirkol<sup>2,6</sup>, N. Lintzeris<sup>2,6</sup>. <sup>1</sup>National Drug and Alcohol Centre, University of New South Wales, Australia; <sup>2</sup>University of Sydney, Australia; <sup>3</sup>Hunter New England Area Health Service, Australia; <sup>4</sup>University of Newcastle, Australia; <sup>5</sup>Centre for Population Health, Burnet Institute, Australia; <sup>6</sup>South Eastern Sydney Local Health District, Australia
546. *Attitudes toward access to health care services among homeless and impoverished crack cocaine users in Saint Lucia*  
L.R. Norman<sup>1</sup>, M.P. Day<sup>2</sup>. <sup>1</sup>Ponce School of Medicine and Health Sciences, United States; <sup>2</sup>Caribbean Drug Abuse Research Institute, Saint Lucia
547. *Incarceration as drug treatment: Insight from Georgian prison system*  
D. Otiashvili, N. Balanchivadze, I. Kirtadze. Addiction Research Center, Alternative Georgia, Georgia
548. *Polydrug dependence among outpatients receiving treatment in Montevideo*  
A. Pascale<sup>1</sup>, C. Bares<sup>2</sup>, F. Del Cioppo<sup>1</sup>, C. Lopez<sup>1</sup>, A. Usher<sup>1</sup>. <sup>1</sup>Grupo de Cavia Outpatient Treatment Program–Montevideo, Uruguay; <sup>2</sup>School of Social Work, Virginia Commonwealth University, United States
549. *Effects of stress and drug-related cues among opiate-dependent individuals*  
I. Pericot-Valverde<sup>1</sup>, S.E. Back<sup>2</sup>. <sup>1</sup>Department of Psychology, University of Oviedo, Spain; <sup>2</sup>Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States
550. *Evaluation of state opioid substitution treatment program in Republic of Georgia*  
G. Piralishvili, M. Chavchanidze, I. Gamkrelidze, N. Nikolaishvili. Center for Mental Health and Prevention of Addiction, Georgia
551. *Getting insight throughout treatment: Developing an instrument to measure addictive disease awareness*  
Y. Quevedo, L. Arriagada, A. Borzutzky, N. Valdés. Instituto Médico Schilktrut, Chile
552. *Effects of omega-3 fatty acids on tobacco craving: A double-blind, randomized, placebo-controlled pilot study*  
S. Rabinovitz-Shenkar. School of Criminology, University of Haifa, Israel

553. *Clinician beliefs and behaviors regarding screening and brief intervention for drug use of their community health center patients*  
A. Reddy, R. Andersen, L. Gelberg. University of California, Los Angeles, United States
554. *United Nations Office on Drugs and Crime–World Health Organization Programme on Drug Dependence Treatment and Care: Jointly building treatment capacity in low- and middle-income countries*  
E. Saenz<sup>1</sup>, G. Gerra<sup>1</sup>, A. Busse<sup>1</sup>, N. Clark<sup>2</sup>, V. Poznyak<sup>2</sup>. <sup>1</sup>Health Branch, United Nations Office on Drugs and Crime, Austria; <sup>2</sup>Management of Substance Abuse, World Health Organization, Switzerland
555. *Contingency management of smoking abstinence versus contingency management with shaping for smoking cessation among treatment-seeking patients*  
R. Secades-Villa, C. López-Núñez, I. Pericot-Valverde, F. Alonso-Pérez, O. García-Rodríguez. University of Oviedo, Spain
556. *Feasibility and acceptability of adding an opium tincture substitution treatment program to opioid substitution treatment clinics in Iran*  
L. Seiri<sup>1</sup>, A. Noroozi<sup>2</sup>, A. Mokri<sup>2</sup>, H. Dezhakam<sup>3</sup>. <sup>1</sup>Aftab Clinic, Iran; <sup>2</sup>Iranian National Center for Addiction Studies, Iran; <sup>3</sup>Congress 60, nonprofit organization, Iran
557. *Role of stigma in self-esteem and well-being of people with substance use disorder*  
S. Shahzad<sup>1</sup>, N. Begum<sup>2</sup>. <sup>1</sup>Institute of Clinical Psychology, University of Karachi, Pakistan; <sup>2</sup>Area Study Centre for Europe, University of Karachi, Pakistan
558. *Oxidative stress, brain-derived neurotrophic factor, and severity of crack cocaine use in early withdrawal*  
A. Sordi, F. Kessler, F. Pechansky, L. von Diemen. Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil
559. *Incubation of alcohol craving during abstinence in patients with alcohol dependence*  
H-Q. Sun<sup>1,2</sup>, P. Li<sup>1</sup>, P. Wu<sup>1</sup>, X. Xin<sup>3</sup>, Y-L. Fan<sup>4</sup>, G-B. Wang<sup>5</sup>, F. Wang<sup>4</sup>, M-Y. Ma<sup>4</sup>, M-M. Xue<sup>3</sup>, Y-X. Luo<sup>1</sup>, F-D. Yang<sup>4</sup>, J. Shi<sup>1</sup>, L. Lu<sup>1,2</sup>. <sup>1</sup>National Institute on Drug Dependence, Peking University, China; <sup>2</sup>Institute of Mental Health, Peking University, China; <sup>3</sup>Department of Physiology, Basic Medical College, Inner Mongolia Medical University, China; <sup>4</sup>Department of Alcohol and Drug Dependence, Beijing Hui-Long-Guan Hospital, Peking University, China; <sup>5</sup>Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, China



560. *Benzodiazepine use among methadone maintenance treatment patients in Jakarta, Indonesia*  
Z. Syarif<sup>1,2</sup>, H. Susami<sup>3</sup>, R. Sarasvita<sup>4</sup>, D. Utami<sup>5</sup>, A. Nurhidayat<sup>6</sup>, A. Desrosiers<sup>2</sup>, M. Chawarski<sup>2</sup>, G. Woody<sup>7</sup>, D. Metzger<sup>7</sup>. <sup>1</sup>Addiction and AIDS Research Center, Indonesia; <sup>2</sup>School of Medicine, Yale University, United States; <sup>3</sup>Special Working Group on AIDS, Faculty of Medicine, University of Indonesia, Indonesia; <sup>4</sup>Drug Abuse Division, Ministry of Health, Indonesia; <sup>5</sup>The Indonesia National Narcotics Board, Indonesia; <sup>6</sup>Drug Dependence Hospital RSKO–Jakarta, Indonesia; <sup>7</sup>University of Pennsylvania, United States
561. *Factors affecting the retention of patients in a methadone maintenance treatment program in Vietnam*  
N.T.M. Tam<sup>1</sup>, N.Q. Mai<sup>1</sup>, P.D. Manh<sup>1</sup>, N.T. Long<sup>2</sup>, H.H. Vu<sup>3</sup>. <sup>1</sup>Vietnam Authority of HIV/AIDS Control, Vietnam; <sup>2</sup>Ministry of Health, Vietnam; <sup>3</sup>Substance Abuse and Mental Health Services Administration, United States Embassy, Vietnam
562. *Effectiveness of methadone maintenance treatment in “crocodile” users*  
K. Todadze, S. Mosia, T. Qutateladze. Center for Mental Health and Prevention of Addiction, Georgia
563. *Acute stress response in cocaine-dependent subjects with comorbid depression*  
M. Torrens<sup>1,2,3</sup>, R.R. Minguela<sup>1</sup>, D. Martinez-Sanvisens<sup>1,2</sup>, C. Pérez-Mañá<sup>1,3</sup>, E. Papaseit<sup>1</sup>, F. Fonseca<sup>1,2</sup>, M. Farré<sup>1,3</sup>. <sup>1</sup>Institut Hospital Del Mar d’Investigacions Mèdiques, IMIM, Parc de Salut Mar, Spain; <sup>2</sup>Institut de Neuropsiquiatria i Addiccions, IMIM, Parc de Salut Mar, Spain; <sup>3</sup>Facultad de Medicina, Universidad Autónoma de Barcelona, Spain
564. *Adherence and associated factors in methadone clinics in Nam Dinh Province, Vietnam*  
Q. Tran<sup>1</sup>, H. Vu<sup>2</sup>. <sup>1</sup>Provincial HIV/AIDS Center, Department of Health, Vietnam; <sup>2</sup>Substance Abuse and Mental Health Services Administration, United States Embassy, Vietnam
565. *Hepatitis C virus testing and treatment among HIV-infected people who inject drugs in St. Petersburg Russia*  
J.I. Tsui<sup>1,2</sup>, E. Krupitsky<sup>3,4</sup>, L. Wulach<sup>2</sup>, C.E. Chaisson<sup>1</sup>, J.H. Samet<sup>1,2</sup>. <sup>1</sup>Boston University, United States; <sup>2</sup>Boston Medical Center, United States; <sup>3</sup>First St. Petersburg Pavlov State Medical University, Russia; <sup>4</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, Russia
566. *The use of drugs other than heroin by opiate-dependent patients in remission stabilized on naltrexone*  
A. Tyurina<sup>1</sup>, E. Krupitsky<sup>2</sup>, E. Zvartau<sup>1</sup>, E. Blokhina<sup>1</sup>, E. Verbitskaya<sup>1</sup>, N. Bushara<sup>1</sup>, V. Palatkin<sup>1</sup>, G. Woody<sup>3</sup>. <sup>1</sup>St. Petersburg State Pavlov Medical University, Russia; <sup>2</sup>St. Petersburg V.M. Bekhterev Research Psychoneurological Institute, Russia; <sup>3</sup>Department of Psychiatry, University of Pennsylvania, United States

567. *Brain-derived neurotrophic factor levels of crack users are associated with clinical outcome during inpatient treatment*  
L. von Diemen<sup>1</sup>, F. Kapczynski<sup>2</sup>, A. Orgle-Sordi<sup>1</sup>, F. Kessler<sup>1</sup>, J. Narvaez<sup>1</sup>, F. Pechansky<sup>1</sup>. <sup>1</sup>Center for Drug and Alcohol Research, Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Brazil; <sup>2</sup>Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil
568. *Fatal and nonfatal overdose after narcology hospital discharge among HIV-infected Russians*  
A.Y. Walley<sup>1</sup>, E. Krupitsky<sup>2</sup>, D.M. Cheng<sup>1,3</sup>, E.K. Quinn<sup>3</sup>, L. Wulach<sup>1</sup>, P.O. Coffin<sup>4</sup>, J.H. Samet<sup>1,3</sup>. <sup>1</sup>Boston Medical Center, School of Medicine, Boston University, United States; <sup>2</sup>Pavlov State University, Russia; <sup>3</sup>School of Public Health, Boston University, United States; <sup>4</sup>San Francisco Department of Public Health, United States
569. *A positron emission tomography imaging study of the effects of pharmacotherapy on brain mechanisms underlying cocaine dependence in cocaine and heroin-dependent patients.*  
A. Weinstein<sup>1,2</sup>, N. Freedman<sup>1</sup>, I. Herman<sup>3</sup>, E. Mishani<sup>1</sup>, H. Atlan<sup>1</sup>, R. Chisin<sup>1</sup>. <sup>1</sup>Department of Medical Biophysics and Nuclear Medicine, The Human Biology Research Center, Hadassah Medical Center, Israel; <sup>2</sup>Department of Behavioral Sciences, University of Ariel, Israel; <sup>3</sup>Jaffa Treatment Center for Drug Victims, Israel
570. *Evaluation process for community-based drug treatment program in Indonesia*  
E. Wijoyo<sup>1</sup>, R. Sarasvita<sup>2</sup>, A. Rachman<sup>3</sup>. <sup>1</sup>Kapeta Foundation, Indonesia; <sup>2</sup>Indonesian Ministry of Health, Indonesia; <sup>3</sup>National Aids Commission, Indonesia
571. *Take-home naloxone training: Comparing the effects on knowledge and attitudes between family members and drug users*  
A.V. Williams, J. Marsden, J. Strang. Addictions Department, Institute of Psychiatry, King's College London, United Kingdom
572. *Accreditation standards "patient rights": Revision and current state in drug addiction treatment centers in Colombia*  
M.A. Zapata. Group of Research in Mental Health, University CES, Colombia

**Poster Session II  
(Breakfast)**

**GRAN SALON  
LOS ROSALES  
8:00 - 10:00 AM**

**Odd-numbered posters manned first hour;  
Even-numbered, second hour**

**Set-up time begins Monday, 1 PM  
Must be removed by Tuesday 12 Noon**

**SEX/GENDER 1**

- 1 *Sex differences in patterns of alcohol use among nightclub patrons in Brazil*  
Z. M. Sanchez<sup>1</sup>, S. Andreoni<sup>1</sup>, A. Sanudo<sup>1</sup>, S. S. Martins<sup>2</sup>, <sup>1</sup>Department of Preventive Medicine, Universidade Federal de São Paulo, São Paulo, Brazil, <sup>2</sup>Department of Epidemiology, Columbia University, New York, NY
- 2 *Profiling alcoholic drinking and dating psychological abuse in a sample of college students in China*  
Y. Liu<sup>1</sup>, Y. Duan<sup>2,4</sup>, W. Chen<sup>1</sup>, M. Li<sup>1</sup>, Y. Wang<sup>1</sup>, Y. Ma<sup>1</sup>, S. Liu<sup>3</sup>, J. Grady<sup>4</sup>, H. Wu<sup>5</sup>, <sup>1</sup>School of Medicine, Ningbo University, Ningbo, China, <sup>2</sup>Community Medicine & Healthcare, University of Connecticut Health Center (UCHC), Farmington, CT, <sup>3</sup>Shanghai University of Traditional Chinese Medicine, Shanghai, China, <sup>4</sup>Connecticut Institute for Clinical and Translational Science (CICATS), UCHC, Farmington, CT, <sup>5</sup>Psychiatry, UCHC, Farmington, CT
- 3 *Attitudes toward computer interventions for partner abuse and drug use among women in the emergency department*  
E. Choo<sup>1</sup>, M. Ranney<sup>1</sup>, T. Wetle<sup>3</sup>, K. Morrow<sup>2</sup>, M. Mello<sup>1</sup>, D. Squires<sup>4</sup>, A. Garro<sup>1</sup>, C. Tape<sup>1</sup>, C. Zlotnick<sup>2</sup>, <sup>1</sup>Depart. of Emergency Medicine, <sup>2</sup>Depart. of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, <sup>3</sup>School of Public Health, Brown University, Providence, RI, <sup>4</sup>Depart. of Behavioral and Social Sciences, Brown University, Providence, RI
- 4 *Gender differences in hepatitis C risk behaviors*  
A. Batchelder<sup>1</sup>, C. L. Masson<sup>1</sup>, J. Sorensen<sup>1</sup>, D. Perlman<sup>2</sup>, <sup>1</sup>University of California, San Francisco, CA, <sup>2</sup>Beth Israel Medical Center, New York City, NY
- 5 *Sex and HIV serostatus effects on high-risk decision making*  
E. Martin<sup>1</sup>, R. Gonzalez<sup>2</sup>, J. Vassileva<sup>3</sup>, P. Maki<sup>3</sup>, A. Bechara<sup>4</sup>, M. Brand<sup>5</sup>, <sup>1</sup>Rush University Medical Center, Chicago, IL, <sup>2</sup>Florida International University, Miami, FL, <sup>3</sup>University of Illinois, Chicago, IL, <sup>4</sup>University of Southern California, Los Angeles, CA, <sup>5</sup>University of Duisberg-Essen, Duisberg, Germany
- 6 *Emerging adult gender differences in sexual discounting and HIV risk behavior*  
S. Thamocharan, S. Fields, Psychology, Texas A&M University, College Station, TX
- 7 *Gender differences in the influence of child sexual abuse on drug use and related health risks during young adulthood: The moderating effects of DRD4*  
K. M. Nowotny, J. D. Boardman, Department of Sociology & Population Program, University of Colorado at Boulder, Boulder, CO
- 8 *Teen girls and boys of treated substance-abusing mothers*  
A. Kadooka<sup>1</sup>, H. Lanza<sup>2</sup>, M. T. Schulte<sup>2</sup>, L. Li<sup>2</sup>, Y. Hser<sup>2</sup>, <sup>1</sup>Hawaii School of Professional Psychology at Argosy University, Honolulu, HI, <sup>2</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA

- 9 *Sex-differences in cognition and behaviors in children with family history of substance use disorders*  
K. Lee<sup>1</sup>, L. Pritchett<sup>1</sup>, G. Løhaugen<sup>2,3</sup>, S. Kogachi<sup>1</sup>, E. Fukaya<sup>1</sup>, A. Hernandez<sup>1</sup>, C. Jiang<sup>1</sup>, D. Alicata<sup>1</sup>, T. Ernst<sup>1</sup>, L. Chang<sup>1</sup>, <sup>1</sup>Medicine, University of Hawaii, Honolulu, HI, <sup>2</sup>Pediatrics and Child Rehabilitation, Norwegian University of Science and Technology, Arendal, Norway, <sup>3</sup>Laboratory Medicine, Norwegian University of Science and Technology, Trondheim, Norway
- 10 *Predictors of the response to oral  $\Delta$ 9-THC in regular cannabis users: Focus on sex differences*  
J. Fogel, T. Kelly, R. Charnigo, A. Harvanko, J. Lile, University of Kentucky, Lexington, KY
- 11 *Sexually dimorphic effects of early life experience and adolescent  $\Delta$ -9-tetrahydrocannabinol exposure in the rat*  
L. Silva<sup>1</sup>, R. Black<sup>2</sup>, D. Dow-Edwards<sup>1</sup>, <sup>1</sup>SUNY Downstate Medical Center, Brooklyn, NY, <sup>2</sup>Wellesley College, Wellesley, MA
- 12 *Evaluation of sex differences in cannabinoid withdrawal in rats*  
J. A. Marusich<sup>1</sup>, T. Lefever<sup>1</sup>, R. Craft<sup>2</sup>, J. L. Wiley<sup>1</sup>, <sup>1</sup>RTI International, Research Triangle Park, NC, <sup>2</sup>Washington State University, Pullman, WA
- 13 *Progressive ratio responding for morphine is differentially altered in the presence of chronic peripheral neuropathy in male vs. female C57Bl/6 mice*  
H. Neelakantan, S. J. Ward, E. A. Walker, Temple University, Philadelphia, PA
- 14 *Effects of sex and remifentanyl dose on the acquisition of responding for a remifentanyl-associated stimulus*  
J. W. Bertz, J. H. Woods, Pharmacology, University of Michigan, Ann Arbor, MI
- 15 *Effect of menstrual phase and social stress on cognitive performance of female monkeys*  
S. A. Kromrey, P. W. Czoty, M. A. Nader, Physiology & Pharmacology, Wake Forest School of Medicine, Winston Salem, NC
- 16 *Region specific sexually dimorphic intracellular responses after cocaine-induced conditioned place preference expression*  
S. K. Nygard<sup>1,2</sup>, A. Klambatsen<sup>1,2</sup>, V. Quinones-Jenab<sup>1,2</sup>, S. Jenab<sup>1,2</sup>, <sup>1</sup>Psychology, Hunter College, CUNY, New York, NY, <sup>2</sup>Biopsychology and Behavioral Neuroscience, The CUNY Graduate School and University Center, New York, NY
- 17 *Sex differences in FosB expression in reward circuitry after administration of cocaine, methamphetamine, and cannabinoids*  
C. Daly<sup>1,2</sup>, A. Toussaint<sup>1</sup>, M. Altubi<sup>1</sup>, J. Encarnacion<sup>1</sup>, S. Jenab<sup>1,2</sup>, V. Quinones-Jenab<sup>1,2</sup>, <sup>1</sup>Hunter College, New York, NY, <sup>2</sup>Cuny Graduate Center, New York, NY
- 18 *Long-term cocaine self-administration in female cynomolgus monkeys: Changes in behavior and in dopamine transporters and D2-like receptor availability*  
M. C. Rowe<sup>1</sup>, S. H. Nader<sup>1</sup>, A. N. Duke<sup>1</sup>, R. Voll<sup>2</sup>, L. Howell<sup>3</sup>, M. A. Nader<sup>1</sup>, <sup>1</sup>Physiology & Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC, <sup>2</sup>Radiology, Emory University School of Medicine, Atlanta, GA, <sup>3</sup>Psychiatry, Emory University School of Medicine, Atlanta, GA
- 19 *Dopamine D3 receptor availability: Sex differences and effects of chronic drug exposure*  
S. Martelle<sup>1</sup>, S. H. Nader<sup>1</sup>, P. W. Czoty<sup>1</sup>, W. S. John<sup>1</sup>, A. H. Newman<sup>2</sup>, M. A. Nader<sup>1</sup>, <sup>1</sup>Physiology and Pharmacology, WFUSM, Winston Salem, NC, <sup>2</sup>Molecular Targets and Medications Discovery, NIDA-IRP, Baltimore, MD

### STIMULANTS - ANIMALS I

- 20 *Locus-specific epigenetic reprogramming for the study of reward pathology*  
E. Heller<sup>1</sup>, H. Cates<sup>1</sup>, H. Sun<sup>1</sup>, C. J. Pena<sup>1</sup>, D. Ferguson<sup>1</sup>, S. Knight<sup>2</sup>, F. Zhang<sup>3</sup>, S. Zhang<sup>4</sup>, E. J. Nestler<sup>1</sup>, <sup>1</sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>2</sup>Sigma Aldrich, Saint Louis, MO, <sup>3</sup>MIT, Cambridge, MA, <sup>4</sup>Sangamo Biosciences, Richmond, CA
- 21 *Epigenetic regulation of cortical serotonin (5-HT) 5-HT<sub>2A</sub>:5-HT<sub>2C</sub> receptor balance in maladaptive impulsivity*  
N. C. Anastasio<sup>1</sup>, J. L. Saavedra<sup>1</sup>, A. L. Miller<sup>1</sup>, R. B. Pyles<sup>1</sup>, F. Moeller<sup>2</sup>, K. Cunningham<sup>1</sup>, <sup>1</sup>Ctr Addiction Res, UTMB, Galveston, TX, <sup>2</sup>Psychiatry, VCU, Richmond, VA
- 22 *Serotonin (5-HT) 2C receptor interaction with protein phosphatase and tensin homologue results in distinct patterns of cortical ERK<sub>1/2</sub> activation*  
C. Soto<sup>1,2</sup>, N. C. Anastasio<sup>1,2</sup>, R. Hartley<sup>1,2</sup>, R. G. Fox<sup>1,2</sup>, H. Du<sup>3</sup>, S. Gilbertson<sup>3</sup>, K. Cunningham<sup>1,2</sup>, <sup>1</sup>Ctr for Addiction Res, UTMB, Galveston, TX, <sup>2</sup>Dept Pharm&Tox, UTMB, Galveston, TX, <sup>3</sup>Dept Chem, Univ Houston, Houston, TX
- 23 *Loss of serotonin (5-HT) 2C receptor (5-HT<sub>2C</sub>R) tone in the ventral tegmental area modulates cocaine-related behaviors*  
S. E. Swinford-Jackson, N. C. Anastasio, R. G. Fox, S. J. Stutz, K. Cunningham, Center for Addiction Research, UTMB, Galveston, TX
- 24 *Effects of amygdalar CaMKII activity on extinction and reconsolidation of a cocaine-associated memory*  
M. T. Rich<sup>1</sup>, M. L. Bertholomey<sup>1</sup>, L. E. Rupperecht<sup>1</sup>, T. B. Abbott<sup>2</sup>, E. E. Glucicek<sup>2</sup>, K. L. Stone<sup>2</sup>, L. Chung<sup>2</sup>, C. M. Colangelo<sup>2</sup>, J. R. Taylor<sup>2</sup>, M. M. Torregrossa<sup>1</sup>, <sup>1</sup>University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Yale University, New Haven, CT
- 25 *Overexpression of miR-495 in nucleus accumbens attenuates cocaine intake on a progressive ratio schedule of reinforcement*  
R. M. Bastle<sup>1</sup>, R. J. Oliver<sup>2</sup>, N. S. Pentkowski<sup>1</sup>, A. S. Gardiner<sup>2</sup>, N. I. Perrone-Bizzozero<sup>2</sup>, J. L. Neisewander<sup>1</sup>, <sup>1</sup>Arizona State Univ, Tempe, AZ, <sup>2</sup>Univ New Mexico, Albuquerque, NM
- 26 *Modulation of microRNA expression in the amygdala by binge cocaine and withdrawal*  
M. Doura<sup>1</sup>, Y. Li<sup>2</sup>, W. Cornwell<sup>3</sup>, T. J. Rogers<sup>3</sup>, E. Unterwald<sup>1</sup>, <sup>1</sup>CSAR, Temple University, Philadelphia, PA, <sup>2</sup>Fox Chase Cancer Center, Philadelphia, PA, <sup>3</sup>Center for Inflammation, Translational and Clinical Lung Research, Temple University, Philadelphia, PA
- 27 *Predisposing genetic differences contribute to vulnerability to escalate cocaine intake in rats*  
M. Valenza, R. Picetti, V. Yuferov, M. Kreek, The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY
- 28 *Genetic background influences the change from the discriminative stimulus to the rewarding effects of psychostimulants in rats*  
T. Suzuki, D. Aikawa, A. Takanohashi, T. Saeki, M. Shibasaki, T. Mori, Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan
- 29 *Discrete-trial choice procedure: Methamphetamine vs. an alternative nondrug reward*  
D. Caprioli, L. Xuan, T. Zeric, N. Marchant, J. Bossert, Y. Shaham, Behavioral Neuroscience, National Institute on Drug Abuse IRP, Baltimore, MD
- 30 *96-Hour methamphetamine self-administration in male and female rats: Effects on brain reward pathways*  
E. M. Cornett, N. E. Goeders, Pharmacology, Toxicology, Neuroscience, LSU Health Sciences Center, Shreveport, LA

- 31 *Social interaction may reduce amphetamine reward in male adolescent rats by activating mesocorticolimbic dopamine systems*  
V. G. Weiss, R. S. Hofford, J. R. Yates, M. T. Bardo, University of Kentucky, Lexington, KY
- 32 *Methamphetamine self-administration in rats is diminished by wheel access in the prior 22 hours*  
M. A. Taffe, S. M. Aarde, K. Creehan, S. A. Vandewater, CNAD, The Scripps Research Institute, La Jolla, CA
- 33 *Effects of the combination of exercise (wheel running) and atomoxetine on cocaine-seeking behavior in rats*  
N. Zlebnik, M. E. Carroll, University of Minnesota, Minneapolis, MN
- 34 *mTOR-dependent plasticity: Don't forget macroautophagy*  
C. A. Torres<sup>1,2</sup>, D. Garton<sup>3</sup>, W. Setlik<sup>4</sup>, M. Gershon<sup>4</sup>, D. Sulzer<sup>2</sup>, <sup>1</sup>Integrated Program in Cellular, Molecular, and Biomedical Studies, Columbia University, New York, NY, <sup>2</sup>Departments of Psychiatry, Neurology and Pharmacology, Columbia University, New York, NY, <sup>3</sup>Columbia College, Columbia University, New York, NY, <sup>4</sup>Department of Pathology, Columbia University, New York, NY
- 35 *Exposure to fluoxetine during adolescence increases sensitivity to the rewarding effects of cocaine in adulthood*  
S. J. Nieto<sup>1</sup>, L. M. Riggs<sup>1</sup>, N. N. Zamora<sup>1</sup>, A. R. Zavala<sup>2</sup>, S. D. Iniguez<sup>1</sup>, <sup>1</sup>Psychology, California State University, San Bernardino, CA, <sup>2</sup>Psychology, California State University, Long Beach, CA
- 36 *The effects of social learning on the acquisition of cocaine self-administration*  
M. A. Smith, R. T. Lacy, J. T. Strickland, Davidson College, Davidson, NC
- 37 *Role of NR4A1 (Nur77) and NR4A3 (NOR-1) in the nucleus accumbens in conferring the protective addiction phenotype from environmental enrichment*  
E. Crofton<sup>1,2,3</sup>, Y. Zhang<sup>1,2</sup>, D. Li<sup>1,2</sup>, T. Green<sup>1,2</sup>, <sup>1</sup>Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>3</sup>Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX
- 38 *Overexpression of  $\Delta$ FosB in rat nucleus accumbens shell mimics environmental enrichment in sucrose self-administration and cocaine seeking*  
Y. Zhang<sup>1,2</sup>, E. Crofton<sup>1,2,4</sup>, D. Li<sup>1,2</sup>, X. Fan<sup>1,2</sup>, E. J. Nestler<sup>3</sup>, T. Green<sup>1,2</sup>, <sup>1</sup>Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>3</sup>Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, <sup>4</sup>Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX
- 39 *Behavioral and molecular factors contributing to beneficial effects of environmental enrichment and extinction training on cocaine relapse prevention*  
J. M. Gauthier<sup>1</sup>, A. Lin<sup>2</sup>, B. A. Nic Dhonnchadha<sup>1</sup>, H. Man<sup>2</sup>, K. M. Kantak<sup>1</sup>, <sup>1</sup>Psychology, Boston University, Boston, MA, <sup>2</sup>Biology, Boston University, Boston, MA
- 40 *Cocaine-conditioned locomotor response: Modulating roles of environmental context and neural plasticity*  
J. Nguyen, M. B. Gatch, M. J. Forster, Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX

**IMAGING**

- 41 *Temporal profile of fronto-striatal-limbic activity during implicit decisions in drug dependence*  
D. Yamamoto<sup>1</sup>, J. Reynolds<sup>2</sup>, T. Krmpotich<sup>1</sup>, M. Banich<sup>3,1</sup>, L. Thompson<sup>1</sup>, J. Tanabe<sup>1</sup>,  
<sup>1</sup>University of Colorado Denver, Aurora, CO, <sup>2</sup>University of Denver, Denver, CO, <sup>3</sup>University  
of Colorado Boulder, Boulder, CO
- 42 *A hyper-connected and resilient small-world network in the cocaine-dependent brain*  
Z. Wang<sup>1</sup>, J. Suh<sup>1</sup>, Z. A. Monge<sup>1</sup>, C. P. O'Brien<sup>1,2</sup>, A. Childress<sup>1,2</sup>, <sup>1</sup>Psychiatry, U of  
Pennsylvania, Philadelphia, PA, <sup>2</sup>VAMC, Philadelphia VA, Philadelphia, PA
- 43 *Can we use cue-related brain responses to predict which cocaine patients will take more risks?*  
Z. A. Monge<sup>1</sup>, K. Jagannathan<sup>1</sup>, J. Suh<sup>1,2</sup>, R. Ehrman<sup>1,2</sup>, K. A. Young<sup>1</sup>, T. Franklin<sup>1</sup>,  
D. Langleben<sup>1,2</sup>, C. P. O'Brien<sup>1,2</sup>, A. Childress<sup>1</sup>, <sup>1</sup>Psychiatry, University of Pennsylvania,  
Philadelphia, PA, <sup>2</sup>VA MIRECC, Philadelphia, PA
- 44 *Self-regulation of craving-related brain activation in cocaine users via realtime fMRI*  
M. Canterberry, T. LeMatty, C. A. Hanlon, M. S. George, K. T. Brady, Medical University of  
South Carolina, Charleston, SC
- 45 *Modeling causal relationship between memory and craving-related brain networks in non-  
treatment seeking cocaine smokers using IMAGES, a graph theoretic approach*  
S. Ray<sup>1</sup>, C. Hanson<sup>2</sup>, M. Haney<sup>3</sup>, B. Biswal<sup>4</sup>, S. J. Hanson<sup>2,5</sup>, <sup>1</sup>CAS, Rutgers University,  
Piscataway, NJ, <sup>2</sup>RUBIC, Rutgers University, Newark, NJ, <sup>3</sup>Columbia University, New  
York, NY, <sup>4</sup>New Jersey Institute of Technology, Newark, NJ, <sup>5</sup>Psychology, Rutgers  
University, Newark, NJ
- 46 *A PET imaging study on the effects of treatment with modafinil and topiramate on brain  
mechanisms underlying cocaine dependence in concurrent cocaine-and heroin-dependent  
patients*  
A. M. Weinstein<sup>1,2</sup>, N. Freedman<sup>1</sup>, I. Herman<sup>3</sup>, E. Mishani<sup>1</sup>, H. Atlan<sup>1</sup>, R. Chisin<sup>1</sup>, <sup>1</sup>Nuclear  
Medicine and Medical Biophysics, Hadassah Hospital, Jerusalem, Israel, <sup>2</sup>Behavioral  
Sciences, University of Ariel, Ariel, Israel, <sup>3</sup>Jaffa Treatment Center for Drug Victims, Jaffa,  
Israel
- 47 *Increased ventral striatum activation in response to heroin cues in heroin-dependent women  
after extended-release naltrexone injection*  
A. Wang<sup>1</sup>, K. Jagannathan<sup>1</sup>, I. Elman<sup>2</sup>, A. R. Childress<sup>1</sup>, H. R. Kranzler<sup>1</sup>, C. P. O'Brien<sup>1</sup>,  
D. Langleben<sup>1,3</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Harvard University,  
Cambridge, MA, <sup>3</sup>Veterans Administration, Philadelphia, PA
- 48 *Childhood maltreatment and amygdala connectivity in methamphetamine dependence*  
M. Kohno<sup>1</sup>, A. C. Dean<sup>1</sup>, G. Helleman<sup>1</sup>, E. London<sup>1,2</sup>, <sup>1</sup>Department of Psychiatry and  
Biobehavioral Sciences and Semel Institute, David Geffen School of Medicine, University  
of California, Los Angeles, CA, <sup>2</sup>Department of Molecular and Medical Pharmacology,  
University of California, Los Angeles, CA
- 49 *Striatal dopamine D2/3 receptors in methamphetamine users: Recovery with exercise and  
abstinence*  
C. Robertson<sup>1,4</sup>, J. Chudzynski<sup>2</sup>, R. Rawson<sup>2</sup>, C. Cooper<sup>3</sup>, L. Mooney<sup>2</sup>, A. Brown<sup>5,4</sup>,  
M. Mandelkern<sup>4</sup>, K. Ishibashi<sup>2,4</sup>, E. London<sup>1,2,4</sup>, <sup>1</sup>Pharmacology, UCLA, Los Angeles, CA,  
<sup>2</sup>Psychiatry, UCLA, Los Angeles, CA, <sup>3</sup>Physiology, UCLA, Los Angeles, CA, <sup>4</sup>VA Health  
System, Los Angeles, CA, <sup>5</sup>Charles Drew Univ, Los Angeles, CA
- 50 *Craving for methamphetamine is negatively associated with gray-matter volume*  
A. M. Morales<sup>1</sup>, M. Kohno<sup>1</sup>, A. Dean<sup>1</sup>, E. D. London<sup>2</sup>, <sup>1</sup>Psychiatry and Biobehavioral  
Sciences, UCLA, Los Angeles, CA, <sup>2</sup>Molecular and Medical Pharmacology, UCLA, Los  
Angeles, CA

- 51 *Age of cigarette smoking onset is associated with P300 smoking cue reactivity: Preliminary EEG findings*  
Y. Mashhoon, S. L. Farmer, G. H. Trksak, S. E. Lukas, McLean Imaging Center, McLean Hospital | Harvard Medical School, Belmont, MA
- 52 *d-Amphetamine effects and monetary incentive delay task performance: An fMRI Study*  
T. H. Kelly<sup>1</sup>, A. Anderson<sup>1</sup>, S. Jenkins<sup>1</sup>, A. M. Harvanko<sup>1</sup>, C. Martin<sup>1</sup>, J. S. Fogel<sup>1</sup>, J. Joseph<sup>2</sup>, J. A. Lile<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>Medical University of South Carolina, Charleston, SC
- 53 *Real-time functional MRI feedback attenuates cue-induced craving in non-treatment-seeking nicotine-dependent smokers*  
K. T. Brady<sup>1,2</sup>, C. A. Hanlon<sup>1</sup>, K. Hartwell<sup>1,2</sup>, J. Borckardt<sup>1</sup>, J. Prisciandaro<sup>1</sup>, M. Canterbury<sup>1</sup>, X. Li<sup>1</sup>, T. LeMatty<sup>1</sup>, M. Owens<sup>1</sup>, M. E. Saladin<sup>1</sup>, M. Moran-Santa Maria<sup>1</sup>, M. George<sup>1,2</sup>, <sup>1</sup>Psychiatry, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Ralph H. Johnson VAMC, Charleston, SC
- 54 *WITHDRAWN*
- 55 *Intending to quit smoking is associated with frontostriatal grey matter volume variation*  
P. McConnell<sup>1</sup>, A. R. Mathew<sup>1</sup>, E. Garland<sup>2</sup>, J. McClernon<sup>3</sup>, B. Froeliger<sup>1,3</sup>, <sup>1</sup>Neurosciences, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Huntsman Cancer Institute, University of Utah, Salt Lake, UT, <sup>3</sup>Psychiatry & Behavioral Medicine, Duke University, Durham, NC
- 56 *Associations between gray matter volume, smoker status, and smoking heaviness*  
A. R. Mathew<sup>1</sup>, P. McConnell<sup>1</sup>, J. McClernon<sup>2</sup>, B. Froeliger<sup>1,2</sup>, <sup>1</sup>Neurosciences, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Department of Psychiatry and Behavioral Medicine, Duke University Medical Center, Durham, NC
- 57 *Effects of cannabis and cigarette smoking on gray matter volume: A voxel-based morphometry study*  
R. R. Wetherill, K. Jagannathan, J. Mumma, B. Johnson, H. Rao, A. Childress, T. Franklin, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 58 *Prefrontal and parietal volumes and cognition in emerging adult marijuana users*  
J. S. Price<sup>1</sup>, T. McQueeny<sup>2</sup>, S. Shollenbarger<sup>3</sup>, E. L. Browning<sup>3</sup>, J. Wieser<sup>3</sup>, K. M. Lisdahl<sup>3</sup>, <sup>1</sup>Psychiatry, McLean Hospital-Harvard Medical School, Belmont, MA, <sup>2</sup>Psychology, University of Cincinnati, Cincinnati, OH, <sup>3</sup>Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI
- 59 *Multimodal imaging reveals altered functional and structural connectivity of affective processing in alcohol dependence*  
C. B. Padula<sup>1</sup>, R. M. Anthenelli<sup>2</sup>, J. C. Elliassen<sup>3</sup>, E. Nelson<sup>3</sup>, K. M. Lisdahl<sup>4</sup>, <sup>1</sup>VA Palo Alto Health Care System, Palo Alto, CA, <sup>2</sup>VA San Diego Healthcare System, San Diego, CA, <sup>3</sup>University of Cincinnati, Cincinnati, OH, <sup>4</sup>University of Wisconsin Milwaukee, Milwaukee, WI
- 60 *Development of error processing in children of alcoholics*  
J. Hardee, R. A. Zucker, M. Heitzeg, University of Michigan, Ann Arbor, MI



- 61 *Exploring normative working memory variance to better understand disparities in risk for drug use disorders*  
T. Kearney-Ramos<sup>1</sup>, J. Fausett<sup>1</sup>, J. Gess<sup>1</sup>, A. Reno<sup>2</sup>, J. Peraza<sup>3</sup>, C. Kilts<sup>1</sup>, G. James<sup>1</sup>, <sup>1</sup>University of Arkansas for Medical Sciences, Little Rock, AR, <sup>2</sup>University of Virginia School of Medicine, Charlottesville, VA, <sup>3</sup>University of New Mexico Medical School, Albuquerque, NM

**ALCOHOL**

- 62 *The role of GABA<sub>A</sub> receptors on ethanol-induced type 1 IP<sub>3</sub> receptor up-regulation*  
K. Mizuno<sup>1</sup>, K. Kurokawa<sup>1</sup>, T. Suzuki<sup>2</sup>, S. Ohkuma<sup>1</sup>, <sup>1</sup>Department of Pharmacology, Kawasaki Medical School, Kurashiki, Japan, <sup>2</sup>Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Shinagawa, Japan
- 63 *Sex-related differences in oral operant ethanol self-administration in C57BL/6J mice*  
A. M. Stafford, D. H. Brunzell, Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA
- 64 *Ethanol metabolism in neural stem cells*  
E. McGrath, T. J. Dunn, J. Gao, P. Wu, Human Pathophysiology and Translational Medicine Translational Medicine, University of Texas Medical Branch, Galveston, TX
- 65 *Brain biomarkers of alcohol abuse at autopsy*  
M. Taherian<sup>1</sup>, J. Jones<sup>2</sup>, C. Williams<sup>1</sup>, L. Duque<sup>1</sup>, D. C. Mash<sup>1</sup>, <sup>1</sup>Neurology, UM Miller Medical School, Miami, FL, <sup>2</sup>US Drug Testing Lab, Des Plaines, IL
- 66 *The effects of intranasal oxytocin on social cognition, implicit preferences and craving in alcoholics*  
J. Mitchell<sup>1</sup>, D. Weinstein<sup>1</sup>, P. Arcuni<sup>2</sup>, J. Laxamana<sup>1</sup>, J. Woolley<sup>2</sup>, <sup>1</sup>Neurology, UCSF, San Francisco, CA, <sup>2</sup>Psychiatry, UCSF, San Francisco, CA
- 67 *Unique factors associated with young women in substance use treatment: Craving, impulsivity, emotion regulation, and physiological response*  
C. Vinci<sup>1,2</sup>, J. Schumacher<sup>1</sup>, S. F. Coffey<sup>1</sup>, <sup>1</sup>University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>G.V. (Sonny) Montgomery VAMC, Jackson, MS
- 68 *Affect and impulsivity in daily risky behavior*  
J. A. Bonsu<sup>1</sup>, K. J. Derefinko<sup>1</sup>, R. J. Charnigo<sup>1</sup>, D. R. Lynam<sup>2</sup>, R. Milich<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>Purdue University, West Lafayette, IN
- 69 *Planned disinhibition? Risky sexual behavior, problematic alcohol use, and gender*  
R. MacLean, G. E. Shishkoff, S. J. Wilson, Psychology, Penn State, University Park, PA
- 70 *How does binge drinking affect risky behaviors on the road?*  
G. Pasa<sup>1</sup>, T. R. Sousa<sup>1</sup>, J. Lunnen<sup>2</sup>, F. P. Pechansky<sup>1</sup>, <sup>1</sup>Center for Drug and Alcohol Research - CPAD, Federal University of Rio Grande do Sul - UFRGS, Porto Alegre, Brazil, <sup>2</sup>Johns Hopkins International Injury Research Unit, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 71 *Examining the risk for developing alcohol-related problems among adult children of alcoholics*  
E. M. Murphy, M. L. Kelley, Old Dominion University, Norfolk, VA
- 72 *Maternal risk-taking propensity and children's alcohol use: A latent growth curve approach*  
J. W. Felton, J. M. Shadur, A. Vijay, A. N. Banducci, R. Stadnik, L. MacPherson, C. W. Lejuez, Psychology, University of Maryland, College Park, MD
- 73 *Model minority stereotype, psychological distress, substance use among Asian-American young adults*  
D. Iwamoto, C. W. Lejuez, E. Hamilton, M. Grivel, Univ. of Maryland, College Park, MD

- 74 *Trajectories of neighborhood disorder, alcohol initiation, and alcohol use among urban adolescents*  
A. J. Milam<sup>1,2</sup>, C. M. Furr-Holden<sup>1</sup>, P. J. Leaf<sup>1</sup>, N. Ialongo<sup>1</sup>, <sup>1</sup>Mental Health, Johns Hopkins School of Public Health, Baltimore, MD, <sup>2</sup>School of Medicine, Wayne State University, Detroit, MI
- 75 *Motives underlying the association of borderline personality disorder and alcohol-related problems*  
J. M. Loya, A. K. Matusiewicz, S. Z. Chen, C. W. Lejuez, CAPER/Psychology, University of Maryland, College Park, MD
- 76 *Loss of self-control over drinking and the relationship of alexithymia to quality of life in alcohol-dependent patients*  
F. A. Thorberg<sup>1,2,3</sup>, R. M. Young<sup>3,5</sup>, M. Lyvers<sup>4</sup>, J. P. Connor<sup>6,5</sup>, R. Tyssen<sup>2</sup>, A. S. Landheim<sup>1</sup>, E. London<sup>7</sup>, G. Feeney<sup>5,6</sup>, <sup>1</sup>Innlandet Hosp Trust, Brummundal, Norway, <sup>2</sup>Univ Oslo, Oslo, Norway, <sup>3</sup>Qld Univ Technol, Brisbane, QLD, Australia, <sup>4</sup>Bond Univ, Gold Coast, QLD, Australia, <sup>5</sup>Princess Alexandra Hosp, Brisbane, QLD, Australia, <sup>6</sup>Univ Qld, Brisbane, QLD, Australia, <sup>7</sup>Univ Calif Los Angeles, Los Angeles, CA
- 77 *The relationship between genetics and personality factors in peer-pressure susceptibility*  
R. S. Boyle, K. E. Siffin, M. B. Kitchens, M. Niculescu, Psychology, Lebanon Valley College, Annville, PA
- 78 *Alcohol consumption and loneliness in mid- and late-life*  
S. L. Canham, P. M. Mauro, C. N. Kaufmann, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 79 *What is the most cost-effective advertising strategy for alcohol pharmacotherapy clinical trials?*  
D. A. Tompkins, J. A. Harrison, E. C. Strain, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 80 *Impact of heavy drinking among drug users identified by screening in primary care*  
C. Maynié-François, D. M. Cheng, J. H. Samet, C. A. Lloyd-Tavaglino, T. P. Palfai, J. A. Bernstein, R. Saitz, Boston University, Boston Medical Center, Boston, MA
- 81 *Methods of pre-post analysis in the presence of missing data*  
A. Glass<sup>1</sup>, J. J. Mariani<sup>2</sup>, M. Pavlicova<sup>3</sup>, E. V. Nunes<sup>2</sup>, F. R. Levin<sup>2</sup>, M. M. Wall<sup>1,3</sup>, <sup>1</sup>Biostatistics, New York State Psychiatric Institute, New York, NY, <sup>2</sup>Psychiatry, Columbia University, New York, NY, <sup>3</sup>Biostatistics, Columbia University, New York, NY
- 82 *A brief behavioral telehealth intervention for veterans with alcohol use disorders in VA primary care: A pilot investigation*  
E. J. Santa Ana<sup>1,2</sup>, K. Lamb<sup>1,2</sup>, S. LaRowe<sup>1,2</sup>, P. Nietert<sup>1</sup>, <sup>1</sup>MUSC, Charleston, SC, <sup>2</sup>Charleston VAMC, Charleston, SC
- 83 *The role of drinking motives among tobacco-using problem drinkers in terms of cognitive-based smoking processes and quit failure*  
L. Garey<sup>1</sup>, D. W. Foster<sup>2</sup>, M. J. Zvolensky<sup>1</sup>, J. W. Ditte<sup>3</sup>, N. B. Schmidt<sup>4</sup>, <sup>1</sup>University of Houston, Houston, TX, <sup>2</sup>Harvard University, Cambridge, MA, <sup>3</sup>Syracuse University, Syracuse, NY, <sup>4</sup>Florida State University, Tallahassee, FL

**POLYDRUG ABUSE I**

- 84 *Caffeine and alcohol intake and nicotine dependence severity in female smokers*  
C. Riyad<sup>1</sup>, K. M. Gray<sup>1</sup>, M. E. Saladin<sup>2,1</sup>, <sup>1</sup>Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Department of Health Science and Research, Medical University of South Carolina, Charleston, SC

- 85 *Transitions in polydrug use among heroin and methamphetamine injectors in Tijuana, Mexico*  
M. C. Meacham<sup>1,2</sup>, K. D. Wagner<sup>1</sup>, T. Mackey<sup>1</sup>, T. L. Patterson<sup>1</sup>, S. Strathdee<sup>1</sup>, S. Roesch<sup>2</sup>,  
<sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>San Diego State University, San Diego, CA
- 86 *Mood, alexithymia, dispositional mindfulness, sensitivity to reward and punishment, frontal systems functioning and impulsivity in clients undergoing treatment for substance use disorders*  
M. Lyvers<sup>1</sup>, R. Hinton<sup>1</sup>, M. S. Edwards<sup>1</sup>, F. A. Thorberg<sup>2</sup>, <sup>1</sup>Psychology, Bond University, Gold Coast, QLD, Australia, <sup>2</sup>Medicine, University of Oslo, Oslo, Norway
- 87 *Associations of smoking history with cigarette smoking expectancies among adults in residential substance use treatment*  
E. Hoffman, K. Long, J. Soldigner, L. MacPherson, Psychology, University of Maryland College Park, College Park, MD
- 88 *Non-heterosexual identity and substance use disorders: The mediating role of borderline personality disorder features*  
L. R. Few<sup>1</sup>, C. A. Sloan<sup>2</sup>, N. G. Martin<sup>3</sup>, T. J. Trull<sup>4</sup>, A. Agrawal<sup>1</sup>, M. T. Lynskey<sup>5</sup>,  
<sup>1</sup>Washington University School of Medicine, Saint Louis, MO, <sup>2</sup>VA Boston Healthcare System, Boston, MA, <sup>3</sup>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia, <sup>4</sup>University of Missouri, Columbia, MO, <sup>5</sup>King's College London, London, United Kingdom
- 89 *Connecting states and traits: A look at personality and response to stress in real-time*  
M. L. Jobes, D. H. Epstein, K. A. Phillips, K. L. Preston, NIDA IRP, Baltimore, MD
- 90 *Neuropsychological changes during residential substance use treatment*  
S. J. Lookatch<sup>1,3</sup>, E. Katz<sup>2</sup>, S. Anderson<sup>3</sup>, R. Shorey<sup>1,3</sup>, G. Stuart<sup>1</sup>, T. Moore<sup>1</sup>, <sup>1</sup>Psychology, University of Tennessee, Knoxville, TN, <sup>2</sup>Psychology, Towson University, Towson, MD, <sup>3</sup>Cornerstone of Recovery, Louisville, TN
- 91 *Relationship between sleep problems and heavy/problem substance use in primary care patients*  
T. Moore<sup>1</sup>, T. Verno<sup>1</sup>, A. Werntz<sup>1</sup>, P. Dillon<sup>1</sup>, T. Gentry<sup>1</sup>, V. Walters<sup>2</sup>, S. R. Hursh<sup>2,3</sup>, P. G. Roma<sup>2,3</sup>, B. Rybarczyk<sup>1</sup>, D. Svikis<sup>1</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Institutes for Behavior Resources, Baltimore, MD, <sup>3</sup>Johns Hopkins University School of Medicine, Baltimore, MD
- 92 *Strategies to influence attitudes towards pharmacotherapies for alcohol and opioid use disorders*  
K. Alanis-Hirsch<sup>1</sup>, R. Croff<sup>2</sup>, J. Ford<sup>3</sup>, L. Schmidt<sup>4</sup>, D. McCarty<sup>2</sup>, M. Chalk<sup>1</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Oregon Health & Science University, Portland, OR, <sup>3</sup>Center for Health Enhancement System Studies, Madison, WI, <sup>4</sup>University of California, San Francisco, CA
- 93 *Smoking crack might increase high risk injection practices among people who inject drugs*  
E. Roy<sup>1,2,3</sup>, C. Blanchette<sup>4</sup>, P. Leclerc<sup>3</sup>, M. Alary<sup>2,4</sup>, C. Morissette<sup>2,3</sup>, K. Blouin<sup>2</sup>, <sup>1</sup>Sciences de la santé communautaire, Université de Sherbrooke, Longueuil, QC, Canada, <sup>2</sup>Institut National de Santé Publique du Québec, Montréal, QC, Canada, <sup>3</sup>Direction de Santé Publique de Montréal, Montréal, QC, Canada, <sup>4</sup>Département de médecine sociale et préventive, Université Laval, Québec, QC, Canada
- 94 *Factors associated with precursors to initiating other people into injection drug use*  
R. Bluthenthal<sup>1</sup>, L. Wenger<sup>2</sup>, J. Thing<sup>1</sup>, D. Chu<sup>1</sup>, J. Lorvick<sup>2</sup>, B. Quinn<sup>3</sup>, A. Kral<sup>2</sup>, <sup>1</sup>Preventive Medicine, University of Southern California, Los Angeles, CA, <sup>2</sup>Urban Health, RTI International, San Francisco, CA, <sup>3</sup>Burnet Institute, Melbourne, VIC, Australia

- 95 *Clinician beliefs and behaviors regarding screening and brief intervention for drug use of their community health center patients*  
A. Reddy, L. Gelberg, R. Andersen, University of California Los Angeles, Los Angeles, CA
- 96 *Feasibility of the Quit Using Drugs Intervention Trial*  
M. Vahidi<sup>1</sup>, M. Rico<sup>1</sup>, J. Scholtz<sup>1</sup>, M. Garcia<sup>1</sup>, R. Andersen<sup>2</sup>, J. Yacenda<sup>1</sup>, L. Gelberg<sup>1,2</sup>,  
<sup>1</sup>Family Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, <sup>2</sup>UCLA School of Public Health, Los Angeles, CA
- 97 *Screening and brief treatment for illicit drug use in primary care: Feasibility and acceptability*  
A. C. Brooks<sup>1</sup>, C. M. Carpenedo<sup>1</sup>, J. Lauby<sup>2</sup>, D. Metzger<sup>1,3</sup>, E. Byrne<sup>2</sup>, K. Favor<sup>4</sup>,  
K. C. Kirby<sup>1,3</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Public Health Management Corporation, Philadelphia, PA, <sup>3</sup>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Department of Psychology, Lincoln University, Lincoln University, PA
- 98 *RecoveryTrack-ExtendedCare™, a novel monitoring and outreach intervention*  
J. Cacciola<sup>1,2</sup>, A. C. Brooks<sup>1</sup>, K. Kizina<sup>1</sup>, E. Moberg<sup>1</sup>, J. Berman<sup>1</sup>, G. DiGuseppi<sup>1</sup>, <sup>1</sup>Center on the Continuum of Care, Treatment Research Institute, Philadelphia, PA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA
- 99 *Computer vs. in-person brief intervention for drug misuse: 12-month outcomes*  
R. P. Schwartz<sup>1</sup>, J. Gryczynski<sup>1</sup>, S. G. Mitchell<sup>1</sup>, A. Gonzales<sup>2</sup>, T. Peterson<sup>2</sup>, A. Moseley<sup>2</sup>,  
K. E. O'Grady<sup>3</sup>, S. J. Ondersma<sup>4</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Sangre de Cristo Community Health Partnership, Santa Fe, NM, <sup>3</sup>University of Maryland, College Park, MD, <sup>4</sup>Wayne State University, Detroit, MI
- 100 *An Internet-acquired recovery sample: Initial findings from the International Quit and Recovery Registry*  
A. G. Wilson<sup>1</sup>, C. Franck<sup>2</sup>, M. N. Koffarnus<sup>1</sup>, R. Reese<sup>3</sup>, K. D. Bixel<sup>1</sup>, W. K. Bickel<sup>1</sup>, <sup>1</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Virginia Tech, Blacksburg, VA, <sup>3</sup>Jefferson College of Health Sciences, Roanoke, VA
- 101 *Ecological momentary assessment to predict the risk of relapse*  
M. L. Dennis, C. K. Scott, R. R. Funk, Chestnut Health Systems, Normal and Chicago, IL
- 102 *Predicting mood and craving from real-time neighborhood surroundings*  
K. L. Preston<sup>1</sup>, M. Tyburski<sup>1</sup>, K. A. Phillips<sup>1</sup>, M. L. Jobes<sup>1</sup>, C. D. Furr-Holden<sup>2</sup>,  
M. Vahabzadeh<sup>1</sup>, M. Mezghanni<sup>1</sup>, J. Lin<sup>1</sup>, D. H. Epstein<sup>1</sup>, <sup>1</sup>NIDA Intramural Research Program, Baltimore, MD, <sup>2</sup>Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
- 103 *Uncomfortably numb: Substance use associated with elder mistreatment*  
D. V. Flores<sup>1,2,3</sup>, J. Burnett<sup>1,2,3</sup>, J. Booker<sup>4,2</sup>, C. B. Dyer<sup>1,2,3</sup>, <sup>1</sup>University of Texas Medical School, Houston, TX, <sup>2</sup>Texas Elder Abuse and Mistreatment Institute, Houston, TX, <sup>3</sup>Harris Health System, Houston, TX, <sup>4</sup>Adult Protective Services Region 6, Houston, TX
- 104 *Associations between childhood maltreatment, intimate partner violence, and substance use disorders*  
K. Walsh, D. S. Hasin, Columbia University, New York, NY
- 105 *Do social support and negative emotions condition the effect of child custody loss on drug use?*  
K. Harp<sup>1,2</sup>, C. B. Oser<sup>2,3</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, <sup>3</sup>Sociology, University of Kentucky, Lexington, KY

- 106 *Childcare in families with SUD mothers or fathers*  
H. R. Lawrence<sup>1</sup>, M. L. Kelley<sup>2</sup>, E. M. Murphy<sup>2</sup>, G. M. D'Lima<sup>2</sup>, R. J. Milletich<sup>2</sup>, B. Hollis<sup>2</sup>, C. G. Cooke<sup>2</sup>, M. Stockstad<sup>3</sup>, <sup>1</sup>Department of Psychology, University of Maine, Orono, ME, <sup>2</sup>Department of Psychology, Old Dominion University, Norfolk, VA, <sup>3</sup>Department of Psychology, Appalachian State University, Boone, NC
- 107 *Family history of drug problems as a marker for other health risks in primary care patients*  
A. Alvanzo<sup>1</sup>, G. Villalobos<sup>2</sup>, P. Dillon<sup>2</sup>, S. Ondersma<sup>3</sup>, D. Svikis<sup>2</sup>, <sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>Virginia Commonwealth University, Richmond, VA, <sup>3</sup>Wayne State University, Detroit, MI
- 108 *What predicts continued substance use among probationers?*  
J. Lerch<sup>1</sup>, F. Taxman<sup>1</sup>, S. Walters<sup>2</sup>, <sup>1</sup>George Mason University, Fairfax, VA, <sup>2</sup>University of North Texas Health Science Center, Fort Worth, TX

**PSYCHIATRIC COMORBIDITY I**

- 109 *Distress tolerance moderates the relationship between social rejection and major depressive disorder in inner-city substance users*  
B. Ali, K. R. Hamilton, N. Bounoua, C. W. Lejuez, University of Maryland, College Park, MD
- 110 *Perceived discrimination, depressive symptoms, and substance use among African-American and Afro-Caribbean young adults*  
T. Clark<sup>1</sup>, J. Brook<sup>2</sup>, <sup>1</sup>School of Social Work, University of North Carolina, Chapel Hill, NC, <sup>2</sup>Psychiatry, New York University School of Medicine, New York, NY
- 111 *Significantly lower prevalence of psychopathology in Asian compared to non-Asian methadone-maintained patients*  
G. Bart, S. Lenz, Medicine, Hennepin County Medical Center, Minneapolis, MN
- 112 *Gender differences in psychiatric symptoms among opiate-dependent patients in Russia*  
A. Desrosiers<sup>1</sup>, E. Blokhina<sup>2</sup>, E. Krupitsky<sup>2</sup>, M. C. Chawarski<sup>1</sup>, <sup>1</sup>Yale School of Medicine, New Haven, CT, <sup>2</sup>St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation
- 113 *The impact of eye movement desensitization and reprocessing and schema therapy on addiction severity among a sample of French women suffering from PTSD and SUD*  
B. Perez-Dandieu<sup>1,2</sup>, H. Lenoir<sup>3</sup>, E. Othily<sup>3</sup>, G. Tapia<sup>3</sup>, M. Cassen<sup>2</sup>, J. Delile<sup>1,2</sup>, <sup>1</sup>Addiction, CEID, Bordeaux, France, <sup>2</sup>IMM, Cenon, France, <sup>3</sup>EA4139, Laboratoire Psychologie, Santé et Qualité de Vie, Université de Bordeaux, Bordeaux, France
- 114 *Past year non-medical opioid use and PTSD diagnosis: Interactions with gender and associations with symptom clusters*  
S. A. Cercone<sup>1</sup>, P. H. Smith<sup>2</sup>, K. M. Smith<sup>3</sup>, G. G. Homish<sup>1</sup>, S. McKee<sup>3</sup>, <sup>1</sup>Community Health and Health Behavior, University at Buffalo, The State University of New York, Buffalo, NY, <sup>2</sup>Epidemiology and Public Health, Yale University, New Haven, CT, <sup>3</sup>Department of Psychiatry, Yale University School of Medicine, New Haven, CT
- 115 *Pathways to change: Trajectories following treatment in women with co-occurring PTSD and substance use disorders*  
T. Lopez-Castro<sup>1</sup>, M. Hu<sup>2</sup>, D. A. Hien<sup>1</sup>, <sup>1</sup>The City College of New York, NY, NY, <sup>2</sup>NY State Psychiatric Institute, NY, NY
- 116 *Incentivizing adherence to prolonged exposure for PTSD: Preliminary results*  
J. M. Peirce<sup>1</sup>, R. L. Schacht<sup>2</sup>, V. L. King<sup>1</sup>, R. K. Brooner<sup>1</sup>, <sup>1</sup>Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Psychology, University of Maryland, Baltimore County, Baltimore, MD

- 117 *To reduce or abstain? Substance use goals in the treatment of veterans with substance use disorders and comorbid PTSD*  
B. E. Lozano<sup>1,2</sup>, D. Teer<sup>1</sup>, S. E. Back<sup>1,2</sup>, <sup>1</sup>Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Mental Health Service, Ralph H. Johnson VAMC, Charleston, SC
- 118 *How does change in alcohol misuse and depression comorbidity impact on neuropsychological test performance after 12 months?*  
S. A. Hunt, A. L. Baker, P. Michie, University of Newcastle, Newcastle, NSW, Australia
- 119 *Relationship of alcohol and cocaine on mood episodes among HIV-infected adults with bipolar disorder and major depressive disorder*  
L. J. King, M. D. Key, S. Towe, C. S. Meade, Duke University, Durham, NC
- 120 *Increasing psychiatric comorbidity in recent smoking birth-cohorts*  
A. Talati<sup>1</sup>, K. Keyes<sup>2</sup>, D. S. Hasin<sup>2,1</sup>, <sup>1</sup>Psychiatry, Columbia University and New York State Psychiatric Institute, New York, NY, <sup>2</sup>Epidemiology, Columbia University Mailman School of Public Health, New York, NY
- 121 *Cigarette smoking and the onset and persistence of major depressive disorder among adults in the United States: 1994-2005*  
M. Zvolensky<sup>1,2</sup>, J. Bakhshaie<sup>1</sup>, R. Goodwin<sup>3,4</sup>, <sup>1</sup>Psychology, University of Houston, Houston, TX, <sup>2</sup>MD Anderson Cancer Center, Houston, TX, <sup>3</sup>Psychology, Queens College, City University of New York, New York, NY, <sup>4</sup>Epidemiology, Columbia University, New York, NY
- 122 *Examining vulnerability to smokeless tobacco use among adolescents and adults with major depressive disorder*  
R. Redner<sup>1,2</sup>, T. J. White<sup>1,2</sup>, S. T. Higgins<sup>1,2,3</sup>, V. Harder<sup>2,3</sup>, <sup>1</sup>Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, <sup>2</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>3</sup>Psychology, University of Vermont, Burlington, VT
- 123 *Changes in the prevalence of depression and anxiety disorders among daily smokers in the United States: 1990 to 2001*  
R. Goodwin<sup>1,2</sup>, S. Galea<sup>2</sup>, M. J. Zvolensky<sup>3,4</sup>, M. Wall<sup>5,6</sup>, Y. Nomura<sup>1,7</sup>, D. S. Hasin<sup>2,5,6</sup>, <sup>1</sup>Psychology, City University of New York (CUNY), Flushing, NY, <sup>2</sup>Epidemiology, Columbia University, New York, NY, <sup>3</sup>Psychology, University of Houston, Houston, TX, <sup>4</sup>Psychiatry, MD Anderson Cancer Center, Houston, TX, <sup>5</sup>Psychiatry, Columbia University, New York, NY, <sup>6</sup>Psychiatry, New York State Psychiatric Institute, New York, NY, <sup>7</sup>Psychiatry, Mount Sinai School of Medicine, New York, NY
- 124 *Depression, nicotine withdrawal, and smoking urges in smoking cessation*  
H. H. Reid<sup>1,2</sup>, D. M. Ledgerwood<sup>2</sup>, <sup>1</sup>Psychology, Wayne State University, Detroit, MI, <sup>2</sup>Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI
- 125 *Comparing smoking cessation interventions for persons with serious mental illness*  
P. Penn<sup>1</sup>, S. M. Gallagher<sup>2</sup>, E. Schindler<sup>3</sup>, W. K. Layne<sup>1</sup>, <sup>1</sup>La Frontera Arizona, Tucson, AZ, <sup>2</sup>S. Arizona VA, Tucson, AZ, <sup>3</sup>Child & Family Resources, Tucson, AZ
- 126 *Tobacco-related mortality among persons with mental health and substance abuse problems*  
F. Bandiera<sup>1</sup>, J. Gwydish<sup>1</sup>, B. Anteneh<sup>2</sup>, <sup>1</sup>University of California, San Francisco, San Francisco, CA, <sup>2</sup>Oregon Health Authority, Salem, OR

- 127 *Individualized treatment for tobacco dependence in addictions treatment settings: The role of current depressive symptoms on outcomes at 3 and 6 months*  
L. Zawertailo<sup>1,2</sup>, D. Baliunas<sup>1</sup>, P. L. Selby<sup>1,3</sup>, <sup>1</sup>Addictions Program, Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada, <sup>3</sup>Family and Community Medicine, University of Toronto, Toronto, ON, Canada
- 128 *Baseline depressive symptoms and contingency management outcomes in smokers*  
O. Garcia-Rodriguez, S. Weidberg, V. Martínez Loredó, J. R. Fernández-Hermida, R. Secades-Villa, Department of Psychology, University of Oviedo, Oviedo, Spain
- 129 *Cannabis smoking may exacerbate depression-attributable functional impairment among recently active depressed cases*  
B. J. Fairman, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

**PROGRAM DESCRIPTION**

- 130 *Disseminating information to psychologists on evidence-based practices to treat smoking in health priority populations*  
L. Beatty<sup>1</sup>, M. Iguchi<sup>2</sup>, F. Z. Belgrave<sup>3</sup>, G. Keita<sup>1</sup>, E. Andoh<sup>1</sup>, P. DiSandro<sup>1</sup>, <sup>1</sup>American Psychological Association, Washington, DC, <sup>2</sup>Georgetown University, Washington, DC, <sup>3</sup>Virginia Commonwealth, Richmond, VA
- 131 *Identification and evaluation of Internet forum discussion as a component of a post market-surveillance strategy for tobacco products*  
E. C. McNaughton, S. Bowman, K. McHugh, M. Behling, S. F. Butler, S. H. Budman, Inflexion, Inc, Newton, MA
- 132 *Exploratory interviews with e-cigarette and snus users*  
S. Bowman, E. C. McNaughton, K. McHugh, M. Behling, S. F. Butler, S. H. Budman, Inflexion, Inc, Newton, MA
- 133 *A pilot specialty jail diversion program for justice-involved veterans with co-occurring disorders*  
D. Smelson<sup>1,2</sup>, D. A. Pinals<sup>3,2</sup>, L. Sawh<sup>1,2,4</sup>, C. Fulwiler<sup>2</sup>, S. Singer<sup>2</sup>, K. O'Connor<sup>2</sup>, W. Fisher<sup>4</sup>, S. Hartwell<sup>5</sup>, G. Gonzalez<sup>2</sup>, <sup>1</sup>Department of Veterans Affairs, Bedford, MA, <sup>2</sup>University of Massachusetts Medical School, Worcester, MA, <sup>3</sup>Massachusetts Department of Mental Health, Boston, MA, <sup>4</sup>University of Massachusetts Lowell, Lowell, MA, <sup>5</sup>University of Massachusetts Boston, Boston, MA
- 134 *The use of fingernail drug screening in multiply convicted OWI offenders in Kenosha County, WI*  
D. E. Lewis<sup>1</sup>, G. Brown<sup>2</sup>, I. Shu<sup>1</sup>, J. Jones<sup>1</sup>, <sup>1</sup>U.S. Drug Testing Labs, Des Plaines, IL, <sup>2</sup>Hope Council, Kenosha, WI
- 135 *Studies on medications for addiction treatment in correctional settings*  
R. P. Schwartz<sup>2</sup>, J. D. Lee<sup>3</sup>, D. Farabee<sup>4</sup>, R. K. Chandler<sup>1</sup>, <sup>1</sup>National Institute on Drug Abuse, North Bethesda, MD, <sup>2</sup>Friends Research Institute, Baltimore, MA, <sup>3</sup>New York University, New York City, NY, <sup>4</sup>University of California - Los Angeles, Los Angeles, CA
- 136 *Combining strategies: Using evidence-based interventions to build a more effective treatment program*  
J. Rhodes<sup>1</sup>, D. C. Lott<sup>1,2</sup>, <sup>1</sup>Addiction Treatment Programs, Linden Oaks Hospital at Edward, Naperville, IL, <sup>2</sup>Psychiatry, University of Illinois at Chicago, Chicago, IL

- 137 *Developing an evidence-based intervention targeting high-risk migrant workers*  
R. Shrestha<sup>1</sup>, M. Copenhaver<sup>2</sup>, <sup>1</sup>Department of Community Medicine & Health Care, University of Connecticut, Farmington, CT, <sup>2</sup>Department of Allied Health & Sciences, University of Connecticut, Storrs, CT
- 138 *Web-based screening, brief intervention, and referral to treatment program in high schools*  
B. L. Curtis, A. T. McLellan, A. Woodworth, Treatment Research Institute, Philadelphia, PA
- 139 *Navigating the world of adolescent substance abuse treatment through a web-based consumer guide*  
K. Meyers, J. Cacciola, S. Bates, K. C. Kirby, A. T. McLellan, Treatment Research Institute, Philadelphia, PA
- 140 *Web-based medical school education on substance use disorders*  
A. T. McLellan<sup>1,2</sup>, B. L. Curtis<sup>1</sup>, B. Nordstrom<sup>3</sup>, J. Skrajewski<sup>4</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Dartmouth College, Hanover, NH, <sup>4</sup>Betty Ford Institute, Rancho Mirage, CA
- 141 *UNODC-WHO Program on Drug Dependence Treatment and Care: Building treatment capacity in low- and middle-income countries*  
E. Saenz<sup>2,1</sup>, G. Gerra<sup>1</sup>, A. Busse<sup>2</sup>, <sup>1</sup>Drug Prevention and Health Branch, United Nations Office on Drugs and Crime, Vienna, Austria, <sup>2</sup>Prevention, Treatment and Rehabilitation Section, United Nations Office on Drugs and Crime, Vienna, Austria
- 142 *Implementing opioid overdose education and naloxone distribution in an outpatient community treatment program*  
D. C. Lott<sup>1,2</sup>, J. Rhodes<sup>1</sup>, <sup>1</sup>Addiction Treatment Programs, Linden Oaks Hospital at Edward, Naperville, IL, <sup>2</sup>Psychiatry, University of Illinois at Chicago, Chicago, IL
- 143 *Implementation of drug and HIV risk counseling in MMT programs in Taiwan*  
T. Lee<sup>1</sup>, M. C. Chawarski<sup>2</sup>, C. Peng<sup>1</sup>, C. Hung<sup>3</sup>, D. Metzger<sup>4</sup>, <sup>1</sup>National Taiwan Normal University, Taipei, Taiwan, <sup>2</sup>Psychiatry, Yale School of Medicine, New Haven, CT, <sup>3</sup>Taichung Veteran General Hospital, Taichung, Taiwan, <sup>4</sup>University of Pennsylvania, Philadelphia, PA
- 144 *Treatment of women with substance use disorder at high risk of stigmatization*  
P. Dolezalova, Clinic of Addictology, First Faculty of Medicine, Charles University, Prague, Czech Republic

**PRESCRIPTION DRUGS**

- 145 *Evaluation of the relationship between pain level and craving of prescription opioids*  
L. Ashrafioun<sup>1,2</sup>, H. Rosenberg<sup>1</sup>, <sup>1</sup>Psychology, Bowling Green State University, Bowling Green, OH, <sup>2</sup>Mental Health Services, VA Ann Arbor Healthcare System, Ann Arbor, MI
- 146 *Neurobiological and subjective stress reactivity among individuals with prescription opioid dependence: What is the role of interpersonal trauma exposure?*  
J. C. Hellmuth<sup>1</sup>, J. L. McCauley<sup>1</sup>, K. T. Brady<sup>1,2</sup>, S. E. Back<sup>1,2</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Ralph H. Johnson VAMC, Charleston, SC
- 147 *Nonmedical use of oxycodone and other opiate analgesics in the US, 2004-2011: Are military veterans at increased risk?*  
R. Kato Price<sup>1,2</sup>, M. Shroff<sup>1</sup>, C. van den Berk-Clark<sup>1</sup>, G. Widner<sup>1</sup>, S. Balan<sup>1</sup>, E. Nelson<sup>1</sup>, <sup>1</sup>Psychiatry, Washington University School of Medicine, Saint Louis, MO, <sup>2</sup>Research and Development, VA St. Louis Health Care System, Saint Louis, MO
- 148 *College student opinions about the use of non-medical prescription drugs*  
K. A. Parks, K. Levonyan-Radloff, S. Przybyla, A. Hequembourg, Research Institute on Addictions, University at Buffalo, Buffalo, NY



- 149 *A typology of prescription drug misuse: A Latent Class Approach to contexts and risks*  
B. C. Kelly<sup>1</sup>, H. J. Rendina<sup>2</sup>, B. E. Wells<sup>2</sup>, J. T. Parsons<sup>2</sup>, <sup>1</sup>Purdue University, West Lafayette, IN, <sup>2</sup>City University of New York, New York, NY
- 150 *Correlates of prescription drug market involvement*  
M. Vuolo<sup>1</sup>, B. C. Kelly<sup>1</sup>, B. E. Wells<sup>2</sup>, J. T. Parsons<sup>2</sup>, <sup>1</sup>Purdue University, West Lafayette, IN, <sup>2</sup>City University of New York, New York, NY
- 151 *Comparison of adolescent self-reports of the nonmedical use of scheduled prescription medications in self-administered surveys vs. semi-structured interviews*  
P. L. Ross-Durow, P. T. Veliz, S. E. McCabe, C. J. Boyd, Institute for Research on Women & Gender, University of Michigan, Ann Arbor, MI
- 152 *Experiences of discrimination and psychosocial health problems as correlates of recent prescription drug misuse among YMSM: Evidence of a syndemic effect*  
A. Kecojevic, S. Lankenau, Drexel University School of Public Health, Philadelphia, PA
- 153 *Prevalence and correlates of prescription stimulant misuse among youth in the emergency department*  
L. K. Whiteside<sup>1</sup>, R. Cunningham<sup>2</sup>, E. E. Bonar<sup>2</sup>, F. C. Blow<sup>2</sup>, P. Ehrlich<sup>2</sup>, M. Walton<sup>2</sup>, <sup>1</sup>Emergency Medicine, University of Washington, Seattle, WA, <sup>2</sup>Psychiatry, Surgery and Emergency Medicine, University of Michigan, Ann Arbor, MI
- 154 *Prescription opioid misuse among youth in primary care: A comparison of risk factors*  
L. A. Lin, M. A. Walton, F. C. Blow, Department of Psychiatry, University of Michigan, Ann Arbor, MI
- 155 *Identifying prescription drug misuse in primary care patients: A tale of two instruments*  
M. Weaver, G. Villalobos, T. Moore, P. Dillon, D. Svikis, Virginia Commonwealth University, Richmond, VA
- 156 *Primary care buprenorphine detoxification vs. maintenance for prescription opioid dependence*  
D. Fiellin, C. J. Cutter, B. A. Moore, D. Barry, P. O'Connor, R. S. Schottenfeld, Yale, New Haven, CT
- 157 *Patterns of concurrent substance use among prescription stimulant misusers: Results from the National Survey on Drug Use and Health*  
L. Chen<sup>1</sup>, R. Crum<sup>1,2,3</sup>, C. N. Kaufmann<sup>1</sup>, S. S. Martins<sup>4</sup>, E. C. Strain<sup>2</sup>, R. Mojtabai<sup>1,2</sup>, <sup>1</sup>Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3</sup>Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>4</sup>Epidemiology, Mailman School of Public Health, New York, NY
- 158 *Global impact of prescription opioid misuse: Europe and U.S.*  
J. L. Green<sup>1</sup>, E. M. Martinez<sup>1</sup>, A. Rosenblum<sup>1</sup>, T. Cicero<sup>1</sup>, R. C. Dart<sup>1</sup>, S. Walcher<sup>2</sup>, L. Somaini<sup>3</sup>, G. Deruvo<sup>3</sup>, H. Desel<sup>4</sup>, G. Milanese<sup>5</sup>, F. Sesana<sup>5</sup>, M. Guareschi<sup>6</sup>, K. McBride<sup>1</sup>, I. Maremmanni<sup>7</sup>, M. Parrino<sup>1</sup>, <sup>1</sup>RADARS(r) System, RMPDC, DHHA, Denver, CO, <sup>2</sup>CONCEPT, Munich, Italy, <sup>3</sup>SerT (Biella & Bitonto), Biella, Italy, <sup>4</sup>GIZ-Nord Poisons Centre, Gottingen, Germany, <sup>5</sup>Milan Poison Centre, Milan, Italy, <sup>6</sup>AU-CNS, Pietrarsa, Italy, <sup>7</sup>Santa Chiara University Hospital, Pisa, Italy
- 159 *Strategies to reduce prescription opioid abuse in the United States: How have they influenced the epidemic?*  
T. Green<sup>1,2</sup>, S. Bowman<sup>1,2</sup>, C. Los<sup>1</sup>, K. McHugh<sup>1</sup>, P. D. Friedmann<sup>2</sup>, <sup>1</sup>Inflexxion, Inc., Newton, MA, <sup>2</sup>Rhode Island Hospital, Providence, RI
- 160 *Prescription drug use, impairment warnings, and perceived risks among U.S. drivers*  
R. Pollini, J. Yao, T. Kelley-Baker, Pacific Institute for Research and Evaluation, Calverton, MD

- 161 *Florida's prescription drug monitoring program and oxycodone-caused mortality: A monthly time series analysis, 2003-2012*  
C. Delcher<sup>1,2,4</sup>, A. Wagenaar<sup>1,4</sup>, B. Goldberger<sup>3</sup>, M. Maldonado-Molina<sup>1,4</sup>, <sup>1</sup>Health Outcome and Policy, University of Florida, Gainesville, FL, <sup>2</sup>Epidemiology, University of Florida, Gainesville, FL, <sup>3</sup>Pathology, University of Florida, Gainesville, FL, <sup>4</sup>Institute of Child Health Policy, University of Florida, Gainesville, FL
- 162 *Prescription opioid use is associated with increased mortality in the Reasons for Geographic and Racial Differences in Stroke study*  
Y. Khodneva<sup>1</sup>, P. Muntner<sup>1</sup>, S. Kertesz<sup>2,1</sup>, G. Howard<sup>1</sup>, M. Safford<sup>1</sup>, <sup>1</sup>UAB, Birmingham, AL, <sup>2</sup>VAMC, Birmingham, AL

## **Symposium X**

**BALLROOM A  
10:00 - 12:00 PM**

### **CB2 FUNCTIONS IN THE BRAIN AND THE PERIPHERY**

Chairs: Toby K. Eisenstein and Vishnudutt Purohit

- 10:00 *Differential CB2 receptor involvement in cocaine and nicotine reward*  
Aron Lichtman, Virginia Commonwealth University, Richmond, VA
- 10:25 *CB2 agonists and neuropathic pain*  
Andrea G. Hohmann, Indiana University, Bloomington, IN
- 10:50 *CB2 activation in brain endothelium: A new way to protect the blood brain barrier*  
Yuri Persidsky, Temple University School of Medicine, Philadelphia, PA
- 11:15 *CB2 agonists as immunosuppressants*  
Toby K. Eisenstein, Temple University School of Medicine, Philadelphia, PA
- 11:40 *DISCUSSANT: Assessing the potential of CB2 compounds as therapeutics for neuropathic pain, drug addiction, inflammation, and a leaky BBB*  
Vishnudutt Purohit, National Institute on Drug Abuse, Bethesda, MD

## **Symposium XI**

**BALLROOM B  
10:00 - 12:00 PM**

### **TRAJECTORIES OF HEROIN USE: INSIGHTS FROM LONGITUDINAL STUDIES**

Chairs: Linda Cottler and Christina Marel

- 10:00 *Recovery from heroin addiction: Findings based on a 33-year follow-up study of heroin addicts*  
Yih-Ing Hser, University of California, Los Angeles, Los Angeles, CA
- 10:25 *Gender differences in 30-year trajectories of heroin and other drug use and health outcomes*  
Christine E. Grella, University of California, Los Angeles, Los Angeles, CA
- 10:50 *Using drug treatment outcome research to drive innovative treatment policy change*  
Catherine Comiskey, Trinity College, Dublin, Dublin, Ireland
- 11:15 *Longitudinal trajectories: New findings from the 11-year follow-up of the Australian Treatment Outcome Study*  
Maree Teesson, University of New South Wales, Sydney, NSW, Australia
- 11:40 *DISCUSSANT: Similarities across the globe*  
Linda Cottler, University of Florida, Gainesville, FL

**Oral Communications 9**

**BALLROOM C  
10:00 - 12:00 PM**

**BABY STEPS TOWARDS UNDERSTANDING PERINATAL  
DRUG ABUSE**

Chairs: Loretta P. Finnegan and Erin Fukaya

- 10:00 *Perinatal substance use: A prospective evaluation of abstinence and relapse*  
A. Forray<sup>1</sup>, B. Merry<sup>1</sup>, J. P. Rugar<sup>2</sup>, K. A. Yonkers<sup>1</sup>, <sup>1</sup>Yale School of Medicine, New Haven, CT, <sup>2</sup>Perelman School of Medicine, Philadelphia, PA
- 10:15 *Growth models of maternal perinatal drinking patterns in a national sample*  
W. Liu<sup>1</sup>, E. Mumford<sup>1</sup>, H. Petras<sup>2</sup>, <sup>1</sup>NORC at the Univ. of Chicago, Bethesda, MD, <sup>2</sup>JBS International, Inc., North Bethesda, MD
- 10:30 *Drug and tobacco use during pregnancy transmit genetic influences on developmental risk for substance use*  
K. Marceau<sup>1,2</sup>, V. Knopik<sup>2,1</sup>, D. Reiss<sup>3</sup>, D. Shaw<sup>4</sup>, M. Natsuaki<sup>5</sup>, P. Fisher<sup>6</sup>, L. D. Leve<sup>6</sup>, J. M. Neiderhiser<sup>7</sup>, <sup>1</sup>Brown University, Providence, RI, <sup>2</sup>Rhode Island Hospital, Providence, RI, <sup>3</sup>Yale University, New Haven, CT, <sup>4</sup>University of Pittsburgh, Pittsburgh, PA, <sup>5</sup>University of California-Riverside, Riverside, CA, <sup>6</sup>University of Oregon, Eugene, OR, <sup>7</sup>Penn State, State College, PA
- 10:45 *Prenatal cigarette smoke exposure, childhood aggression and adolescent cigarette use*  
N. De Genna<sup>1,2</sup>, L. Goldschmidt<sup>2</sup>, M. Cornelius<sup>1,2</sup>, <sup>1</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>2</sup>Western Psychiatric Institute and Clinic (WPIC), Pittsburgh, PA
- 11:00 *Lower oxidative stress in umbilical blood cord of newborns exposed to crack during pregnancy*  
C. M. Szobot<sup>1</sup>, M. Zavaschi<sup>1</sup>, V. Mardini<sup>1</sup>, F. Kapczynski<sup>1</sup>, M. Kauer-Sant'anna<sup>1</sup>, G. Colpo<sup>1</sup>, B. Aguiar<sup>1</sup>, G. Cunha<sup>1</sup>, L. Manna<sup>1</sup>, A. Childress<sup>2</sup>, D. Langleben<sup>2</sup>, K. M. Cereser<sup>1</sup>, L. A. Rohde<sup>1</sup>, <sup>1</sup>Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>2</sup>Treatment Research Center, Philadelphia, PA
- 11:15 *Motor development in children prenatally exposed to methamphetamine and tobacco*  
E. Fukaya<sup>1</sup>, J. Skranes<sup>2,3</sup>, G. Lohaugen<sup>2,3</sup>, C. Cloak<sup>1</sup>, C. Jiang<sup>1</sup>, L. Chang<sup>1</sup>, <sup>1</sup>Univ of Hawaii Manoa, Honolulu, HI, <sup>2</sup>Children's and Women's Health, Norwegian Univ of Science and Technology, Trondheim, Norway, <sup>3</sup>Pediatrics, Sorlandet Hospital, Arendal, Norway
- 11:30 *Effects of maternal opioid maintenance therapy on neonatal outcomes: Methadone vs. buprenorphine*  
L. Brandt<sup>1</sup>, S. Fischberger<sup>2</sup>, R. Jagsch<sup>3</sup>, G. Fischer<sup>1,2</sup>, <sup>1</sup>Center for Public Health, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria, <sup>3</sup>Psychology, University of Vienna, Vienna, Austria
- 11:45 *Reliability of pupil diameter measurements in neonates*  
S. H. Heil, D. J. Hand, C. L. Bergeria, D. E. Gaalema, G. J. Badger, A. M. Johnston, University of Vermont, Burlington, VT

**Oral Communications 10**

**SAN CRISTOBAL  
10:00 - 12:00 PM**

**JOIN THE CLUB: RESEARCH ON CLUB DRUGS**

Chairs: Doris Payer and Michael H. Baumann

- 10:00 *Pharmacology of “next generation” synthetic cathinones: The future is now*  
M. H. Baumann, K. R. Lehner, O. Bukhari, R. B. Rothman, J. S. Partilla, Designer Drug Research Unit, IRP, NIDA, NIH, Baltimore, MD
- 10:15 *Human pharmacology of mephedrone: A dose-finding pilot study*  
E. Papaseit<sup>1,3</sup>, C. Perez-Mañá<sup>1,3</sup>, M. Pujadas<sup>1</sup>, F. Fonseca<sup>2</sup>, M. Torrens<sup>2,3</sup>, R. De La Torre<sup>1,4</sup>, M. Farre<sup>1,3</sup>, <sup>1</sup>Human Pharmacology and Neurosciences, Hospital del Mar Medical Research Institute-IMIM, Barcelona, Spain, <sup>2</sup>Drug Addiction Unit, Hospital del Mar-INAD, Barcelona, Spain, <sup>3</sup>Universidad Autonoma de Barcelona-UAB, Barcelona, Spain, <sup>4</sup>Universidad Pompeu Fabra-UPF, Barcelona, Spain
- 10:30 *Exploring brain morphology in poly-stimulant abuse: Shape, volume, and surface area abnormalities in ecstasy-cocaine-and methamphetamine-preferring individuals*  
D. Payer<sup>1</sup>, M. Park<sup>1</sup>, S. Kish<sup>1</sup>, J. Lerch<sup>2</sup>, I. Boileau<sup>1,3</sup>, M. Chakravarty<sup>1,3</sup>, <sup>1</sup>Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>Medical Biophysics, University of Toronto, Toronto, ON, Canada, <sup>3</sup>Psychiatry, University of Toronto, Toronto, ON, Canada
- 10:45 *Psychiatric symptoms in a sample of young, sexual minority Brazilian ecstasy and LSD users*  
F. P. Pechansky<sup>1</sup>, L. S. Remy<sup>1</sup>, H. Surratt<sup>2</sup>, S. S. Kurtz<sup>2</sup>, <sup>1</sup>Psychiatry, Center for Drug and Alcohol Studies - Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>2</sup>Center for Applied Research on Substance Use and Health Disparities Nova Southeastern University, Miami, FL
- 11:00 *THC-like effects of novel synthetic cannabinoids found on the gray market*  
M. J. Forster, M. B. Gatch, Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX
- 11:15 *Synthetic cannabinoid use in cannabis smokers*  
Z. D. Cooper, M. Haney, Psychiatry, Columbia University, NYSPI, New York, NY
- 11:30 *Comparison of synthetic substances: Diffusion of Innovation framework*  
C. L. Arfken<sup>1</sup>, C. Madeja<sup>1</sup>, D. Owens<sup>2</sup>, <sup>1</sup>Wayne State University, Detroit, MI, <sup>2</sup>Southeast Michigan Community Alliance, Taylor, MI
- 11:45 *Detecting a signal in the noise: Results of a pilot project to monitor the global spread of new drugs by monitoring media*  
M. M. Young<sup>1,2</sup>, C. Dubeau<sup>1</sup>, K. Diedrich<sup>1</sup>, O. Corazza<sup>3</sup>, <sup>1</sup>Research and Policy, Canadian Centre on Substance Abuse, Ottawa, ON, Canada, <sup>2</sup>Psychology, Carleton University, Ottawa, ON, Canada, <sup>3</sup>Department of Postgraduate Medicine, University of Hertfordshire, Hatfield, United Kingdom

## **Animal Forum**

**AUDITORIUM  
12:15 - 1:15 PM**

### **HOW ANIMAL RESEARCHERS CAN HAVE A STRONGER VOICE**

Chairs: Marilyn E. Carroll and Toby K. Eisenstein

*Building the STAR Coalition with larger numbers, more visibility, more advocacy*

Marilyn E. Carroll<sup>1</sup>, Toby K. Eisenstein<sup>2</sup>, <sup>1</sup>University of Minnesota, Minneapolis, MN,  
<sup>2</sup>Temple University School of Medicine, Philadelphia, PA

*Stop hiding: Engage in educational opportunities e.g., Cindy Buckmaster, on You Tube,  
and working in different venues, from elementary school to vet school*

Marilyn E. Carroll, University of Minnesota, Minneapolis, MN

*How to deal with overzealous IACUC's*

Marilyn Carroll, Michael Gatch, Bert Weiss

*Regulatory burden on federally funded research: The NSF Report*

Toby K. Eisenstein, Michael Gatch, Bert Weiss

## **Reproducibility of Research Forum**

**BALLROOM B  
12:15 - 2:15 PM**

### **IRREPRODUCIBLE RESEARCH: IS IT RELEVANT TO THE ADDICTION RESEARCH COMMUNITY? OR (REPRODUCIBILITY OF RESEARCH RESULTS: IS IT RELEVANT TO THE ADDICTION RESEARCH COMMUNITY?)**

Chairs: Elena Koustova and Mark Swieter

*Introduction and NIH update*

Elena Koustova, NIDA/NIH/DHHS, Rockville, MD

*NIDA's Plans*

Mark Swieter, NIDA/NIH/DHHS, Rockville, MD

*Scientific Journal Editors*

## **Media Forum**

**BALLROOM C  
1:15 - 2:15 PM**

### **WHAT'S HOT: PIVOTAL RESEARCH IN CPDD 2014**

Chairs: Bertha K. Madras and Anna Rose Childress

*Introduction to media and format*

Bertha K. Madras, Harvard Medical School-NEPRC, Southborough, MA

*Introduction to each speaker*

Anna Rose Childress, University of Pennsylvania, Philadelphia, PA

**Grant-Writing Workshop**  
(PRE-REGISTRANTS ONLY)

**LAS OLAS**  
**1:15 - 5:00 PM**

**Film Screening:**  
**Addiction Incorporated**

**AUDITORIUM**  
**5:00 - 6:15 PM**

**Primm-Singleton Awardees Reception**

**BOARDROOM 1**  
**5:00 - 6:30 PM**

**Workshop X**

**BALLROOM A**  
**7:00 - 9:00 PM**

**THE USE OF GIS & GPS TECHNOLOGY IN ADDICTION RESEARCH**

Chairs: C. Debra M. Furr-Holden and Kenzie L. Preston

*Biomapping: Future innovations in drug treatment research*

C. Debra M. Furr-Holden, Johns Hopkins University, Baltimore, MD

*Advances in GIS methods for addiction research*

Adam J. Milam, Wayne State University School of Medicine, Detroit, MI

*The use of GPS technology and electronic diary reports in drug treatment research*

David Epstein, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD

*The role of gene environment interactions in substance use and dependence*

Brion Maher, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

*DISCUSSANT: The future of GIS & GPS technology in addiction research*

Kenzie L. Preston, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD

**Workshop XI**

**BALLROOM B**  
**7:00 - 9:00 PM**

**IMPROVING THE WRITING OF EMERGING INVESTIGATORS IN  
ADDICTION SCIENCE: INNOVATIVE TRAINING, EVALUATION  
METHODS, AND RESOURCES**

Chairs: James Sorensen and Joseph Guydish

*Improvement of writing by integrating a professional skills development course and writers' workgroup*

Christine E. Grella, University of California, Los Angeles, Los Angeles, CA

*Getting on track: How to become an intrepid writer*

Adam Carrico, University of California, San Francisco, Los Angeles, CA

*Improving the writing of emerging investigators in addiction science*

Helen Knudsen, University of Kentucky, Lexington, KY

*Writers' task force to improve writing and increase journal submissions of young investigators*

Carmen L. Masson, University of California, San Francisco, San Francisco, CA

*Discussant: Writing manuscript reviews that assist both authors and editors*

Jeffrey Samet, Boston University Schools of Medicine and Public Health, Boston, MA

## **Workshop XII**

**BALLROOM C  
7:00 - 9:00 PM**

### **UPDATE ON THE ABUSE-DETERRENT SCIENCE MEETING ON THE FDA DRAFT GUIDANCE FOR INDUSTRY ON ABUSE- DETERRENT OPIOIDS—EVALUATION AND LABELING**

Chairs: Beatriz Rocha and Cynthia Arons

*Lessons from the lab and the clinic: An academic perspective on the draft ADF guidance*  
Sharon L. Walsh, University of Kentucky, Lexington, KY

*Considerations in abuse-liability testing: An industry perspective on the draft ADF guidance*  
Marta Sokolowska, Grunenthal USA, Inc., Bedminster, NJ

*From evaluation to labeling: A regulatory perspective on the draft ADF guidance*  
Michael Klein, Controlled Substances Staff, Food and Drug Administration, Silver  
Spring, MD

*DISCUSSANT: Opportunities and challenges in an emerging area of pharmaceutical and  
regulatory science*  
Beatriz Rocha, Covance, Princeton, NJ

## **Workshop XIII**

**SAN CRISTOBAL  
7:00 - 9:00 PM**

### **ADDICTION TREATMENT RESEARCH VS. USUAL CARE: WHAT ARE THE FORESEEABLE RISKS?**

Chair: Andrew Saxon

*Using treatment as usual in research: Current debate regarding disclosure of risks*  
Carmen Rosa, NIDA, Bethesda, MD

*A cautionary tale: Do not include risks of usual care in study consent forms*  
Andrew Saxon, Veterans Affairs Puget Sound Health Care System, Seattle, WA

*Treatment as usual in vulnerable populations: Case study of two clinical trials in HIV-infected  
participants*  
Todd Korthuis, Oregon Health and Science University, Portland, OR

*Does research treatment always pose increased risk over usual care, and does it matter?*  
David A. Gorelick, University of Maryland, Baltimore, MD

*Discussant*  
Collin O'Neil, New York University, New York, NY

## Poster Session III (Breakfast)

GRAN SALON  
LOS ROSALES  
8:00 - 10:00 AM

Odd-numbered posters manned first hour;  
Even-numbered, second hour

Set-up time begins Tuesday 1 PM  
Must be removed by Wednesday 12 Noon

### POLICY

- 1 *Immunization increases the reinforcement threshold but not elasticity of demand for nicotine in an animal model of nicotine reduction policy*  
M. G. LeSage<sup>1,2</sup>, M. Staley<sup>1</sup>, P. R. Pentel<sup>1,2</sup>, <sup>1</sup>Medicine, Minneapolis Medical Research Foundation, Minneapolis, MN, <sup>2</sup>Medicine, University of Minnesota, Minneapolis, MN
- 2 *Availability of smoking cessation services in SUD treatment in the context of health reform*  
H. K. Knudsen<sup>1</sup>, P. M. Roman<sup>2</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Sociology, University of Georgia, Athens, GA
- 3 *Willingness to enter drug treatment: The role of treatment models, copays and financial incentives*  
C. Barry<sup>1</sup>, S. Busch<sup>2</sup>, A. Epstein<sup>3</sup>, D. Fiellin<sup>2</sup>, <sup>1</sup>Johns Hopkins, Baltimore, MD, <sup>2</sup>Yale, New Haven, CT, <sup>3</sup>University of Pennsylvania, Philadelphia, PA
- 4 *Incentives in public addiction treatment payment systems: Intended and unintended effects*  
S. Reif, M. Stewart, C. M. Horgan, B. Mohr, Institute for Behavioral Health, The Heller School, Brandeis University, Waltham, MA
- 5 *FISCAL: An all-data approach to assessing financial capability in people with psychiatric disabilities and substance use*  
M. Rosen<sup>1,2</sup>, A. C. Black<sup>1,2</sup>, C. M. Lazar<sup>1</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>VA Connecticut Healthcare, West Haven, CT
- 6 *Using data mining of spontaneous adverse event reports and multivariate statistical methods for assessing abuse potential*  
C. Arons<sup>1</sup>, E. Hung<sup>2</sup>, S. Ratcliffe<sup>1</sup>, M. Hauben<sup>2</sup>, <sup>1</sup>Pfizer, Groton, CT, <sup>2</sup>Pfizer, New York, NY
- 7 *Assessing standards of evidence in evidence-based program registers for behavioral health treatments*  
S. Magura, J. Burkhardt, D. Schroeter, S. Means, Y. Vladimirovna, C. Coryn, Western Michigan University, Kalamazoo, MI
- 8 *Validation of the Substance Use Brief Screen in primary care*  
J. McNeely<sup>1</sup>, S. Strauss<sup>2</sup>, P. N. Halkitis<sup>1,3</sup>, R. Saitz<sup>4</sup>, J. Rotrosen<sup>1</sup>, D. Shelley<sup>1</sup>, C. Cleland<sup>2</sup>, M. N. Gourevitch<sup>1</sup>, <sup>1</sup>NYU School of Medicine, New York, NY, <sup>2</sup>NYU College of Nursing, New York, NY, <sup>3</sup>NYU Steinhardt School, New York, NY, <sup>4</sup>Boston University, Boston, MA
- 9 *Predictors of positive drug screens after deployment to Iraq or Afghanistan in the military drug testing program*  
M. Larson<sup>1</sup>, B. A. Mohr<sup>1</sup>, R. Adams<sup>1</sup>, T. V. Williams<sup>2</sup>, <sup>1</sup>Heller School for Social Policy and Management, Brandeis University, Waltham, MA, <sup>2</sup>Defense Health Agency, Department of Defense, Falls Church, VA



- 10 *Early evaluation of the experiences and opinions of pharmacists towards the Ontario Narcotics Monitoring System*  
B. Sproule<sup>1,2</sup>, K. Liu<sup>1,2</sup>, J. Chundamala<sup>1</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada
- 11 *Estimated effect of state syringe policy on source of last-used injection equipment*  
P. Janulis, J. C. Anthony, NIDA T32 Training Program, Michigan State University, East Lansing, MI
- 12 *The impact of state medical marijuana legislation on adolescent marijuana use*  
J. McConnell<sup>4</sup>, E. Choo<sup>1</sup>, N. Zaller<sup>2</sup>, M. Benz<sup>1</sup>, O. Warren<sup>1</sup>, K. Rising<sup>3</sup>, <sup>1</sup>Department of Emergency Medicine, Brown University, Providence, RI, <sup>2</sup>Department of Medicine, Brown University, Providence, RI, <sup>3</sup>Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Department of Emergency Medicine, Oregon Health & Science University, Portland, OR
- 13 *Reported use of non-prescribed marijuana for biomedical and psychiatric conditions among regular marijuana users*  
K. J. Lauritsen, L. A. Osborn, A. K. Davis, N. Cross, B. A. Lang, H. Rosenberg, Psychology, Bowling Green State University, Bowling Green, OH
- 14 *Physician supply for the treatment of opioid use disorders: The influence of state policies*  
B. D. Stein<sup>1,2</sup>, A. J. Gordon<sup>1,4</sup>, A. Dick<sup>2</sup>, R. M. Burns<sup>2</sup>, R. Pacula<sup>3</sup>, C. Farmer<sup>2</sup>, D. Leslie<sup>5</sup>, <sup>1</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>2</sup>RAND Corporation, Pittsburgh, PA, <sup>3</sup>RAND Corporation, Santa Monica, CA, <sup>4</sup>VA Pittsburgh Healthcare System, Pittsburgh, PA, <sup>5</sup>Penn State College of Medicine, Hershey, PA
- 15 *Expansion of buprenorphine opioid agonist therapy in the United States: Facility-level factors*  
R. Liccardo Pacula<sup>3</sup>, A. J. Gordon<sup>1,4</sup>, A. W. Dick<sup>2</sup>, R. M. Burns<sup>2</sup>, C. Farmer<sup>2</sup>, D. Leslie<sup>5</sup>, M. Sorbero<sup>2</sup>, B. D. Stein<sup>1,2</sup>, <sup>1</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>2</sup>RAND Corporation, Pittsburgh, PA, <sup>3</sup>RAND Corporation, Santa Monica, CA, <sup>4</sup>VA Pittsburgh Healthcare System, Pittsburgh, PA, <sup>5</sup>Penn State College of Medicine, Hershey, PA
- 16 *How does one measure buprenorphine diffusion? The challenges of alternative measures of success*  
R. M. Burns<sup>2</sup>, R. Pacula<sup>3</sup>, A. W. Dick<sup>2</sup>, A. J. Gordon<sup>1,4</sup>, M. Sorbero<sup>2</sup>, D. L. Leslie<sup>5</sup>, C. Farmer<sup>2</sup>, B. D. Stein<sup>2,1</sup>, <sup>1</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>2</sup>RAND Corporation, Pittsburgh, PA, <sup>3</sup>RAND Corporation, Santa Monica, CA, <sup>4</sup>VA Pittsburgh Healthcare System, Pittsburgh, PA, <sup>5</sup>Penn State College of Medicine, Hershey, PA
- 17 *Buprenorphine dissemination in the public sector: Social network analysis and institutional constraints of prescribers in New York City*  
H. Hansen<sup>1</sup>, P. Bearman<sup>2</sup>, S. Mendoza<sup>1</sup>, J. Rotrosen<sup>1</sup>, <sup>1</sup>Psychiatry, New York University, NY, NY, <sup>2</sup>Sociology, Columbia University, NY, NY
- 18 *Increasing access to opioid agonist treatment in U.S. treatment shortage areas*  
A. Dick<sup>2</sup>, R. Pacula<sup>3</sup>, A. J. Gordon<sup>1,4</sup>, M. Sorbero<sup>2</sup>, R. M. Burns<sup>2</sup>, C. Farmer<sup>2</sup>, D. Leslie<sup>5</sup>, B. D. Stein<sup>2,1</sup>, <sup>1</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>2</sup>RAND Corporation, Pittsburgh, PA, <sup>3</sup>RAND Corporation, Santa Monica, CA, <sup>4</sup>VA Pittsburgh Healthcare System, Pittsburgh, PA, <sup>5</sup>Penn State College of Medicine, Hershey, PA
- 19 *WITHDRAWN*

### OPIOIDS II

- 20 *Predictors of sublingual buprenorphine induction and detoxification response among heroin-dependent adults*  
E. A. Woodcock, M. K. Greenwald, L. H. Lundahl, Wayne State University, Detroit, MI

- 21 *Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone vs. buprenorphine*  
M. A. Sullivan, A. Bisaga, K. Carpenter, J. J. Mariani, K. Mishlen, E. V. Nunes, Columbia University/ New York State Psychiatric Institute, New York, NY
- 22 *Workforce attitudes regarding the implementation of extended release naltrexone to treat opioid dependence*  
L. Andrich<sup>1</sup>, K. T. Garvey<sup>1</sup>, E. M. Klemperer<sup>2,1</sup>, T. R. Rieckmann<sup>1</sup>, <sup>1</sup>Oregon Health & Science University, Portland, OR, <sup>2</sup>University of Vermont, Burlington, VT
- 23 *Interest for treatment with extended-release naltrexone among Norwegian opiate users*  
K. S. Haase<sup>1,6</sup>, A. Opheim<sup>2</sup>, N. Kunoe<sup>1</sup>, L. S. Stavseth<sup>1</sup>, Z. Latif<sup>3</sup>, A. N. Mjølhus<sup>4</sup>, M. Moller<sup>5</sup>, L. Tanum<sup>3,1</sup>, <sup>1</sup>Oslo University Hospitals, Norwegian Center for Addiction Research, Oslo, Norway, <sup>2</sup>Bergen Hospital Trust, Bergen, Norway, <sup>3</sup>Akershus University Hospital, Lorenskog, Norway, <sup>4</sup>Stavanger University Hospitals, Stavanger, Norway, <sup>5</sup>Ostfold Hospital Trust, Fredrikstad, Norway, <sup>6</sup>Vestfold Hospital Trust, Tonsberg, Norway
- 24 *Existential anxiety in first-time recipients of XR-NTX for opioid addiction*  
A. Opheim<sup>1</sup>, K. S. Haase<sup>2,3</sup>, L. Tanum<sup>4</sup>, N. Kunø<sup>3</sup>, S. Nesvåg<sup>5</sup>, L. Stavseth<sup>6</sup>, H. Z. Latif<sup>4</sup>, A. L. Mjølhus<sup>4</sup>, M. Møller<sup>7</sup>, <sup>1</sup>Haukeland University Hospital, Bergen, Norway, <sup>2</sup>Norwegian Centre of Addiction Research, Oslo, Norway, <sup>3</sup>Vestfold Hospital Trust, Tønsberg, Norway, <sup>4</sup>Akershus University Hospital Trust, Oslo, Norway, <sup>5</sup>Stavanger University Hospital, Stavanger, Norway, <sup>6</sup>Oslo University Hospital, Oslo, Norway, <sup>7</sup>Østfold Hospital Trust, Fredrikstad, Norway
- 25 *Implantable and oral naltrexone for preventing relapse in opiate addicts: A psychometric evaluation*  
E. Blokhina<sup>2</sup>, E. Krupitsky<sup>2</sup>, N. Bushara<sup>2</sup>, T. Yaroslavtseva<sup>2</sup>, A. Tiurina<sup>2</sup>, V. Palatkin<sup>2</sup>, E. Verbitskaya<sup>2</sup>, E. Zvartau<sup>2</sup>, G. E. Woody<sup>1</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation
- 26 *Depot naltrexone as relapse prevention for opioid-dependent parolees*  
C. P. O'Brien<sup>1</sup>, P. D. Friedmann<sup>2</sup>, E. Nunes<sup>3</sup>, J. D. Lee<sup>4</sup>, T. W. Kinlock<sup>5</sup>, <sup>1</sup>Psychiatry, Univ Pennsylvania, Philadelphia, PA, <sup>2</sup>Psychiatry, Rhode Island Hosp, Providence, RI, <sup>3</sup>Psychiatry, Columbia University, New York, NY, <sup>4</sup>Psychiatry, New York University, New York, NY, <sup>5</sup>Addiction, Friends Medical Research, Baltimore, MD
- 27 *Feasibility of very low dose naltrexone and buprenorphine transition from opioid use to extended-release naltrexone*  
P. Mannelli, K. S. Peindl, L. Wu, Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
- 28 *Naltrexone-facilitated discontinuation of buprenorphine*  
E. Dakwar, H. D. Kleber, Psychiatry, NYSPI/Columbia, New York, NY
- 29 *Dose and other factors associated with decreased pain intensity among patients initiating buprenorphine/naloxone*  
W. Becker<sup>1,2</sup>, D. Ganoczy<sup>3</sup>, D. Fiellin<sup>2</sup>, A. S. Bohnert<sup>3</sup>, <sup>1</sup>VA Connecticut, West Haven, CT, <sup>2</sup>Yale University, New Haven, CT, <sup>3</sup>Ann Arbor VA, Ann Arbor, MI
- 30 *Does early response to buprenorphine-naloxone predict treatment outcome in prescription opioid dependence?*  
R. Weiss<sup>1,2</sup>, K. McDermott<sup>1</sup>, M. L. Griffin<sup>1,2</sup>, E. Hilario<sup>1</sup>, H. Connery<sup>1,2</sup>, <sup>1</sup>Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA, <sup>2</sup>Psychiatry, Harvard Medical School, Boston, MA

- 31 *Buprenorphine/naloxone pediatric ingestion: Exposure rates differ between film and tablet formulations*  
S. G. Severtson<sup>1</sup>, E. M. Martinez<sup>1</sup>, J. L. Green<sup>1</sup>, R. C. Dart<sup>1,2</sup>, E. J. Lavonas<sup>1,2</sup>, <sup>1</sup>Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO, <sup>2</sup>Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO
- 32 *Medicaid budget impact of generic buprenorphine / naloxone tablet*  
E. Clay<sup>2</sup>, E. Kharitonova<sup>2</sup>, S. Aballea<sup>2</sup>, J. Ruby<sup>3</sup>, V. Zah<sup>1</sup>, <sup>1</sup>HEOR, ZRx Outcomes Research Inc., Toronto, ON, Canada, <sup>2</sup>HEOR, Creativ-Ceutical, Chicago, IL, <sup>3</sup>Medical Affairs, Reckitt Benckiser, Richmond, VA
- 33 *Characteristics of buprenorphine opioid agonist treatment in a longitudinal U.S. Medicaid population*  
A. J. Gordon<sup>1,2</sup>, W. Lo Ciganic<sup>1</sup>, G. Cochran<sup>1</sup>, W. F. Gellad<sup>1,2</sup>, J. M. Donohue<sup>1</sup>, <sup>1</sup>University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>VA Pittsburgh Healthcare System, Pittsburgh, PA
- 34 *Expanding access to MAT in Puerto Rico: Attitudes, perceptions and training needs of pharmacists and technicians toward dispensing buprenorphine for patients with opioid dependence*  
C. G. Grana Morales, J. Márquez, S. Rivera, J. Ruiz, J. Avilés, C. Albizu-García, University of Puerto Rico, San Juan
- 35 *Memantine improves buprenorphine treatment for opioid-dependent young adults*  
G. Gonzalez<sup>1,2,3</sup>, G. DiGirolamo<sup>1,2</sup>, M. E. Kolodziej<sup>1</sup>, D. Smelson<sup>1</sup>, M. Romero-Gonzalez<sup>1,3</sup>, <sup>1</sup>Division of Addiction Psychiatry, University of Massachusetts Medical School, Worcester, MA, <sup>2</sup>Psychology, College of the Holy Cross, Worcester, MA, <sup>3</sup>MAYU of New England, New Haven, CT
- 36 *Differences between heroin and non-prescription opioid analgesics users in treatment-seeking opioid-dependent young adults*  
M. Romero-Gonzalez<sup>1,2</sup>, G. DiGirolamo<sup>1</sup>, G. Gonzalez<sup>1,2</sup>, <sup>1</sup>Division of Addiction Psychiatry, University of Massachusetts Medical School, Worcester, MA, <sup>2</sup>MAYU of New England, New Haven, CT
- 37 *Health and social factors associated with alternate routes of administration of prescription opioids among young adult multidrug users*  
M. E. Buttram, S. P. Kurtz, Center for Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL
- 38 *Malmö treatment referral and intervention study: Effective referral from syringe exchange to treatment for heroin dependence*  
M. Bråbäck<sup>2,1</sup>, P. Isendahl<sup>2,1</sup>, S. Nilsson<sup>2,1</sup>, A. Håkansson<sup>2,1</sup>, <sup>1</sup>Psychiatry, Lund University, Lund, Sweden, <sup>2</sup>Addiction Center Malmö, Psychiatry Skane, Malmö, Sweden
- 39 *Mobile phone and text messaging in a public sector, office-based buprenorphine program*  
B. Tofighi<sup>1</sup>, E. Grossman<sup>1</sup>, E. Buirkle<sup>2</sup>, J. D. Lee<sup>2</sup>, <sup>1</sup>Population Health, New York University School of Medicine, New York City, NY, <sup>2</sup>New York University School of Medicine, New York City, NY
- 40 *Evaluation of an electronic information system to enhance practice at a medication-assisted opioid treatment program*  
L. S. Brown, S. Kritz, M. Lin, B. Louie, R. Zavala, START Treatment and Recovery Centers (formerly ARTC), Brooklyn, NY

- 41 *Mobile interventions based on ecological momentary assessment: Perspectives of patients and providers in China, Taiwan, and the United States*  
Y. Hser<sup>1</sup>, M. T. Schulte<sup>1</sup>, F. Wu<sup>2</sup>, Y. Lan<sup>3</sup>, W. Tsay<sup>4</sup>, J. Du<sup>5</sup>, M. Zhao<sup>5</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>University of Maryland, College Park, MD, <sup>3</sup>China Medical University, Taichung, Taiwan, <sup>4</sup>Food & Drug Administration, Taipei, Taiwan, <sup>5</sup>Shanghai Mental Health Center, Shanghai, China
- 42 *Developing ecological momentary intervention content for relapse prevention*  
M. T. Schulte, Y. Hser, UCLA, Los Angeles, CA
- 43 *Attitudes, beliefs, and barriers to adopting an automated naloxone delivery system to overcome opioid overdose: Interviews of opioid injectors and physicians*  
J. Mendelson<sup>1</sup>, O. Clavier<sup>2</sup>, D. Kynor<sup>2</sup>, G. Galloway<sup>1</sup>, <sup>1</sup>Addiction & Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA, <sup>2</sup>Creare, Inc., Hanover, NH
- 44 *Smartphone-reported stress and drug events and day-end perceived stress, hassles, and mood in methadone-maintained individuals*  
K. A. Phillips, D. H. Epstein, M. L. Jobes, K. L. Preston, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD
- 45 *Call behavior and reported drug use within an automated telephone-based treatment system for methadone patients*  
B. A. Moore<sup>1</sup>, C. J. Cutter<sup>1</sup>, A. P. Mahoney<sup>2</sup>, N. Grandpre<sup>3</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>University of New Haven, New Haven, CT, <sup>3</sup>University of Hartford, West Hartford, CT

### PERINATAL DRUG ABUSE

- 46 *Neonatal abstinence syndrome in methadone exposed infants: Role of genetic variability*  
A. L. Fielder<sup>1</sup>, J. K. Coller<sup>2</sup>, M. R. Hutchinson<sup>2</sup>, R. R. Haslam<sup>3</sup>, N. Lu<sup>4</sup>, S. Adeniyi-Jones<sup>4</sup>, M. Ehrlich<sup>5</sup>, W. K. Kraft<sup>4</sup>, <sup>1</sup>Nursing & Midwifery, Sansom Institute, University of South Australia, Adelaide, SA, Australia, <sup>2</sup>University of Adelaide, Adelaide, SA, Australia, <sup>3</sup>Women's & Children's Hospital, Adelaide, SA, Australia, <sup>4</sup>Thomas Jefferson University, Philadelphia, PA, <sup>5</sup>Mt. Sinai School of Medicine, New York, NY
- 47 *Correlates of risk for prenatal alcohol use among WIC recipients*  
Y. Washio<sup>1</sup>, A. A. Mericle<sup>1</sup>, H. Cassey<sup>2</sup>, A. Daubert<sup>2</sup>, K. C. Kirby<sup>1</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Temple University, Philadelphia, PA
- 48 *Cigarette smoking and other behavioral risk factors related to unintended pregnancy*  
D. J. Hand<sup>1,2</sup>, S. H. Heil<sup>1,2,3</sup>, S. C. Sigmon<sup>1,2,3</sup>, S. T. Higgins<sup>1,2,3</sup>, <sup>1</sup>Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, <sup>2</sup>Dept. of Psychiatry, University of Vermont, Burlington, VT, <sup>3</sup>Dept. of Psychology, University of Vermont, Burlington, VT
- 49 *Tobacco use and exposure to second-hand smoke in Mexican pregnant women*  
O. Campollo<sup>1,2</sup>, F. Hernandez<sup>3</sup>, E. Angulo<sup>4</sup>, A. Guzman<sup>3</sup>, A. Munguia<sup>1</sup>, M. García<sup>1</sup>, J. K. Cunningham<sup>5</sup>, <sup>1</sup>Center of Studies on Alcohol and Addictions, University of Guadalajara, Guadalajara, Mexico, <sup>2</sup>Clinica para Dejar de Fumar, Hospital Civil de Guadalajara, Guadalajara, Mexico, <sup>3</sup>Obstetrics, Hospital Civil de Guadalajara, Guadalajara, Mexico, <sup>4</sup>Neonatology, Hospital Civil de Guadalajara, Guadalajara, Mexico, <sup>5</sup>Family & Community Medicine, University of Arizona, Tucson, AZ

- 50 *Evaluating potential moderators of efficacy for a single-session computer-delivered 5As intervention for smoking in pregnancy*  
S. J. Ondersma<sup>1,2</sup>, D. M. Ledgerwood<sup>1</sup>, D. Svikis<sup>3</sup>, <sup>1</sup>Dept. of Psychiatry & Behavioral Neurosciences, Wayne State University, Detroit, MI, <sup>2</sup>Merrill Palmer Skillman Institute, Wayne State University, Detroit, MI, <sup>3</sup>Institute for Women's Health; Psychology; Psychiatry; Ob/Gyn, Virginia Commonwealth University, Richmond, VA
- 51 *The role of self-efficacy in predicting perinatal women's ability to reduce smoking*  
J. Temple, V. D. Le, G. Hankins, M. S. Ahmed, T. Nanovskaya, Department of Obstetrics & Gynecology, UTMB, Galveston, TX
- 52 *Predictors of changes in smoking from 3rd trimester to 9 months postpartum*  
S. Shisler<sup>1</sup>, G. G. Homish<sup>2</sup>, D. Molnar<sup>1</sup>, R. D. Eiden<sup>1</sup>, <sup>1</sup>Research Institute on Addictions, SUNY Buffalo, Buffalo, NY, <sup>2</sup>Community Health and Health Behavior, SUNY Buffalo, Buffalo, NY
- 53 *Differences between recent quitters and current smokers during pregnancy*  
V. H. Coleman-Cowger<sup>1</sup>, V. Belur<sup>1</sup>, M. Terplan<sup>2</sup>, <sup>1</sup>Lighthouse Institute, Chestnut Health Systems, Bloomington, IL, <sup>2</sup>Department of Obstetrics, Gynecology & Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD
- 54 *The role of human placental transporters in the efflux of bupropion*  
S. Patrikeeva, D. Vernikovskaya, M. S. Ahmed, G. Hankins, T. Nanovskaya, Department of Obstetrics & Gynecology, UTMB, Galveston, TX
- 55 *Determination of cotinine in the urine of pregnant patients enrolled in a clinical trial for the use of bupropion sustained-release as an aid for smoking cessation*  
V. M. Fokina<sup>1,2</sup>, X. Wang<sup>1</sup>, M. S. Ahmed<sup>1</sup>, G. Hankins<sup>1</sup>, T. Nanovskaya<sup>1</sup>, <sup>1</sup>Obstetrics & Gynecology, UTMB, Galveston, TX, <sup>2</sup>Pharmacology & Toxicology, UTMB, Galveston, TX
- 56 *Prenatal stimulant exposure alters infant growth in term-born infants*  
A. Hernandez, R. Yamakawa, H. Johansen, C. Jiang, C. Cloak, T. Ernst, L. Chang, Medicine, University of Hawaii, John A. Burns School of Medicine, Honolulu, HI
- 57 *Behavior problems among cocaine-exposed children: Role of physiological regulation and parenting*  
B. Finger<sup>1</sup>, P. Schuetze<sup>3</sup>, R. Eiden<sup>2</sup>, <sup>1</sup>Montana State University Billings, Billings, MT, <sup>2</sup>Research Institute on Addictions, Buffalo, NY, <sup>3</sup>Buffalo State College, Buffalo, NY
- 58 *Cocaine use in late adolescence: Impact of prenatal cocaine exposure, sex/gender, and ongoing caregiver cocaine use*  
E. S. Bandstra<sup>1</sup>, V. H. Accornero<sup>1</sup>, D. C. Vidot<sup>2</sup>, E. Mansoor<sup>1</sup>, L. Xue<sup>1</sup>, C. Morrow<sup>1</sup>, J. C. Anthony<sup>3</sup>, <sup>1</sup>Pediatrics, University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, <sup>3</sup>Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
- 59 *Differential influence of prenatal maternal aggression on childhood externalizing symptoms and adolescent substance use by gender*  
M. Horner, M. Cornelius, K. Kim, R. Tarter, University of Pittsburgh, Pittsburgh, PA

### ADOLESCENT DRUG ABUSE II

- 60 *Marijuana use, motives, and change intentions in adolescents*  
G. Dash, K. G. Anderson, Psychology, Reed College, Portland, OR

- 61 *Influences of behavior and academic problems at school entry on marijuana use during adolescence among African Americans*  
B. A. Reboussin<sup>1</sup>, N. S. Ialongo<sup>2</sup>, K. M. Green<sup>3</sup>, <sup>1</sup>Wake Forest University School of Medicine, Winston-Salem, NC, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>3</sup>University of Maryland School of Public Health, College Park, MD
- 62 *Daily co-occurrences of marijuana use, alcohol use, and sexual intercourse among at-risk, truant adolescent girls*  
H. Graves, L. Hernandez, C. Kahler, A. Spirito, Brown University, Providence, RI
- 63 *Substance use and risk profiles of adolescent medical patients*  
M. Lightfoot, J. Morgan-Jackson, L. Pollack, Medicine, University of California, San Francisco, San Francisco, CA
- 64 *Effects of immigration to the United States on alcohol, tobacco and cannabis use among Colombian adolescents*  
C. Lopez-Quintero, M. De La Rosa, The Center for Research on U.S. Latino HIV/AIDS and Drug Abuse (CRUSADA), Florida International University, Miami, FL
- 65 *Results from the first nationwide survey of students in Collegiate Recovery Programs*  
A. B. Laudet<sup>1</sup>, K. Harris<sup>2</sup>, K. Winters<sup>3</sup>, D. Moberg<sup>4</sup>, T. Kimball<sup>2</sup>, <sup>1</sup>NDRI, NYC, NY, <sup>2</sup>Texas Tech, Lubbock, TX, <sup>3</sup>University of Minnesota, Minneapolis, MN, <sup>4</sup>University of Wisconsin, Milwaukee, WI
- 66 *A comparison of young adults seeking treatment for cannabis and opioid dependence*  
E. Evans, K. Mishlen, A. Glass, M. Pavlicova, J. J. Mariani, F. R. Levin, M. Sullivan, Psychiatry, Columbia University, New York State Psychiatric Institute, New York, NY
- 67 *Developmental heritability of internalizing symptoms and cigarette use co-occurrence*  
C. B. Bares<sup>1</sup>, K. S. Kendler<sup>3,2</sup>, J. Silberg<sup>2</sup>, <sup>1</sup>School of Social Work, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Department of Human Genetics, Virginia Commonwealth University, Richmond, VA, <sup>3</sup>Department of Psychiatry, Virginia Commonwealth University, Richmond, VA
- 68 *Reasons for e-cigarette initiation and discontinuation among adolescents and young adults*  
G. Kong, D. R. Camenga, D. A. Cavallo, A. Palmer, M. Morean, S. Krishnan-Sarin, Yale University School of Medicine, New Haven, CT
- 69 *Cognitive bias modification combined with cognitive behavioral therapy: A smoking cessation intervention for adolescents*  
H. Larsen<sup>1</sup>, G. Kong<sup>2</sup>, D. Becker<sup>1</sup>, D. A. Cavallo<sup>2</sup>, J. Cousijn<sup>1</sup>, E. Salemin<sup>1</sup>, A. Collot D'Escury-Koenigs<sup>1</sup>, S. Krishnan-Sarin<sup>2</sup>, R. Wiers<sup>1</sup>, <sup>1</sup>Developmental Psychology, University of Amsterdam, Amsterdam, Netherlands, <sup>2</sup>Psychiatry, Yale University School of Medicine, New Haven, CT
- 70 *Self-efficacy mediates treatment outcome in a smoking cessation program for adolescent smokers*  
P. Simon, C. Connell, G. Kong, M. E. Morean, D. A. Cavallo, D. Camenga, S. Krishnan-Sarin, Department of Psychiatry, Yale School of Medicine, New Haven, CT
- 71 *High rates of relapse in adolescent crack users after inpatient clinic discharge*  
R. S. Pedroso, L. B. Zanetello, M. Mazzom, V. M. Gonçalves, R. L. Rosa, T. G. Pianca, L. S. Guimarães, M. Pettenon, F. H. Kessler, F. P. Pechansky, Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

- 72 *Feasibility and acceptability of the implementation of Program Unplugged for the prevention of drug use among school adolescents in Brazil*  
D. R. Schneider<sup>1</sup>, J. F. Horr<sup>1</sup>, G. M. Peres<sup>1</sup>, P. F. de Medeiros<sup>2</sup>, J. I. Cruz<sup>2</sup>, L. C. Oltramari<sup>1</sup>, T. M. Grigolo<sup>3</sup>, M. C. Prado<sup>2</sup>, A. D. Pereira<sup>2</sup>, Z. M. Sanchez<sup>2</sup>, <sup>1</sup>Universidade Federal de Santa Catarina, Florianópolis, Brazil, <sup>2</sup>Universidade Federal de São Paulo, São Paulo, Brazil, <sup>3</sup>Complexo de Ensino Superior de Santa Catarina, Florianópolis, Brazil
- 73 *Evaluation of the Environmental Support Scale in adolescence*  
C. M. Risco<sup>1</sup>, A. Collado-Rodriguez<sup>1</sup>, E. Reynolds<sup>2</sup>, C. W. Lejuez<sup>1</sup>, L. MacPherson<sup>1</sup>, <sup>1</sup>Psychology, University of Maryland, College Park, MD, <sup>2</sup>Child and Adolescent Psychiatry, The Johns Hopkins Hospital, Baltimore, MD
- 74 *Identifying latent classes of adolescent drug treatment services: An outcomes analysis*  
M. Schuler<sup>1</sup>, B. Griffin<sup>2</sup>, E. Letourneau<sup>1</sup>, E. Stuart<sup>1,3</sup>, <sup>1</sup>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>RAND, Arlington, VA, <sup>3</sup>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 75 *Prevalence and predictors of driving under the influence in Spanish youngsters*  
M. González<sup>1</sup>, A. Morales<sup>1</sup>, K. W. Griffin<sup>2</sup>, M. Orgiles<sup>1</sup>, J. P. Espada<sup>1</sup>, <sup>1</sup>Universidad Miguel Hernandez, Elche, Spain, <sup>2</sup>Weill Cornell Medical College, New York, NY
- 76 *Alcohol use among traumatized youth in Zambia*  
J. C. Kane<sup>1</sup>, L. Michalopoulos<sup>2</sup>, J. Bass<sup>1</sup>, P. Bolton<sup>3,1</sup>, L. Murray<sup>1</sup>, <sup>1</sup>Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Columbia University School of Social Work, New York, NY, <sup>3</sup>International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 77 *Pathways from caregiver problematic alcohol use to child internalizing and externalizing behaviors in a child protective services sample*  
K. D. Seay, Brown School of Social Work, Washington University in St. Louis, St. Louis, MO
- 78 *DSM-5 substance use disorder vs. DSM-IV substance abuse and dependence among pediatric patients*  
S. M. Kelly<sup>1</sup>, K. E. O'Grady<sup>2</sup>, J. Gryczynski<sup>1</sup>, S. G. Mitchell<sup>1</sup>, A. Kirk<sup>3</sup>, R. P. Schwartz<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Univ. of MD, College Park, MD, <sup>3</sup>Total Health Care, Baltimore, MD
- 79 *Brief tools for pediatricians to screen 9- to 12-year-olds in need of prevention for substance use disorder*  
T. Ridenour<sup>1,2</sup>, M. D. Reynolds<sup>2</sup>, <sup>1</sup>Research Triangle Institute, Allison Park, PA, <sup>2</sup>University of Pittsburgh, Pittsburgh, PA
- 80 *Validation and performance of the Alcohol, Smoking, and Substance Involvement Screening Test in adolescent primary care patients*  
J. Gryczynski<sup>1</sup>, S. M. Kelly<sup>1</sup>, S. G. Mitchell<sup>1</sup>, A. Kirk<sup>2</sup>, K. E. O'Grady<sup>3</sup>, R. P. Schwartz<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Total Health Care, Baltimore, MD, <sup>3</sup>University of Maryland, College Park, MD

### POLYDRUG ABUSE II

- 81 *Longitudinal predictors of 12-step attendance among substance-abusing women*  
D. D. Bowers, A. Murnan, X. Guo, N. Slesnick, Ohio State University, Columbus, OH
- 82 *Ancillary treatment use in the Stage II community-based Women's Recovery Group therapy trial*  
D. Sugarman<sup>1,2</sup>, S. Wigderson<sup>1</sup>, H. Connery<sup>1,2</sup>, G. Bailey<sup>3,4</sup>, G. Fitzmaurice<sup>1,2</sup>, S. F. Greenfield<sup>1,2</sup>, <sup>1</sup>McLean Hospital, Belmont, MA, <sup>2</sup>Harvard Medical School, Cambridge, MA, <sup>3</sup>Stanley Street Treatment & Resources, Fall River, MA, <sup>4</sup>Brown University, Providence, RI

- 83 *Factors associated with differential use of mental health services among women over 8 years after substance abuse treatment*  
E. Evans, L. Li, V. Lin, Y. Hser, Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 84 *Non-ETOH drug use among women in outpatient treatment for alcohol dependence*  
E. E. Epstein<sup>1</sup>, B. S. McCrady<sup>2</sup>, S. Cook<sup>1</sup>, N. Jensen<sup>1</sup>, A. Gaba<sup>1</sup>, M. L. Steinberg<sup>1</sup>, K. Bold<sup>1</sup>,  
<sup>1</sup>Rutgers University, Piscataway, NJ, <sup>2</sup>University of New Mexico, Albuquerque, NM
- 85 *Availability of women-centered drug treatment services: An analysis of NSSATS 2002-2010*  
N. Longinaker<sup>1</sup>, L. Appel<sup>2</sup>, M. Terplan<sup>2,1</sup>, <sup>1</sup>Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, <sup>2</sup>Department of Obstetrics, Gynecology & Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD
- 86 *Addiction services for women in Eastern Europe: What is available and where?*  
A. O. Abagiu<sup>1</sup>, P. Dolezalova<sup>2</sup>, Z. Alexandercikova<sup>3</sup>, J. K. Csorba<sup>4</sup>, V. Bogdanova<sup>5</sup>,  
A. Kastelici<sup>6</sup>, <sup>1</sup>National Institute for Infectious Diseases Prof. dr. Matei Bals, OST ARENA Center, Bucharest, Romania, <sup>2</sup>Clinic of Addictology, Prague, Czech Republic, <sup>3</sup>Center for Treatment of Drug Dependencies, Bratislava, Slovakia, <sup>4</sup>Drug Outpatient and Prevention Center, Gyula, Hungary, <sup>5</sup>Drug Demand Reduction Department, Sofia, Bulgaria, <sup>6</sup>Center for Treatment of Drug Addiction, Ljubljana, Slovenia
- 87 *Preliminary evidence of injecting drug reduction from a woman-focused RCT in Republic of Georgia*  
I. Kirtadze<sup>1</sup>, D. Otiashvili<sup>1</sup>, K. E. O'Grady<sup>2</sup>, H. Jones<sup>3</sup>, W. Zule<sup>5</sup>, E. Krupitsky<sup>4</sup>,  
W. Wechsberg<sup>5</sup>, <sup>1</sup>Addiction Research Center, Alternative Georgia, Tbilisi, Georgia, <sup>2</sup>Dept. of Psychology, U. of Maryland, College Park, MD, <sup>3</sup>UNC Horizons, Dept. of Obstetrics and Gynecology, U. of North Carolina at Chapel Hill, Carrboro, NC, <sup>4</sup>Dept. of Addictions, Bekhterev Research Psychoneurological Inst., St. Petersburg, Russian Federation, <sup>5</sup>RTI International, RTP, NC
- 88 *Do chief complaints allow targeting of SBIRT in the emergency department?*  
R. P. McCormack<sup>1</sup>, P. Gauthier<sup>1</sup>, B. McClure<sup>1</sup>, L. Moy<sup>1</sup>, M. Hu<sup>2</sup>, M. Pavlicova<sup>2</sup>, E. V. Nunes<sup>2</sup>,  
D. Thompson<sup>3</sup>, M. Bogenschutz<sup>5</sup>, R. Mandler<sup>4</sup>, J. Rotrosen<sup>1</sup>, <sup>1</sup>New York Univ. School of Medicine, New York, NY, <sup>2</sup>Columbia Univ., New York, NY, <sup>3</sup>Northwestern Univ., Chicago, IL, <sup>4</sup>NIDA, Bethesda, MD, <sup>5</sup>Univ. of New Mexico, Albuquerque, NM
- 89 *Race and ethnicity differences in a MI-based brief intervention delivered in an ED setting*  
A. A. Forcehimes<sup>1</sup>, M. Bogenschutz<sup>1</sup>, G. Sharma<sup>2</sup>, R. Mandler<sup>3</sup>, <sup>1</sup>UNM CASAA, Albuquerque, NM, <sup>2</sup>EMMES, Rockville, MD, <sup>3</sup>NIDA, Bethesda, MD
- 90 *Correlates of drug use problems among substance users presenting in emergency departments: Results of a multi-site study*  
W. Macias Konstantopoulos<sup>1,2</sup>, J. A. Dreifuss<sup>1,3</sup>, K. A. McDermott<sup>3</sup>, B. A. Parry<sup>2</sup>,  
M. L. Howell<sup>2</sup>, R. N. Mandler<sup>4</sup>, M. Bogenschutz<sup>5</sup>, R. Weiss<sup>1,3</sup>, <sup>1</sup>Harvard Medical School, Boston, MA, <sup>2</sup>Massachusetts General Hospital, Boston, MA, <sup>3</sup>McLean Hospital, Belmont, MA, <sup>4</sup>NIDA, Bethesda, MD, <sup>5</sup>University of New Mexico, Albuquerque, NM
- 91 *A quality improvement innovation to establish a PCMH tailored to homeless veterans who utilize the ED*  
B. Patel<sup>1</sup>, R. Manchanda<sup>1</sup>, R. Andersen<sup>1,2</sup>, L. Altman<sup>1,2</sup>, L. Gelberg<sup>1,2</sup>, <sup>1</sup>Department of Veterans Affairs, Los Angeles, CA, <sup>2</sup>University of California Los Angeles, Los Angeles, CA
- 92 *VA health service use for homeless and low-income veterans: A spotlight on Los Angeles' VA Supportive Housing program*  
S. Gabrielian<sup>1,2</sup>, A. H. Yuan<sup>1</sup>, R. Andersen<sup>2,1</sup>, L. Rubenstein<sup>1,2</sup>, L. Gelberg<sup>2,1</sup>, <sup>1</sup>VAGLA, Los Angeles, CA, <sup>2</sup>UCLA, Los Angeles, CA



- 93 *Trajectories of drug use frequency after substance abuse treatment among a sample of homeless youth*  
X. Guo, N. Slesnick, X. Feng, The Ohio State University, Columbus, OH
- 94 *Relations between psychopathy factors, substance use disorders, and treatment readiness among adults in inpatient substance use treatment*  
K. Long<sup>1</sup>, L. MacPherson<sup>1</sup>, E. Verona<sup>2</sup>, C. W. Lejuez<sup>1</sup>, <sup>1</sup>Psychology, University of Maryland, College Park, MD, <sup>2</sup>Psychology, University of Illinois, Champaign, IL
- 95 *Motivational enhancement, readiness to change, and treatment success in African-American substance users*  
J. E. Korte<sup>1</sup>, L. Montgomery<sup>2</sup>, K. T. Brady<sup>1,3</sup>, K. Burlew<sup>2</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>University of Cincinnati, Cincinnati, OH, <sup>3</sup>Ralph H. Johnson VA Medical Center, Charleston, SC
- 96 *Brazilian crack cocaine users: Preliminary results from a nationwide survey*  
M. Malta, N. Bertoni, F. I. Bastos, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
- 97 *A multisite randomized controlled trial of Motivational Enhancement Treatment in outpatient addiction care centers in Mexico*  
R. Marín-Navarrete<sup>1</sup>, V. E. Horigian<sup>2</sup>, J. C. Fernandez Mondragon<sup>1</sup>, R. Verdeja<sup>2</sup>, E. Alonso<sup>2</sup>, L. Templos-Nuñez<sup>1</sup>, A. Eliosa-Hernandez<sup>1</sup>, D. Feaster<sup>2</sup>, R. Sánchez-Huesca<sup>3</sup>, A. De la Fuente-Martin<sup>1</sup>, C. Lima-Rodriguez<sup>4</sup>, C. Berlnaga<sup>5</sup>, M. E. Medina-Mora<sup>5</sup>, <sup>1</sup>Clinical Trials Unit on Addiction and Mental Health, National Institute of Psychiatry (Mexico), Distrito Federal, Mexico, <sup>2</sup>Florida Node Alliance / NIDA-CTN, University of Miami, Miami FL, FL, <sup>3</sup>Centros de Integración Juvenil AC (Mexico), Distrito Federal, Mexico, <sup>4</sup>Consejo Estatal Contra las Adicciones de Puebla, Puebla, Mexico, <sup>5</sup>National Institute of Psychiatry (Mexico), Distrito Federal, Mexico
- 98 *Employment-based reinforcement of opiate and cocaine abstinence in out-of-treatment injection drug users*  
A. Holtyn<sup>1</sup>, M. N. Koffarnus<sup>2</sup>, A. DeFulio<sup>1</sup>, S. O. Sigurdsson<sup>3,1</sup>, E. C. Strain<sup>1</sup>, R. P. Schwartz<sup>4</sup>, K. Silverman<sup>1</sup>, <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>3</sup>Florida Institute of Technology, Melbourne, FL, <sup>4</sup>Friends Research Institute, Baltimore, MD
- 99 *Incentives and alerts for improving substance abuse treatment in Washington State*  
D. W. Garnick<sup>1</sup>, C. M. Horgan<sup>1</sup>, A. Acevedo<sup>1</sup>, M. Lee<sup>1</sup>, E. L. Merrick<sup>1</sup>, G. Ritter<sup>1</sup>, L. Panas<sup>1</sup>, K. Campbell<sup>2</sup>, A. Huber<sup>3</sup>, E. Larson<sup>2</sup>, F. Wrede<sup>2</sup>, <sup>1</sup>Institute for Behavioral Health, Heller School, Brandeis University, Waltham, MA, <sup>2</sup>The Division of Behavioral Health and Recovery, Washington State Department of Social and Health Services, Olympia, WA, <sup>3</sup>Dept. of Social and Health Services, Research and Data Analysis Division, Olympia, WA
- 100 *Managing substance use treatment in private U.S. health plans*  
E. L. Merrick, C. M. Horgan, S. Reif, A. Quinn, M. Stewart, D. W. Garnick, D. Hodgkin, A. Mateucci, Institute for Behavioral Health, Heller School, Brandeis University, Waltham, MA
- 101 *Managing and improving behavioral health care quality in private health plans*  
C. M. Horgan, E. L. Merrick, D. W. Garnick, S. Reif, M. Stewart, C. Ramos, D. Hodgkin, A. Quinn, Institute for Behavioral Health, Heller School, Brandeis University, Waltham, MA

- 102 *Prevalence of illicit drug use among patients of community health centers in East Los Angeles and Tijuana*  
M. Garcia<sup>1</sup>, M. Rico<sup>1</sup>, J. Scholtz<sup>1</sup>, M. Vahidi<sup>1</sup>, G. Natera<sup>3</sup>, R. Andersen<sup>2</sup>, I. Bojorquez<sup>4</sup>, J. Yacenda<sup>1</sup>, M. Arroyo<sup>3</sup>, M. Gonzalez<sup>5</sup>, L. Gelberg<sup>1,2</sup>, <sup>1</sup>Family Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, <sup>2</sup>UCLA School of Public Health, Los Angeles, CA, <sup>3</sup>National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico, <sup>4</sup>El Colegio de la Frontera Norte Department of Population Studies, Tijuana, Mexico, <sup>5</sup>National Commission Against Addictions, Mexico City, Mexico
- 103 *How important are counselor and client characteristics in determining overall client satisfaction with 12-Step focused community counseling groups?*  
R. Baroni<sup>1</sup>, D. Boyd<sup>1</sup>, A. Christmann<sup>1</sup>, E. Hutz<sup>1</sup>, C. M. Carpenedo<sup>1</sup>, A. C. Brooks<sup>1</sup>, A. B. Laudet<sup>2</sup>, K. C. Kirby<sup>1,3</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>National Development and Research Institutes, New York, NY, <sup>3</sup>University of Pennsylvania School of Medicine, Philadelphia, PA
- 104 *Effects of dissemination efforts to promote client engagement in recovery-oriented activities in community-based treatment*  
D. J. Knoblach<sup>1</sup>, A. Mericle<sup>2</sup>, E. Hutz<sup>2</sup>, A. C. Brooks<sup>2</sup>, A. B. Laudet<sup>3</sup>, D. Carise<sup>4</sup>, <sup>1</sup>University of Maryland, Baltimore County, Catonsville, MD, <sup>2</sup>Treatment Research Institute, Philadelphia, PA, <sup>3</sup>National Development and Research Institutes, New York, NY, <sup>4</sup>CRC Health Group, Inc., Cupertino, CA
- 105 *Process evaluation of a community collaborative board: Using community-based participatory research to create a substance abuse/ health intervention*  
A. Jemal<sup>1,2</sup>, V. C. Smith<sup>3</sup>, <sup>1</sup>Rutgers University, New Brunswick, NJ, <sup>2</sup>NDRI, New York, NY, <sup>3</sup>Cabrini College, Radnor, PA
- 106 *Strategies to increase family influence on patient decisions about medication-assisted treatment*  
R. Croff<sup>1</sup>, K. Alanis-Hirsch<sup>2</sup>, J. Ford<sup>3</sup>, L. Schmidt<sup>4</sup>, M. Chalk<sup>2</sup>, D. McCarty<sup>1</sup>, <sup>1</sup>Oregon Health & Science University, Portland, OR, <sup>2</sup>Treatment Research Institute, Philadelphia, PA, <sup>3</sup>Center for Health Enhancement System Studies, Madison, WI, <sup>4</sup>University of California, San Francisco, CA
- 107 *Patients' economic considerations of treatment for methamphetamine and opiate use at an innovative drug treatment center in Malaysia*  
S. Brown<sup>1</sup>, A. Krishnan<sup>1</sup>, M. Ghani<sup>2</sup>, F. Khan<sup>2</sup>, A. Kamarulzaman<sup>1,3</sup>, F. Altice<sup>1,3</sup>, <sup>1</sup>Internal Medicine, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Yale College, New Haven, CT, <sup>3</sup>Center of Excellence for Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia
- 108 *Indigenous culture as intervention in addictions treatment*  
C. A. Dell<sup>1</sup>, S. Acoose<sup>2</sup>, <sup>1</sup>Sociology & School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada, <sup>2</sup>Indian Social Work, First Nations University of Canada, Saskatoon, SK, Canada
- 109 *Nurses' screening and referral behaviors and opinions about brief interventions before and after implementation of Project Engage*  
A. Pecoraro<sup>1</sup>, R. Mooney<sup>2</sup>, T. Horton<sup>2</sup>, G. E. Woody<sup>1</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Christiana Hospital, Christiana, DE

### HIV/HCV II

- 110 *Substance use and sexual risk among men who have sex with men and women and their female partners*  
T. P. Dyer<sup>1</sup>, M. R. Khan<sup>2</sup>, M. Sandoval<sup>3</sup>, M. Bolyard<sup>4</sup>, S. R. Friedman<sup>3</sup>, <sup>1</sup>Epidemiology and Biostatistics, University of Maryland, College Park, MD, <sup>2</sup>Epidemiology, University of Florida, Gainesville, FL, <sup>3</sup>Institute for Infectious Disease Research, National Development and Research Institutes, New York, NY, <sup>4</sup>Office of Institutional Research, Planning, and Effectiveness (OIRPE), Emory University, Atlanta, GA
- 111 *HSV-2 and HIV among MSM who use cocaine and heroin in New York City*  
J. P. Feelemyer<sup>1</sup>, D. C. Des Jarlais<sup>1</sup>, K. Arasteh<sup>1</sup>, C. McKnight<sup>1</sup>, H. L. Cooper<sup>3</sup>, H. Hagan<sup>2</sup>, R. Stall<sup>4</sup>, D. Perlman<sup>1</sup>, <sup>1</sup>The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York, NY, <sup>2</sup>School of Nursing, New York University, New York, NY, <sup>3</sup>Rollins School of Public Health, Emory University, Atlanta, GA, <sup>4</sup>Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA
- 112 *Drug use among male sex workers in Vietnam: Timing of initiation in relation to sex work*  
G. M. Le<sup>1</sup>, M. Clatts<sup>2</sup>, L. Goldsamt<sup>3</sup>, V. D. Vu<sup>1</sup>, S. M. Nguyen<sup>1</sup>, <sup>1</sup>Hanoi Medical University, Hanoi, Viet Nam, <sup>2</sup>University of Puerto Rico, San Juan, <sup>3</sup>National Development and Research Institutes, New York, NY
- 113 *Sexual relationship power, victimization, and HIV risky sexual behavior in substance-abusing African-American women*  
C. Ahuama-Jonas, K. Burlew, Psychology, University of Cincinnati, Cincinnati, OH
- 114 *Impaired executive function, drug and sex risk, and HIV infection in African-American men*  
W. W. Latimer<sup>1</sup>, M. R. Khan<sup>2</sup>, J. D. Scheidell<sup>2</sup>, E. M. Dunne<sup>1</sup>, <sup>1</sup>Clinical and Health Psychology, University of Florida, Gainesville, FL, <sup>2</sup>Epidemiology, University of Florida, Gainesville, FL
- 115 *The differential role of executive dysfunction on HIV risk behaviors among African-American drug users*  
A. Diggins<sup>1</sup>, E. M. Dunne<sup>1</sup>, B. E. Mancha<sup>1</sup>, R. Trenz<sup>1</sup>, K. Ritter<sup>2</sup>, W. W. Latimer<sup>1</sup>, <sup>1</sup>Clinical and Health Psychology, University of Florida, Gainesville, FL, <sup>2</sup>University of Tennessee, Knoxville, TN
- 116 *Characteristics of poly-substance users engaging in high HIV-risk behaviors*  
K. Williams, J. J. Stoltman, M. K. Greenwald, Psychiatry, Wayne State University, Detroit, MI
- 117 *High dead-space syringe use among people who inject drugs in Tijuana, Mexico*  
C. Rafful<sup>1,2</sup>, W. Zule<sup>3</sup>, P. E. Gonzalez-Zuñiga<sup>1</sup>, M. Medina-Mora<sup>4</sup>, C. Magis-Rodriguez<sup>5</sup>, S. Strathdee<sup>1</sup>, <sup>1</sup>Global Health, University of California San Diego, San Diego, CA, <sup>2</sup>San Diego State University, San Diego, CA, <sup>3</sup>RTI International, Research Triangle, NC, <sup>4</sup>Mexican National Institute of Psychiatry, Mexico City, Mexico, <sup>5</sup>CENSIDA, Mexico, Mexico City, Mexico
- 118 *WITHDRAWN*
- 119 *Sex, drugs and healthcare utilization among HIV+ patients: The role of marijuana*  
L. H. Lundahl, D. M. Ledgerwood, C. L. Arfken, M. K. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI
- 120 *Intoxication at last sexual intercourse and unprotected sex among HIV-positive and HIV-negative individuals in Uganda: An event-level analysis*  
B. Kerridge<sup>1</sup>, P. Tran<sup>2</sup>, D. S. Hasin<sup>1</sup>, <sup>1</sup>Columbia University, New York City, NY, <sup>2</sup>Medical School, St. George, True Blue, Grenada

- 121 *Avoiding treatment due to fears of violence: The first report of gender-based and intimate partner violence in the community and in the hospital among female heroin users in Dar es Salaam, Tanzania*  
D. Balaji<sup>1</sup>, B. Lambdin<sup>2</sup>, J. Mbwambo<sup>3</sup>, O. Chang<sup>2</sup>, C. Nyandindi<sup>3</sup>, M. Copenhaver<sup>4</sup>, R. Bruce<sup>1,2</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>Pangea Global AIDS Foundation, Oakland, CA, <sup>3</sup>Psychiatry, Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania, <sup>4</sup>Allied Health Sciences, University of Connecticut, Storrs, CT
- 122 *Fatal and non-fatal overdose after narcology hospital discharge among HIV-infected Russians*  
A. Y. Walley<sup>1</sup>, E. Krupitsky<sup>2</sup>, D. M. Cheng<sup>3,1</sup>, E. K. Quinn<sup>3</sup>, L. Wulach<sup>1</sup>, P. O. Coffin<sup>4</sup>, J. Samet<sup>1,3</sup>, <sup>1</sup>Boston University School of Medicine/ Boston Medical Center, Boston, MA, <sup>2</sup>Pavlov State University, St. Petersburg, Russian Federation, <sup>3</sup>Boston University School of Public Health, Boston, MA, <sup>4</sup>San Francisco Department of Public Health, San Francisco, CA
- 123 *WITHDRAWN*
- 124 *Study attrition among HIV-infected Russian risky drinkers*  
T. Kiriazova<sup>1,2,3</sup>, D. M. Cheng<sup>1</sup>, S. Coleman<sup>1</sup>, E. Blokhina<sup>4</sup>, E. Krupitsky<sup>4,5</sup>, M. C. Lira<sup>2</sup>, C. Bridgen<sup>2</sup>, A. Raj<sup>6</sup>, J. Samet<sup>1,2</sup>, <sup>1</sup>Boston University, Boston, MA, <sup>2</sup>Boston Medical Center, Boston, MA, <sup>3</sup>Future without AIDS, Odessa, Ukraine, <sup>4</sup>First Pavlov State Medical University, St. Petersburg, Russian Federation, <sup>5</sup>Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation, <sup>6</sup>University of California San Diego, San Diego, CA
- 125 *Using the VACS Index to track health outcomes associated with abstinence among HIV-infected patients receiving opioid agonist treatment*  
K. McGinnis<sup>1</sup>, E. J. Edelman<sup>2</sup>, J. Tate<sup>2</sup>, A. Justice<sup>2</sup>, D. Fiellin<sup>2</sup>, <sup>1</sup>U Pittsburgh, Pittsburgh, PA, <sup>2</sup>Yale, New Haven, CT
- 126 *HIV stigma among substance-abusing PLWH: Implications for HIV treatment, ARV adherence and diversion*  
M. A. Levi Minzi, H. Surratt, Nova Southeastern University, Miami, FL
- 127 *Receipt of opioid therapy guideline-concordant care among HIV+ and HIV- veterans*  
J. R. Gaither<sup>1</sup>, E. Edelman<sup>1</sup>, W. Becker<sup>1,2</sup>, S. Crystal<sup>4</sup>, K. Gordon<sup>2</sup>, J. Goulet<sup>1,2</sup>, R. Kerns<sup>1,2</sup>, M. Skanderson<sup>3</sup>, D. Weisberg<sup>1</sup>, K. Bryant<sup>5</sup>, A. Justice<sup>1,2</sup>, D. Fiellin<sup>1</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>VA CT HCS, New Haven, CT, <sup>3</sup>VA Pittsburgh HCS, New Haven, CT, <sup>4</sup>Rutgers University, New Brunswick, NJ, <sup>5</sup>NIH/NIAAA, Bethesda, MD

### ABUSE LIABILITY

- 128 *Assessment of human abuse potential of preladenant (a centrally-acting A<sub>2A</sub> antagonist) compared to phentermine and placebo in recreational stimulant users*  
K. Schoedel<sup>1</sup>, N. Levy-Cooperman<sup>1</sup>, P. Basseches<sup>2</sup>, K. Butterfield<sup>2</sup>, D. Hewitt<sup>2</sup>, P. Larson<sup>2</sup>, M. Troyer<sup>2</sup>, E. M. Sellers<sup>3</sup>, J. Udo de Haes<sup>2</sup>, <sup>1</sup>Altreos Research Partners Inc, Toronto, ON, Canada, <sup>2</sup>Merck & Co, Inc, Whitehouse Station, NJ, <sup>3</sup>DL Global Partners, Inc, Toronto, ON, Canada
- 129 *The effects of pioglitazone, a PPAR $\gamma$  receptor agonist, on the abuse liability of oxycodone*  
J. D. Jones, M. Sullivan, J. M. Manubay, S. Mogali, V. Metz, S. Comer, Division of Substance Abuse, Columbia University, New York, NY
- 130 *Effect of co-administration of naloxone on intravenous hydromorphone abuse potential in non-treatment-seeking, opioid-dependent drug users*  
N. Levy-Cooperman<sup>1</sup>, K. A. Schoedel<sup>1</sup>, J. Reiz<sup>2</sup>, D. Thompson<sup>2</sup>, B. Chakaraborty<sup>3</sup>, P. Geoffroy<sup>3</sup>, K. Michalko<sup>2</sup>, <sup>1</sup>Altreos Research Partners, Toronto, ON, Canada, <sup>2</sup>Purdue Pharma (Canada), Toronto, ON, Canada, <sup>3</sup>INC Research, Toronto, ON, Canada

- 131 *Preliminary report of THC influence on subject ability to discriminate between active opioid and placebo in human abuse liability study*  
M. Smith, J. Jenkins, M. Iverson, L. R. Webster, PRA (formerly CRI Lifetree), Salt Lake City, UT
- 132 *Buprenorphine/naloxone abuse and diversion: Film rates are less than tablet rates*  
R. C. Dart<sup>1</sup>, H. Surratt<sup>1</sup>, E. J. Lavonas<sup>1</sup>, E. M. Martinez<sup>1</sup>, S. G. Severtson<sup>2</sup>, T. Cicero<sup>3</sup>, S. P. Kurtz<sup>4</sup>, A. Rosenblum<sup>3</sup>, J. L. Green<sup>1</sup>, <sup>1</sup>Denver Health and Hospital Authority, Denver, CO, <sup>2</sup>Washington University School of Medicine, St. Louis, MO, <sup>3</sup>Nova Southeastern University, Miami, FL, <sup>4</sup>National Development and Research Institutes, New York, NY
- 133 *The street prices of immediate- and extended-release tapentadol are lower than other Schedule II opioid tablets/capsules*  
M. C. Le Lait<sup>1</sup>, S. G. Severtson<sup>1</sup>, N. Dasgupta<sup>2</sup>, J. L. Green<sup>1</sup>, A. Hall<sup>1</sup>, R. C. Dart<sup>1,3</sup>, <sup>1</sup>RADARS(r) System, RMPDC, DHHA, Denver, CO, <sup>2</sup>Epidemico, Boston, MA, <sup>3</sup>U of Colorado Denver School of Medicine, Denver, CO
- 134 *Comparing abuse of extended-release vs. immediate-release opioid analgesics adjusted for number of prescriptions and morphine-equivalent dose*  
S. F. Butler<sup>1</sup>, T. A. Cassidy<sup>1</sup>, P. Coplan<sup>2</sup>, <sup>1</sup>Inflexxion, Inc., Newton, MA, <sup>2</sup>Purdue Pharma, L.P., Stamford, CT
- 135 *Evaluation of an ADF product's route-of-administration profile*  
T. A. Cassidy, S. H. Budman, S. F. Butler, Inflexxion, Inc, Newton, MA
- 136 *Routes of administration and frequency of abuse of OxyContin® and immediate-release oxycodone in a rural Kentucky county following introduction of reformulated OxyContin: Results from the first 71 follow-up interviews*  
J. R. Havens<sup>1</sup>, A. DeVeugh-Geiss<sup>2</sup>, C. Leukefeld<sup>1</sup>, H. Kale<sup>2</sup>, P. Coplan<sup>2</sup>, H. Chilcoat<sup>2</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Purdue Pharma LP, Stamford, CT
- 137 *Regional concentrations of Opana® ER abuse before and after introduction of a tamper-resistant formulation in 2012*  
S. G. Severtson<sup>1</sup>, M. C. Le Lait<sup>1</sup>, J. L. Green<sup>1</sup>, R. C. Dart<sup>1,2</sup>, <sup>1</sup>RADARS(r) System, RMPDC, DHHA, Denver, CO, <sup>2</sup>University of Colorado Denver School of Medicine, Denver, CO
- 138 *Trends in abuse and diversion in multiple surveillance systems three years after introduction of reformulated OxyContin*  
H. Chilcoat<sup>1</sup>, B. Bucher Bartelson<sup>2</sup>, S. G. Severtson<sup>2</sup>, S. F. Butler<sup>3</sup>, T. A. Cassidy<sup>3</sup>, P. Coplan<sup>1</sup>, <sup>1</sup>Purdue Pharma, Stamford, CT, <sup>2</sup>RADARS, Denver, CO, <sup>3</sup>Inflexxion, Newton, MA

### EPIDEMIOLOGY

- 139 *iEpi. Epidemiology of one*  
G. Bobashev<sup>1</sup>, D. Liao<sup>1</sup>, J. Hampton<sup>1</sup>, J. Helzer<sup>2</sup>, L. Hoffer<sup>3</sup>, R. Morris<sup>1</sup>, <sup>1</sup>RTI International, Durham, NC, <sup>2</sup>University of Vermont, Burlington, VT, <sup>3</sup>Case Western Reserve University, Cleveland, OH
- 140 *The association between exposure to guns and gambling among community-recruited substance using women*  
K. Vaddiparti, C. W. Striley, L. Cottler, Epidemiology, University of Florida, Gainesville, FL
- 141 *Different dynamic relationship between stress and illicit drug use from pregnancy to postpartum among drug-using women*  
H. Wu<sup>1</sup>, E. Coman<sup>2</sup>, H. Tennen<sup>3</sup>, J. Grady<sup>3</sup>, <sup>1</sup>Psychiatry, U Conn Health Center, Farmington, CT, <sup>2</sup>TRIPP Center, UConn Health Center, Farmington, CT, <sup>3</sup>Community Medicine and Health Care, U Conn Health Center, Farmington, CT

- 142 *Female cocaine users are at excess risk of becoming cocaine dependent soon after onset of cocaine use: Estimates for the United States, 2002-2011*  
A. M. Mohammed, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
- 143 *Patterns of crack use among drug-using females in Mexico City*  
N. Negi<sup>1</sup>, A. Valdez<sup>2</sup>, A. Cepeda<sup>2</sup>, G. Natera<sup>3</sup>, <sup>1</sup>School of Social Work, University of Maryland, Baltimore, Baltimore, MD, <sup>2</sup>School of Social Work, University of Southern California, Los Angeles, CA, <sup>3</sup>Instituto de Psiquiatría, Ramón de la Fuente Muñiz, Mexico, Mexico
- 144 *Follow up of crack users after hospital discharge based on probabilistic record linkage methodology*  
V. M. Gonçalves<sup>1,2</sup>, R. S. Pedroso<sup>1</sup>, A. M. dos Santos<sup>2</sup>, F. P. Pechansky<sup>1</sup>, <sup>1</sup>Center for Drug and Alcohol Research, University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>2</sup>Informatics Department, Ministry of Health, Porto Alegre, Brazil
- 145 *Addiction and barriers to treatment in a sample of community-recruited methamphetamine users in a South African township*  
C. S. Meade<sup>1</sup>, S. Towe<sup>1</sup>, M. H. Watt<sup>1</sup>, D. Skinner<sup>2</sup>, B. Myers<sup>3</sup>, S. Kimani<sup>1</sup>, J. C. MacFarlane<sup>1</sup>, D. Pieterse<sup>2</sup>, <sup>1</sup>Duke University, Durham, NC, <sup>2</sup>Stellenbosch University, Cape Town, South Africa, <sup>3</sup>South African Medical Research Council, Cape Town, South Africa
- 146 *A novel measure of assessing the frequency and route of administration of various substances of abuse*  
A. Ninnemann<sup>1</sup>, J. Elmquist<sup>2</sup>, J. Febres<sup>2</sup>, H. Brasfield<sup>2</sup>, R. C. Shorey<sup>2</sup>, H. Zapor<sup>2</sup>, C. Wolford-Celvenger<sup>2</sup>, L. MacPherson<sup>1</sup>, G. L. Stuart<sup>2</sup>, <sup>1</sup>University of Maryland, College Park, MD, <sup>2</sup>University of Tennessee, Knoxville, TN
- 147 *Associations between blood lead level and substance use among adults in the United States*  
H. Hu, J. Scheidell, A. Coatsworth, X. Xu, M. R. Khan, Department of Epidemiology, University of Florida, Gainesville, FL
- 148 *WITHDRAWN*
- 149 *What is the evidence for hardening? Trends in nicotine dependence in the U.S., 2002-2011*  
P. H. Smith<sup>1</sup>, J. S. Rose<sup>2</sup>, G. A. Giovino<sup>3</sup>, C. M. Mazure<sup>1</sup>, S. A. McKee<sup>1</sup>, <sup>1</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Psychology, Wesleyan University, Middletown, CT, <sup>3</sup>Community Health and Health Behavior, University at Buffalo, SUNY, Buffalo, NY
- 150 *Tobacco outlets and tobacco use in Baltimore City from 2004-2009*  
Q. L. Brown, A. J. Milam, C. M. Furr-Holden, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 151 *Risk of starting to smoke tobacco cigarettes in the United States: Estimates for foreign-born vs. U.S.-born young people, 2002-2009*  
W. Xue, C. Lopez-Quintero, J. C. Anthony, Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
- 152 *Latinos' access to online and formal mental health support*  
R. Parra-Cardona<sup>1</sup>, J. C. Anthony<sup>1</sup>, D. DeAndrea<sup>2</sup>, <sup>1</sup>Human Development and Family Studies, Michigan State University, East Lansing, MI, <sup>2</sup>School of Communication, The Ohio State University, Columbus, OH
- 153 *Effectiveness of Ambassador plus Navigator vs. Navigator alone to enroll current drug users in health studies*  
C. W. Striley, C. Ruktanonchai, L. Cottler, Epidemiology, University of Florida, Gainesville, FL

- 154 *Association between age, substance use and health service use in Medicare elderly prostate cancer patients*  
S. Chhatre<sup>1</sup>, D. Metzger<sup>1</sup>, G. E. Woody<sup>1</sup>, R. Jayadevappa<sup>2</sup>, <sup>1</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Medicine, University of Pennsylvania, Philadelphia, PA
- 155 *Racial and ethnic disparities in substance use and outcomes in elderly prostate cancer patients*  
R. Jayadevappa<sup>2</sup>, D. Metzger<sup>1</sup>, G. E. Woody<sup>1</sup>, S. Chhatre<sup>1</sup>, <sup>1</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Medicine, University of Pennsylvania, Philadelphia, PA
- 156 *Opioid use disorders: Trends and correlates*  
M. J. Dennis, M. L. Dennis, R. R. Funk, Chestnut Health Systems, Normal, IL
- 157 *Opioid substitution therapy in New South Wales 2001-2012: Comparison between buprenorphine and methadone*  
L. Burns, N. Gisev, L. Degenhardt, S. Larney, NDARC, UNSW, Sydney, NSW, Australia
- 158 *When less is more: A web-based study of user beliefs about buprenorphine dosing in self-treatment of opioid withdrawal symptoms*  
R. Daniulaityte<sup>1</sup>, R. Carlson<sup>1</sup>, D. Cameron<sup>2</sup>, G. A. Smith<sup>2</sup>, A. P. Sheth<sup>2</sup>, <sup>1</sup>Community Health, Wright State University, Dayton, OH, <sup>2</sup>Computer Science and Engineering, Wright State University, Dayton, OH
- 159 *A latent class analysis of traumatic events experienced by drug users and their partners: Associations between distinct trauma patterns and psychiatric and substance use disorders, sex trade, and sexually transmitted infections*  
C. Cavanaugh<sup>1</sup>, H. Petras<sup>2,3</sup>, W. W. Latimer<sup>4</sup>, <sup>1</sup>Psychology, Rutgers University, Camden, NJ, <sup>2</sup>JBS International, North Bethesda, MD, <sup>3</sup>Johns Hopkins University, Baltimore, MD, <sup>4</sup>Clinical and Health Psychology, University of Florida, Gainesville, FL
- 160 *Factors associated with internalized injection drug user stigma among injection drug users in New York City*  
A. V. Rivera<sup>1</sup>, J. DeCuir<sup>1</sup>, N. D. Crawford<sup>2</sup>, C. Fuller<sup>1</sup>, <sup>1</sup>Epidemiology, Columbia University Mailman School of Public Health, New York, NY, <sup>2</sup>Epidemiology and Biostatistics, Georgia State University School of Public Health, Atlanta, GA
- 161 *Initiating people into illicit drug injection*  
A. Kral<sup>1</sup>, L. Wenger<sup>1</sup>, D. Chu<sup>2</sup>, B. Quinn<sup>3</sup>, J. Thing<sup>3</sup>, J. Lorvick<sup>1</sup>, R. Bluthenthal<sup>2</sup>, <sup>1</sup>RTI International, San Francisco, CA, <sup>2</sup>University of Southern California, Los Angeles, CA, <sup>3</sup>Burnet Institute, Melbourne, VIC, Australia
- 162 *Risk and protective factors for heroin initiation and re-initiation among rural prescription opioid users*  
J. P. Harp<sup>1,2</sup>, J. R. Havens<sup>1,2</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY

## Symposium XII

**SAN CRISTOBAL**  
**10:00 - 12:00 PM**

### **BILL WOOLVERTON'S GREATEST HITS: DRUGS, CHOICES, AND CONSEQUENCES**

Chairs: James Rowlett and Michael A. Nader

10:00 *The band plays on: Reinforcing efficacy, choice, and the music of Bill Woolverton*  
James Rowlett, University of Mississippi Medical Center, Jackson, MS

10:25 *Animal models of cocaine choice: Drugs, environment, and social context*  
Michael A. Nader, Wake Forest University School of Medicine, Winston-Salem, NC

- 10:50 *Delay discounting and the choice to take a drug*  
Sally L. Huskinson, University of Mississippi Medical Center, Jackson, MS
- 11:15 *Punishment of drug choice: Insights from the study of drugs as punishers*  
Kevin B. Freeman, University of Mississippi Medical Center, Jackson, MS
- 11:40 *DISCUSSANT: Across the Great Divide: Behavior meets pharmacology according to Bill Woolverton*  
Robert Balster, Virginia Commonwealth University, Richmond, VA

### Oral Communications 11

**BALLROOM A**  
**10:00 - 12:00 PM**

#### ADDICTION DEPICTION: IMAGING

Chairs: Anna Rose Childress and Daniel Langleben

- 10:00 *Adolescents are driven by incentive valence, not magnitude, on the monetary incentive delay task*  
J. Joseph<sup>1</sup>, X. Zhu<sup>1</sup>, C. Benca<sup>1</sup>, G. Baik<sup>1</sup>, F. Davies<sup>1</sup>, T. H. Kelly<sup>2</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>University of Kentucky, Lexington, KY
- 10:15 *Choosing money over drugs: The underpinnings of rational choice in cocaine addicts*  
M. J. Wesley<sup>1</sup>, T. Lohrenz<sup>1</sup>, M. N. Koffarnus<sup>1</sup>, S. M. McClure<sup>2</sup>, R. De La Garza II<sup>3</sup>, T. F. Newton<sup>3</sup>, W. K. Bickel<sup>1</sup>, P. Montague<sup>1</sup>, <sup>1</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Stanford University, Stanford, CA, <sup>3</sup>Baylor College of Medicine, Houston, TX
- 10:30 *Cocaine use-related temporal changes in white matter as detected by DTI*  
L. Ma<sup>1,2</sup>, J. L. Steinberg<sup>1,3</sup>, D. Ramesh<sup>1,4</sup>, L. A. Keyser-Marcus<sup>1,3</sup>, F. G. Moeller<sup>1,3,4</sup>, <sup>1</sup>Institute for Drug and Alcohol Studies, Virginia Commonwealth University (VCU), Richmond, VA, <sup>2</sup>Department of Radiology, VCU, Richmond, VA, <sup>3</sup>Department of Psychiatry, VCU, Richmond, VA, <sup>4</sup>Department of Pharmacology and Toxicology, VCU, Richmond, VA
- 10:45 *"Destined for success"? Brain responses during drug cue exposure foretell clinical outcome in cocaine patients*  
A. R. Childress<sup>1,2</sup>, J. Suh<sup>1,2</sup>, K. Jagannathan<sup>1</sup>, K. A. Young<sup>1</sup>, T. Franklin<sup>1</sup>, R. Ehrman<sup>1,2</sup>, Z. Monge<sup>1</sup>, D. Langleben<sup>1,2</sup>, K. M. Kampman<sup>1</sup>, R. Wetherill<sup>1</sup>, M. J. Gawrysiak<sup>2</sup>, C. P. O'Brien<sup>1</sup>, <sup>1</sup>Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, <sup>2</sup>VA MIRECC, Philadelphia, PA
- 11:00 *Use of real-time functional magnetic resonance imaging for facilitation of self-regulation of nucleus accumbens response in cocaine abusers*  
M. Shane<sup>1,2</sup>, S. Posse<sup>3</sup>, <sup>1</sup>Forensic Psychology, University of Ontario Institute of Technology, Toronto, ON, Canada, <sup>2</sup>Clinical Affective Neuroscience Laboratory, The Mind Research Network, Albuquerque, NM, <sup>3</sup>Department of Neurology, University of New Mexico, Albuquerque, NM
- 11:15 *Attenuated insular and frontocingulate decision-making related activation during an aversive interoceptive state in methamphetamine-dependent individuals*  
J. L. Stewart<sup>1</sup>, A. C. May<sup>1</sup>, N. Poppa<sup>1</sup>, P. W. Davenport<sup>2</sup>, S. F. Tapert<sup>3,1</sup>, M. P. Paulus<sup>3,1</sup>, <sup>1</sup>Psychiatry, University of California, San Diego, La Jolla, CA, <sup>2</sup>Physiological Sciences, University of Florida, Gainesville, FL, <sup>3</sup>Psychiatry Service, Veterans Affairs San Diego Healthcare System, San Diego, CA



- 11:30 *Prefrontal and striatal fMRI response predicts adherence to injectable extended-release naltrexone in opioid dependence*  
D. Langleben, E. Dowd, K. Jagannathan, J. Suh, K. M. Kampman, A. Wang, C. P. O'Brien, A. R. Childress, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 11:45 *Neural function and structure among young men with cannabis dependence: Relationship to treatment response*  
S. W. Yip, E. E. DeVito, H. Kober, K. M. Carroll, M. N. Potenza, Psychiatry, Yale School of Medicine, Yale, CT

### Oral Communications 12

**BALLROOM B**  
**10:00 - 12:00 PM**

#### DANGEROUS DUO: PSYCHIATRIC COMORBIDITY

Chairs: Katherine Mills and Emma L. Barrett

- 10:00 *Substance use during pregnancy among young women with symptoms of psychological stress and depression*  
A. Pienta, J. Barber, J. Kusunoki, H. Gatny, University of Michigan, Ann Arbor, MI
- 10:15 *Effects of smoking cessation on postpartum depression*  
A. A. Lopez<sup>1,2,3</sup>, S. T. Higgins<sup>1,2,3</sup>, J. M. Skelly<sup>4</sup>, <sup>1</sup>Vermont Center on Behavior & Health, University of Vermont, Burlington, VT, <sup>2</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>3</sup>Psychology, University of Vermont, Burlington, VT, <sup>4</sup>Medical Biostatistics, University of Vermont, Burlington, VT
- 10:30 *Evaluation of a brief smoking cessation intervention for inpatient substance users with elevated depressive symptoms*  
A. N. Banducci, C. W. Lejuez, L. MacPherson, University of Maryland, College Park, MD
- 10:45 *Acute stress response in cocaine-dependent subjects with comorbid depression*  
M. Torrens<sup>1,2,3</sup>, R. R. Minguela<sup>1</sup>, D. Martínez-Sanvisens<sup>1,2</sup>, C. Pérez-Mañá<sup>1,3</sup>, E. Papaseit<sup>1</sup>, F. Fonseca<sup>1,2</sup>, M. Farre<sup>1,3</sup>, <sup>1</sup>Institut Hospital Del Mar d'Investigacions Mèdiques-IMIM, Parc de Salut Mar, Barcelona, Spain, <sup>2</sup>Institut de Neuropsiquiatria i Addiccions (INAD), IMIM - Parc de Salut Mar, Barcelona, Spain, <sup>3</sup>Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain
- 11:00 *The long-term impact of post traumatic stress disorder on recovery from heroin dependence*  
K. Mills<sup>1,2</sup>, C. Marel<sup>1,2</sup>, S. Darke<sup>1</sup>, J. Ross<sup>1,2</sup>, T. Slade<sup>1,2</sup>, L. Burns<sup>1,2</sup>, M. Teesson<sup>1,2</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>NHMRC Centre of Research Excellence in Mental Health and Substance Use, University of New South Wales, Sydney, NSW, Australia
- 11:15 *Post-traumatic stress disorder and change in drug and alcohol dependence among recent veterans*  
A. S. Bennett, E. R. Pouget, A. Golub, National Development and Research Institutes, New York, NY
- 11:30 *Enhancing the effects of cognitive behavioral therapy for PTSD and alcohol use disorders with antidepressant medication: A randomized clinical trial*  
D. A. Hien<sup>1</sup>, F. R. Levin<sup>2</sup>, L. Ruglass<sup>1</sup>, T. Lopez-Castro<sup>1</sup>, <sup>1</sup>The City College of New York, NY, NY, <sup>2</sup>NY State Psychiatric Institute, NY, NY
- 11:45 *Substance use and mental health consequences of childhood trauma: An epidemiological investigation*  
E. L. Barrett, M. Teesson, C. Chapman, T. Slade, N. Carragher, K. Mills, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia

**Oral Communications 13****BALLROOM C  
10:00 - 12:00 PM****POT LUCK: THC RESEARCH**

Chairs: Joshua Lile and Denise C. Vidot

- 10:00 *Current marijuana use and cardiometabolic disease risk in United States emerging adults, 2005-2010*  
D. C. Vidot<sup>1,2</sup>, K. L. Arheart<sup>1</sup>, G. Prado<sup>1</sup>, W. M. Hlaing<sup>1</sup>, A. Acheampong<sup>3</sup>, S. E. Messiah<sup>1,2</sup>,  
<sup>1</sup>Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL,  
<sup>2</sup>Pediatrics, University of Miami Miller School of Medicine, Miami, FL, <sup>3</sup>Epidemiology,  
University of Florida, Gainesville, FL
- 10:15 *Acute stress response in marijuana smokers and relapse to marijuana in the human laboratory*  
R. Balter<sup>1</sup>, G. Bedi<sup>1,2</sup>, M. Haney<sup>1,2</sup>, <sup>1</sup>Psychiatry, Columbia, New York, NY, <sup>2</sup>NYSPI, New  
York, NY
- 10:30 *Cannabis self-administration in the laboratory and use in the natural environment during outpatient tiagabine maintenance*  
J. Lile, T. Kelly, W. Stoops, J. Fogel, A. Harvanko, R. Charnigo, L. Hays, University of  
Kentucky, Lexington, KY
- 10:45 *Marijuana use predicts cognitive impairment and white matter alterations*  
S. A. Gruber<sup>1,2</sup>, M. Dahlgren<sup>1</sup>, K. Sagar<sup>1</sup>, M. Dreman<sup>1</sup>, M. Racine<sup>1</sup>, A. Gonenc<sup>1,2</sup>,  
S. E. Lukas<sup>2,3</sup>, <sup>1</sup>Imaging Center, McLean Hospital, Belmont, MA, <sup>2</sup>Department of Psychiatry,  
Harvard Medical School, Boston, MA, <sup>3</sup>Behavioral Psychopharmacology Research Lab,  
McLean Hospital, Belmont, MA
- 11:00 *A comparison of temporal discounting in adolescents and adults in treatment for cannabis use disorders*  
D. C. Lee, C. Stanger, A. J. Budney, Psychiatry, Geisel School of Medicine at Dartmouth,  
Lebanon, NH
- 11:15 *A pilot study of zolpidem pharmacotherapy in the treatment of cannabis use disorders*  
R. Vandrey<sup>1</sup>, A. J. Budney<sup>2</sup>, M. Smith<sup>1</sup>, E. Herrmann<sup>1</sup>, A. Hampson<sup>3</sup>, M. L. Stitzer<sup>1</sup>, <sup>1</sup>Johns  
Hopkins University, Baltimore, MD, <sup>2</sup>Dartmouth, Lebanon, NH, <sup>3</sup>National Institute on Drug  
Abuse, Bethesda, MD
- 11:30 *Changes in cigarette and alcohol use during cannabis abstinence*  
D. J. Allsop<sup>1,5</sup>, A. Dunlop<sup>2,3</sup>, C. Sadler<sup>2</sup>, G. Rivas<sup>4</sup>, J. Copeland<sup>1</sup>, <sup>1</sup>National Cannabis  
Prevention and Information Centre, University of New South Wales, Sydney, NSW,  
Australia, <sup>2</sup>Drug & Alcohol Clinical Services, Hunter New England Local Health District,  
Newcastle, NSW, Australia, <sup>3</sup>School of Medicine and Public Health, University of  
Newcastle, Newcastle, NSW, Australia, <sup>4</sup>Drug and Alcohol Services, New South Wales  
Ministry of Health, Sydney, NSW, Australia, <sup>5</sup>School of Psychology, University of Sydney,  
Sydney, NSW, Australia
- 11:45 *Diabetes mellitus outcomes: Is cannabis smoking protective?*  
O. Alshaarawy, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University,  
East Lansing, MI

**Drug Evaluation History Forum  
(Brown Bag Lunch)**

**BALLROOM B  
12:15 - 2:15 PM**

**THE DRUG EVALUATION PROGRAM OF THE CPDD:  
HISTORY AND SCOPE**

Chairs: James H. Woods and Kenner Rice

*The NIH chemical synthesis program of CPDD*

Kenner Rice, NIDA/NIAAA, Rockville, MD

*The academic-preclinical pharmacology program of CPDD*

James H. Woods, University of Michigan, Ann Arbor, MI

*The human clinical drug assessment program of CPDD*

Charles W. Gorodetsky, Consultant, Kansas City, MO

*Discussant*

Andrew Coop, University of Maryland, Baltimore, MD

**Symposium XIII**

**SAN CRISTOBAL  
2:30 - 4:30 PM**

**ENVIRONMENTAL AND PHYSIOLOGICAL FACTORS  
PREDISPOSING SUSCEPTIBILITY TO DRUG ABUSE**

Chairs: Ellen Unterwald and Sari Izenwasser

2:30 *Diet-induced obesity differentially alters drug reward in male and female rats*

Sari Izenwasser, University of Miami Miller School of Medicine, Miami, FL

2:55 *Cocaine abuse susceptibility and dopamine dysfunction in a rodent model of PTSD*

Ellen Unterwald, Temple University School of Medicine, Philadelphia, PA

3:20 *Adult cocaine abuse risk associated with adolescent treatment with ADHD medications*

Kathleen Katak, Boston University, Boston, MA

3:45 *Adolescent dopamine markers predict vulnerability to cocaine abuse and relapse in nonhuman primates*

Linda Porrino, Wake Forest University School of Medicine, North Carolina, NC

4:10 *DISCUSSANT: Taking it to the streets: Implications for treatment and prevention*

Colleen A. Hanlon, Medical University of South Carolina, Charleston, SC

**Oral Communications 14**

**BALLROOM A  
2:30 - 4:30 PM**

**WHEN MORE IS LESS—STUDYING POLYSUBSTANCE ABUSE**

Chairs: Shannon G. Mitchell and Sarah S. Dermody

2:30 *Risk of polysubstance use and co-occurring internalizing and externalizing symptoms among adolescent sexual minority girls*

S. S. Dermody<sup>1</sup>, M. P. Marshal<sup>2</sup>, J. Cheong<sup>3</sup>, T. Chung<sup>2</sup>, S. Stepp<sup>2</sup>, A. Hipwell<sup>2</sup>, <sup>1</sup>Department of Psychology, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>Department of Health Behavior, University of Alabama, Birmingham, AL

- 2:45 *PlayForward: A videogame that increases drug, alcohol and sexual risk knowledge in teens*  
L. E. Fiellin<sup>1</sup>, K. D. Hieftje<sup>1</sup>, T. Fakhouri<sup>1</sup>, L. R. Duncan<sup>2</sup>, B. Sawyer<sup>3</sup>, D. Fiellin<sup>1</sup>, <sup>1</sup>Internal Medicine, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Department of Kinesiology, McGill University, Montreal, QC, Canada, <sup>3</sup>Digitalmill, Inc., Portland, ME
- 3:00 *The effect of marijuana commercialization on adolescent polysubstance use and treatment*  
K. Belendiuk<sup>1</sup>, T. Black<sup>1</sup>, C. Thurstone<sup>1,2</sup>, <sup>1</sup>Department of Psychiatry, University of Colorado, Aurora, CO, <sup>2</sup>Denver Health and Hospital Authority, Denver, CO
- 3:15 *Parent-teen drug use discussions: Associations with substance use*  
T. M. Chaplin<sup>1</sup>, A. Hansen<sup>1</sup>, J. Simmons<sup>2</sup>, L. C. Mayes<sup>2</sup>, R. E. Hommer<sup>3</sup>, M. J. Crowley<sup>2</sup>, <sup>1</sup>Psychology, George Mason University, Fairfax, VA, <sup>2</sup>Yale University School of Medicine, New Haven, CT, <sup>3</sup>National Institutes of Health, Bethesda, MD
- 3:30 *Integrated treatment for mothers involved in child welfare for substance abuse*  
L. Saldana<sup>1</sup>, P. Chamberlain<sup>1</sup>, A. Sheidow<sup>2</sup>, <sup>1</sup>OSLC, Eugene, OR, <sup>2</sup>MUSC, Charleston, SC
- 3:45 *Adolescent SBIRT implementation in an urban FQHC: The first 6 months*  
S. G. Mitchell<sup>1</sup>, K. Dusek<sup>1</sup>, J. Gryczynski<sup>1</sup>, M. Oros<sup>2</sup>, C. Hosler<sup>2</sup>, A. Kirk<sup>3</sup>, K. O'Grady<sup>4</sup>, B. Brown<sup>1</sup>, R. P. Schwartz<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Mosaic Group, Baltimore, MD, <sup>3</sup>Total Health Care, Baltimore, MD, <sup>4</sup>University of Maryland, College Park, MD
- 4:00 *Caregiver and youth engagement in mandated juvenile drug treatment: Influence on substance use*  
P. M. Mauro<sup>1</sup>, M. R. McCart<sup>2</sup>, S. Naeger<sup>1</sup>, A. J. Sheidow<sup>2</sup>, E. J. Letourneau<sup>1</sup>, <sup>1</sup>Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Medical University of South Carolina, Charleston, SC
- 4:15 *Delay discounting in polysubstance dependence*  
L. Moody<sup>1,2</sup>, C. Franck<sup>1,3</sup>, L. Hatz<sup>1</sup>, W. K. Bickel<sup>1,2</sup>, <sup>1</sup>Psychology, Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Psychology, Virginia Tech, Blacksburg, VA, <sup>3</sup>Statistics, Virginia Tech, Blacksburg, VA

## Oral Communications 15

**BALLROOM B**  
**2:30 - 4:30 PM**

### NO MORE "EXCUSES": EMERGING CUE RESEARCH

Chairs: Jesse Suh and Shervin Liddle

- 2:30 *Attentional bias to alcohol-related stimuli and the self-reported desire to drink following a dose of alcohol*  
W. Roberts, M. T. Fillmore, Psychology, University of Kentucky, Lexington, KY
- 2:45 *Protracted abstinence influences the 'Tug of War' between pleasant and cocaine-related cues in addicted individuals: Evidence from a longitudinal ERP study*  
M. A. Parvaz<sup>1</sup>, S. J. Moeller<sup>1</sup>, A. B. Konova<sup>2</sup>, G. H. Proudfit<sup>2</sup>, N. Alia-Klein<sup>1</sup>, R. Z. Goldstein<sup>1</sup>, <sup>1</sup>Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, <sup>2</sup>Psychology, Stony Brook University, Stony Brook, NY
- 3:00 *Poorer pre-potent response inhibition in cocaine-dependent patients vs. healthy controls during an affect-congruent Go-NoGo task*  
J. Suh<sup>1,2</sup>, R. Ehrman<sup>1,2</sup>, M. Goldman<sup>1</sup>, Z. Singer<sup>1</sup>, T. Franklin<sup>1</sup>, K. Marquez<sup>1</sup>, C. P. O'Brien<sup>1</sup>, A. R. Childress<sup>1,2</sup>, <sup>1</sup>University of Pennsylvania, Phila, PA, <sup>2</sup>VAMC-MIRECC, Phila, PA

- 3:15 *Changes in attentional bias to drug cues and fMRI stroop with behavioral treatment for cocaine dependence*  
E. E. DeVito, C. Nich, M. N. Potenza, K. M. Carroll, Yale, New Haven, CT
- 3:30 *Cocaine-dependent subjects display attentional bias toward cocaine-related but not alcohol-related stimuli*  
K. R. Marks<sup>1,3</sup>, W. W. Stoops<sup>1,3</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Psychiatry, University of Kentucky, Lexington, KY, <sup>3</sup>Psychology, University of Kentucky, Lexington, KY
- 3:45 *Strength of cocaine-associated memory: Acquisition, extinction and reinstatement*  
S. Liddie, Y. Itzhak, Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL
- 4:00 *Long-access methamphetamine self-administration alters reactivity to novel cues: Implications for cue-induced relapse*  
J. Peters, M. Scofield, S. M. Ghee, C. M. Reichel, Department of Neurosciences, Medical University of South Carolina, Charleston, SC
- 4:15 *Procedure-dependent effects of antagonism of nicotinic acetylcholine receptors on conditioned nicotine seeking in rat models of smoking relapse*  
X. Liu, University of Mississippi Medical Center, Jackson, MS

## Oral Communications 16

**BALLROOM C**  
**2:30 - 4:30 PM**

### KNOW YOUR ATCGS—HOW GENETICS INFLUENCES SUBSTANCE USE

Chairs: Eugeny Krupitsky and Joy Schmitz

- 2:30 *Stress-related genes and heroin addiction: A role for functional FKBP5 variants*  
O. Levran<sup>1</sup>, E. Peles<sup>2</sup>, M. Randesi<sup>1</sup>, Y. Li<sup>3</sup>, J. Rotrosen<sup>4</sup>, J. Ott<sup>5,1</sup>, M. Adelson<sup>6,2,1</sup>, M. Kreek<sup>1</sup>, <sup>1</sup>Rockefeller University, New York, NY, <sup>2</sup>Adelson Clinic for Drug Abuse Treatment and Research, Sourasky Medical Center, Tel Aviv, Israel, <sup>3</sup>Shanxi University of Finance & Economics, Shanxi, China, <sup>4</sup>NYU School of Medicine, New York, NY, <sup>5</sup>Institute of Psychology, Chinese Academy of Sciences, Beijing, China, <sup>6</sup>Adelson Clinic for Drug Abuse, Treatment and Research, Las Vegas, NV
- 2:45 *Pharmacogenetics of treatment of opioid dependence with oral naltrexone and long-acting sustained-release naltrexone implant*  
E. Krupitsky<sup>1</sup>, A. Kibitov<sup>1</sup>, E. Zvartau<sup>1</sup>, E. Blokhina<sup>2</sup>, E. Verbitskaya<sup>2</sup>, V. Palatkin<sup>3</sup>, E. Nielsen<sup>4</sup>, T. Kosten<sup>5</sup>, G. E. Woody<sup>5</sup>, <sup>1</sup>St. Petersburg State Pavlov Medical University, St. Petersburg, Russian Federation, <sup>2</sup>St. Petersburg Bekhtrev Research Psychoneurological Institute, St. Petersburg, Russian Federation, <sup>3</sup>National Research Center of Addictions, St. Petersburg, Russian Federation, <sup>4</sup>Baylor College of Medicine, Waco, TX, <sup>5</sup>University of Pennsylvania, Philadelphia, PA
- 3:00 *Pharmacogenetics of buprenorphine therapy of cocaine addiction*  
D. A. Nielsen<sup>1,2</sup>, R. Walker<sup>3</sup>, S. C. Hamon<sup>4</sup>, M. H. Harding<sup>1,2</sup>, W. Ling<sup>5</sup>, T. R. Kosten<sup>1,2</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, <sup>2</sup>DeBakey VAMC, Houston, TX, <sup>3</sup>UT Southwestern, Dallas, TX, <sup>4</sup>The Rockefeller University, New York, NY, <sup>5</sup>UCLA, Los Angeles, CA

- 3:15 *Nicotine consumption and dependence: Genetic and environmental risk factors show indirect effects through nicotine craving*  
D. Shmulewitz, J. L. Meyers, K. Keyes, E. Aharonovich, D. S. Hasin, Columbia University, New York, NY
- 3:30 *CYP2A6 metabolism in the development of nicotine dependence in adolescents and young adults*  
E. Olfson<sup>1</sup>, J. Bloom<sup>1</sup>, S. Bertelsen<sup>1</sup>, J. Budde<sup>1</sup>, V. Hesselbrock<sup>2</sup>, J. Kramer<sup>3</sup>, A. Goate<sup>1</sup>, L. Bierut<sup>1</sup>, <sup>1</sup>Washington University School of Medicine, St. Louis, MO, <sup>2</sup>University of Connecticut School of Medicine, Farmington, CT, <sup>3</sup>University of Iowa Carver College of Medicine, Iowa City, IA
- 3:45 *COMT Val/Met genotype associations with treatment response from a randomized clinical trial of CBT4CBT*  
K. M. Carroll, A. Herman, E. E. DeVito, T. Frankforter, M. Sofuoglu, Psychiatry, Yale University School of Medicine, West Haven, CT
- 4:00 *Novel genetic variant associated with substance use in two independent populations*  
J. L. Meyers<sup>1</sup>, L. Almlil<sup>4</sup>, S. Galea<sup>1</sup>, A. E. Aiello<sup>2</sup>, M. Uddin<sup>3</sup>, D. E. Wildman<sup>3</sup>, B. Bradley<sup>4</sup>, K. J. Ressler<sup>4</sup>, K. C. Koenen<sup>1</sup>, <sup>1</sup>Epidemiology and Psychiatry, Columbia University, New York, NY, <sup>2</sup>Epidemiology, University of Michigan, Ann Arbor, MI, <sup>3</sup>Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, <sup>4</sup>Psychiatry, Emory University, Atlanta, GA
- 4:15 *The influence of dopamine  $\beta$ -hydroxylase gene polymorphism -1021C  $\rightarrow$  T on levodopa/carbidopa treatment for cocaine dependence: A preliminary study*  
J. Schmitz<sup>1</sup>, S. Liu<sup>2</sup>, C. Green<sup>1</sup>, S. D. Lane<sup>1</sup>, T. R. Kosten<sup>2</sup>, F. Moeller<sup>3</sup>, D. A. Nielsen<sup>2</sup>, <sup>1</sup>University of Texas Medical School, Houston, TX, <sup>2</sup>Baylor College of Medicine, Houston, TX, <sup>3</sup>Virginia Commonwealth University Medical School, Richmond, VA

### Late-Breaking Research

**SAN CRISTOBAL  
4:45 - 5:45 PM**

### Business Meeting (MEMBERS ONLY)

**SAN CRISTOBAL  
6:00 - 7:00 PM**

### DINNER AND DANCING BADGES MUST BE WORN FOR ADMISSION

**SAN GERONIMO  
7:30 - 10:30 PM**

**Poster Session IV  
(Breakfast)**

**GRAN SALON  
LOS ROSALES  
8:00 - 10:00 AM**

**Odd-numbered posters manned first hour;  
Even-numbered, second hour**

**Set-up time begins Wednesday 1 PM  
Must be removed by Thursday 12 Noon**

**CRIMINAL JUSTICE**

- 1 *Family, friend, and significant other support and HIV-related drug and sex risk prior to incarceration among African-American men in prison*  
A. Coatsworth<sup>1</sup>, D. Wohl<sup>2</sup>, N. E. Whitehead<sup>3</sup>, J. Scheidell<sup>1</sup>, C. Golin<sup>2</sup>, S. Monk<sup>2</sup>, S. Brown<sup>2</sup>, M. R. Khan<sup>1</sup>, <sup>1</sup>Department of Epidemiology, University of Florida, Gainesville, FL, <sup>2</sup>School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, <sup>3</sup>Department of Clinical and Health Psychology, University of Florida, Gainesville, FL
- 2 *Substance use and STI/HIV risk among African-American men incarcerated in North Carolina*  
M. R. Khan<sup>1</sup>, S. R. Friedman<sup>2</sup>, A. Coatsworth<sup>1</sup>, C. Golin<sup>3</sup>, A. Adimora<sup>3</sup>, J. D. Scheidell<sup>1</sup>, L. Keen<sup>4</sup>, M. Hobbs<sup>3</sup>, D. Wohl<sup>3</sup>, <sup>1</sup>Epidemiology, University of Florida, Gainesville, FL, <sup>2</sup>National Development and Research Institute, New York, NY, <sup>3</sup>University of North Carolina, Chapel Hill, NC, <sup>4</sup>Clinical and Health Psychology, University of Florida, Gainesville, FL
- 3 *Examining HCV and other risks among rural women offenders*  
C. Leukefeld<sup>1</sup>, K. Harp<sup>1</sup>, M. Webster<sup>1</sup>, M. Staton-Tindall<sup>2</sup>, C. B. Oser<sup>3</sup>, J. R. Havens<sup>1</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Social Work, University of Kentucky, Lexington, KY, <sup>3</sup>Sociology, University of Kentucky, Lexington, KY
- 4 *Longitudinal gender differences in HIV and criminal justice outcomes*  
J. P. Meyer, J. Cepeda, F. L. Altice, Yale, New Haven, CT
- 5 *Prevalence of substance use disorders and HIV among female prisoners in Ukraine*  
A. Krishnan<sup>1</sup>, L. Azbel<sup>1,2</sup>, J. A. Wickersham<sup>1</sup>, F. L. Altice<sup>1</sup>, <sup>1</sup>AIDS Program, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Ukrainian Institute on Public Health Policy, Kyiv, Ukraine
- 6 *Borderline Personality Disorder symptoms and HIV risk behaviors among African-American incarcerated men*  
J. D. Scheidell<sup>1</sup>, C. Lejuez<sup>2</sup>, D. Wohl<sup>3</sup>, C. Golin<sup>3</sup>, S. Monk<sup>3</sup>, G. Dockery<sup>3</sup>, M. R. Khan<sup>1</sup>, <sup>1</sup>Epidemiology, University of Florida, Gainesville, FL, <sup>2</sup>Psychology, University of Maryland, College Park, MD, <sup>3</sup>University of North Carolina, Chapel Hill, NC
- 7 *International rates of SUD and ADHD symptoms among prison inmates: Individual data and pooled effects*  
R. González<sup>1</sup>, A. Alicea<sup>1</sup>, Y. Ginsberg<sup>2</sup>, G. Gudjonsson<sup>3</sup>, M. Konstenius<sup>2</sup>, F. R. Levin<sup>4</sup>, M. Vélez<sup>1</sup>, S. Young<sup>5</sup>, C. Albizu<sup>1</sup>, <sup>1</sup>University of Puerto Rico, San Juan, <sup>2</sup>Karolinska Institute, Solna, Sweden, <sup>3</sup>Kings College, London, United Kingdom, <sup>4</sup>Columbia University, New York, NY, <sup>5</sup>Imperial College, London, United Kingdom
- 8 *qEEG abnormalities in alcohol dependence offenders*  
A. Calzada-Reyes, A. Alvarez Amador, Clinical Neurophysiology Department, Legal Medicine Institute, Havana, Cuba

- 9 *Pre-military victimization and trauma among a sample of justice-involved veterans*  
L. Sawh<sup>1,2,3</sup>, D. A. Pinals<sup>4,2</sup>, D. Smelson<sup>1,2</sup>, C. Fulwiler<sup>2</sup>, S. Singer<sup>2</sup>, K. O'Connor<sup>2</sup>, W. Fisher<sup>3</sup>, S. Hartwell<sup>5</sup>, G. Gonzalez<sup>2</sup>, <sup>1</sup>Department of Veterans Affairs, Bedford, MA, <sup>2</sup>University of Massachusetts Medical School, Worcester, MA, <sup>3</sup>University of Massachusetts Lowell, Lowell, MA, <sup>4</sup>Massachusetts Department of Mental Health, Boston, MA, <sup>5</sup>University of Massachusetts Boston, Boston, MA
- 10 *A needs comparison of justice-involved Iraq/Afghanistan veterans to other service eras*  
K. O'Connor<sup>1,2</sup>, D. A. Pinals<sup>3,1</sup>, D. Smelson<sup>1,2</sup>, L. Sawh<sup>2,4,1</sup>, C. Fulwiler<sup>1</sup>, S. Singer<sup>1</sup>, W. Fisher<sup>4</sup>, S. Hartwell<sup>5</sup>, G. Gonzalez<sup>1</sup>, <sup>1</sup>University of Massachusetts Medical School, Worcester, MA, <sup>2</sup>US Department of Veterans Affairs, Bedford, MA, <sup>3</sup>Massachusetts Department of Mental Health, Boston, MA, <sup>4</sup>University of Massachusetts, Lowell, Lowell, MA, <sup>5</sup>University of Massachusetts, Boston, Boston, MA
- 11 *Mental health and HIV risk behavior among drug-using rural women in jail*  
M. Staton-Tindall<sup>1</sup>, K. Harp<sup>2</sup>, C. B. Oser<sup>3</sup>, M. Webster<sup>2</sup>, J. R. Havens<sup>2</sup>, C. Leukefeld<sup>2</sup>, <sup>1</sup>Social Work, University of Kentucky, Lexington, KY, <sup>2</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>3</sup>Sociology, University of Kentucky, Lexington, KY
- 12 *Psychiatric problems and sex-trading among drug-using African-American women: Does family support matter?*  
D. Stevens-Watkins, C. Leukefeld, C. B. Oser, University of Kentucky, Lexington, KY
- 13 *A comparison of outcomes by sexual orientation among women in integrated substance use and mental health disorder treatment*  
H. Amaro<sup>2</sup>, J. Goldbach<sup>1</sup>, L. Duan<sup>1</sup>, S. E. Spear<sup>1</sup>, G. Prado<sup>3</sup>, <sup>1</sup>Social Work, University of Southern California, Los Angeles, CA, <sup>2</sup>Social Work and Preventive Medicine, University of Southern California, Los Angeles, CA, <sup>3</sup>Department of Public Health Sciences, University of Miami, Miami, FL
- 14 *Heightened vulnerability associated with criminal justice involvement among women who use drugs*  
J. Lorvick<sup>1</sup>, M. L. Comfort<sup>1,2</sup>, B. Quinn<sup>3</sup>, C. Krebs<sup>4</sup>, A. Kral<sup>1</sup>, <sup>1</sup>Urban Health Program, RTI International, San Francisco, CA, <sup>2</sup>Center for AIDS Prevention Studies, University of California, San Francisco, CA, <sup>3</sup>Burnet Institute, Melbourne, VIC, Australia, <sup>4</sup>Crime, Violence and Justice Program, RTI International, Research Triangle Park, NC
- 15 *Impaired driving histories among rural female drug-involved offenders*  
M. Webster, M. Staton-Tindall, C. Leukefeld, J. R. Havens, C. B. Oser, K. Harp, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 16 *The size of African-American female's health networks: The role of drug and criminal histories*  
C. B. Oser, E. L. Pullen, C. Leukefeld, D. Stevens-Watkins, M. Staton-Tindall, J. R. Havens, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 17 *Predictors of sentenced inmates' drug use transition from community to prison*  
G. Caraballo-Correa, C. E. Albizu, R. Ramirez, J. J. Ruiz, Graduate School of Public Health, University of Puerto Rico, San Juan
- 18 *Development and pilot testing of an online training to raise awareness among criminal justice professionals of medications used to treat opioid addiction*  
J. Matejkowski<sup>1,2</sup>, K. L. Dugosh<sup>2</sup>, N. Clements<sup>3,2</sup>, D. S. Festinger<sup>2,4</sup>, <sup>1</sup>University of Kansas, Lawrence, KS, <sup>2</sup>Treatment Research Institute, Philadelphia, PA, <sup>3</sup>St. Joseph's University, Philadelphia, PA, <sup>4</sup>University of Pennsylvania, Philadelphia, PA



- 19 *WITHDRAWN*
- 20 *A brief behavioral activation treatment for substance use associated with lower rates of recidivism at a one-year follow-up*  
C. Seitz-Brown<sup>1</sup>, D. DeGeorge<sup>1</sup>, E. Blevins<sup>1</sup>, J. Williams<sup>1</sup>, C. W. Lejuez<sup>1</sup>, S. B. Daughters<sup>2</sup>,  
<sup>1</sup>University of Maryland, College Park, MD, <sup>2</sup>University of North Carolina, Chapel Hill, NC
- 21 *Improving outcomes for low-risk/low-need drug court clients: Life in the fast lane*  
D. S. Festinger<sup>1</sup>, K. L. Dugosh<sup>1</sup>, D. Marlowe<sup>2,1</sup>, <sup>1</sup>Treatment Research Institute,  
Philadelphia, PA, <sup>2</sup>National Association of Drug Court Professionals, Alexandria, VA

### SEX/GENDER II

- 22 *Risky behaviors on the road: Do women and men act differently after drinking?*  
T. R. Sousa<sup>1</sup>, G. Pasa<sup>1</sup>, J. Lunnen<sup>2</sup>, F. P. Pechansky<sup>1</sup>, <sup>1</sup>Center for Drug and Alcohol Research,  
Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>2</sup>Johns Hopkins International  
Injury Research Unit, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 23 *Prescription drug use in a national sample of female drivers*  
T. Kelley-Baker, J. Yao, R. Pollini, Pacific Institute for Research and Evaluation,  
Calverton, MD
- 24 *Gender differences in polysubstance use among those who misuse prescription opioids*  
A. Acheampong<sup>1</sup>, D. C. Vidot<sup>2</sup>, L. Cottler<sup>1</sup>, <sup>1</sup>Epidemiology, University of Florida,  
Gainesville, FL, <sup>2</sup>Pediatrics, University of Miami, Miami, FL
- 25 *Female opioid users may be at excess risk of becoming dependent soon after extra-medical  
prescription pain reliever use in adolescence but not in young adulthood: Estimates for the  
United States, 2002-2011*  
H. H. Yeh, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University, East  
Lansing, MI
- 26 *Characterizing sex differences among pain medication abusers*  
B. Lewis, L. Hoffman, S. J. Nixon, Psychiatry, University of Florida, Gainesville, FL
- 27 *Gender differences in smoking and treatment outcome among opioid-maintained smokers*  
A. C. Meyer, M. E. Patrick, S. H. Heil, S. T. Higgins, S. C. Sigmon, University of Vermont,  
Burlington, VT
- 28 *Is voluntary household smoking ban differentially effective for men's and women's smokeless  
tobacco use and addiction? Findings from the Global Adult Tobacco Survey in India*  
S. Balan, S. Pandey, C. van den Berk-Clark, R. K. Price, Washington University in St. Louis,  
St. Louis, MO
- 29 *Gender differences in laboratory stress response among prescription opioid-dependent  
individuals*  
J. L. McCauley<sup>1</sup>, M. A. Mercer<sup>1</sup>, A. Teer<sup>1</sup>, F. Beylotte<sup>1</sup>, K. T. Brady<sup>1,2</sup>, S. E. Back<sup>1,2</sup>,  
<sup>1</sup>Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC,  
<sup>2</sup>Ralph H. Johnson VAMC, Charleston, SC
- 30 *Effects of oral contraceptive use on stress response in acute smoking abstinence*  
K. Harrison, A. M. Allen, S. Allen, M. al'Absi, University of Minnesota, Minneapolis, MN
- 31 *"I take my refuge in tik": Understanding gender differences in the initiation of  
methamphetamine use in South Africa*  
A. L. Hobkirk<sup>1</sup>, M. Watt<sup>1</sup>, K. Guidera<sup>1</sup>, S. Kimani<sup>1</sup>, D. Skinner<sup>2</sup>, D. Pieterse<sup>2</sup>, C. S. Meade<sup>1</sup>,  
<sup>1</sup>Duke Global Health Institute, Duke University, Durham, NC, <sup>2</sup>Research on Health & Society,  
Stellenbosch University, Tygerberg, South Africa

- 32 *Reproductive health needs among drug treatment clients*  
M. Bryant-Genevieve<sup>1</sup>, L. Appel<sup>1</sup>, K. D. Mark<sup>1</sup>, M. Terplan<sup>1,2</sup>, <sup>1</sup>Obstetrics Gynecology & Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD, <sup>2</sup>Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD
- 33 *Family/social problems as a greater barrier to treatment entry for women than men*  
A. M. Heads, R. Suchting, C. Green, J. Schmitz, N. Rathnayaka, S. D. Lane, University of Texas HSC at Houston, Houston, TX
- 34 *How well do we understand older female substance abusers in the U.S.? An analysis of TEDS-D 2006-09*  
M. Terplan<sup>3,1</sup>, N. Longinaker<sup>1</sup>, M. S. Chisolm<sup>2</sup>, <sup>1</sup>Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, <sup>2</sup>Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3</sup>Obstetrics, Gynecology & Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD
- 35 *Effects of alcohol intake on balance and stability in older adults: A pilot study*  
Y. Duan<sup>1,5</sup>, L. Barry<sup>2</sup>, J. Covault<sup>3</sup>, A. Kenny<sup>3</sup>, C. Oncken<sup>3</sup>, R. Bohannon<sup>4</sup>, J. Grady<sup>5</sup>, H. Wu<sup>6</sup>, <sup>1</sup>Community Medicine & Healthcare, University of Connecticut Health Center, Farmington, CT, <sup>2</sup>Center on Aging, UCHC, Farmington, CT, <sup>3</sup>Medicine, UCHC, Farmington, CT, <sup>4</sup>Dept of Kinesiology, University of Connecticut, Storrs, CT, <sup>5</sup>Connecticut Institute for Clinical and Translational Science (CICATS), University of Connecticut Health Center, Farmington, CT, <sup>6</sup>Psychiatry, University of Connecticut Health Center, Farmington, CT
- 36 *MOVED TO #3 ON TUESDAY POSTER SESSION*
- 37 *Gender differences in acceptability and treatment outcomes of Internet-based treatment for substance use disorders*  
A. Campbell<sup>1</sup>, M. Hu<sup>3</sup>, S. F. Greenfield<sup>2</sup>, E. Nunes<sup>1</sup>, <sup>1</sup>New York State Psychiatric Institute, New York, NY, <sup>2</sup>Harvard Medical School, Boston, MA, <sup>3</sup>Columbia University, New York, NY
- 38 *Predictors of illicit drug use in low-income African-American women: A multilevel analysis of demographic and cultural factors*  
E. L. Pullen, C. B. Oser, Sociology, University of Kentucky, Lexington, KY
- 39 *Gender differences in trauma and substance use characteristics among veterans with PTSD and substance use disorders*  
S. E. Back<sup>1,2</sup>, T. Killeen<sup>1</sup>, A. Teer<sup>1</sup>, F. Beylotte<sup>1</sup>, J. L. McCauley<sup>1</sup>, D. F. Gros<sup>1,2</sup>, J. Hellmuth<sup>1</sup>, K. T. Brady<sup>1,2</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Ralph H. Johnson VA Medical Center, Charleston, SC

### LITERATURE REVIEW

- 40 *Role of the endogenous cannabinoid system in fear circuitry: Translational findings and clinical implications for post-traumatic stress disorder*  
S. Papini<sup>1,2</sup>, D. A. Hien<sup>1,2</sup>, Y. Neria<sup>2</sup>, F. Levin<sup>2</sup>, <sup>1</sup>City College, New York, NY, <sup>2</sup>New York State Psychiatric Institute, New York, NY

- 41 *Cannabis use among women and during pregnancy*  
F. Alharbi<sup>1,2</sup>, N. El-guebaly<sup>3,4</sup>, <sup>1</sup>King Abdulaziz Medical City, Riyadh, Saudi Arabia, <sup>2</sup>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia, <sup>3</sup>University of Calgary, Calgary, AB, Canada, <sup>4</sup>Alberta Health Services, Calgary, AB, Canada
- 42 *The impact of cannabis use on opioid-dependence treatment: A systematic review*  
K. Z. Smith<sup>1,2</sup>, S. Ravven<sup>1</sup>, J. W. Boyd<sup>3,4</sup>, <sup>1</sup>Yale School of Medicine, New Haven, CT, <sup>2</sup>Wayne State University, Detroit, MI, <sup>3</sup>Cambridge Health Alliance, Cambridge, MA, <sup>4</sup>Harvard Medical School, Cambridge, MA
- 43 *Marijuana use among low-income urban youth: A systematic review*  
R. M. Johnson<sup>1</sup>, C. Kaczmarek<sup>2</sup>, K. A. Power<sup>2</sup>, <sup>1</sup>Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Community Health Sciences, Boston University School of Public Health, Boston, MA
- 44 *Impact of marijuana use on memory in patients with HIV/AIDS: A systematic review*  
L. Skalski, S. Towe, K. Sikkema, S. Teitell, C. S. Meade, Duke University, Durham, NC
- 45 *WITHDRAWN*
- 46 *Effective HIV and substance abuse prevention programs for African-American women: Attending to culture and context*  
F. Z. Belgrave<sup>1</sup>, D. Jones<sup>2</sup>, J. Richardson<sup>1</sup>, L. Beatty<sup>3</sup>, <sup>1</sup>Psychology, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Service Research Branch, NIDA, Bethesda, MD, <sup>3</sup>American Psychological Association, District of Columbia, DC
- 47 *Time to first cigarette: A potential clinical screening tool for nicotine dependence and cancer risk*  
M. Mercincavage<sup>1</sup>, S. A. Branstetter<sup>1</sup>, J. E. Muscat<sup>2</sup>, <sup>1</sup>Biobehavioral Health, The Pennsylvania State University, University Park, PA, <sup>2</sup>Public Health Sciences, Penn State College of Medicine, Hershey, PA
- 48 *Smoking and cardiac rehabilitation participation*  
D. E. Gaalema<sup>1</sup>, P. Ades<sup>2</sup>, S. T. Higgins<sup>1</sup>, <sup>1</sup>University of Vermont, Burlington, VT, <sup>2</sup>Fletcher Allen Health Care, Burlington, VT
- 49 *A review of the relationship of drug dreams with craving and consumption*  
N. Cross, H. Rosenberg, Psychology, Bowling Green State University, Bowling Green, OH
- 50 *Publication trends from 1950–2009: Opioids, benzodiazepines, barbiturates, and amphetamines*  
M. Zhang<sup>1,2</sup>, B. Sproule<sup>1,2</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada
- 51 *WITHDRAWN*
- 52 *Influence of pharmacokinetics on the abuse liability of controlled-release opioid formulations: The case of oxycodone*  
B. Rafat<sup>1,2</sup>, B. Sproule<sup>1,2</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada
- 53 *A comparison of drug-related deaths in Florida, 2007–2012*  
C. J. Reissig, J. M. Vojtech, Health and Human Services, U.S. Food and Drug Administration, Silver Spring, MD
- 54 *A systematic review of community opioid overdose prevention and naloxone distribution programs*  
A. K. Clark, E. L. Winstanley, C. M. Wilder, University of Cincinnati, Cincinnati, OH

- 55 *Evaluation of the effectiveness of drug prevention programs: Analysis of the international scientific production (2002-2011)*  
R. Aleixandre-Benavent<sup>1</sup>, D. Ribeiro Schneider<sup>2</sup>, F. Bissoli Jr<sup>2</sup>, M. Bolaños-Pizarro<sup>1</sup>, F. Bueno Cañigral<sup>3</sup>, J. Pérez de los Cobos Peris<sup>4</sup>, <sup>1</sup>Unidad de Información e Investigación Social y Sanitaria, IHMC López Piñero (CSIC–Universidad de Valencia), Valencia, Spain, <sup>2</sup>Núcleo de Pesquisas em Psicologia Clínica - PSICLIN. Departamento de Psicologia, Universidade Federal de Santa Catarina, Florianópolis, Brazil, <sup>3</sup>Plan Municipal de Drogodependencias. Concejalía de Sanidad y Consumo, Ayuntamiento de Valencia, Valencia, Spain, <sup>4</sup>Servicio de Psiquiatría, Hospital de la Santa Creu y Sant Pau, Barcelona, Spain

56 *WITHDRAWN*

- 57 *Understanding the predictive value of abuse potential assessments*  
D. B. Horton, A. N. Mead, Global Safety Pharmacology, Drug Safety Research and Development, Pfizer, Inc., Groton, CT

### SEDATIVE - HYPNOTICS

- 58 *Misuse of alprazolam among people who inject drugs: A prescription for harm?*  
R. Bruno<sup>1,2</sup>, S. Reddel<sup>3</sup>, P. Dietze<sup>3</sup>, B. de Graaff<sup>1</sup>, S. Nielsen<sup>2</sup>, L. Burns<sup>2</sup>, <sup>1</sup>School of Medicine, University of Tasmania, Hobart, TAS, Australia, <sup>2</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>3</sup>Burnet Institute, Centre for Population Health, Melbourne, VIC, Australia
- 59 *Benzodiazepine use among a sample of chronic pain patients prescribed opioids*  
S. Nielsen<sup>1</sup>, R. Bruno<sup>2</sup>, G. Campbell<sup>1</sup>, M. Cohen<sup>3</sup>, M. Farrell<sup>1</sup>, W. Hall<sup>4</sup>, B. Hoban<sup>1</sup>, B. Larance<sup>5</sup>, N. Lintzeris<sup>1</sup>, R. Mattick<sup>1</sup>, L. Degenhardt<sup>1</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Randwick, NSW, Australia, <sup>2</sup>University of Tasmania, Hobart, TAS, Australia, <sup>3</sup>St Vincent's Hospital, Sydney, NSW, Australia, <sup>4</sup>University of Queensland, Herston, QLD, Australia, <sup>5</sup>SESLHD, Surry Hills, NSW, Australia
- 60 *Abuse potential of eslicarbazepine acetate in recreational sedative users*  
D. Blum<sup>1</sup>, N. Levy-Cooperman<sup>2</sup>, H. Cheng<sup>1</sup>, B. Chakaraborty<sup>3</sup>, T. Hopyan<sup>3</sup>, J. Faulkner<sup>3</sup>, K. Schoedel<sup>2</sup>, <sup>1</sup>Sunovion Pharmaceuticals Inc., Marlborough, MA, <sup>2</sup>Altreos Research Partners, Toronto, ON, Canada, <sup>3</sup>INC Research, Toronto, ON, Canada
- 61 *Abuse potential of a dual orexin receptor antagonist: A randomized, double-blind, crossover study in recreational drug users*  
E. M. Sellers<sup>1</sup>, H. Cruz<sup>2</sup>, J. Dingemans<sup>2</sup>, B. Chakaraborty<sup>3</sup>, K. Schoedel<sup>4</sup>, <sup>1</sup>DL Global Partners, Inc, Toronto, ON, Canada, <sup>2</sup>Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, <sup>3</sup>INC Research, Toronto, ON, Canada, <sup>4</sup>Altreos Research Partners Inc, Toronto, ON, Canada
- 62 *Physical dependence liability of Retigabine in rats*  
M. Tessari<sup>2</sup>, L. Dacome<sup>2</sup>, M. Pilla<sup>2</sup>, W. Rycroft<sup>1</sup>, J. Prescott<sup>3</sup>, A. Giarola<sup>1</sup>, <sup>1</sup>Safety Pharmacology, GlaxoSmithKline, Ware, United Kingdom, <sup>2</sup>Preclinical Pharmacology, Aptuit Verona, Verona, Italy, <sup>3</sup>Safety Assessment, GlaxoSmithKline, RTP, NC
- 63 *Differential effects of the benzodiazepines alprazolam and oxazepam on methamphetamine-related behaviors in rats*  
A. Spence, G. F. Guerin, N. E. Goeders, Pharmacology, Toxicology, & Neuroscience, LSU Health Sciences Center, Shreveport, LA
- 64 *Effects of HZ-166, a novel  $\alpha 2$  and  $\alpha 3$  subunit-containing GABA<sub>A</sub> receptor agonist, on inflammatory pain and operant behavior in mice*  
B. D. Fischer<sup>1</sup>, C. Kroll<sup>1</sup>, M. Poe<sup>2</sup>, J. M. Cook<sup>2</sup>, <sup>1</sup>Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, <sup>2</sup>Department of Chemistry and Biochemistry, University of Wisconsin, Milwaukee, WI

- 65 *Involvement of mGlu5 receptor signal cascade in the enhancement of morphine-induced hyperlocomotion under chronic treatment with zolpidem*  
M. Shibasaki, K. Ishii, T. Mori, T. Suzuki, Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan

### STIMULANTS - ANIMALS II

- 66 *GluA1 phosphorylation: A potential mechanism to attenuate cocaine seeking in rats*  
C. Keller, M. F. Salvatore, G. F. Guerin, N. E. Goeders, Pharmacology, Toxicology & Neuroscience, LSU Health Sciences Center, Shreveport, LA
- 67 *The role of glutamate on incentive value attribution: Acquisition and expression*  
J. J. Chow, J. S. Beckmann, Psychology, University of Kentucky, Lexington, KY
- 68 *Cocaine addiction: Role for glutamate, glia and chemokine*  
J. K. Kim<sup>1</sup>, C. S. Tallarida<sup>1</sup>, S. H. Ramirez<sup>2</sup>, S. Rawls<sup>1</sup>, <sup>1</sup>Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, <sup>2</sup>Department of Pathology, Temple University School of Medicine, Philadelphia, PA
- 69 *Orexin/hypocretin in the paraventricular nucleus of the thalamus mediates cocaine-seeking behavior in rats*  
A. Matzeu, T. M. Kerr, F. Weiss, R. Martin-Fardon, Molecular and Cellular Neuroscience Dept, The Scripps Research Institute, La Jolla, CA
- 70 *Concomitant adrenal hormonal stress responses are required for cocaine-induced locomotor sensitization*  
D. F. Pena, L. M. Keller, C. B. Masterson, E. J. Cottor, J. R. Mantsch, Biomedical Sciences, Marquette University, Milwaukee, WI
- 71 *Glucocorticoid-endocannabinoid interactions in the prelimbic cortex mediate stress-potentiated reinstatement of cocaine seeking*  
J. R. McReynolds<sup>1</sup>, O. Vranjkovic<sup>1</sup>, E. N. Graf<sup>1</sup>, C. J. Hillard<sup>2</sup>, J. R. Mantsch<sup>1</sup>, <sup>1</sup>Biomedical Sciences, Marquette University, Milwaukee, WI, <sup>2</sup>Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI
- 72 *Rearing environment modulates the effect of a glucocorticoid receptor antagonist on cocaine self-administration in rats*  
R. S. Hofford, M. T. Bardo, Psychology, University of Kentucky, Lexington, KY
- 73 *A re-engineered anticocaine monoclonal antibody: Determining h2E2 thermostability and thermodynamics of ligand binding*  
W. J. Ball<sup>1</sup>, M. R. Tabet<sup>1</sup>, N. Tabaja<sup>2</sup>, N. Garbett<sup>3</sup>, A. B. Norman<sup>1</sup>, <sup>1</sup>Pharmacology, University of Cincinnati, Cincinnati, OH, <sup>2</sup>Molecular Genetics, University of Cincinnati, Cincinnati, OH, <sup>3</sup>James B Brown Cancer Center, University of Louisville, Louisville, KY
- 74 *Chronic treatment with the monoamine releaser phenmetrazine reduces cocaine self-administration and cocaine-induced reinstatement*  
L. N. Thomas<sup>1</sup>, B. E. Blough<sup>2</sup>, T. J. Beveridge<sup>1</sup>, <sup>1</sup>Phys Pharm, Wake Forest School of Medicine, Winston Salem, NC, <sup>2</sup>Drug Discovery, RTI International, Research Triangle Park, NC
- 75 *A procedure for rapid determination of delay discounting of drug and non-drug reinforcers in monkeys*  
S. L. Huskinson<sup>1</sup>, L. Green<sup>2</sup>, J. Myerson<sup>2</sup>, K. B. Freeman<sup>1</sup>, <sup>1</sup>University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Washington University, St. Louis, MO
- 76 *Acute cocaine and concordance across measures of impulsive choice for food*  
J. R. Smethells, M. E. Carroll, Psychiatry, University of Minnesota, Minneapolis, MN

- 77 *Persistent effects of tacrine on reinstatement of non-reinforced responding for cocaine*  
K. Grasing, S. He, Substance Abuse Research, VA Medical Center, Kansas City, MO
- 78 *(±)-Modafinil potentiates cocaine self-administration but not the effects on DA levels in rodents*  
G. Tanda<sup>1,2</sup>, M. Mereu<sup>2</sup>, T. Hiranita<sup>2</sup>, A. H. Newman<sup>1,3</sup>, J. Katz<sup>2</sup>, <sup>1</sup>Medications Development Program, NIDA/IRP, Baltimore, MD, <sup>2</sup>Psychobiology Section, NIDA/IRP, Baltimore, MD, <sup>3</sup>Medicinal Chemistry Section, NIDA/IRP, Baltimore, MD
- 79 *Dopamine D2/D3 receptor modulation of food-drug choice in rhesus monkeys*  
W. S. John<sup>1</sup>, A. H. Newman<sup>2</sup>, M. A. Nader<sup>1</sup>, <sup>1</sup>Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC, <sup>2</sup>Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD
- 80 *Effects of the dopamine D3/D2 receptor antagonist bupirone on food/cocaine choice in socially housed male cynomolgus monkeys*  
M. Coller, P. W. Czoty, M. A. Nader, Physiology & Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC
- 81 *Effects of intramuscular and oral bupirone on physiology and behavior in monkeys*  
K. T. Szeliga, S. E. Martelle, M. A. Nader, Physiology & Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC
- 82 *Preference and c-fos activation of drug reward vs. natural reward: Are female pheromones more rewarding than cocaine?*  
K. Y. Salas-Ramirez<sup>1</sup>, K. Uribe<sup>2</sup>, L. Vidal<sup>3</sup>, E. Friedman<sup>1</sup>, <sup>1</sup>Physiology, Pharmacology and Neuroscience, The Sophie Davis School of Biomedical Education at The City College of New York, New York, NY, <sup>2</sup>Biology, The City College of New York, New York, NY, <sup>3</sup>Anatomy, Touro College of Osteopathic Medicine, New York, NY
- 83 *A progressive ratio determination of the relative reinforcing effect of methylphenidate versus cocaine by intravenous self-administration testing in rats*  
N. W. Buckley, J. Gosden, E. Johnson, S. L. Smith, D. J. Heal, RenaSci Ltd, Nottingham, United Kingdom
- 84 *Effect of methylphenidate preexposure on methylphenidate-induced conditioned taste avoidance*  
M. Muller, B. B. Wetzell, S. M. Flax, H. E. King, A. L. Riley, Psychopharmacology Laboratory, Department of Psychology, American University, Washington, DC
- 85 *A preclinical model of natural reward devaluation in cocaine addiction: Effects of dose*  
J. Green, L. Dykstra, R. M. Carelli, University of North Carolina, Chapel Hill, NC
- 86 *MDPV-induced conditioned taste aversions in the F344/N and LEW rat strains*  
H. E. King<sup>1</sup>, K. Rice<sup>2</sup>, A. L. Riley<sup>1</sup>, <sup>1</sup>Psychology, American University, Washington, DC, <sup>2</sup>Chemical Biology Research Branch, National Institute on Drug Abuse, Bethesda, MD
- 87 *Discriminative and locomotor effects of three synthetic cathinones*  
M. J. Forster, M. Rutledge, M. B. Gatch, Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX
- 88 *Alpha-pyrrolidinovalerophenone (alpha-PVP): Self-administration and acute drug challenges in rats*  
S. M. Aarde, S. Vandewater, K. Creehan, M. A. Taffe, Committee on Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA

**STIMULANTS - HUMANS II**

- 89 *Methamphetamine dependence and intensive Motivational Interviewing*  
D. L. Polcin, R. A. Korcha, M. Nayak, J. Bond, Alcohol Research Group, Emeryville, CA

- 90 *Contingency management and case management for out-of-treatment methamphetamine users*  
K. F. Corsi, C. Garver-Apgar, R. E. Booth, Psychiatry, University of Colorado School of Medicine, Denver, CO
- 91 *Methamphetamine treatment-seeking women: Is referral source an indication of treatment retention?*  
S. M. Stemmler, S. Shoptaw, Center for Behavioral and Addiction Medicine, UCLA, Los Angeles, CA
- 92 *Behavioral incentives to promote exercise compliance in cocaine-dependent women*  
L. Islam, D. Svikis, Virginia Commonwealth University, Richmond, VA
- 93 *Cocaine-induced subjective effects differ between African Americans and Caucasians*  
C. N. Haile<sup>1,2</sup>, D. G. Thompson-Lake<sup>1,2</sup>, J. J. Mahoney<sup>1,2</sup>, T. F. Newton<sup>1,2</sup>, R. De La Garza, II<sup>1,2</sup>,  
<sup>1</sup>Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX, <sup>2</sup>Michael E. DeBakey VAMC, Houston, TX
- 94 *Initial abstinence status and contingency management treatment outcomes: Does race matter?*  
L. Montgomery<sup>1</sup>, K. Carroll<sup>2</sup>, N. Petry<sup>3</sup>, <sup>1</sup>School of Human Services, University of Cincinnati, Cincinnati, OH, <sup>2</sup>Psychiatry, Yale University, New Haven, CT, <sup>3</sup>Psychiatry, University of Connecticut, Farmington, CT
- 95 *Race and ethnicity differences among adults with stimulant use disorders in a residential treatment setting: A baseline analysis of the STRIDE cohort*  
K. Sanchez<sup>1,3</sup>, K. G. Chartier<sup>2</sup>, T. L. Greer<sup>3</sup>, R. Walker<sup>3</sup>, T. Carmody<sup>3</sup>, C. D. Rethorst<sup>3</sup>, K. M. Ring<sup>3</sup>, A. M. dela Cruz<sup>3</sup>, M. H. Trivedi<sup>3</sup>, <sup>1</sup>School of Social Work, The University of Texas, Arlington, TX, <sup>2</sup>School of Social Work, Virginia Commonwealth University, Richmond, VA, <sup>3</sup>Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX
- 96 *Risk and protective correlates of METH-associated externalizing problems among European-American and U.S. Latino/a METH-dependent users*  
G. Carlo<sup>1</sup>, J. Simpson<sup>2</sup>, K. Grant<sup>3</sup>, M. M. Martinez<sup>4</sup>, C. Pudiak<sup>4</sup>, R. Bevins<sup>4</sup>, <sup>1</sup>University of Missouri, Columbia, MO, <sup>2</sup>Midland University, Fremont, NE, <sup>3</sup>VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, <sup>4</sup>University of Nebraska-Lincoln, Lincoln, NE
- 97 *Patterns of consumption and medical complications of cocaine base paste use in Uruguay*  
A. Pascale<sup>1,2</sup>, S. García<sup>2</sup>, A. Negrin<sup>1,2</sup>, P. Yemini<sup>2</sup>, R. Ormaechea<sup>2</sup>, <sup>1</sup>Department of Toxicology, School of Medicine, Montevideo, Uruguay, <sup>2</sup>Drug Reference and Information Center “Portal Amarillo”, State Health Services Administration, Montevideo, Uruguay
- 98 *Sex and drugs in the lives of minority women: A multi-level analysis of smartphone-based daily diary data*  
G. L. Reynolds<sup>1</sup>, D. G. Fisher<sup>1</sup>, J. Laurenceau<sup>2</sup>, <sup>1</sup>California State University, Long Beach, Long Beach, CA, <sup>2</sup>University of Delaware, Newark, DE
- 99 *Comparison of perceptions of HIV risk and risky sexual practices among heterosexual cocaine-dependent individuals*  
D. G. Thompson-Lake<sup>1</sup>, K. Cooper<sup>1</sup>, J. J. Mahoney<sup>1</sup>, K. Gatchalian<sup>2</sup>, M. Koffarnus<sup>2</sup>, R. Salas<sup>1</sup>, T. Lohrenz<sup>2</sup>, W. Bickel<sup>2</sup>, P. R. Montague<sup>2</sup>, T. F. Newton<sup>1</sup>, R. De La Garza, II<sup>1</sup>, <sup>1</sup>Psychiatry, Baylor College of Medicine, Houston, TX, <sup>2</sup>Virginia Tech Carilion Research Institute, Roanoke, VA

- 100 *Cocaine-dependent adults are more likely than controls to choose immediate unsafe sex over delayed safe sex*  
M. N. Koffarnus<sup>1</sup>, M. W. Johnson<sup>2</sup>, M. J. Wesley<sup>1</sup>, T. Lohrenz<sup>1</sup>, P. R. Montague<sup>1</sup>, W. K. Bickel<sup>1</sup>, <sup>1</sup>Virginia Tech Carilion Research Institute, Virginia Tech, Roanoke, VA, <sup>2</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 101 *Depressive symptoms and impulsivity among trauma-exposed, cocaine-dependent adults: Associations with HIV-relevant drug and sex risk behaviors*  
A. Vujanovic, R. Suchting, D. Atkinson, C. Green, J. Schmitz, Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX
- 102 *Careless and overprotective fathers are associated with antisocial crack users*  
M. Pettenon<sup>1</sup>, L. P. Guimarães<sup>1</sup>, R. S. Pedroso<sup>1</sup>, G. E. Woody<sup>2</sup>, F. P. Pechansky<sup>1</sup>, F. P. Kessler<sup>1</sup>, <sup>1</sup>CPAD-Centro de Pesquisa em Alcool e Drogas, UFRGS-Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, <sup>2</sup>University of Pennsylvania, Philadelphia, PA
- 103 *Crack cocaine use and perceived life chances*  
J. Davis, D. G. Fisher, G. L. Reynolds, L. Napper, S. A. Meyers, Center for Behavioral Research and Services, California State University, Long Beach, Long Beach, CA
- 104 *Crack cocaine users show low adherence rates in Brazilian public outpatient treatment*  
S. Faller, A. R. Stolf, F. P. Pechansky, F. Kessler, Center for Drug and Alcohol Research of the Federal University of Rio Grande do Sul (CPAD), Porto Alegre, Brazil
- 105 *Adherence monitoring for substance abuse clinical trials*  
R. Pal<sup>1</sup>, G. Galloway<sup>1</sup>, O. Clavier<sup>2</sup>, K. Garrison<sup>1</sup>, J. Mendelson<sup>1</sup>, <sup>1</sup>Addiction & Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA, <sup>2</sup>Creare, Inc., Hanover, NH
- 106 *A remote wireless sensor network/electrocardiographic approach to discriminating cocaine use*  
G. A. Angarita<sup>1</sup>, A. Natarajan<sup>2</sup>, E. C. Gaiser<sup>1</sup>, A. Parate<sup>2</sup>, B. Marlin<sup>2</sup>, R. Gueorguieva<sup>3</sup>, D. Ganesan<sup>2</sup>, R. T. Malison<sup>1</sup>, <sup>1</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>2</sup>School of Computer Science, University of Massachusetts, Amherst, MA, <sup>3</sup>Biostatistics, Yale University School of Medicine, New Haven, CT
- 107 *Agreement between Timeline Follow-Back (TLFB) and Audio Computer-Assisted Self Interview (A-CASI) in HIV primary care patients: Assessment of days used primary drug*  
D. S. Hasin<sup>1,2</sup>, E. Aharonovich<sup>1,2</sup>, <sup>1</sup>Columbia University Medical Center, New York, NY, <sup>2</sup>New York State Psychiatric Institute, New York, NY

### TREATMENT

- 108 *Frequency and intensity of craving among addicted patients during outpatient treatment*  
H. Hurmic<sup>1,2</sup>, F. Serre<sup>1,2</sup>, M. Fatseas<sup>1,2</sup>, M. Alix<sup>1,2</sup>, M. Auriacombe<sup>1,2</sup>, <sup>1</sup>Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, <sup>2</sup>Addiction Treatment Center, CH Ch. Perrens et CHU Bordeaux, Bordeaux, France
- 109 *Sleep quality in patients with SUD and behavioral addictions assessed by actigraphy : A prospective study*  
C. Kervran<sup>1</sup>, F. Serre<sup>1</sup>, M. Fatseas<sup>1</sup>, R. Debrabant<sup>1</sup>, C. Trouba<sup>2</sup>, J. Taillard<sup>2</sup>, P. Philip<sup>1</sup>, M. Auriacombe<sup>1</sup>, <sup>1</sup>Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, <sup>2</sup>Sleep Clinic, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France
- 110 *Training in contingency management: Effects on staff intervention delivery skill, knowledge, adoption readiness, and attitudes after 90 days of implementation experience*  
B. Hartzler, Alcohol & Drug Abuse Institute, University of Washington, Seattle, WA



- 111 *Effects of training and implementation experience on clinical skills involved in delivering contingency management*  
B. E. Jones, B. Hartzler, Alcohol & Drug Abuse Institute, University of Washington, Seattle, WA
- 112 *Anxiety sensitivity and the discrepancy between motivation to change and perceived ability to change*  
R. McHugh<sup>1,2</sup>, E. Hilario<sup>1</sup>, K. McDermott<sup>1</sup>, M. L. Griffin<sup>1,2</sup>, R. Weiss<sup>1,2</sup>, <sup>1</sup>McLean Hospital, Belmont, MA, <sup>2</sup>Harvard Medical School, Boston, MA
- 113 *Understanding organization readiness to use of technology-based treatment approaches*  
S. E. Lord<sup>1</sup>, A. Ramsey<sup>2</sup>, <sup>1</sup>Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth College, Lebanon, NH, <sup>2</sup>Brown School, Washington University, St. Louis, MO
- 114 *Client predictors of treatment completion using a U.S. national sample*  
G. Stahler<sup>1</sup>, J. P. DuCette<sup>2</sup>, <sup>1</sup>Geography and Urban Studies, Temple University, Philadelphia, PA, <sup>2</sup>Psychological Studies in Education, Temple University, Philadelphia, PA
- 115 *Predictors of substance use outcomes in mentorship for addiction problems*  
K. Tracy<sup>1</sup>, M. Burton<sup>1</sup>, M. Warren<sup>1</sup>, D. Guzman<sup>1</sup>, M. Galanter<sup>1</sup>, T. Babuscio<sup>2</sup>, C. Nich<sup>2</sup>, <sup>1</sup>Psychiatry, New York University School of Medicine, New York, NY, <sup>2</sup>Psychiatry, Yale University School of Medicine, New Haven, CT
- 116 *Therapist turnover intentions: The predictive role of training satisfaction and evidence-based treatment perceptions*  
B. Garner, L. Passetti, B. Hunter, M. Godley, Chestnut Health Systems, Normal, IL
- 117 *Social work students' attitudes towards approaches to alcohol or other drug treatment*  
S. K. Moore, NDRI, New York, NY
- 118 *ASAM treatment placement criteria for gambling disorder*  
D. M. Ledgerwood, C. L. Arfken, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI

**PSYCHIATRIC COMORBIDITY II**

- 119 *Gambling behavior among gamblers with and without attention deficit/hyperactivity disorder*  
J. Alexandre<sup>1,2</sup>, M. Fatseas<sup>1,2</sup>, G. Bouju<sup>2</sup>, C. Legauffre<sup>2</sup>, M. Valleur<sup>2</sup>, D. Magalon<sup>2</sup>, I. Chereau-Boudet<sup>2</sup>, M. Gorsane<sup>2</sup>, M. Auriacombe<sup>1,2</sup>, J. Hardouin<sup>2</sup>, J. Venisse<sup>2</sup>, M. Grall-Bronnec<sup>2</sup>, <sup>1</sup>Addiction Treatment Center, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, <sup>2</sup>Gambling Cohort Group, Univ Nantes, Nantes, France
- 120 *Decision-making, impulsivity, and drug severity in co-occurring substance dependence and pathological gambling*  
J. Tanabe<sup>1,2</sup>, T. Krmopotich<sup>1</sup>, S. Mikulich<sup>2</sup>, J. Sakai<sup>2</sup>, L. Thompson<sup>2</sup>, J. Reynolds<sup>3</sup>, M. T. Banich<sup>2</sup>, <sup>1</sup>Radiology, University of Colorado, Denver, CO, <sup>2</sup>Psychiatry, University of Colorado, Denver, CO, <sup>3</sup>Psychology, University of Denver, Denver, CO
- 121 *Are sleep disturbances associated with craving intensity? What is the influence of psychiatric comorbidity and type of substance on this relationship? A computerized ambulatory monitoring study in patients beginning treatment for addiction*  
F. Serre<sup>1</sup>, M. Fatseas<sup>1</sup>, J. Swendsen<sup>2</sup>, M. Auriacombe<sup>1</sup>, <sup>1</sup>Addiction Psychiatry, Univ. Bordeaux/ CNRS USR 3413, Bordeaux, France, <sup>2</sup>CNRS UMR 5287 - INCIA, Univ. Bordeaux, Bordeaux, France
- 122 *Relationship of trait impulsivity and lifetime cocaine use consequences to current depression*  
J. J. Lister, D. M. Ledgerwood, L. H. Lundahl, M. K. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI

- 123 *Long-term patterns of heroin use and mental health: 11-Year follow-up of the Australian Treatment Outcome Study*  
C. Marel<sup>1</sup>, M. Teesson<sup>1</sup>, K. Mills<sup>1</sup>, S. Darke<sup>1</sup>, J. Ross<sup>1</sup>, T. Slade<sup>1</sup>, L. Burns<sup>1</sup>, M. Lynskey<sup>2</sup>,  
<sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>Washington University, St Louis, MO
- 124 *Illicit drug use harms response to psychiatric treatment*  
V. L. King, J. M. Peirce, R. K. Brooner, M. S. Kidorf, Johns Hopkins School of Medicine, Baltimore, MD
- 125 *Early initiation of alcohol and illicit drug use: Associations with psychopathology among inpatient substance users*  
N. Bounoua, B. Ali, A. Lim, W. Lechner, J. M. Shadur, J. W. Felton, L. MacPherson, C. W. Lejuez, University of Maryland, College Park, College Park, MD
- 126 *“It’s like trying to change a flat tire when you got a blown engine.” Counselor views on treating clients with co-occurring medical conditions*  
L. A. Cathers<sup>1</sup>, A. Armstrong<sup>1</sup>, C. Hawley<sup>1</sup>, J. Bradford<sup>2</sup>, L. A. Keyser-Marcus<sup>1</sup>, D. Svikis<sup>1</sup>,  
<sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>The Fenway Institute, Boston, MA
- 127 *Methamphetamine dependence, psychiatric disorders, and treatment outcomes in individuals treated with methylphenidate*  
L. Mooney, M. P. Hillhouse, A. Ang, J. Jenkins, W. Ling, UCLA Integrated Substance Abuse Programs, Los Angeles, CA
- 128 *Preliminary results from a study evaluating creatine as a treatment option for depression in female methamphetamine users*  
T. Hellem<sup>1,2</sup>, P. F. Renshaw<sup>1</sup>, <sup>1</sup>Brain Institute, Univ of UT, SLC, UT, <sup>2</sup>College of Nursing, Univ of UT, SLC, UT
- 129 *Impact of psychiatric comorbidity in engagement in treatment after referral by an Addiction Liaison Psychiatry Unit*  
F. Fonseca<sup>1,2</sup>, J. Leon<sup>1</sup>, M. Llobet<sup>1</sup>, P. Rossi<sup>1,2</sup>, D. Martínez-Sanvisens<sup>1,2</sup>, C. Tamarit<sup>1,2</sup>, M. Farre<sup>1,2,3</sup>, M. Torrens<sup>1,2,3</sup>, <sup>1</sup>Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain, <sup>2</sup>Institut Hospital Del Mar d’Investigacions Mèdiques (IMIM), Parc de Salut Mar, Barcelona, Spain, <sup>3</sup>Facultad de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain
- 130 *Comparing integrated care capacity among mental health and substance abuse treatment providers*  
M. Chaple, S. Sacks, NDRI, New York, NY

**NICOTINE II**

- 131 *Tobacco use in buprenorphine-maintained patients receiving primary care in a community mental health clinic*  
A. Harrington, M. E. Kolodziej, M. Hobart, G. Gonzalez, Psychiatry, University of Massachusetts, Worcester, MA
- 132 *Analyzing disparities on tobacco use through CBPR*  
S. A. Henry<sup>2,1</sup>, P. Sheikhattari<sup>1,2</sup>, F. A. Wagner<sup>1,2</sup>, <sup>1</sup>Prevention Sciences Research Center, Morgan State University, Baltimore, MD, <sup>2</sup>School of Community Health and Policy, Morgan State University, Baltimore, MD
- 133 *Race as a moderator of the relationship between distress tolerance and cigarette smoking among Black and White women*  
J. R. Dahne<sup>1</sup>, K. Stratton<sup>2</sup>, R. Brown<sup>2</sup>, A. Amstadter<sup>2</sup>, C. W. Lejuez<sup>1</sup>, L. MacPherson<sup>1</sup>,  
<sup>1</sup>Psychology, University of Maryland, College Park, College Park, MD, <sup>2</sup>Virginia Commonwealth University, Richmond, VA

- 134 *Income variability by race in tobacco outlet density in Maryland*  
D. O. Fakunle<sup>1</sup>, A. J. Milam<sup>1,2</sup>, C. D. Furr-Holden<sup>1</sup>, <sup>1</sup>Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>School of Medicine, Wayne State University, Detroit, MI
- 135 *Perceived risk of regular cigarette smoking and marijuana use in the U.S, 2002-2012*  
L. R. Pacek<sup>1</sup>, P. M. Mauro<sup>2</sup>, S. S. Martins<sup>3,2</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Mental Health, Johns Hopkins University, Baltimore, MD, <sup>3</sup>Epidemiology, Columbia University, New York, NY
- 136 *Change in addiction treatment staff and client smoking following a statewide smoking ban*  
A. Pagano, J. Guydish, T. Le, B. Tajima, E. Passalacqua, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA
- 137 *Smokers in addiction treatment see their risk of tobacco-related disease as lower than that of an average smoker*  
T. Le, J. Guydish, A. Pagano, B. Tajima, E. Passalacqua, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA
- 138 *Quit attempt predictors among smokers in addiction treatment*  
C. Martinez<sup>1,2,3</sup>, J. Guydish<sup>1</sup>, T. Le<sup>1</sup>, B. Tajima<sup>1</sup>, E. Passalacqua<sup>1</sup>, <sup>1</sup>Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA, <sup>2</sup>Cancer Prevention and Control Group, Institut d'Investigacio Biomedica de Bellvitge, Barcelona, Spain, <sup>3</sup>Medicine and Health Sciences School, Universitat Internacional de Catalunya, Barcelona, Spain
- 139 *Recruiting for an SMS smoking cessation intervention in Peru: Pilot study results*  
D. Blitchtein<sup>2</sup>, K. Zevallos<sup>2</sup>, M. R. Samolski<sup>2</sup>, J. C. Anthony<sup>1</sup>, <sup>1</sup>Epidemiology, Michigan State University, East Lansing, MI, <sup>2</sup>Salud Mental, Universidad Peruana Cayetano Heredia, Lima, Peru
- 140 *Preliminary results of Project EX in Spain: A classroom-based smoking prevention and cessation program*  
J. P. Espada<sup>1</sup>, M. T. Gonzalez<sup>1</sup>, M. Orgiles<sup>1</sup>, A. Morales<sup>1</sup>, S. Sussman<sup>2</sup>, <sup>1</sup>Miguel Hernandez University, Alicante, Spain, <sup>2</sup>University of Southern California, Los Angeles, CA
- 141 *Role of substance abuse in physical and mental health trajectories throughout the deployment cycle: A National Guard study*  
C. van den Berk Clark<sup>1</sup>, S. Balan<sup>1</sup>, J. Scherrer<sup>2</sup>, G. Widner<sup>1</sup>, M. Shroff<sup>1</sup>, R. K. Price<sup>1</sup>, <sup>1</sup>Psychiatry, Washington University, St. Louis, MO, <sup>2</sup>Family and Community Medicine, St. Louis University, St. Louis, MO
- 142 *Nicotine dependence among distinct smoking typologies*  
W. Pickworth, B. Koszowski, Z. Rosenberry, L. Viray, J. Potts, Health & Analytics, Battelle, Baltimore, MD
- 143 *A non-parametric approach identifies a new gene-gene interaction associated with progression of nicotine dependence*  
M. Li<sup>1</sup>, J. C. Gardiner<sup>2</sup>, N. Breslau<sup>2</sup>, J. C. Anthony<sup>2</sup>, Q. Lu<sup>2</sup>, <sup>1</sup>Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, <sup>2</sup>Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

**THEORETICAL/COMMENTARY**

- 144 *Monkey genomes: A paradigm shift for advancing preclinical research and medications development for addictions*  
G. M. Miller, E. J. Vallender, NEPRC, Harvard University, Southborough, MA

- 145 *Functional approach in modeling drug dependence processes (theoretical overview midway to final results)*  
O. Vsevolozhskaya, J. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
- 146 *Methodological challenges with marijuana research in the U.S*  
S. B. Farley, C. J. Reissig, Controlled Substance Staff (CSS), FDA, Silver Spring, MD
- 147 *Posterior predictive power: A decision-making tool for clinical trial design*  
N. Rathnayaka, R. Suchting, S. D. Lane, J. Schmitz, C. Green, Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX
- 148 *Implications of decision-making processes for improving contingency management*  
P. S. Regier<sup>1</sup>, A. D. Redish<sup>2</sup>, <sup>1</sup>Graduate Program of Neuroscience, University of Minnesota, Minneapolis, MN, <sup>2</sup>Department of Neuroscience, University of Minnesota, Minneapolis, MN
- 149 *Comprehensive women-centered treatment for substance use disorders in the Republic of Georgia: Current status and future directions*  
D. Otiashvili<sup>1</sup>, I. Kirtadze<sup>1</sup>, K. E. O'Grady<sup>2</sup>, W. Zule<sup>3</sup>, E. Krupitsky<sup>4</sup>, W. Wechsberg<sup>3</sup>, H. Jones<sup>5,6</sup>, <sup>1</sup>Addiction Research Center, Alternative Georgia, Tbilisi, Georgia, <sup>2</sup>Department of Psychology, University of Maryland, College Park, MD, <sup>3</sup>RTI International, Research Triangle Park, NC, <sup>4</sup>Department of Addictions, Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation, <sup>5</sup>UNC Horizons, Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, <sup>6</sup>Departments of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, School of Medicine, Johns Hopkins University, Baltimore, MD
- 150 *The role of discrimination, ethnic identity, and acculturation in substance use patterns among Mexican origin transnational youth*  
F. I. Soriano<sup>1</sup>, J. C. Anthony<sup>1,3</sup>, F. Castro<sup>1</sup>, I. Bojorquez<sup>1,2</sup>, <sup>1</sup>Human Development, California State University San Marcos, San Marcos, CA, <sup>2</sup>Department of Epidemiology, Michigan State University, East Lansing, MI, <sup>3</sup>Department of Psychology, University of Texas, El Paso, TX
- 151 *HIV among Puerto Rican people who inject drugs: Health disparities continue*  
S. Deren<sup>1</sup>, C. Gelpi-Acosta<sup>2</sup>, C. Albizu-Garcia<sup>3</sup>, A. Gonzalez<sup>5</sup>, D. Des Jarlais<sup>4</sup>, S. Santiago-Negron<sup>5</sup>, <sup>1</sup>NYU, NY, NY, <sup>2</sup>NDRI, NY, NY, <sup>3</sup>UPR, San Juan, <sup>4</sup>BIMC, NY, NY, <sup>5</sup>ASSMCA, San Juan
- 152 *Development of a workflow for screening for the hepatitis C virus in HIV-positive IV drug users*  
E. Thomas, Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, FL
- 153 *Statistical assessment for abuse deterrent formulation in clinical abuse potential studies*  
L. Chen, Health and Human Services, U.S. Food and Drug Administration, Silver Spring, MD
- 154 *FDA abuse-deterrent guidance. Assessing new technologies*  
S. N. Calderon, J. M. Tolliver, M. Klein, Health and Human Services, U.S. Food and Drug Administration, Silver Spring, MD
- 155 *Assessing stigma towards drug users among health care providers*  
C. E. Albizu, J. N. Caraballo, G. Caraballo-Correa, S. Santiago, A. Mendez, S. Rivera-Suazo, University of Puerto Rico, San Juan
- 156 *Stigmatizing experiences while in drug abuse treatment: A qualitative exploration of client's perceptions*  
S. Rivera-Suazo, C. E. Albizu, S. Santiago, C. Perez, University of Puerto Rico, San Juan

## **Symposium XIV**

**BALLROOM A  
10:00 - 12:00 PM**

### **MEDICATIONS FOR DRUG ADDICTIONS: SEX DIFFERENCES IN OUTCOMES IN ANIMAL AND HUMAN LABORATORY STUDIES AND IN CLINICAL TRIALS**

Chairs: Cora Lee Wetherington and Ivan Montoya

- 10:00 *Differential antidepressant-like effects and potentiation of nicotinic-based antidepressants by guanfacine in males and females mice*  
Yann Mineur, Yale University School of Medicine, New Haven, CT
- 10:25 *Targeting the noradrenergic system for gender-sensitive treatment development for substance dependence*  
Sherry McKee, Yale University School of Medicine, New Haven, CT
- 10:50 *Progesterone to treat cocaine addiction: Results from animal and human studies*  
Marilyn E. Carroll, University of Minnesota, Minneapolis, MN
- 11:15 *Oxytocin in cocaine and marijuana dependence*  
Kathleen T. Brady, Medical University of South Carolina, Charleston, SC
- 11:40 *DISCUSSANT:*  
Ivan Montoya, National Institute on Drug Abuse, Bethesda, MD

## **Symposium XV**

**BALLROOM B  
10:00 - 12:00 PM**

### **DEMYSTIFYING MEDICINAL CHEMISTRY AND DRUG DESIGN**

Chairs: Andrew Coop and Thomas E. Prisinzano

- 10:00 *Fundamental principles of drug design*  
Andrew Coop, University of Maryland School of Pharmacy, Baltimore, MD
- 10:30 *Computer-aided drug design in the 21st century*  
Christopher W. Cunningham, Concordia University of Wisconsin School of Pharmacy, Mequon, WI
- 11:00 *Drug discovery from the ocean*  
Kevin Tidgewell, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA
- 11:30 *DISCUSSANT: The future of drug design and medicinal chemistry*  
Thomas E. Prisinzano, University of Kansas School of Pharmacy, Lawrence, KS

## **Oral Communications 17**

**BALLROOM C  
10:00 - 12:00 PM**

### **RESEARCH AT A FEVERED PITCH: LATEST FINDINGS ON DRUGS AND NEUROINFLAMMATION**

Chairs: Rae R. Matsumoto and Steven B. Harrod

- 10:00 *Cytokines during acute abstinence of crack cocaine: The role of early life stress*  
R. Grassi-Oliveira<sup>1</sup>, M. L. Levandowski<sup>1</sup>, T. W. Viola<sup>1</sup>, L. E. Wearick<sup>1</sup>, J. Pezzi<sup>2</sup>, M. E. Bauer<sup>1</sup>, A. L. Teixeira<sup>1</sup>, E. Brietzke<sup>1</sup>, <sup>1</sup>Centre of Studies and Research in Traumatic Stress, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>2</sup>Pós Graduação em Ciências da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil

- 10:15 *Alteration of circulatory cytokine levels in alcohol-use disorder patients with or without comorbid major depression*  
S. P. Neupane<sup>1</sup>, L. Lien<sup>1,2</sup>, P. Martinez<sup>3</sup>, P. Aukrust<sup>4,5</sup>, T. Ueland<sup>5</sup>, T. E. Mollnes<sup>5</sup>, K. Hestad<sup>2,6</sup>, J. G. Bramness<sup>7</sup>, <sup>1</sup>Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway, <sup>2</sup>Innlandet Hospital Trust, Hamar, Norway, <sup>3</sup>University of California, Berkeley, CA, <sup>4</sup>Oslo University Hospital, Oslo, Norway, <sup>5</sup>Oslo University Hospital, Oslo, Norway, <sup>6</sup>The Norwegian University of Science and Technology, Trondheim, Norway, <sup>7</sup>Norwegian Institute of Public Health, Oslo, Norway
- 10:30 *The association between IL-6 and neurocognitive performance as a function of self-reported lifetime marijuana use*  
L. Keen, W. W. Latimer, Clinical and Health Psychology, University of Florida, Gainesville, FL
- 10:45 *Interleukin-1 $\beta$  in the dorsal hippocampus and the conditioned immune effects of heroin*  
C. Lebonville<sup>1</sup>, J. Szczytkowski-Thomson<sup>2</sup>, D. Lysle<sup>1</sup>, L. Hutson<sup>1</sup>, R. Fuchs<sup>1</sup>, <sup>1</sup>Psychology, UNC-Chapel Hill, Chapel Hill, NC, <sup>2</sup>Psychology, Messiah College, Grantham, PA
- 11:00 *Binge-like ethanol consumption in C57BL/6J mice promotes site-specific increases of interleukin-1 $\beta$  expression in the area of the amygdala*  
J. Casachahua, D. Lysle, T. Thiele, Psychology, UNC-CH, Chapel Hill, NC
- 11:15 *HIV-1 transgenic rats exhibit attenuated motivation and escalation of cocaine self-administration*  
S. B. Harrod, C. F. Mactutus, S. J. Bertrand, A. J. Morgan, R. M. Booze, Psychology, University of South Carolina, Columbia, SC
- 11:30 *HIV-1 transgenic rat: Altered motivated behavior for natural reward*  
S. J. Bertrand, C. F. Mactutus, S. B. Harrod, A. J. Morgan, R. M. Booze, Psychology, University of South Carolina, Columbia, SC
- 11:45 *Attenuation of methamphetamine-induced striatal neurotoxicity involves both neuronal and glial mechanisms*  
R. Matsumoto<sup>1</sup>, M. Robson<sup>1</sup>, R. Turner<sup>2</sup>, Z. Naser<sup>2</sup>, N. Kaushal<sup>1</sup>, C. McCurdy<sup>3</sup>, J. Huber<sup>1</sup>, J. O'Callaghan<sup>4</sup>, <sup>1</sup>Basic Pharmaceutical Sciences, West Virginia University, Morgantown, WV, <sup>2</sup>Neurosurgery, West Virginia University, Morgantown, WV, <sup>3</sup>Medicinal Chemistry, University of Mississippi, University, MS, <sup>4</sup>Health Effects Laboratory Division, CDC/NIOSH, Morgantown, WV

## Oral Communications 18

**SAN CRISTOBAL**  
**10:00 - 12:00 PM**

### NICOTINE

Chairs: Erin A. McClure and Diana Dow-Edwards

- 10:00 *A trans-generational ripple: How a puff during early development led to a global huff in microRNA profiles as well as grand-offspring addictive behavior in *Caenorhabditis elegans**  
F. A. Taki, X. Pan, B. Zhang, Biology, East Carolina University, Greenville, NC
- 10:15 *Nicotine alters behavior in pre-adolescent rats*  
D. Dow-Edwards, A. Edwards, N. Konz, Physiology/Pharmacology, SUNY Downstate, Brooklyn, NY

- 10:30 *Increased weight gain and sucrose intake during extinction of nicotine self-administration in adult male rats*  
P. Grebenstein<sup>1,2</sup>, D. Burroughs<sup>1</sup>, C. Hernandez<sup>1</sup>, M. G. LeSage<sup>1,2</sup>, <sup>1</sup>Medicine, Minneapolis Medical Research Foundation, Minneapolis, MN, <sup>2</sup>Medicine, University of Minnesota, Minneapolis, MN
- 10:45 *Contributions of glial glutamate transport and NMDA receptors in nicotine relapse*  
C. D. Gipson, N. Stankeviciute, Y. Kupchik, M. Scofield, P. W. Kalivas, Neurosciences, Medical University of South Carolina, Charleston, SC
- 11:00 *Environmental enrichment decreases nicotine self-administration and attenuates nicotine-mediated enhancement of orexin-1 receptor gene expression and ERK1/2 activity in rat prefrontal cortex*  
A. M. Gomez<sup>1</sup>, D. Altomare<sup>1</sup>, S. B. Harrod<sup>2</sup>, K. E. Creek<sup>1</sup>, J. Zhu<sup>1</sup>, <sup>1</sup>Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, <sup>2</sup>Psychology, University of South Carolina, Columbia, SC
- 11:15 *An open-label pilot trial of N-acetylcysteine and varenicline in cigarette smokers*  
E. A. McClure<sup>1</sup>, C. Gipson<sup>2</sup>, B. Froeliger<sup>2,1</sup>, P. Kalivas<sup>2</sup>, K. Gray<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Department of Neurosciences, Medical University of South Carolina, Charleston, SC
- 11:30 *Effects of omega-3 fatty acids on tobacco craving: A double-blind, randomized, placebo-controlled pilot study*  
S. Rabinovitz, School of Criminology, University of Haifa, Haifa, Israel
- 11:45 *Secondary analysis of smoking rates from a double-blind, placebo-controlled clinical trial of mixed-amphetamine salts and topiramate for cocaine dependence*  
B. Vaughan<sup>1,2</sup>, J. J. Mariani<sup>1,2</sup>, M. Pavlicova<sup>3</sup>, A. Glass<sup>4</sup>, A. Bisaga<sup>1,2</sup>, E. V. Nunes<sup>1,2</sup>, D. J. Brooks<sup>1,2</sup>, F. R. Levin<sup>1,2</sup>, <sup>1</sup>Psychiatry, Columbia University, New York, NY, <sup>2</sup>Psychiatry, New York State Psychiatric Institute, New York, NY, <sup>3</sup>Biostatistics Department, Columbia University, New York, NY, <sup>4</sup>Biostatistics Division, New York State Psychiatric Institute, New York, NY

### **BRUNCH WITH CHAMPIONS** (PRE-REGISTRANTS ONLY)

**LAS OLAS**  
**12:00 - 1:30 PM**

### **Oral Communications 19**

**BALLROOM A**  
**1:30 - 3:30 PM**

#### **A NOD TO OPIOIDS**

Chairs: Kevin Freeman and Tae Woo Park

- 1:30 *Role of projections from ventral subiculum to nucleus accumbens shell in context-induced reinstatement of heroin seeking*  
J. M. Bossert, R. M. St. Laurent, N. J. Marchant, H. Wang, M. Morales, Y. Shaham, IRP/NIDA/NIH/DHHS, Baltimore, MD
- 1:45 *Reduction of adult hippocampal neurogenesis via cranial irradiation enhances morphine self-administration and morphine-induced locomotor sensitization*  
S. E. Bulin, D. R. Richardson, K. H. Song, T. D. Solberg, A. J. Eisch, University of Texas Southwestern Medical Center, Dallas, TX

- 2:00 *Self-administration of oxycodone by adolescent and adult mice differentially affects hypothalamic mitochondrial metabolism gene expression*  
M. Deutsch-Feldman<sup>1</sup>, Y. Zhang<sup>1</sup>, M. Buonora<sup>1</sup>, A. Brownstein<sup>1</sup>, K. Niikura<sup>1</sup>, A. Ho<sup>1</sup>, J. Ott<sup>2,3</sup>, M. Kreek<sup>1</sup>, <sup>1</sup>The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, <sup>2</sup>The Laboratory of Statistical Genetics, The Rockefeller University, New York, NY, <sup>3</sup>Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- 2:15 *Self-administration of oxycodone alone or as a mixture with the kappa agonist, salvinorin A, by monkeys under a progressive-ratio schedule of reinforcement*  
J. Naylor<sup>1</sup>, T. Prisinzano<sup>2</sup>, K. Freeman<sup>1</sup>, <sup>1</sup>Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Medicinal Chemistry, The University of Kansas, Lawrence, KS
- 2:30 *Naltrexone inhibits the subjective effects of salvinorin-A in humans*  
M. Valle<sup>1</sup>, A. Maqueda<sup>2,1</sup>, J. Bouso<sup>3</sup>, M. Puentes<sup>1</sup>, M. Ballester<sup>1</sup>, M. Garrido<sup>1</sup>, M. González<sup>1</sup>, J. Claramunt<sup>1</sup>, D. Martínez<sup>1</sup>, M. Martínez<sup>1</sup>, G. Seguí<sup>1</sup>, J. Coimbra<sup>1</sup>, J. Pérez de los Cobos<sup>4</sup>, R. Antonijoan<sup>4</sup>, J. Riba<sup>2,1</sup>, <sup>1</sup>IIB Sant Pau, Barcelona, Spain, <sup>2</sup>Human Neuropsychopharmacology Group, Barcelona, Spain, <sup>3</sup>ICEERS, Barcelona, Spain, <sup>4</sup>Hospital de Sant Pau, Barcelona, Spain
- 2:45 *Abuse potential study of intravenous oxycodone hydrochloride alone or in combination with intravenous naltrexone in nondependent, recreational opioid users*  
B. Setnik<sup>1</sup>, A. Bass<sup>1</sup>, K. W. Sommerville<sup>1,2</sup>, K. Matschke<sup>3</sup>, L. R. Webster<sup>4</sup>, <sup>1</sup>Pfizer Inc, Durham, NC, <sup>2</sup>Duke University Medical Center, Durham, NC, <sup>3</sup>Pfizer Inc, Collegeville, PA, <sup>4</sup>CRI Lifetree, Salt Lake City, UT
- 3:00 *The misuse, abuse and diversion of opioid replacement therapies among street abusers*  
S. P. Novak<sup>1</sup>, L. Wenger<sup>2</sup>, J. Lorvick<sup>2</sup>, A. Kral<sup>2</sup>, <sup>1</sup>RTI International, Research Triangle Park, NC, <sup>2</sup>RTI International, San Francisco, CA
- 3:15 *The association between benzodiazepine prescription and aberrant drug behaviors in primary care patients receiving chronic opioid therapy*  
T. Park<sup>1,2</sup>, K. Nelson<sup>2</sup>, Z. Xuan<sup>2</sup>, K. E. Lasser<sup>2</sup>, J. M. Liebschutz<sup>2</sup>, R. Saitz<sup>2</sup>, <sup>1</sup>VA Boston Healthcare System, Boston, MA, <sup>2</sup>Boston University, Boston, MA

## Oral Communication 20

**BALLROOM B**  
**1:30 - 3:30 PM**

### FOCUSING ATTENTION ON ADHD AND ADDICTION

Chairs: Frances R. Levin and Sonam O. Lasopa

- 1:30 *Adolescent atomoxetine, but not methylphenidate, decreases cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder*  
C. J. Jordan<sup>1</sup>, R. C. Harvey<sup>1</sup>, B. M. Baskin<sup>1</sup>, K. Rodriguez<sup>1</sup>, A. Dellamorte<sup>1</sup>, L. P. Dwoskin<sup>2</sup>, K. M. Kantak<sup>1</sup>, <sup>1</sup>Psychology, Boston University, Boston, MA, <sup>2</sup>Pharmaceutical Sciences, University of Kentucky, Lexington, KY
- 1:45 *Decreased norepinephrine transporter function in the orbitofrontal cortex and enhanced cocaine abuse risk following adolescent methylphenidate treatment in a rat model of attention deficit hyperactivity disorder*  
S. S. Somkuwar<sup>1</sup>, K. Kantak<sup>2</sup>, L. P. Dwoskin<sup>1</sup>, <sup>1</sup>Pharmaceutical Sciences, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, Boston University, Boston, MA



- 2:00 *Orbitofrontal connectivity in marijuana smoking youths with and without attention-deficit/hyperactivity disorder*  
M. P. Lopez-Larson<sup>1,2</sup>, J. Rogowska<sup>1</sup>, J. B. King<sup>1</sup>, D. Yurgelun-Todd<sup>1,2,3</sup>, <sup>1</sup>The Brain Institute, University of Utah, Salt Lake City, UT, <sup>2</sup>School of Medicine, University of Utah, Salt Lake City, UT, <sup>3</sup>VISN 19, MIRREC, Salt Lake City, UT
- 2:15 *ADHD as risk factor for early onset and later severity of illicit substance use: An accelerated gateway model*  
E. M. Dunne, L. Hearn, J. J. Rose, W. W. Latimer, Clinical and Health Psychology, University of Florida, Gainesville, FL
- 2:30 *Mixed amphetamine salts-extended release for ADHD adults with cocaine use disorder*  
F. R. Levin<sup>1,3</sup>, J. J. Mariani<sup>1,3</sup>, A. Mahony<sup>3</sup>, D. J. Brooks<sup>3</sup>, L. Eberly<sup>2</sup>, Y. Bai<sup>2</sup>, S. Specker<sup>2</sup>, M. Mooney<sup>2</sup>, E. V. Nunes<sup>1,3</sup>, J. Grabowski<sup>2</sup>, <sup>1</sup>Psychiatry, Columbia University, New York, NY, <sup>2</sup>University of Minnesota, Minneapolis, MN, <sup>3</sup>Substance Abuse, NYSPI, New York, NY
- 2:45 *Gender differences in risk factors for nonmedical use of prescription stimulants among youth 10 to 18 years in the U.S*  
S. O. Lasopa, L. Cottler, K. Vaddiparti, C. W. Striley, University of Florida, Gainesville, FL
- 3:00 *Substance use patterns associated with adult ADHD in SUD treatment-seeking patients: Results from the Aquitaine Addiction Cohort Study*  
M. Fatseas<sup>1,2</sup>, H. Hurmic<sup>1,2</sup>, R. Debrabant<sup>1,2</sup>, F. Serre<sup>1,2</sup>, M. Auriacombe<sup>1,2</sup>, <sup>1</sup>Addiction Psychiatry, Univ. Bordeaux / CNRS USR 3413, Bordeaux, France, <sup>2</sup>Addiction Treatment Center, CH Ch. Perrens et CHU Bordeaux, Bordeaux, France
- 3:15 *Osmotic-release methylphenidate randomized controlled trial for adolescents with attention-deficit/hyperactivity disorders and substance use disorders: A missing data sensitivity analysis*  
S. McPherson, M. Mamey, C. Barbosa-Leiker, S. M. Murphy, J. Roll, Washington State University, Spokane, WA

## Oral Communications 21

**BALLROOM C**

**1:30 - 3:30 PM**

### **YOU'RE NOT THE BOSS OF ME: ADOLESCENT SUBSTANCE ABUSE**

Chairs: Carol J. Boyd and Lora M. Cope

- 1:30 *Disordered eating and substance use: Findings from a national sample of adolescents*  
K. Lange, S. Fields, Psychology, Texas A&M University, College Station, TX
- 1:45 *A prospective study of youth's nonmedical use of opioids, anxiolytics and sedatives*  
C. J. Boyd<sup>1,2</sup>, E. A. Meier<sup>2</sup>, P. T. Veliz<sup>2</sup>, Q. Epstein-Ngo<sup>2</sup>, S. E. McCabe<sup>2</sup>, <sup>1</sup>School of Nursing, University of Michigan, Ann Arbor, MI, <sup>2</sup>Institute for Research on Women & Gender, University of Michigan, Ann Arbor, MI
- 2:00 *Impulsivity and early onset of alcohol and cigarette use in adolescents*  
S. Fernández-Artamendi, V. Martínez-Loredo, R. Secades-Villa, O. Garcia-Rodriguez, J. R. Fernández-Hermida, Addictive Behaviors Research Group, University of Oviedo, Oviedo, Spain
- 2:15 *Greater exposure to stressors during preadolescence predicts early adolescent substance use*  
N. E. Charles, A. Acheson, C. W. Mathias, D. Dougherty, The University of Texas Health Science Center at San Antonio, San Antonio, TX

- 2:30 *Childhood maltreatment and adolescent binge drinking: New findings on a longitudinal relationship*  
S. Shin, School of Social Work, Virginia Commonwealth University, Richmond, VA
- 2:45 *Differential incentive processing in youth before and after substance use initiation*  
L. M. Cope, M. D. Tobias, J. E. Hardee, M. E. Soules, D. B. Steinberg, R. A. Zucker, M. M. Heitzeg, University of Michigan, Ann Arbor, MI
- 3:00 *Effects of environmental enrichment on amphetamine self-administration under a fixed-ratio and progressive-ratio schedule following nicotine exposure*  
D. J. Stairs, S. Ewin, M. Kangiser, C. Salvatore, M. Pfaff, PS, Creighton University, Omaha, NE
- 3:15 *Age effects in methylphenidate-induced taste avoidance and BDNF/TrkB activity in the insular cortex*  
B. B. Wetzell<sup>1</sup>, M. M. Muller<sup>1</sup>, J. L. Cobuzzi<sup>1</sup>, Z. E. Hurwitz<sup>1</sup>, K. DeCicco-Skinner<sup>2</sup>, A. L. Riley<sup>1</sup>, <sup>1</sup>Psychopharmacology Lab, American University, Washington, DC, <sup>2</sup>Department of Biology, American University, Washington, DC

### **SWEEPSTAKES DRAWING**

**BALLROOM B  
3:35 - 3:55 PM**

***YOU MUST BE SEATED IN ONE OF THE SESSIONS STARTING AT  
1:30 PM IN ORDER TO HAVE YOUR BADGE COLLECTED***

HAVE A SAFE TRIP HOME!

SEE YOU IN PHOENIX, ARIZONA, JUNE 13-18, 2015

## AUTHOR INDEX

- Aarde, S. M. 59, 107  
 Abagiu, A. O. 85  
 Aballea, S. 80  
 Abbott, T. B. 58  
 Accornero, V. H. 82  
 Acevedo, A. 86  
 Acheampong, A. 95, 102  
 Acheson, A. 15, 118  
 Acoose, S. 87  
 Acri, Jane B. 7  
 Adams, R. 77  
 Adelson, M. 20, 98  
 Adeniyi-Jones, S. 81  
 Ades, P. 104  
 Adimora, A. 100  
 Agrawal, Arpana 2, 64  
 Aguiar, B. 72  
 Aharonovich, E. 22, 23, 99, 109  
 Ahluwalia, J. 25  
 Ahmed, M. S. 82  
 Ahuama-Jonas, C. 88  
 Aiello, A. E. 99  
 Aikawa, D. 58  
 al'Absi, M. 102  
 Alanis-Hirsch, K. 64, 87  
 Alary, M. 64  
 Albizu-García, C. 80, 100, 113  
 Albizu, C. E. 24, 101, 113  
 Alcorn, J. L. 18  
 Alegria, Margarita 8  
 Aleixandre-Benavent, R. 105  
 Alexandercikova, Z. 85  
 Alexandre, J. 110  
 Alford, D. 6  
 Alharbi, F. 104  
 Ali, B. 66, 111  
 Alia-Klein, N. 97  
 Alicata, D. 25, 57  
 Alicea, A. 100  
 Alix, M. 109  
 Allen, A. M. 25, 102  
 Allen, S. 102  
 Allsop, D. J. 15, 95  
 Almli, L. 99  
 Alonso-Pérez, F. 14  
 Alonso, E. 86  
 Alshaarawy, O. 95  
 Altice, F. L. 87, 100  
 Altman, L. 85  
 Altomare, D. 116  
 Altschuler, J. 9  
 Altubi, M. 57  
 Alvanzo, A. 66  
 Alvarez Amador, A. 100  
 Amaro, H. 101  
 Amstadter, A. 111  
 Anastasio, N. C. 17, 28, 58  
 Andersen, R. 65, 85, 87  
 Anderson, A. 61  
 Anderson, K. G. 82  
 Anderson, S. 64  
 Andoh, E. 68  
 Andrade, A. 10  
 Andreoni, S. 56  
 Andrich, L. 79  
 Ang, A. 111  
 Angarita, G. A. 109  
 Angulo, E. 81  
 Anteneh, B. 67  
 Anthenelli, R. M. 27, 61  
 Anthony, James C. 1, 8, 11, 68, 78, 82, 91, 95, 102, 112, 113  
 Antonijoan, R. 117  
 Apawu, A. 16  
 Appel, L. 85, 103  
 Appel, Nathan 7  
 Arasteh, K. 4, 88  
 Arcuni, P. 62  
 Arfken, C. L. 73, 88, 110  
 Arheart, K. L. 95  
 Armstrong, A. 111  
 Arons, Cynthia 76, 77  
 Aronson, I. D. 22  
 Arora, R. 4  
 Arria, A. M. 16  
 Arroyo, M. 87  
 Ashrafioun, L. 15, 69  
 Aston, E. 15  
 Atkinson, D. 109  
 Atlan, H. 60  
 Augutis, M. 21  
 Aukrust, P. 115  
 Auriacombe, Marc 3, 5, 21, 109, 110, 118  
 Avilés, J. 80  
 Azbel, L. 100  
 Babalonis, S. 13, 17  
 Babuscio, T. 28, 110  
 Bachtell, R. K. 28  
 Back, Sudie E. 2, 67, 69, 102, 103  
 Badger, G. J. 72  
 Bagley, S. 20  
 Bai, Y. 118  
 Baik, G. 93  
 Bailey, G. 84  
 Baker, A. L. 67  
 Bakhshaie, J. 67  
 Balaji, D. 89  
 Balan, S. 69, 102, 112  
 Baliunas, D. 68  
 Ball, W. J. 106  
 Ballard, M. E. 10  
 Ballester, M. 117  
 Balster, Robert 26, 93  
 Balter, R. 95  
 Bandiera, F. 67  
 Bandstra, E. S. 82  
 Banducci, A. N. 62, 94  
 Bandyopadhyay, S. 23  
 Bania, T. 22  
 Banich, M. T. 11, 60, 110  
 Barber, J. 94  
 Barbosa-Leiker, C. 118  
 Bardo, M. T. 4, 59, 106  
 Bares, C. B. 83  
 Barger, J. 27  
 Baroni, R. 87  
 Barrett, Emma L. 94  
 Barrett, F. S. 16  
 Barry, C. 77  
 Barry, D. T. 6, 19, 70  
 Barry, L. 103  
 Bart, G. 66  
 Baskin, B. M. 117  
 Bass, A. 117  
 Bass, J. 84  
 Basseches, P. 89

## AUTHOR INDEX

- Bastle, R. M. 58  
 Bastos, F. I. 86  
 Batchelder, A. 56  
 Bates, S. 69  
 Bauer, M. E. 114  
 Baumann, Michael H. 16, 17, 73  
 Bearman, P. 78  
 Beatty, L. 68, 104  
 Bechara, A. 56  
 Becker, D. 83  
 Becker, J. 15  
 Becker, W. 22, 79, 89  
 Beckham, J. 13  
 Beckmann, J. S. 106  
 Bedi, G. 95  
 Behling, M. 68  
 Beitel, M. 19  
 Belendiuk, K. 97  
 Belgrave, F. Z. 68, 104  
 Beltran, V. 3, 21  
 Belur, V. 82  
 Benca, C. 93  
 Bennett, A. S. 94  
 Bennett, D. 27  
 Bennett, L. 13  
 Bennett, R. S. 4  
 Benz, M. 78  
 Berge, J. 24  
 Bergeria, C. L. 21, 72  
 Bergman, J. 17  
 Bernaga, C. 86  
 Berman, J. 65  
 Bernstein, J. A. 63  
 Bertelsen, S. 99  
 Bertholomey, M. L. 58  
 Bertoni, N. 86  
 Bertrand, S. J. 18, 115  
 Bertz, J. W. 57  
 Beveridge, T. J. 106  
 Bevins, R. 108  
 Beylotte, F. 102, 103  
 Bickel, W. K. 25, 65, 93, 97, 108, 109  
 Bickel, Warren K. 26  
 Bidlack, Jean M. 1  
 Bierut, L. 14, 99  
 Bisaga, A. 13, 79, 116  
 Bissoli Jr, F. 105  
 Biswal, B. 60  
 Bixel, K. D. 65  
 Black, A. C. 77  
 Black, R. 57  
 Black, T. 97  
 Blanchette, C. 64  
 Blanken, P. 19  
 Blevins, E. 102  
 Blitchtein, D. 112  
 Blokhina, E. 66, 79, 89, 98  
 Bloom, J. 99  
 Blough, B. E. 17, 106  
 Blouin, K. 64  
 Blow, F. C. 5, 12, 70  
 Blum, D. 105  
 Bluthenthal, R. 64, 92  
 Boardman, J. D. 56  
 Bobashev, G. 90  
 Bogdanova, V. 85  
 Bogenschutz, M. 85  
 Bohannon, R. 103  
 Bohn, Laura 24  
 Bohnert, A. S. 79  
 Bohnert, K. 12  
 Boileau, I. 73  
 Bojorquez, I. 87, 113  
 Bolaños-Pizarro, M. 105  
 Bold, K. 85  
 Bolin, B. L. 19  
 Bolman, C. 13  
 Bolton, P. 84  
 Bolyard, M. 88  
 Bonar, Erin E. 5, 12, 70  
 Bond, J. 107  
 Bonsu, J. A. 62  
 Booker, J. 65  
 Booth, B. M. 12  
 Booth, R. E. 108  
 Booth, R. G. 17  
 Booze, R. M. 18, 115  
 Borckardt, J. 61  
 Bossert, J. M. 58, 116  
 Bouju, G. 110  
 Boukli, N. 21  
 Bounoua, N. 11, 66, 111  
 Bouso, J. 117  
 Bowen, S. 16  
 Bowers, D. D. 84  
 Bowman, S. 68, 70  
 Boyd, Carol J. 70, 118  
 Boyd, D. 87  
 Boyd, J. W. 104  
 Boyle, R. S. 63  
 Bråbäck, M. 80  
 Bradford, J. 111  
 Bradley, B. 99  
 Bradshaw, C. 12  
 Bradstreet, M. P. 16  
 Brady, Kathleen T. 60, 61, 69, 86, 102, 103, 114  
 Braithwaite, S. 3  
 Bramness, J. G. 24, 115  
 Brand, M. 56  
 Brands, B. 24  
 Brandt, L. 72  
 Branstetter, S. A. 104  
 Brasfield, H. 91  
 Brason, F. W. 20  
 Brents, L. K. 18  
 Breslau, N. 112  
 Brewer, A. 28  
 Brewerton, Timothy 30  
 Bridden, C. 89  
 Brietzke, E. 114  
 Brook, J. 66  
 Brooks, A. C. 65, 87  
 Brooks, D. J. 116, 118  
 Brooner, R. K. 66, 111  
 Brophy, M. K. 17  
 Brown, A. 60  
 Brown, B. 97  
 Brown, G. 68  
 Brown, L. S. 80  
 Brown, Q. L. 91  
 Brown, R. 111  
 Brown, R. W. 12  
 Brown, S. 87, 100  
 Brown, Sandra A. 30  
 Brown, V. 11  
 Browning, E. L. 61

## AUTHOR INDEX

- Brownstein, A. 117  
 Bruce, R. 89  
 Bruchas, Michael 23  
 Bruno, R. 105  
 Brunzell, D. H. 62  
 Bryant-Genevier, M. 103  
 Bryant, K. 89  
 Bryon, D. 28  
 Bucher Bartelson, B. 90  
 Buckley, N. W. 107  
 Buckner-Petty, S. 14  
 Budde, J. 99  
 Budman, S. H. 68, 90  
 Budney, Alan J. 2, 12, 95  
 Budsock, T. D. 14  
 Bueno Cañigral, F. 105  
 Bugbee, B. A. 16  
 Buirkle, E. 80  
 Bukhari, O. 73  
 Bulin, S. E. 116  
 Buonora, M. 117  
 Burkhardt, J. 77  
 Burlew, K. 86, 88  
 Burnett, J. 65  
 Burns, L. 24, 25, 92, 94, 105, 111  
 Burns, R. M. 78  
 Burroughs, D. 116  
 Burton, M. 110  
 Busatto, G. 10  
 Busch, S. 77  
 Bushara, N. 79  
 Busse, A. 69  
 Butelman, E. 9, 19  
 Butler, S. F. 68, 90  
 Butler, T. 25  
 Butterfield, K. 89  
 Buttram, M. E. 80  
 Byrne, E. 65  
  
 Cacciola, J. 65, 69  
 Caetano, S. 10  
 Caldeira, K. M. 16  
 Calderon, S. N. 113  
 Calzada-Reyes, A. 100  
 Camenga, D. R. 20, 83  
 Cameron, D. 92  
  
 Campbell, A. 103  
 Campbell, C. 20  
 Campbell, G. 105  
 Campbell, K. 86  
 Campollo, O. 81  
 Canal, C. E. 17  
 Canham, S. L. 63  
 Canterbury, M. 25, 60, 61  
 Caprioli, D. 58  
 Caraballo-Correa, G. 101, 113  
 Caraballo, J. N. 113  
 Carbonaro, T. M. 16, 17  
 Carelli, R. M. 107  
 Carise, D. 87  
 Carlo, G. 11, 108  
 Carlson, Robert 6, 92  
 Carmody, T. 108  
 Carpenedo, C. M. 65, 87  
 Carpenter, K. 79  
 Carragher, N. 94  
 Carrico, Adam W. 27, 75  
 Carroll, Ivy 23, 24  
 Carroll, K. M. 28, 94, 98, 99, 108  
 Carroll, Marilyn E. 59, 74, 106,  
 114  
 Carter, P. 12  
 Casachahua, J. 115  
 Cashman, J. R. 17  
 Cassen, M. 66  
 Cassey, H. 81  
 Cassidy, J. 11  
 Cassidy, R. 12, 15  
 Cassidy, T. A. 90  
 Castellon, P. 23  
 Castro, F. 113  
 Cates, H. 58  
 Cathers, L. A. 111  
 Cavallet, M. 10  
 Cavallo, D. A. 83  
 Cavanaugh, C. 92  
 Cavazos-Rehg, P. 14  
 Cepeda, J. A. 24, 91, 100  
 Cercone, S. A. 66  
 Cerdá, M. 21  
 Cereser, K. M. 72  
 Cerulli, C. 23  
  
 Cerullo, K. J. 27  
 Cha, H. 15  
 Chain, T. 10  
 Chaisson, C. E. 3  
 Chakaraborty, B. 89, 105  
 Chakravarty, M. 73  
 Chalk, M. 64, 87  
 Chamberlain, P. 97  
 Chan, C. 21  
 Chandler, R. K. 68  
 Chang, L. 22, 25, 57, 72, 82  
 Chang, O. 89  
 Chaple, M. 111  
 Chaplin, T. M. 97  
 Chapman, C. 94  
 Charles, N. E. 118  
 Charnigo, R. J. 10, 11, 57, 62, 95  
 Chartier, K. G. 108  
 Chartoff, E. 25  
 Chawarski, M. C. 66, 69  
 Chen, C. 21  
 Chen, K. 3  
 Chen, L. 70, 113  
 Chen, S. Z. 63  
 Chen, W. 56  
 Cheng, D. M. 6, 20, 63, 89  
 Cheng, H. 105  
 Cheong, J. 96  
 Chereau-Boudet, I. 110  
 Chermack, S. T. 5  
 Cheverie, M. 24  
 Chhatre, S. 92  
 Chi, T. 3  
 Chiang, Y. 3  
 Chilcoat, Howard 7, 20, 90  
 Childress, Anna Rose 1, 25, 60,  
 61, 72, 74, 93, 94, 97  
 Chisin, R. 60  
 Chisolm, M. S. 103  
 Choo, E. 78, 103  
 Chow, J. J. 106  
 Christmann, A. 87  
 Chu, D. 64, 92  
 Chudzynski, J. 60  
 Chundamala, J. 78  
 Chung, L. 58

## AUTHOR INDEX

- Chung, T. 96  
 Cicero, T. 70, 90  
 Claramunt, J. 117  
 Clark, A. K. 20, 104  
 Clark, T. 66  
 Clark, Westley 30  
 Clatts, M. 88  
 Clavier, O. 81, 109  
 Clay, E. 80  
 Cleland, C. 77  
 Clements, N. 101  
 Cloak, C. 72, 82  
 Coatsworth, A. 91, 100  
 Cobuzzi, J. L. 119  
 Cochran, G. 80  
 Cochran, S. 14  
 Coffey, S. F. 62  
 Coffin, P. O. 22, 89  
 Cohen, A. E. 13  
 Cohen, M. 105  
 Coimbra, J. 117  
 Colangelo, C. M. 58  
 Colby, S. M. 12  
 Coleman-Cowger, V. H. 82  
 Coleman, S. 89  
 Collado-Rodriguez, A. 84  
 Collado, A. 11  
 Coller, J. K. 81  
 Coller, M. 107  
 Colley, G. 22  
 Collins, D. T. 18  
 Collot D'Escury-Koenigs, A. 83  
 Colpo, G. 72  
 Colucci, S. 17  
 Coman, E. 90  
 Comer, Sandra D. 2, 21, 29, 30, 89  
 Comfort, M. L. 101  
 Comiskey, Catherine 71  
 Compton, Wilson 5  
 Connell, C. 83  
 Connery, H. 79, 84  
 Connor, J. P. 63  
 Cook, J. M. 105  
 Cook, S. 85  
 Cooke, C. G. 66  
 Coop, Andrew 2, 96, 114  
 Cooper, C. 60  
 Cooper, H. L. 4, 88  
 Cooper, K. 108  
 Cooper, L. 11  
 Cooper, Z. D. 73  
 Cope, Lora M. 118, 119  
 Copeland, Jan 8, 15, 95  
 Copenhaver, M. 69, 89  
 Coplan, P. 20, 90  
 Corazza, O. 73  
 Cornelius, M. 72, 82  
 Cornett, E. M. 58  
 Cornwell, W. 58  
 Corsi, K. F. 108  
 Coryn, C. 77  
 Cottler, Linda 9, 71, 90, 91, 102, 118  
 Cottor, E. J. 106  
 Cousijn, J. 83  
 Cousins, S. J. 27  
 Covault, J. 103  
 Covey, L. S. 13  
 Craft, R. 57  
 Cranston, M. N. 18  
 Crawford, N. D. 92  
 Creehan, K. 59, 107  
 Creek, K. E. 116  
 Creemers, H. 14  
 Crevecoeur-MacPhail, D. A. 27  
 Croff, R. 64, 87  
 Crofton, E. 59  
 Crooks, P. A. 4  
 Cross, N. 15, 78, 104  
 Crowley, M. J. 97  
 Crowley, T. J. 11  
 Crum, R. 70  
 Cruz, H. 105  
 Cruz, J. I. 84  
 Crystal, S. 89  
 Csorba, J. K. 85  
 Culver, J. P. 4  
 Cummins, C. 22  
 Cunha, G. 72  
 Cunha, P. J. 10  
 Cuning, S. 56  
 Cunningham, Christopher W. 114  
 Cunningham, J. K. 81  
 Cunningham, K.  
 Cunningham, Kathryn A. 5, 17, 28, 58  
 Cunningham, R. M. 5, 12, 70  
 Curley, L. E.  
 Curtin, K. 10  
 Curtis, B. L. 69  
 Cutter, C. J. 6, 19, 70, 81  
 Czoty, P. W. 5, 57, 107  
 D'Aunno, T. 3, 21  
 D'Lima, G. M. 66  
 D'Onofrio, Gail 7  
 Dacome, L. 105  
 Dahlgren, M. 95  
 Dahne, J. R. 111  
 Dakwar, E. 79  
 Dalwani, M. S. 11  
 Daly, C. 57  
 Daniulaityte, R. 92  
 Darke, S. 94, 111  
 Dart, R. C. 70, 80, 90  
 Dasgupta, N. 90  
 Dash, G. 82  
 Daubert, A. 81  
 Daughters, S. B. 102  
 Daulouède, J. 3, 21  
 Davenport, P. W. 93  
 Davies, F. 93  
 Davis, A. K. 15, 78  
 Davis, A. N. 11  
 Davis, J. 109  
 De Genna, N. 72  
 de Graaff, B. 105  
 De la Fuente-Martin, A. 86  
 De La Garza, II, R. 15, 19, 28, 93, 108  
 De La Rosa, M. 83  
 De La Torre, R. 73  
 de Medeiros, P. F. 84  
 De Vries, H. 13  
 Dean, A. C. 10, 60  
 DeAndrea, D. 91  
 Deaver, D. 18  
 Debinski, B. 16

## AUTHOR INDEX

- Debnam, K. 12  
 Debrabant, R. 109, 118  
 DeCicco-Skinner, K. 119  
 Decker, A. M. 16, 17  
 DeCuir, J. 92  
 DeFulio, A. 86  
 Degenhardt, L. 24, 25, 92, 105  
 DeGeorge, D. 102  
 dela Cruz, A. M. 108  
 Delcher, C. 71  
 Delforterie, M. 14  
 Delile, J. 66  
 Dell, C. A. 87  
 Dellamorte, A. 117  
 Denehy, E. D. 4  
 Denis, C. M. 3, 21  
 Dennis, Michael L. 30, 65, 92  
 Dennis, P. 13  
 Derefinko, K. J. 11, 62  
 Deren, S. 113  
 Dermody, Sarah S. 96  
 Deruvo, G. 70  
 Des Jarlais, Don C. 3, 4, 88, 113  
 Desel, H. 70  
 Desrosiers, A. 66  
 Deutsch-Feldman, M. 117  
 Deutsch, A. 11  
 DeVeagh-Geiss, A. 20, 90  
 DeVito, E. E. 94, 98, 99  
 Dewey, William L. 26  
 DeYoung, D. 10  
 Dias, N. 15, 18  
 Dick, A. W. 78  
 Dick, D. 9  
 Dickerson, D. 4  
 Diedrich, K. 73  
 Dietze, P. 105  
 Diggins, A. 88  
 DiGirolamo, G. J. 10, 80  
 DiGuisseppi, G. 65  
 Dillon, P. 9, 64, 66, 70  
 Ding, C. 17, 28  
 Dingemanse, J. 105  
 DiSandro, P. 68  
 Disney, E. 16  
 Ditre, J. W. 63  
 Diwadkar, V. 19  
 Dobbins, T. 24, 25  
 Dockery, G. 100  
 Dolezalova, P. 69, 85  
 Domany, Y. 20  
 Dombrowski, K. 3  
 Donohue, J. M. 80  
 Dore, G. 3  
 dos Santos, A. M. 91  
 Douet, V. 22  
 Dougherty, D. M. 15, 118  
 Doura, M. 58  
 Dow-Edwards, Diana 57, 115  
 Dowd, E. 94  
 Dreifuss, J. A. 85  
 Dreman, M. 95  
 Du, H. 58  
 Du, J. 81  
 Duan, L. 101  
 Duan, Y. 56, 103  
 Dubeau, C. 73  
 Ducat, E. A. 9  
 DuCette, J. P. 110  
 Dugosh, K. L. 19, 101, 102  
 Duke, A. N. 57  
 Duncan, A. 14  
 Duncan, L. R. 97  
 Dunlop, A. 95  
 Dunn, Kelly E. 8, 27  
 Dunn, T. J. 62  
 Dunne, E. M. 88, 118  
 Duque, L. 62  
 Dusek, K. 97  
 Dwoskin, Linda P. 1, 4, 117  
 Dyer, C. B. 65  
 Dyer, T. P. 88  
 Dykstra, L. 107  
 Eberly, L. 118  
 Ebrahimpoor, M. 10  
 Edelman, E. J. 22, 89  
 Edwards, A. 115  
 Edwards, M. S. 64  
 Edwards, R. R. 6  
 Egan, K. L. 16  
 Ehrich, Elliot 4  
 Ehrlich, M. 81  
 Ehrlich, P. 70  
 Ehrman, R. 60, 93, 97  
 Eiden, R. D. 82  
 Eisch, A. J. 116  
 Eisenstein, Toby K. 71, 74  
 Eissenberg, Thomas 26  
 Ekhtiari, H. 10  
 El-guebaly, N. 104  
 Elfeddali, I. 13  
 Eliosa-Hernandez, A. 86  
 Elliassen, J. C. 61  
 Elliott, J. C. 23  
 Elman, I. 60  
 Elmquist, J. 91  
 Encarnacion, J. 57  
 Enman, N. 27  
 Epstein-Ngo, Q. 12, 118  
 Epstein, A. 77  
 Epstein, David H. 19, 64, 65, 75, 81  
 Epstein, E. E. 14, 85  
 Erensen, J. G. 20  
 Erlyana, E. 22  
 Ernst, T. 25, 57, 82  
 Espada, J. P. 11, 84, 112  
 Evans, E. 20, 83, 85  
 Evatt, D. 5  
 Ewin, S. 119  
 Fairman, B. J. 68  
 Fakhouri, T. 97  
 Fakunle, D. O. 112  
 Faller, S. 109  
 Fan, X. 59  
 Farabee, D. 68  
 Farley, S. B. 113  
 Farmer, C. 78  
 Farmer, S. L. 61  
 Farre, M. 73, 94, 111  
 Farrell, M. 24, 25, 105  
 Fatseas, M. 3, 21, 109, 110, 118  
 Faulkner, J. 105  
 Fausett, J. 62  
 Favor, K. 65  
 Feaster, D. 23, 86

## AUTHOR INDEX

- Febres, J. 91  
 Feelemyer, J. P. 4, 88  
 Feeney, G. 63  
 Feeney, K. 6  
 Felton, J. 11  
 Felton, J. W. 11, 62, 111  
 Feng, X. 86  
 Fenn, J. 21  
 Ferguson, D. 58  
 Fernandez Mondragon, J. C. 86  
 Fernández-Artamendi, S. 118  
 Fernández-Hermida, J. R. 68, 118  
 Fernández, Y. 23  
 Festinger, D. S. 19, 101, 102  
 Festinger, David S. 24  
 Few, L. R. 64  
 Fielder, A. L. 81  
 Fields, S. 12, 15, 56, 118  
 Fiellin, D. 6, 22, 70, 77, 79, 89, 97  
 Fiellin, L. E. 6, 97  
 Fillmore, M. T. 97  
 Finger, B. 82  
 Finnegan, Loretta P. 72  
 Fischberger, S. 72  
 Fischer, B. D. 105  
 Fischer, G. 21, 72  
 Fisher, D. G. 22, 108, 109  
 Fisher, P. 72  
 Fisher, W. 68, 101  
 Fitzmaurice, G. 84  
 Flax, S. M. 107  
 Fleckenstein, A. E. 10  
 Fleming, A. B. 17  
 Flores, D. V. 65  
 Fogel, J. 57, 95  
 Fogel, J. S. 10, 61  
 Fokina, V. M. 82  
 Fonseca, F. 73, 94, 111  
 Forcehimes, A. A. 85  
 Ford, J. 64, 87  
 Forray, A. 72  
 Forster, M. J. 59, 73, 107  
 Foster, D. W. 63  
 Foulds, Jonathan 26  
 Fox, R. G. 17, 28, 58  
 France, C. P. 18  
 Franck, C. 25, 65, 97  
 Franke, A. 22  
 Frankforter, T. 99  
 Franklin, Teresa R. 25, 60, 61, 93, 97  
 Freedman, N. 60  
 Freeman, Kevin B. 93, 106, 116, 117  
 Friedman, E. 107  
 Friedman, S. R. 21, 22, 23, 88, 100  
 Friedmann, P. D. 70, 79  
 Frimpong, J. A. 3, 21  
 Froeliger, B. 61, 116  
 Fuchs, R. 115  
 Fukaya, Erin 57, 72  
 Fuller, C. 92  
 Fulwiler, C. 68, 101  
 Funk, R. R. 65, 92  
 Furnari, M. A. 19  
 Furr-Holden, C. Debra M. 12, 14, 63, 65, 75, 91, 112  
 Furst, B. 10  
 Gaalema, D. E. 72, 104  
 Gaba, A. 85  
 Gabrielian, S. 85  
 Gaiser, E. C. 109  
 Gaither, J. R. 20, 22, 89  
 Galanter, M. 110  
 Galea, S. 67, 99  
 Gallagher, S. M. 67  
 Galloway, G. 81, 109  
 Ganesan, D. 109  
 Ganoczy, D. 79  
 Gao, J. 62  
 Garbett, N. 106  
 Garcia-Rodriguez, O. 14, 68, 118  
 Garcia-Romeu, A. P. 13  
 García, M. 65, 81, 87  
 García, S. 108  
 Gardiner, A. S. 58  
 Gardiner, J. C. 112  
 Garey, L. 63  
 Garland, E. 61  
 Garner, B. 110  
 Garnick, D. W. 86  
 Garrido, M. 117  
 Garrison, K. 109  
 Garro, A. 103  
 Garton, D. 59  
 Garver-Apgar, C. 108  
 Garvey, K. T. 79  
 Gatch, Michael B. 59, 73, 74, 107  
 Gatchalian, K. 108  
 Gatny, H. 94  
 Gauthier, J. M. 59  
 Gauthier, P. 85  
 Gawrysiak, M. J. 93  
 Gelberg, L. 65, 85, 87  
 Gellad, W. F. 80  
 Gelpi-Acosta, C. 19, 21, 113  
 Gentry, T. 64  
 Geoffroy, P. 89  
 George, M. S. 60, 61  
 Gerak, L. R. 18  
 German, N. A. 16  
 Gerra, G. 69  
 Gershon, M. 59  
 Gess, J. 62  
 Ghahremani, D. 19  
 Ghani, M. 87  
 Ghee, S. M. 98  
 Giarola, A. 105  
 Gibson, A. 24, 25  
 Gibson, K. D. 13  
 Gilbertson, S. 58  
 Gilmour, B. P. 16  
 Ginsberg, Y. 100  
 Gintzler, Alan 74  
 Giovino, G. A. 91  
 Gipson, C. D. 116  
 Girma, S. 9  
 Gisev, N. 24, 25, 92  
 Glaser, P. E. 4, 19  
 Glass, A. 16, 28, 63, 83, 116  
 Glucicek, E. E. 58  
 Goate, A. 99  
 Godley, M. 110  
 Goeders, N. E. 58, 105, 106  
 Goldbach, J. 101  
 Goldberger, B. 71  
 Goldman, M. 97



## AUTHOR INDEX

- Goldsamt, L. 88  
 Goldschmidt, L. 72  
 Goldstein, R. Z. 97  
 Goldstick, J. E. 12  
 Golesorkhi, M. 10  
 Golin, C. 100  
 Golub, A. 94  
 Gomez, A. M. 116  
 Goncalves, P. D. 10  
 Gonçalves, V. M. 83, 91  
 Gonenc, A. 95  
 Gonzales, A. 65  
 Gonzalez-Zuñiga, P. E. 88  
 Gonzalez, A. 113  
 Gonzalez, G. 6, 10, 68, 80, 101, 111  
 González, M. 87, 117  
 González, R. 100  
 Gonzalez, R. 56  
 González, M. T. 11, 84, 112  
 Goodwin, R. 14, 67  
 Gordon, A. J. 22, 78, 80  
 Gordon, K. S. 22, 89  
 Gorelick, David A. 17, 76  
 Gorsane, M. 110  
 Gosden, J. 107  
 Goulet, J. 89  
 Gourevitch, M. N. 77  
 Grabowski, J. 118  
 Grady, J. 56, 90, 103  
 Graf, E. N. 106  
 Grall-Bronnec, M. 110  
 Grana Morales, C. G. 80  
 Grandpre, N. 81  
 Grant, K. 108  
 Grant, Steven 5  
 Grasing, K. 107  
 Grassi-Oliveira, R. 114  
 Graves, H. 83  
 Gray, K. M. 63, 116  
 Grebenstein, P. 116  
 Green, A. I. 27  
 Green, C. 18, 20, 99, 103, 109, 113  
 Green, J. 107  
 Green, J. L. 70, 80, 90  
 Green, K. M. 83  
 Green, L. 106  
 Green, T. 59, 70  
 Greenfield, S. F. 84, 103  
 Greenwald, M. K. 19, 21, 25, 78, 88, 110  
 Greer, T. L. 108  
 Gregg, R. A. 16  
 Grella, Christine E. 14, 71, 75  
 Griffin, B. 84  
 Griffin, K. W. 84  
 Griffin, M. L. 79, 110  
 Griffiths, R. R. 5, 13, 16  
 Grigolo, T. M. 84  
 Grinberg, A. 14  
 Grivel, M. 62  
 Gros, D. F. 103  
 Grossman, E. 80  
 Gruber, S. A. 95  
 Grucza, R. 14  
 Gryczynski, J. 65, 84, 97  
 Guareschi, M. 70  
 Guarino, H. 11  
 Gudjonsson, G. 100  
 Gueorguieva, R. 109  
 Guerin, G. F. 105, 106  
 Guevremont, N. 10  
 Guidera, K. 102  
 Guido, J. J. 23  
 Guillen, A. 11  
 Guimarães, L. P. 109  
 Guimarães, L. S. 83  
 Guise, J. B. 11  
 Gunn, A. 21  
 Guo, X. 84, 86  
 Guydish, Joseph 67, 75, 112  
 Guzman, A. 81  
 Guzman, D. 110  
 Haase, K. S. 79  
 Haddox, J. D. 20  
 Hagan, H. 3, 4, 21, 88  
 Hager, N. 25  
 Haile, C. N. 108  
 Håkansson, A. C. 24, 80  
 Halkitis, P. N. 77  
 Hall, A. 90  
 Hall, W. 105  
 Hamilton, E. 62  
 Hamilton, K. R. 66  
 Hamon, S. C. 98  
 Hampson, A. 17, 95  
 Hampton, J. 90  
 Hand, D. J. 21, 72, 81  
 Haney, Margaret 2, 60, 73, 95  
 Hankins, G. 82  
 Hanlon, Colleen A. 25, 60, 61, 96  
 Hansen, A. 97  
 Hansen, H. 78  
 Hanson, C. 60  
 Hanson, G. R. 10  
 Hanson, S. J. 60  
 Hardee, J. E. 61, 119  
 Harder, V. 67  
 Harding, M. H. 98  
 Hardouin, J. 110  
 Harp, J. P. 92  
 Harp, K. 65, 100, 101  
 Harrington, A. 111  
 Harris, D. L. 16  
 Harris, K. 83  
 Harris, L. S. 18  
 Harris, S. 17  
 Harrison, J. A. 63  
 Harrison, K. 102  
 Harrod, Steven B. 12, 18, 114, 115, 116  
 Hart, C. L. 14  
 Hartley, R. 17, 28, 58  
 Hartwell, K. 61  
 Hartwell, S. 68, 101  
 Hartzler, B. 109, 110  
 Harvanko, A. M. 10, 57, 61, 95  
 Harvey, R. C. 117  
 Hasin, Deborah S. 5, 22, 23, 65, 67, 88, 99, 109  
 Haslam, R. R. 81  
 Hatsukami, D. 25  
 Hatz, L. 97  
 Hauben, M. 77  
 Havens, Jennifer R. 6, 90, 92, 100, 101  
 Hawley, C. 111

## AUTHOR INDEX

- Hays, L. R. 4, 95  
 He, S. 107  
 Heads, A. M. 103  
 Heal, D. J. 107  
 Hearn, L. 3, 118  
 Heil, S. H. 21, 72, 81, 102  
 Heilig, Markus 2  
 Heimer, R. 24  
 Heinzerling, K. G. 6, 10  
 Heitzeg, M. M. 61, 119  
 Hellem, T. 111  
 Hellemann, G. 60  
 Heller, E. 58  
 Hellmuth, J. C. 69, 103  
 Helzer, J. 90  
 Hendrickson, H. 28  
 Henry, S. A. 111  
 Hepner, Kimberly 7  
 Hequembourg, A. 69  
 Herman, A. 99  
 Herman, I. 60  
 Hernandez, A. 57, 82  
 Hernandez, C. 116  
 Hernández, D. 23  
 Hernandez, F. 81  
 Hernandez, J. 4  
 Hernandez, L. 83  
 Herrick, A. 12  
 Herrmann, Evan S. 27, 95  
 Hess, K. 27  
 Hesselbrock, V. 99  
 Hestad, K. 115  
 Hester, R. 61  
 Hesterberg, K. 27  
 Hewitt, D. 89  
 Hieftje, K. D. 97  
 Hien, D. A. 66, 94, 103  
 Higgins, Stephen T. 8, 10, 13, 21, 67, 81, 94, 102, 104  
 Hilario, E. 79, 110  
 Hillard, C. J. 106  
 Hillborg, H. 21  
 Hillhouse, M. P. 4, 111  
 Hinton, R. 64  
 Hipwell, A. 96  
 Hiranita, T. 107  
 Hlaing, W. M. 95  
 Ho, A. 117  
 Ho, I. 3, 21  
 Hoban, B. 105  
 Hobart, M. 111  
 Hobbs, M. 100  
 Hobkirk, A. L. 102  
 Hodgkin, D. 86  
 Hoffer, L. 90  
 Hoffman, E. 64  
 Hoffman, L. 102  
 Hofford, R. S. 59, 106  
 Hohmann, Andrea G. 71  
 Hollis, B. 66  
 Holmes, N. 22  
 Holtyn, A. 86  
 Holtz, N. A. 18  
 Homish, G. G. 66, 82  
 Hommer, R. E. 97  
 Hopyan, T. 105  
 Horgan, C. M. 77, 86  
 Horigian, V. E. 86  
 Horner, M. 82  
 Horr, J. F. 84  
 Horton, D. B. 105  
 Horton, T. 87  
 Hosler, C. 97  
 Houston-Ludlam, A. 13  
 Howard, G. 71  
 Howell, L. 57  
 Howell, M. L. 85  
 Hser, Y. 3, 20, 56, 81, 85  
 Hser, Yih-Ing 71  
 Hu, H. 91  
 Hu, M. 13, 66, 85, 103  
 Huang, C. 3, 21  
 Huang, D. Y. 20  
 Huang, K. 16  
 Huang, X. 16  
 Huber, A. 86  
 Huber, J. 115  
 Hughes, J. 27  
 Huizink, A. 14  
 Hung, C. 69  
 Hung, E. 77  
 Hunt, S. A. 67  
 Hunter, B. 110  
 Hurd, Y. L. 15  
 Huriaux, E. 22  
 Hurmic, H. 109, 118  
 Hursh, S. R. 64  
 Hurwitz, Z. E. 119  
 Huskinson, Sally L. 93, 106  
 Hutchinson, M. R. 81  
 Hutchison, K. E. 27  
 Hutson, L. 115  
 Hutz, E. 87  
 Ialongo, N. S. 14, 63, 83  
 Iguchi, Martin Y. 26, 68  
 Iniguez, S. D. 59  
 Iqbal, T. 15, 19  
 Isendahl, P. 80  
 Ishibashi, K. 60  
 Ishii, K. 106  
 Islam, L. 108  
 Itzhak, Y. 98  
 Ivanov, Iliyan 23  
 Iverson, E. 14  
 Iverson, M. 90  
 Iwamoto, D. 62  
 Izenwasser, Sari 96  
 Jackson, J. 9  
 Jagannathan, K. 25, 60, 61, 93, 94  
 Jagsch, R. 72  
 James, G. 18, 62  
 Janoff, S. 20  
 Janulis, P. 78  
 Jasinski, Donald R.  
 Jayadevappa, R. 92  
 Jemal, A. 87  
 Jenab, S. 57  
 Jenkins, J. 4, 90, 111  
 Jenkins, S. 61  
 Jensen, N. 85  
 Jesse, R. 16  
 Jiang, C. 25, 57, 72, 82  
 Jin, H. 22  
 Jing, L. 28  
 Jobes, M. L. 19, 64, 65, 81  
 Johansen, H. 82

## AUTHOR INDEX

- John, W. S. 57, 107  
 Johnson, B. 25, 61  
 Johnson, E. 107  
 Johnson, Matthew W. 13, 16, 26, 109  
 Johnson, R. M. 14, 104  
 Johnston, A. M. 72  
 Jones, B. E. 110  
 Jones, D. 104  
 Jones, H. 85, 113  
 Jones, J. 62, 68  
 Jones, J. D. 11, 89  
 Jones, M. 18  
 Jones, Y. 22  
 Jordan, A. E. 3, 21  
 Jordan, C. J. 117  
 Jose, C. 20  
 Joseph, J. 61, 93  
 Justice, A. 22, 89  
  
 Kaczmarsky, C. 104  
 Kadakia, A. 20  
 Kadooka, A. 56  
 Kahler, C. W. 12, 83  
 Kale, H. 90  
 Kalechstein, A. 19  
 Kalivas, P. W. 116  
 Kallman, Mary Jeanne 18,  
 Kamarulzaman, A. 87  
 Kaminski, B. J. 27  
 Kampman, K. M. 6, 93, 94  
 Kane, J. C. 84  
 Kang, H. 15  
 Kangiser, M. 119  
 Kantak, Kathleen M. 59, 96, 117  
 Kapczinski, F. 9, 72  
 Kastelici, A. 85  
 Kato Price, R. 69  
 Katz, E. 64  
 Katz, J. 107  
 Kauer-Sant'anna, M. 72  
 Kaufman, Marc J. 29  
 Kaufmann, C. N. 63, 70  
 Kaushal, N. 115  
 Kay-Lambkin, Frances 2, 3  
 Kearney-Ramos, T. 62  
  
 Kecojevic, A. 70  
 Keen, L. 100, 115  
 Keita, G. 68  
 Keith, D. 14  
 Keller, C. 106  
 Keller, L. M. 106  
 Kelley-Baker, T. 70, 102  
 Kelley, M. L. 62, 66  
 Kelly, B. C. 70  
 Kelly, John F. 30  
 Kelly, M. A. 16  
 Kelly, S. M. 84  
 Kelly, T. H. 10, 57, 61, 93, 95  
 Kandler, K. S. 9, 83  
 Kenny, A. 103  
 Kerns, R. 89  
 Kerr, T. M. 106  
 Kerridge, B. 88  
 Kertesz, S. 71  
 Kervran, C. 109  
 Keshvari, F. 10  
 Kessler, Andrew 26  
 Kessler, F. H. 9, 83, 109  
 Kessler, J. 3  
 Key, M. D. 67  
 Keyes, K. 67, 99  
 Keyser-Marcus, L. A. 10, 93, 111  
 Khan, B. 3  
 Khan, F. 87  
 Khan, M. R. 88, 91, 100  
 Khan, S. R. 9  
 Kharitonova, E. 80  
 Khodneva, Y. 71  
 Khokhar, J. Y. 27  
 Kibitov, A. 98  
 Kidorf, M. S. 111  
 Kiguchi, N. 13  
 Killeen, Therese 30, 103  
 Killoren, S. E. 11  
 Kilts, C. D. 18, 62  
 Kim, H. 15  
 Kim, J. K. 106  
 Kim, K. 82  
 Kim, M. S. 17  
 Kim, Y. 15  
 Kimani, S. 91, 102  
  
 Kimball, T. 83  
 Kimber, J. 24, 25  
 King, H. E. 107  
 King, J. B. 118  
 King, L. J. 22, 67  
 King, V. L. 66, 111  
 Kinlock, T. W. 79  
 Kinsey, B. M. 4  
 Kirby, K. C. 65, 69, 81, 87  
 Kiriazova, T. 89  
 Kirk, A. 84, 97  
 Kirk, I. J. 61  
 Kirtadze, I. 85, 113  
 Kish, S. 73  
 Kishioka, S. 13  
 Kitchens, M. B. 63  
 Kizina, K. 65  
 Klambatsen, A. 57  
 Kleber, H. D. 28, 79  
 Klein, Michael 76, 113  
 Klemperer, E. M. 27, 79  
 Knight, S. 58  
 Knoblach, D. J. 87  
 Knopik, V. 72  
 Knudsen, Helen K. 75, 77  
 Kobayashi, Y. 13  
 Kober, H. 94  
 Koch, R. 9  
 Koenen, K. C. 99  
 Koffarnus, M. N. 25, 65, 86, 93, 108, 109  
 Kogachi, S. 25, 57  
 Kohno, M. 60  
 Koken, J. 22  
 Kollins, Scott H. 13, 23  
 Kolodziej, M. E. 80, 111  
 Kong, G. 83  
 Konova, A. B. 97  
 Konstenius, M. 100  
 Konz, N. 115  
 Koob, George F. 1  
 Kopecky, E. A. 17  
 Kopetz, C. 13  
 Korcha, R. A. 107  
 Kornør, H. 104  
 Kornstein, S. 9

## AUTHOR INDEX

- Korte, J. E. 86  
 Korthuis, Todd 76  
 Kosten, T. 98  
 Kosten, T. A. 4  
 Kosten, T. R. 4, 11, 15, 98, 99  
 Koszowski, B. 112  
 Koustova, Elena 74  
 Kraft, W. K. 81  
 Kral, A. 64, 92, 101, 117  
 Kramer, J. 99  
 Kranzler, H. R. 60  
 Krauss, M. 14  
 Krebs, C. 101  
 Kreek, M. 9, 18, 19, 27, 58, 98, 117  
 Kreutzer, J. S. 10  
 Krishnan-Sarin, Suchitra 26, 83  
 Krishnan, A. 87, 100  
 Kritz, S. 80  
 Krmpotich, T. 60, 110  
 Kroll, C. 105  
 Kromrey, S. A. 57  
 Krupitsky, Eugeny 3, 66, 79, 85, 89, 98, 113  
 Kunoe, N. 79  
 Kupchik, Y. 116  
 Kurokawa, K. 62  
 Kurtz, S. P. 80, 90  
 Kurtz, S. S. 73  
 Kusunoki, J. 94  
 Kydd, R. R. 61  
 Kynor, D. 81
- Lachewitz, J. 6  
 Lacy, R. T. 12, 17, 59  
 Lalonde, T. L. 15  
 Lamb, K. 63  
 Lambdin, B. 89  
 Lan, Y. 3, 81  
 Landavazo, A. 17  
 Landheim, A. S. 63  
 Lane, S. D. 10, 15, 18, 99, 103, 113  
 Lang, B. A. 78  
 Lange, K. 118  
 Langleben, Daniel 60, 72, 93, 94  
 Lanier, R. K. 13  
 Lankenau, S. 14, 70
- Lanza, H. 56  
 Larance, B. 105  
 Larney, Sarah 24, 25, 92  
 LaRowe, S. 63  
 Larsen, H. 13, 83  
 Larson, E. 86  
 Larson, M. 77  
 Larson, P. 89  
 Laruitsen, K. 15  
 Lasopa, Sonam O. 9, 117, 118  
 Lasser, K. E. 117  
 Latif, H. Z. 79  
 Latimer, W. W. 3, 88, 92, 115, 118  
 Lauby, J. 65  
 Laudet, A. B. 83, 87  
 Laurenceau, J. 108  
 Lauritsen, K. J. 78  
 Lavalley, M. 14  
 Lavonas, E. J. 80, 90  
 Lawrence, H. R. 66  
 Laxamana, J. 62  
 Layne, W. K. 67  
 Lazar, C. M. 77  
 Le Lait, M. C. 90  
 Le, G. M. 88  
 Le, T. 112  
 Le, V. D. 82  
 Leaf, P. J. 14, 63  
 Lebonville, C. 18, 115  
 Lechner, W. 111  
 Leclerc, P. 64  
 Ledgerwood, D. M. 21, 67, 82, 88, 110  
 Lee, Dustin C. 2, 95  
 Lee, J. D. 68, 79, 80  
 Lee, K. 15, 57  
 Lee, M. 86  
 Lee, M. H. 14  
 Lee, S. 12  
 Lee, Steve 23  
 Lee, T. 69  
 Lefever, T. 57  
 Legauffre, C. 110  
 Lehner, K. R. 73  
 Lejuez, C. 100  
 Lejuez, C. 11, 62, 63, 66, 84, 86, 94, 102, 111
- LeMatty, T. 60, 61  
 Len-Rios, M. E. 11  
 Lenoir, H. 66  
 Lenz, S. 66  
 Leon, J. 111  
 Leoutsakos, J. S. 16  
 Lerch, J. 66, 73  
 Leri, F. 18  
 Leri, Francesco 74  
 LeSage, M. G. 77, 116  
 Leslie, D. 78  
 Leslie, D. L. 78  
 Letourneau, E. 84  
 Letourneau, E. J. 97  
 Leukefeld, C. 20, 90, 100, 101  
 Levandowski, M. L. 114  
 Leve, L. D. 72  
 Leventhal, J. 20  
 Levi Minzi, M. A. 22, 89  
 Levin, F. 103  
 Levin, F. R. 13, 16, 63, 83, 94, 100, 116, 118  
 Levin, Frances R. 117  
 Levina, O. 24  
 Levine, A. R. 21  
 Levis, S. C. 28  
 Levonyan-Radloff, K. 69  
 Levrán, O. 19, 98  
 Levy-Cooperman, N. 17, 89, 105  
 Levy-Cooperman, Naama 30  
 Levy, A. 18  
 Lewis, B. 102  
 Lewis, D. 28  
 Lewis, D. E. 68  
 Li, D. 59  
 Li, Jun-Xu 28  
 Li, L. 20, 56, 85  
 Li, M. 56, 112  
 Li, X. 16, 22, 61  
 Li, Y. 58, 98  
 Liao, D. 90  
 Liccardo Pacula, R. 78  
 Lichtman, Aron 71  
 Liddie, S. 98  
 Liddie, Shervin 97

## AUTHOR INDEX

- Liebschutz, J. M. 117  
 Liebschutz, Jane M. 7  
 Lien, L. 115  
 Lightfoot, M. 83  
 Lile, J. 57, 95  
 Lile, J. A. 10, 61  
 Lile, Joshua 95  
 Lim, A. 111  
 Lima-Rodriguez, C. 86  
 Lima, V. 22  
 Lin, A. 59  
 Lin, J. 65  
 Lin, L. A. 70  
 Lin, M. 80  
 Lin, V. 85  
 Lindsey, A. 18  
 Ling, W. 4, 6, 98, 111  
 Ling, Walter 4  
 Linklater, R. 56  
 Lintzeris, N. 105  
 Liong, C. 19  
 Lipton, R. 12  
 Lira, M. C. 6, 89  
 Lisdahl, K. M. 15, 27, 61  
 Lister, J. J. 110  
 Liu, K. 78  
 Liu, L. 20  
 Liu, S. 15, 56, 99  
 Liu, W. 72  
 Liu, X. 98  
 Liu, Y. 16, 21, 56  
 Llobet, M. 111  
 Lloyd-Tavaglini, C. A. 63  
 Lloyd, A. 3  
 Lo Ciganic, W. 80  
 Lobmaier, P. P. 104  
 Loescher, J. L. 13  
 Lofwall, M. R. 13, 17  
 Løhaugen, G. 57, 72  
 Lohrenz, T. 93, 108, 109  
 London, E. D. 10, 19, 60, 63  
 Long, Ed 26  
 Long, K. 64, 86  
 Longinaker, N. 85, 103  
 Lookatch, S. J. 64  
 Lopez-Castro, T. 66, 94  
 Lopez-Larson, M. P. 118  
 López-Núñez, C. 14  
 Lopez-Quintero, C. 83, 91  
 Lopez, A. A. 94  
 Lopez, S. 21  
 Lord, S. E. 110  
 Lorvick, J. 64, 92, 101, 117  
 Los, C. 70  
 Lott, D. C. 68, 69  
 Louie, B. 80  
 Louza, M. 10  
 Low, M. J. 27  
 Loya, J. M. 63  
 Lozano, B. E. 67  
 Lu, N. 81  
 Lu, Q. 112  
 Lukas, S. E. 61, 95  
 Lundahl, L. H. 19, 21, 25, 78, 88, 110  
 Lunnan, J. 62, 102  
 Luo, S. X. 13  
 Lynam, D. R. 11, 62  
 Lynch, K. G. 6  
 Lynskey, M. T. 64, 111  
 Lysle, D. 18, 115  
 Lyubimova, A. 24  
 Lyvers, M. 63, 64  
  
 Ma, L. 93  
 Ma, Y. 56  
 MacFarlane, J. C. 91  
 Macias Konstantopoulos, W. 85  
 Mackey, T. 64  
 MacKillop, J. 15  
 MacLean, K. A. 16  
 MacLean, R. 62  
 MacPherson, L. 11, 13, 62, 64, 84, 86, 91, 94, 111  
 Mactutus, C. F. 18, 115  
 Madeja, C. 73  
 Madras, Bertha K. 1, 15, 29, 74  
 Magalon, D. 110  
 Magis-Rodriguez, C. 88  
 Maguire, D. R. 18  
 Magura, S. 77  
 Maher, Brion 75  
 Maher, L. 3  
 Mahoney, A. P. 81  
 Mahoney, J. J. 15, 19, 28, 108  
 Mahoney, M. 13  
 Mahony, A. 118  
 Maidment, N. T. 18  
 Maki, P. 56  
 Malbergier, A. 10  
 Maldonado-Molina, M. 71  
 Maldonado, A. 21  
 Malison, R. T. 109  
 Malta, M. 86  
 Mamey, M. 118  
 Man, H. 59  
 Mancha, B. E. 88  
 Manchanda, R. 85  
 Mancino, M. J. 11, 28  
 Mandelkern, M. A. 10, 19, 60  
 Mandler, R. N. 85  
 Manna, L. 72  
 Mannelli, P. 79  
 Mansoor, E. 82  
 Mantsch, John R. 2, 106  
 Manubay, J. M. 89  
 Manza, L. 27  
 Mao, J. 6  
 Maple, K. E. 15, 27  
 Maqueda, A. 117  
 Marceau, K. 72  
 Marchant, N. J. 58, 116  
 Mardini, V. 72  
 Marel, Christina 71, 94, 111  
 Maremmani, I. 70  
 Mariani, J. J. 16, 63, 79, 83, 116, 118  
 Marín-Navarrete, R. 86  
 Mark, K. D. 103  
 Marks, K. R. 98  
 Marlin, B. 109  
 Marlowe, D. 102  
 Márquez, J. 80  
 Marquez, K. 97  
 Marsch, L. A. 22  
 Marshal, M. P. 96  
 Marshall, B. D. 21  
 Martelle, S. E. 57, 107

## AUTHOR INDEX

- Martin-Fardon, R. 106  
 Martin, C. 10, 61  
 Martin, E. 56  
 Martin, N. G. 64  
 Martínez-Loredo, V. 68, 118  
 Martínez-Sanvisens, D. 94, 111  
 Martinez, C. 112  
 Martínez, D. 117  
 Martinez, E. M. 70, 80, 90  
 Martínez, M. 117  
 Martinez, M. M. 108  
 Martinez, P. 115  
 Martins, Silvia S. 6, 21, 56, 70, 112  
 Marusich, J. A. 57  
 Marwitz, J. H. 10  
 Mash, D. C. 62  
 Mashhoon, Y. 61  
 Massey, L. S. 12  
 Masson, Carmen L. 56, 75  
 Masterson, C. B. 106  
 Matejkowski, J. 101  
 Mateu-Gelabert, P. 11  
 Mateucci, A. 86  
 Mathew, A. R. 61  
 Mathews, T. 16  
 Mathias, C. W. 15, 118  
 Mathur, C. 25  
 Matschke, K. 117  
 Matsumoto, Rae R. 114, 115  
 Matthews, A. 30  
 Mattick, R. 25, 105  
 Matusiewicz, A. K. 13, 63  
 Matzeu, A. 106  
 Mauro, P. M. 63, 97, 112  
 Maxwell, Jane C. 29  
 May, A. C. 93  
 Mayes, L. C. 97  
 Maynié-François, C. 63  
 Mays, J. 25  
 Mays, V. 14  
 Mazure, C. M. 91  
 Mazzom, M. 83  
 Mbwambo, J. 89  
 McBride, K. 70  
 McCabe, Sean E. 6, 70, 118  
 McCann, David 1, 4  
 McCart, M. R. 97  
 McCarty, D. 64, 87  
 McCauley, J. L. 69, 102, 103  
 McClernon, F. Joseph 23  
 McClernon, J. 61  
 McClure, B. 85  
 McClure, Erin A. 115, 116  
 McClure, S. M. 93  
 McConnell, J. 78  
 McConnell, P. 61  
 McCormack, R. P. 85  
 McCrady, B. S. 85  
 McCurdy, C. 115  
 McDermott, K. 79, 110  
 McDermott, K. A. 85  
 McGaugh, J. 11  
 McGinnis, K. 89  
 McGrath, E. 62  
 McHugh, K. 68, 70  
 McHugh, R. 110  
 McKee, S. 66  
 McKee, Sherry 91, 114  
 McKnight, C. 4, 88  
 McLellan, A. Thomas 26, 69  
 McNaughton, E. C. 68  
 McNeely, J. 77  
 McNeil, M. P. 14  
 McPherson, S. 118  
 McQueeney, T. 61  
 McReynolds, J. R. 106  
 McWilliams, S. K. 11  
 Meacham, M. C. 64  
 Mead, A. N. 105  
 Meade, Christina S. 22, 26, 67, 91, 102, 104  
 Means, S. 77  
 Medina-Mora, M. E. 86, 88  
 Meier, E. A. 118  
 Melara, R. 14  
 Mello, M. 103  
 Mendelson, J. 81, 109  
 Mendez, I. A. 18, 113  
 Mendoza, S. 78  
 Mercer, M. A. 102  
 Mercincavage, M. 104  
 Meredith, S. 9  
 Meredith, S. E. 5  
 Meredith, Steven 8  
 Meredith, Steven E. 5  
 Mereu, M. 107  
 Mericle, A. 87  
 Mericle, A. A. 81  
 Merrick, E. L. 86  
 Merry, B. 72  
 Messiah, S. E. 95  
 Metrik, J. 15  
 Metsch, L. 23  
 Metsch, L. R. 3  
 Metz, V. 21, 89  
 Metzger, D. 65, 69, 92  
 Meyer, A. C. 10, 102  
 Meyer, J. P. 100  
 Meyer, M. 21  
 Meyers, J. L. 99  
 Meyers, K. 69  
 Meyers, S. A. 109  
 Mezghanni, M. 65  
 Michalko, K. 89  
 Michalopoulos, L. 84  
 Michie, P. 67  
 Mikulich-Gilbertson, S. K. 11  
 Mikulich, S. 110  
 Milam, A. J. 12, 14, 63, 91, 112  
 Milam, Adam J. 75  
 Milanese, G. 70  
 Milich, R. 11, 62  
 Miller, A. L. 58  
 Miller, G. M. 15, 112  
 Miller, S. C. 20  
 Milletich, R. J. 66  
 Milloy, M. 22  
 Mills, K. 94, 111  
 Mills, Katherine 94  
 Min, J. 22  
 Mineur, Yann 114  
 Minguela, R. R. 94  
 Miranda de Leon, S. 23  
 Mishani, E. 60  
 Mishlen, K. 79, 83  
 Mitchell, A. 13  
 Mitchell, J. 13, 62  
 Mitchell, S. G. 65, 84, 97

## AUTHOR INDEX

- Mitchell, Shannon G. 96  
 Mizuno, K. 62  
 Mjølhus, A. L. 79  
 Mjølhus, A. N. 79  
 Moberg, D. 83  
 Moberg, E. 65  
 Modlin, D. 18  
 Moeller, F. Gerard 5, 10, 25, 58, 93, 99  
 Moeller, S. J. 97  
 Mogali, S. 89  
 Mohammed, A. M. 91  
 Mohr, B. A. 77  
 Mojtabai, R. 70  
 Møller, M. 79  
 Mollnes, T. E. 115  
 Molnar, D. 82  
 Moncrief, J. 17, 28  
 Monge, Z. A. 60, 93  
 Monk, S. 100  
 Montague, P. R. 93, 108, 109  
 Montaner, J. 22  
 Monterosso, J. R. 10  
 Montgomery, L. 86, 108  
 Montoya, Ivan 114  
 Moody, L. 97  
 Mooney, L. 4, 60, 111  
 Mooney, M. 118  
 Mooney, R. 87  
 Moore, B. A. 6, 70, 81  
 Moore, S. K. 110  
 Moore, T. 64, 70  
 Morales, A. 11, 84, 112  
 Morales, A. M. 60  
 Morales, M. 116  
 Moran-Santa Maria, M. 61  
 Morean, M. E. 83  
 Morgan-Jackson, J. 83  
 Morgan, A. J. 12, 18, 115  
 Morgan, D. 17  
 Mori, T. 58, 106  
 Morisano, Dominique  
 Morissette, C. 64  
 Morris, L. A. 20  
 Morris, R. 90  
 Morrow, C. 82  
 Morrow, K. 103  
 Morse, D. 23  
 Moseley, A. 65  
 Moser, A. 24  
 Moy, L. 85  
 Muller, M. 107  
 Muller, M. M. 119  
 Mumford, E. 72  
 Mumma, J. 25, 61  
 Munguia, A. 81  
 Muntner, P. 71  
 Murnan, A. 84  
 Murphy, A. 24  
 Murphy, E. M. 62, 66  
 Murphy, N. P. 18  
 Murphy, S. M. 118  
 Murphy, Susan A. 8  
 Murray, L. 84  
 Muscat, J. E. 104  
 Myers, B. 91  
 Myerson, J. 106  
 Nader, Michael A. 29, 57, 92, 107  
 Nader, S. H. 57  
 Naeger, S. 97  
 Nahata, R. 28  
 Namjoshi, O. A. 17  
 Nanovskaya, T. 82  
 Napier, C. 18  
 Napper, L. 109  
 Narvaez, J. 9  
 Naser, Z. 115  
 Natarajan, A. 109  
 Natera, G. 87, 91  
 Natsuaki, M. 72  
 Nayak, M. 107  
 Naylor, J. 117  
 Neelakantan, H. 57  
 Negi, N. 91  
 Negrin, A. 108  
 Neiderhiser, J. M. 72  
 Neisewander, Janet 1, 58  
 Nejati, V. 10  
 Nelson, E. 27, 61, 69  
 Nelson, K. 117  
 Neria, Y. 103  
 Nestler, E. J. 58, 59  
 Nesvåg, S. 79  
 Neupane, S. P. 115  
 Neurer, J. 3  
 Newman, Amy H. 29, 57, 107  
 Newton, M. 12  
 Newton, T. F. 15, 28, 93, 108  
 Newville, H. 22  
 Nguyen, J. 59  
 Nguyen, S. M. 88  
 Nic Dhonnchadha, B. A. 59  
 Nicastrì, S. 10  
 Nich, C. 98, 110  
 Nickell, J. R. 4  
 Niculescu, M. 27, 63  
 Nielsen, D. A. 98, 99  
 Nielsen, E. 98  
 Nielsen, S. 105  
 Nietert, P. 63  
 Nieto, S. J. 59  
 Niikura, K. 117  
 Nikolopoulos, G. K. 23  
 Nilsson, S. 80  
 Ninnemann, A. 91  
 Nixon, S. J. 102  
 Noel, V. 12  
 Nollen, N. 25  
 Nomura, Y. 67  
 Noonan, P. K. 17  
 Nordstrom, B. 69  
 Norman, A. B. 106  
 Nosyk, B. 20, 22  
 Novak, S. P. 117  
 Nowotny, K. M. 24, 56  
 Nunes, E. V. 13, 28, 63, 79, 85, 103, 116, 118  
 Nuzzo, P. A. 13, 17  
 Nyandindi, C. 89  
 Nygard, S. K. 57  
 O'Brien, Charles P. 1, 6, 60, 79, 93, 94, 97  
 O'Callaghan, J. 115  
 O'Connor, K. 68, 101  
 O'Connor, P. G. 6, 20, 70  
 O'Grady, C. L. 22

## AUTHOR INDEX

- O'Grady, K. E. 16, 65, 84, 85, 97, 113  
 O'Neil, Collin E. 28, 76  
 Ogawa, L. M. 15  
 Ohkuma, S. 62  
 Okita, K. 19  
 Olaer, M. 4  
 Olfson, E. 99  
 Oliver, R. J. 58  
 Oliveto, A. 11, 28  
 Oltramari, L. C. 84  
 Ometto, M. 10  
 Oncken, C. 103  
 Ondersma, S. J. 65, 66, 82  
 Opheim, A. 79  
 Orgiles, M. 11, 84, 112  
 Ormaechea, R. 108  
 Oros, M. 97  
 Orson, F. M. 4  
 Orza, P. C. 17  
 Osborn, L. A. 78  
 Oser, C. B. 65, 100, 101, 103  
 Othily, E. 66  
 Otiashvili, D. 85, 113  
 Ott, J. 19, 98, 117  
 Owens, D. 73  
 Owens, M. 61
- Pacek, L. R. 112  
 Pacula, R. 78  
 Padula, C. B. 27, 61  
 Pagano, A. 112  
 Pal, R. 109  
 Palatkin, V. 79, 98  
 Palfai, T. P. 63  
 Palmer, A. 83  
 Pan, X. 115  
 Panas, L. 86  
 Pandes-Carter, L. 11  
 Pandey, S. 102  
 Papaseit, E. 73, 94  
 Papini, S. 103  
 Parate, A. 109  
 Park, M. 73  
 Park, T. 117  
 Park, Tae Woo 7, 116
- Parker, E. 12  
 Parker, M. A. 11  
 Parks, K. A. 69  
 Parra-Cardona, R. 91  
 Parrino, M. 70  
 Parry, B. A. 85  
 Parsons, J. T. 70  
 Partilla, J. S. 17, 73  
 Parvaz, M. A. 97  
 Pasa, G. 62, 102  
 Pascale, A. 108  
 Passalacqua, E. 112  
 Passetti, L. 110  
 Patel, B. 85  
 Patrick, M. E. 10, 102  
 Patrikeeva, S. 82  
 Patterson, T. L. 64  
 Paulus, M. P. 93  
 Pavlicova, M. 16, 63, 83, 85, 116  
 Pavlikova, M. 28  
 Payer, Doris 19, 29, 73  
 Pechansky, F. P. 9, 62, 73, 83, 91, 102, 109  
 Pecoraro, A. 87  
 Pedroso, R. S. 83, 91, 109  
 Peindl, K. S. 79  
 Peirce, J. M. 66, 111  
 Peles, E. 20, 98  
 Peltier, MacKenzie R. 25  
 Pena, C. J. 58  
 Pena, D. F. 106  
 Peng, C. 69  
 Penn, P. 67  
 Pentel, P. R. 77  
 Pentkowski, N. S. 58  
 Peraza, J. 62  
 Pereira, A. D. 84  
 Peres, G. M. 84  
 Pérez de los Cobos Peris, J. 105, 117  
 Perez-Dandieu, B. 66  
 Pérez-Mañà, C. 73, 94  
 Perez, C. 113  
 Pericot-Valverde, I. 14  
 Perlman, D. 4, 21, 56, 88  
 Perna, M. K. 12
- Perrey, D. A. 16  
 Perrin, N. 20  
 Perrino, P. J. 17  
 Perrone-Bizzozero, N. I. 58  
 Persidsky, Yuri 71  
 Persons, A. L. 18  
 Peters, J. 98  
 Peterson, J. 20  
 Peterson, T. 65  
 Petras, H. 72, 92  
 Petry, N. 108  
 Pettenon, M. 83, 109  
 Pettinati, H. M. 6  
 Pettoruto, K. 14  
 Pezzi, J. 114  
 Pfaff, M. 119  
 Philip, P. 109  
 Phillips, K. A. 19, 64, 65, 81  
 Phillips, K. T. 15  
 Phillips, M. M. 15  
 Philogene, H. 13  
 Pianca, T. G. 83  
 Picetti, R. 58  
 Pickworth, W. 112  
 Pienta, A. 94  
 Pieterse, D. 91, 102  
 Pike, E. 4, 10, 11  
 Pilla, M. 105  
 Pinals, D. A. 68, 101  
 Pirie, P. 12  
 Plebani, J. G. 6  
 Poe, M. 105  
 Polak, K. M. 9  
 Polcin, D. L. 107  
 Pollack, L. 83  
 Pollini, R. 70, 102  
 Polshkova, S. 5  
 Pomm, D. 9  
 Poppa, N. 93  
 Porrino, Linda 96  
 Posse, S. 93  
 Potenza, M. N. 94, 98  
 Potts, J. 112  
 Pouget, E. R. 22, 23, 94  
 Power, K. A. 104  
 Prado, G. 95, 101



## AUTHOR INDEX

- Prado, M. C. 84  
 Prescott, J. 105  
 Preston, Kenzie L. 19, 64, 65, 75, 81  
 Pribasnig, A. 21  
 Price, J. S. 61  
 Price, R. K. 102, 112  
 Prisciandaro, J. 61  
 Prisinzano, Thomas E. 24, 114, 117  
 Pritchett, L. 57  
 Pronk, T. W. 13  
 Proudfit, G. H. 97  
 Przybyla, S. 69  
 Pudiak, C. 108  
 Pujadas, M. 73  
 Pullen, E. L. 101, 103  
 Puntos, M. 117  
 Purohit, Vishnudutt 71  
 Puttick, D. 25  
 Pyles, R. B. 58
- Quinn, A. 86  
 Quinn, B. 64, 92, 101  
 Quinn, E. K. 89  
 Quinones-Jenab, V. 57  
 Quisenberry, A. 25
- Rabinovitz, S. 116  
 Raby, Wilfrid N. 28  
 Racine, M. 95  
 Radin, A. 16  
 Rafat, B. 104  
 Rafful, C. 88  
 Raj, A. 89  
 Rajan, S. 22  
 Ramesh, D. 10, 93  
 Ramirez, R. 101  
 Ramirez, S. H. 106  
 Ramos, C. 86  
 Ramsey, A. 110  
 Randesi, M. 19, 98  
 Ranney, M. 12, 103  
 Rao, H. 25, 61  
 Ratcliffe, S. 77  
 Rathnayaka, N. 15, 18, 103, 113
- Ravven, S. 104  
 Rawlinson, W. 3  
 Rawls, S. 13, 16, 106  
 Rawson, R. 27, 60  
 Ray, B. M. 9  
 Ray, S. 60  
 Ray, T. 20  
 Raymond, H. 22  
 Raymond, K. M. 11  
 Reboussin, B. A. 16, 83  
 Reddel, S. 105  
 Reddy, A. 65  
 Redish, A. D. 113  
 Redner, R. 13, 67  
 Reed, B. 9  
 Reed, S. 4  
 Reese, R. 65  
 Regier, P. S. 113  
 Reichel, C. M. 98  
 Reid, H. H. 67  
 Reif, S. 77, 86  
 Reischl, T. 12  
 Reiss, D. 72  
 Reissig, C. J. 104, 113  
 Reiz, J. 89  
 Remy, L. S. 73  
 Rendina, H. J. 70  
 Reno, A. 62  
 Renshaw, P. F. 111  
 Ressler, K. J. 99  
 Rethorst, C. D. 108  
 Reynolds, B. 12  
 Reynolds, E. 84  
 Reynolds, G. L. 22, 108, 109  
 Reynolds, J. 60, 110  
 Reynolds, M. D. 84  
 Rhodes, J. 68, 69  
 Riba, J. 117  
 Ribeiro Schneider, D. 105  
 Rice, Kenner 96, 107  
 Rich, M. T. 58  
 Richardson, D. R. 116  
 Richardson, J. 104  
 Rico, M. 65, 87  
 Ridenour, T. 84  
 Rieckmann, T. R. 79
- Riggs, L. M. 59  
 Riggs, Paula D. 3  
 Riley, A. L. 16, 107, 119  
 Ring, K. M. 108  
 Rios, E. 21  
 Risco, C. M. 84  
 Rising, K. 78  
 Ritter, G. 86  
 Ritter, K. 88  
 Rivas, G. 95  
 Rivera-Suazo, S. 113  
 Rivera, A. V. 92  
 Rivera, S. 24, 80  
 Riyad, C. 63  
 Roark, M. 11  
 Roberts, M. 20  
 Roberts, W. 97  
 Robertson, C. 60  
 Robertson, K. 22  
 Robson, M. 115  
 Rocha, Beatriz I, 76  
 Rodriguez, A. 23  
 Rodriguez, K. 117  
 Rodriguez, L. 6  
 Rodriguez, M. 21  
 Roesch, S. 64  
 Rogers, T. J. 58  
 Rognli, E. B. 24  
 Rogowska, J. 118  
 Rohde, L. A. 72  
 Roley, J. 22  
 Roll, J. 118  
 Roma, P. G. 64  
 Roman, P. M. 77  
 Romero-Gonzalez, M. 80  
 Rosa, Carmen 76  
 Rosa, R. L. 83  
 Rose, J. J. 118  
 Rose, J. L. 17  
 Rose, J. S. 91  
 Rosen, M. 77  
 Rosenberg, D. 21  
 Rosenberg, H. 15, 69, 78, 104  
 Rosenberry, Z. 112  
 Rosenblum, A. 70, 90  
 Ross-Durow, P. L. 70

## AUTHOR INDEX

- Ross, J. 94, 111  
 Rossi, P. 111  
 Rothman, E. F. 14  
 Rothman, R. B. 17, 73  
 Rotrosen, J. 77, 78, 85, 98  
 Rowe, M. C. 57  
 Rowlett, James 92  
 Roy, E. 64  
 Rubenstein, L. 85  
 Rubinstein, M. 27  
 Ruby, J. 80  
 Ruger, J. P. 72  
 Ruglass, L. M. 14, 94  
 Ruiz, J. J. 80, 101  
 Ruktanonchai, C. 91  
 Runyon, Scott P. 23, 24  
 Rupprecht, L. E. 58  
 Rupslaukyte, R. E. 27  
 Rush, C. R. 4, 10, 11, 19, 98  
 Russell, B. R. 61  
 Russell, S. 25  
 Rutledge, M. 107  
 Ryan, S. 20  
 Ryan, S. R. 15  
 Rybarczyk, B. 64  
 Rycroft, W. 105  
  
 Saavedra, J. L. 58  
 Saccone, P. A. 18  
 Sacks, S. 111  
 Sadler, C. 95  
 Saeki, T. 58  
 Saenz, E. 69  
 Safford, M. 71  
 Sagar, K. 95  
 Saika, F. 13  
 Saitz, Richard 7, 63, 77, 117  
 Sakai, J. 110  
 Saladin, M. E. 61, 63  
 Salas-Ramirez, K. Y. 107  
 Salas, R. 108  
 Saldana, L. 97  
 Salemink, E. 83  
 Salvatore, C. 119  
 Salvatore, M. F. 106  
 Samet, J. 3, 6, 22, 89  
 Samet, Jeffrey H. 3, 7, 63, 75  
 Samolski, M. R. 112  
 Sánchez-Huesca, R. 86  
 Sanchez, K. 108  
 Sanchez, Z. M. 56, 84  
 Sandoval, M. 22, 23, 88  
 Sandstrom, L. E. 20  
 Santa Ana, E. J. 63  
 Santaella, J. 21  
 Santana, J. 23  
 Santiago-Negron, S. 113  
 Santos, B. 10  
 Sanudo, A. 56  
 Sason, A. 20  
 Sawh, L. 68, 101  
 Sawyer, B. 97  
 Saxon, Andrew 76  
 Schacht, R. L. 66  
 Schackman, B. 23  
 Schaub, M. P. 15  
 Scheidell, J. 91, 100  
 Scheidell, J. D. 88, 100  
 Scherrer, J. 112  
 Scheuermann, T. S. 25  
 Schindler, E. 67  
 Schmidt, L. 64, 87  
 Schmidt, N. B. 63  
 Schmitz, Joy 10, 15, 18, 98, 99,  
 103, 109, 113  
 Schneider, D. R. 84  
 Schoedel, Kerri A. 17, 29, 89, 105  
 Scholtz, J. 65, 87  
 Schottenfeld, R. S. 6, 19, 70  
 Schreiber, S. 20  
 Schreiner, D. 28  
 Schroeder, J. R. 17  
 Schroeter, D. 77  
 Schuetze, P. 82  
 Schuler, M. 84  
 Schulte, M. T. 56, 81  
 Schumacher, J. 62  
 Schwartz, R. P. 65, 68, 84, 86, 97  
 Scofield, M. 98, 116  
 Scott, C. K. 65  
 Seay, K. D. 84  
 Secades-Villa, R. 14, 68, 118  
 Seguí, G. 117  
 Seitz-Brown, C. 102  
 Selby, P. L. 68  
 Sellers, E. M. 89, 105  
 Seong, W. 15  
 Serre, F. 109, 110, 118  
 Sesana, F. 70  
 Setlik, W. 59  
 Setnik, Beatrice 1, 117  
 Severtson, S. G. 80, 90  
 Sferra, M. S. 15  
 Sgro, M. 18  
 Shadur, J. M. 11, 62, 111  
 Shaham, Yavin 2, 58, 116  
 Shahbabaie, A. 10  
 Shane, M. 93  
 Shapiro, J. 14  
 Sharma, G. 28, 85  
 Shaw, D. 72  
 Sheidow, A. J. 97  
 Sheikhattari, P. 14, 111  
 Sheldon, Behshad 4  
 Shelley, D. 77  
 Shervani, S. 11  
 Sheth, A. P. 92  
 Shibasaki, M. 58, 106  
 Shin, J. 15  
 Shin, S. 119  
 Shishkoff, G. E. 62  
 Shisler, S. 82  
 Shmulewitz, D. 99  
 Shollenbarger, S. 61  
 Shoptaw, Steven 6, 10, 26, 27, 108  
 Shorey, R. C. 64, 91  
 Shram, M. 17  
 Shrestha, R. 69  
 Shroff, M. 69, 112  
 Shu, I. 68  
 Shuster, E. 20  
 Siffin, K. E. 63  
 Sigmon, S. C. 10, 21, 81, 102  
 Sigurdsson, S. O. 86  
 Sikkema, K. 104  
 Silberg, J. 83  
 Silva, L. 57  
 Silva, M. 10

## AUTHOR INDEX

- Silverman, K. 86  
 Simmons, J. 97  
 Simon, P. 83  
 Simpson, J. 108  
 Singer, S. 68, 101  
 Singer, Z. 97  
 Sinha, Rajita 2  
 Skalski, L. 104  
 Skanderson, M. 89  
 Skelly, J. M. 13, 94  
 Skinner, D. 91, 102  
 Skrajewski, J. 69  
 Skranes, J. 72  
 Slade, T. 94, 111  
 Slesnick, N. 84, 86  
 Sloan, C. A. 64  
 Smelson, D. 10, 68, 80, 101  
 Smethells, J. R. 106  
 Smith, G. A. 92  
 Smith, K. M. 66  
 Smith, K. Z. 104  
 Smith, M. 90, 95  
 Smith, M. A. 17, 59  
 Smith, P. H. 66, 91  
 Smith, S. L. 107  
 Smith, T. 17  
 Smith, V. C. 87  
 Sofuoglu, M. 28, 99  
 Sokolowska, Marta 76  
 Solberg, T. D. 116  
 Soldigner, J. 64  
 Somaini, L. 70  
 Somkuwar, S. S. 117  
 Sommerville, K. W. 117  
 Song, K. H. 116  
 Song, L. 28  
 Song, M. 15  
 Sorbero, M. 78  
 Sordi, A. O. 9  
 Sorensen, James 22, 56, 75  
 Soriano, F. I. 113  
 Soto, C. 58  
 Soules, M. E. 119  
 Sousa, T. R. 62, 102  
 Spangler, J. 16  
 Sparenborg, S. 28  
 Spealman, R. D. 17  
 Spear, S. E. 101  
 Specker, S. 118  
 Spence, A. 105  
 Spirito, A. 83  
 Spitznagel, E. 14  
 Sproule, B. 78, 104  
 Squires, D. 103  
 St. Laurent, R. M. 116  
 Stadnik, R. 62  
 Stafford, A. M. 62  
 Stahl, N. F. 14  
 Stahler, G. 110  
 Stairs, D. J. 119  
 Staley, M. 77  
 Stall, R. 88  
 Stanger, C. 12, 95  
 Stankeviciute, N. 116  
 Staton-Tindall, M. 100, 101  
 Stavseth, L. S. 79  
 Stein, B. D. 78  
 Steinberg, D. B. 119  
 Steinberg, J. L. 93  
 Steinberg, M. L. 14, 85  
 Stemmler, S. M. 108  
 Stepp, S. 96  
 Stevens-Watkins, D. 101  
 Stewart, J. L. 93  
 Stewart, M. 77, 86  
 Stiles, G. 20  
 Stitzer, M. L. 95  
 Stockstad, M. 66  
 Stoddard, S. A. 12  
 Stolf, A. R. 109  
 Stoller, K. B. 16  
 Stoltman, J. J. 25, 88  
 Stone, K. L. 58  
 Stoops, William W. 4, 10, 11, 19, 95, 98  
 Stoothoff, B. 27  
 Strain, Eric C. 5, 27, 30, 63, 70, 86  
 Strathdee, S. 64, 88  
 Stratton, K. 111  
 Strauss, S. 77  
 Streit, C. 11  
 Strickland, J. C. 17  
 Strickland, J. T. 59  
 Striley, C. W. 9, 90, 91, 118  
 Stuart, E. 84  
 Stuart, G. L. 64, 91  
 Stutz, S. J. 17, 28, 58  
 Suchting, R. 103, 109, 113  
 Suerken, C. K. 16  
 Sugarman, D. 84  
 Sugita, W. 27  
 Suh, Jesse 60, 93, 94, 97  
 Sullivan, M. A. 79, 83, 89  
 Sulzer, D. 59  
 Sun, H. 58  
 Surratt, H. 22, 73, 89, 90  
 Sussman, S. 112  
 Sutfin, Erin L. 16, 26  
 Suzuki, T. 58, 62, 106  
 Svikis, D. 9, 64, 66, 70, 82, 108, 111  
 Swanson, A. 10  
 Swendsen, J. 110  
 Swieter, Mark 74  
 Swinford-Jackson, S. E. 58  
 Szczytkowski-Thomson, J. 115  
 Szeliga, K. T. 107  
 Szobot, C. M. 72  
 Tabaja, N. 106  
 Tabet, M. R. 106  
 Taffe, Michael A. 29, 59, 107  
 Taha, F. 14  
 Taherian, M. 62  
 Taillard, J. 109  
 Tajima, B. 112  
 Takanohashi, A. 58  
 Taki, F. A. 115  
 Talati, A. 67  
 Tallarida, C. S. 13, 16, 106  
 Tamarit, C. 111  
 Tanabe, J. 60, 110  
 Tanda, G. 107  
 Tanizaki, N. 22  
 Tanum, L. 79  
 Tape, C. 103  
 Tapert, S. F. 93  
 Tapia, G. 66

## AUTHOR INDEX

- Tarter, R. 82  
 Tate, J. 89  
 Taxman, F. 23, 24, 66  
 Taylor, J. R. 58  
 Tedford, S. E. 18  
 Teer, A. 102, 103  
 Teer, D. 67  
 Teesson, Maree 71, 94, 111  
 Teitell, S. 104  
 Teixeira, A. L. 114  
 Temple, J. 82  
 Templos-Nuñez, L. 86  
 Tene, O. 20  
 Tennen, H. 90  
 Ternes, M. 24  
 Terplan, M. 82, 85, 103  
 Tessari, M. 105  
 Thacker, L. 9  
 Thamotharan, S. 15, 56  
 Thanos, Peter 23  
 Thibault, K. 24  
 Thiele, T. 115  
 Thing, J. 64, 92  
 Thomas, B. F. 16  
 Thomas, E. 113  
 Thomas, L. N. 106  
 Thompson-Lake, D. G. 15, 28, 108  
 Thompson, D. 85, 89  
 Thompson, L. 60, 110  
 Thorberg, F. A. 63, 64  
 Thorn, D. A. 28  
 Thornton, T. 24  
 Thostenson, J. D. 11, 28  
 Thurstone, C. 97  
 Tiberg, Fredrik 4  
 Tidey, J. W. 12  
 Tidgewell, Kevin 114  
 Tiffany, E. 20  
 Tiurina, A. 79  
 Tobias, M. D. 119  
 Todenkopf, M. 18  
 Tofighi, B. 80  
 Tolliver, J. M. 113  
 Tompkins, D. A. 63  
 Tormohlen, K. N. 13  
 Torregrossa, M. M. 58  
 Torrens, M. 73, 94, 111  
 Torres Cardona, F. 23  
 Torres, C. A. 59  
 Torres, L. M. 24  
 Torrington, M. 4  
 Toussaint, A. 57  
 Towe, S. 22, 67, 91, 104  
 Tracy, K. 110  
 Tran, P. 88  
 Trenz, R. 88  
 Tripathi, S. 18  
 Trivedi, M. H. 108  
 Trksak, G. H. 61  
 Trouba, C. 109  
 Troyer, M. 89  
 Trull, T. J. 64  
 Tsay, W. 81  
 Tsuang, J. 10  
 Tsui, Judith I. 3, 6  
 Tsuyuki, K. 22  
 Turner, R. 115  
 Tyburski, M. 65  
 Tyson, A. 13  
 Tyssen, R. 63  
 Uddin, M. 99  
 Udo de Haes, J. 89  
 Ueland, T. 115  
 Unterwald, Ellen M. 58, 96  
 Urada, D. 20  
 Uribe, K. 107  
 Vaddiparti, K. 90, 118  
 Vahabzadeh, M. 65  
 Vahidi, M. 65, 87  
 Valdez, A. 24, 91  
 Valenza, M. 58  
 Valle, M. 117  
 Vallender, E. J. 15, 112  
 Valleur, M. 110  
 van den Berk-Clark, C. 69, 102, 112  
 van den Brink, W. 19  
 van Ree, J. M. 19  
 Vandewater, S. A. 59, 107  
 Vandrey, R. 16, 95  
 Varga, M. 13  
 Vargas Vidot, J. 23  
 Vasilev, G. 25  
 Vasquez, E. 27  
 Vassileva, J. 25, 56  
 Vaughan, B. 116  
 Vega, G. D. 24  
 Vélez, M. 100  
 Veliz, P. T. 70, 118  
 Venisse, J. 110  
 Verbitskaya, E. 79, 98  
 Verdeja, R. 86  
 Vernikovskaya, D. 82  
 Verno, T. 64  
 Verona, E. 86  
 Verrico, C. D. 15, 19  
 Vidal, L. 107  
 Vidot, Denise C. 82, 95, 102  
 Vijay, A. 62  
 Villalobos, G. 66, 70  
 Vincent, K. B. 16  
 Vinci, C. 62  
 Viola, T. W. 114  
 Viray, L. 112  
 Vladimirovna, Y. 77  
 Vocci, Jr., Frank 1, 4  
 Vojtech, J. M. 104  
 Volkow, Nora D. 1, 23  
 Voll, R. 57  
 von Diemen, L. 9  
 Vorel, S. R. 13  
 Vouga, A. 16  
 Vranjkovic, O. 106  
 Vsevolozhskaya, O. 113  
 Vu, V. D. 88  
 Vujanovic, A. 109  
 Vuolo, M. 70  
 Wachholtz, A. 6  
 Wagenaar, A. 71  
 Wagner, F. A. 14, 111  
 Wagner, K. D. 64  
 Wagoner, K. G. 16  
 Wakeford, A. G. 16  
 Walcher, S. 70  
 Walentiny, D. M. 18

## AUTHOR INDEX

- Walker, E. A. 57  
 Walker, R. 98, 108  
 Wall, M. 67  
 Wall, M. M. 13, 63  
 Walley, A. Y. 20, 89  
 Walsh, Bob 4  
 Walsh, K. 65  
 Walsh, Sharon L. 13, 17, 29, 76  
 Walters, S. 66  
 Walters, V. 64  
 Walton, M. A. 5, 12, 70  
 Wang, A. 60, 94  
 Wang, H. 116  
 Wang, N. Y. 21  
 Wang, R. 3  
 Wang, S. 21  
 Wang, X. 82  
 Wang, Y. 56  
 Wang, Z. 60  
 Ward, S. J. 57  
 Warren, M. 110  
 Warren, O. 78  
 Washio, Y. 81  
 Watt, M. 102  
 Watt, M. H. 91  
 Wearick, L. E. 114  
 Weatherburn, D. J. 25  
 Weaver, M. 70  
 Webster, L. R. 90, 117  
 Webster, M. 100, 101  
 Wechsberg, W. 85, 113  
 Weerts, E. 27  
 Weerts, Elise 27  
 Weidberg, S. 68  
 Weinstein, A. M. 60  
 Weinstein, D. 62  
 Weisberg, D. 89  
 Weiss, F. 106  
 Weiss, R. 79, 85, 110  
 Weiss, V. G. 59  
 Wells, B. E. 70  
 Wenger, L. 64, 92, 117  
 Werntz, A. 64  
 Wesley, M. J. 93, 109  
 Westmoreland, S. V. 15  
 Wetherill, R. R. 25, 61, 93  
 Wetherington, Cora Lee 114  
 Wetle, T. 103  
 Wetzell, B. B. 107, 119  
 Wheeler, P. 3  
 White, B. 3  
 White, David A. 7  
 White, T. J. 13, 67  
 Whitehead, N. E. 3, 100  
 Whiteside, L. K. 70  
 Wickersham, J. A. 100  
 Widner, G. 69, 112  
 Wiers, R. W. 13, 83  
 Wieser, J. 61  
 Wigderson, S. 84  
 Wild, C. 17, 28  
 Wilder, C. M. 20, 104  
 Wildman, D. E. 99  
 Wiley, J. L. 57  
 Williams, C. 62  
 Williams, J. 102  
 Williams, J. M. 14  
 Williams, K. 88  
 Williams, T. V. 77  
 Wilson, A. G. 65  
 Wilson, J. L. 23  
 Wilson, M. J. 25  
 Wilson, S. J. 62  
 Winhusen, T. 13, 20, 28  
 Winstanley, E. L. 20, 104  
 Winter, M. R. 6  
 Winters, Ken 12, 30, 83  
 Witte, M. A. 17  
 Wohl, D. 100  
 Wolford-Celvenger, C. 91  
 Wolfson, M. 16  
 Wood, E. 22  
 Woodcock, E. A. 25, 78  
 Wooditch, A. 24  
 Woods, James H. 18, 57, 96  
 Woodworth, A. 69  
 Woody, G. E. 79, 87, 92, 98, 109  
 Woolley, J. 62  
 Worley, Matthew J. 6  
 Wray, T. B. 12  
 Wrede, F. 86  
 Wright IV, C. 13  
 Wright, N. E. 15, 27  
 Wu, F. 81  
 Wu, H. 56, 90, 103  
 Wu, J. 3  
 Wu, L. 79  
 Wu, P. 62  
 Wu, Y. 10  
 Wuerzl, J. 21  
 Wulach, L. 89  
 Wulach, L. A. 3  
 Wutchiett, D. M. 3, 21  
 Xu, X. 91  
 Xuan, L. 58  
 Xuan, Z. 117  
 Xue, L. 82  
 Xue, W. 91  
 Yacenda, J. 65, 87  
 Yamakawa, R. 82  
 Yamamoto, C. 13  
 Yamamoto, D. 60  
 Yang, H. 23  
 Yang, Y. 3  
 Yao, J. 70, 102  
 Yaroslavtseva, T. 79  
 Yates, J. R. 59  
 Ye, H. 19  
 Yeh, H. H. 102  
 Yemini, P. 108  
 Yi, R. 13  
 Yi, Y. 10  
 Yip, B. 22  
 Yip, S. W. 94  
 Yonkers, K. A. 72  
 Yoon, J. H. 15  
 Young, J. 18  
 Young, K. A. 60, 93  
 Young, M. M. 73  
 Young, R. M. 63  
 Young, S. 11, 100  
 Yuan, A. H. 85  
 Yuferov, V. 19, 58  
 Yurgelun-Todd, D. 118  
 Zah, V. 80

## AUTHOR INDEX

Zaks, M. E. 18  
Zaller, N. 78  
Zamanian, B. 10  
Zamora, N. N. 59  
Zanetello, L. B. 83  
Zapor, H. 91  
Zavala, A. R. 59  
Zavala, R. 80  
Zavaschi, M. 72  
Zawertailo, Laurie 29, 68  
Zelenock, K. A. 18  
Zeng, H. 19  
Zeric, T. 58  
Zevallos, K. 112  
Zhang, B. 115  
Zhang, F. 58  
Zhang, G. 17, 28  
Zhang, M. 104  
Zhang, S. 58  
Zhang, Y. 16, 18, 28, 59, 117  
Zhao, M. 81  
Zheng, W. 16  
Zheng, X. 19  
Zhou, J. 17, 28  
Zhou, W. 16  
Zhou, Y. 27  
Zhu, J. 18, 116  
Zhu, X. 93  
Zimmer, J. 15  
Zimmerman, M. 12  
Zlebnik, N. 59  
Zlotnick, C. 103  
Zucker, R. A. 61, 119  
Zule, W. 85, 88, 113  
Zvartau, E. 79, 98  
Zvolensky, M. J. 63, 67

## SYMPOSIA

**Sunday, June 15**

I. *Stress and relapse to drug use: From animal models to clinical trials*

Chairs: John Mantsch and Yavin Shaham

The pervasive and uncontrollable nature of stress makes the ability of stressful life events to promote drug use and relapse highly problematic for addicts. Therefore, understanding the neurobiological processes that underlie stress-related relapse to drug use is important for the development of new and more effective therapeutic approaches. Research on this topic has relied heavily on preclinical rodent models. However, such models are only useful insofar as they have predictive validity (i.e., the ability to model the human condition and to identify effective treatments). This symposium brings together preclinical and clinical addiction researchers to explore how findings from studies using rodent models of stress-induced drug relapse relate to human drug addiction. The results of rodent studies investigating stress-induced relapse and the underlying neurobiological mechanisms will be presented and their ability to inform drug development and treatment efforts will be discussed. These results will be related to research findings in human populations examining the dysregulation of the stress response in drug-dependent individuals, the relationship between stress-induced craving and relapse risk, the influence of early-life trauma and co-morbid stress-related pathology on drug use and relapse, and targeted medications to prevent stress-induced drug craving and relapse. The goal of the symposium is to promote dialogue and collaboration among preclinical and clinical researchers with the hope that it will guide the establishment of more effective treatment strategies, particularly those aimed at minimizing the contribution of stress to drug addiction and relapse.

II. *Up in smoke: Cannabis and tobacco, linked at the hip and double trouble*

Chairs: Alan J. Budney and Frances Kay-Lambkin

High prevalence of concurrent use of cannabis and tobacco among adolescents and adults raises multiple public health concerns. There remains a pressing need for more scientific attention to this pattern of substance use, particularly with an increased societal focus on marijuana legalization. This symposium will enhance the audience's understanding of the associations between and consequences of concurrent use of cannabis and tobacco, with outcomes from laboratory and clinical studies illustrating its complexities and challenges. The role of shared genetic influences on cannabis and tobacco during its earliest stages of use (initial reactions and age of onset) and later stages (withdrawal and dependence) will be reviewed. Data from laboratory studies showing that daily marijuana smokers who smoke tobacco are more likely to relapse to marijuana, with subsequent studies showing that active tobacco smoking does not significantly influence marijuana relapse relative to tobacco abstinence will be presented. Other topics examined will include patterns of co-use and alternative clinical approaches for intervention; initial findings from a clinical trial will demonstrate variations in expected outcomes; the especially high rates of concurrent use among those with other psychiatric disorders, and findings illustrating how integrated treatments for cannabis use and psychiatric symptoms are effective, but may inadvertently increase tobacco use; and conversely, how tobacco-focused treatments may improve psychiatric symptoms, cannabis and tobacco use. Implications of concurrent use on adolescents, with special attention to how marijuana legalization impacts such concerns will be discussed.

## SYMPOSIA

**Sunday, June 15**

### III. *New buprenorphine formulations and drug combinations in clinical development*

Chairs: David McCann and Bob Walsh

This symposium will summarize data from the ongoing clinical development of three new buprenorphine-containing products: 1) buprenorphine subdermal implants (Probuphine®); 2) CAM2038 long-acting buprenorphine injection; and 3) ALKS 5461 sublingual tablets. The buprenorphine implant and long-acting injection products may prove especially useful in treating opioid-dependent patients who are non-adherent with daily dosing. In addition, these products appear to have very low potential for diversion and abuse by patients. Probuphine® implants may be effective for up to six months. There are two different CAM2038 formulations: one is intended for weekly injections and the other for monthly injections. Unlike other buprenorphine-containing products, ALKS 5461 also contains a potent, systemically bioavailable mu-opioid receptor antagonist, ALKS 33. The two active agents, in 1:1 (wt:wt) ratio, are co-formulated in a sublingual tablet. The inclusion of ALKS 33 in ALKS 5461 is intended to render the resulting combination devoid of addictive potential. In human clinical pharmacology studies, ALKS 33 has been shown to counteract the actions of buprenorphine at mu-opioid receptors. In phase I and phase II clinical studies, ALKS 5461 has shown efficacy in the adjunctive treatment of major depressive disorder (MDD) in patients showing inadequate response to standard therapies, an indication for which the FDA has granted “fast track status.” ALKS5461 is also viewed as a potential treatment for multiple substance use disorders, and a human laboratory cocaine/ALKS 5461 interaction study has been completed.

### IV. *How translational is behavioral research in addiction*

Chairs: F. Gerard Moeller and Kathryn A. Cunningham

One of the strengths of research in addictions compared with other psychiatric disorders is the existence of animal models with significant face validity. However, in spite of these animal models, there have been a number of medications identified in preclinical studies that have not shown efficacy in clinical trials. The aim of this symposium is to discuss translational (and non-translational) aspects of preclinical and clinical models of addictions. The study of cocaine cue reactivity in rodents and human cocaine-dependent subjects will serve as a case in point to foster discussion on the broader topic of translational behavioral research. With a history of cocaine use, environmental contexts and stimuli (e.g., paraphernalia) become reliably associated with its use leading to durable conditioned responses (“cue reactivity”) that can predict relapse as well as treatment success. Drug cue reactivity is the attentional orientation toward such drug-associated cues that are measurable as conditioned physiological effects (e.g., heart rate), subjective properties (e.g., craving), appetitive approach behaviors (e.g., drug-seeking) and activation of specific corticostriatal sub-circuits. Cocaine cue reactivity is frequently measured as attentional bias (attentional orienting response in a computerized cocaine-word Stroop task) while appetitive approach behavior (lever presses in self-administration context) is assessed in animals under conditions of extinction or forced abstinence. Data will be presented on the overlapping neurobiology of cue reactivity in rodents self-administering cocaine and human cocaine dependent subjects. Differences and similarities between preclinical and clinical research will be discussed in relation to the ultimate goal of development of new treatments for addictions.



## SYMPOSIA

### **Sunday, June 15**

#### *V. DSM-5 substance-related and addictive disorders: Rationale and controversies*

Chairs: Deborah Hasin and Wilson Compton

Substance use disorders in DSM-IV had many strengths, but also problems that required change. The DSM-5 Substance-Related Workgroup recommended changes to preserve the strengths while solving the problems, based on research evidence from over 200,000 participants and much feedback from the field. In this symposium, DSM-5 changes in substance-related disorders, their rationale, and clinical implications will be presented. DSM-IV had two disorders, dependence and abuse, with abuse diagnosed only when dependence was not present. In DSM-5, the two disorders were replaced with a single disorder, indicated by at least two of eleven criteria (7 DSM-IV dependence, 3 DSM-IV abuse and one new criterion: craving). The diagnostic threshold was chosen to maintain consistency in prevalence of substance use disorders between DSM-IV and DSM-5. DSM-5 also includes severity indicators based on the number of criteria (2-3, 4-5 and 6+ for mild, moderate and severe). New criteria for cannabis and caffeine withdrawal were introduced, and criteria for tobacco disorders aligned with the other substances. The rationale for moving gambling disorders to the same chapter as substance disorders will be reviewed, as well as the status of other non-substance, behavioral "addictions". While future studies are needed to address issues that remain, the recommended changes are intended to overcome many problems and reduce clinician burden, given the need to consider only one main disorder rather than two. Reactions of the press and the field to the DSM-5 SUD will be reviewed, as well as alternative diagnostic approaches and how DSM-5 will affect ongoing research.

### **Monday, June 16**

#### *VI. Acute and chronic stimulant effects on motivation and behavioral control*

Chairs: Scott Kollins and Iliyan Ivanov

This panel will present new data from animal, human neuroimaging and pharmacological clinical trials. The presentations aim to address in depth new findings and controversies related to the purported effects of stimulants (e.g. methylphenidate, amphetamines, cocaine) on modulating brain activations related to motivation and behavioral control. These controversies stem from various studies in animals and humans some suggesting that despite their well-documented clinical safety prescription stimulants may have effects on brain structures and functions that could be linked to potentially deleterious long term outcomes. The clinical implications of such neurobiological effects, however, remains poorly understood. For instance, available evidence suggests that the positive effects of prescription stimulants on symptoms of inattention and impulsivity are not sustained over longer periods. In addition, some have hypothesized that stimulant exposure in early life may activate pathways that facilitate the development of later substance use problems. The studies that will be presented in this panel will address the questions of acute effects of stimulants specifically focusing on motivational drives and behavioral control assessed by variety of tasks in animal models as well as humans studied with functional magnetic resonance (fMRI). These reports will provide information about neuroanatomical and neurophysiological changes associated with behavioral modulations resulting from both stimulant challenge and treatment with prescription stimulants. Further, new information will be presented to address questions related to long-term neurobiological effects of stimulants exposure in animals and the clinical outcomes of long-term stimulant treatments in youths and adults with attentional and impulsivity syndromes specifically looking at the relationship between stimulant treatment and later substance use problems.

## SYMPOSIA

**Monday, June 16**

VII. *Neuropeptidergic targets for CNS disorders*

Chair: Ivy Carroll and Scott P. Runyon

This symposium will include studies directed toward: (1) evaluation of ligand bias at the kappa opioid receptor (KOR), where the evaluation of novel compounds that preferentially engage G protein versus  $\beta$ -arrestin 2 interaction with KOR will be discussed; (2) nociceptin/orphanin FQ receptor functional selectivity, signaling, and behavior which will discuss NOPR signaling in vitro as it relates to C-terminal regulation; (3) neoclerodane diterpenes as novel treatments for drug abuse, where studies directed toward the development of novel treatments for drug abuse based on salvinorin A will be discussed; and (4) identification of neuropeptide S antagonists as pharmacotherapies for substances which will present the development of novel neuropeptide S antagonists that are active in rodent models of relapse to cocaine self-administration. The basic research information presented in these four presentations will provide a better understanding of how four different neuropeptidergic targets will lead to potential pharmacotherapies for treatment of various substance abuse problems and other CNS disorders.

VIII. *The effects, use patterns and youth perception of electronic cigarettes*

Chairs: Robert L. Balster and Thomas Eissenberg

There is an explosion of interest in the use of e-cigarettes (ECIGS). The symposium will provide an overview of ECIGS, how they work, and data on how design features of the various products affect their nicotine and toxicant yield, as well as an overview of data on the acute effects of ECIGS, with a primary focus on results of laboratory studies. Results of a comprehensive online survey of a large sample of ECIG users will describe the progression of product use over time, the extent and pattern of smoking cessation and continued dual tobacco use, and the perceived dependence on ECIGS versus cigarettes. Youth perception of ECIGS and results from a qualitative study in adolescents and young adults, grouped by smoking status and gender will be presented, along with the results of a 4-year longitudinal study of college students from 11 colleges in North Carolina and Virginia. Changes in rates of ECIG use over time and on longitudinal trajectories of electronic cigarette use, including initiation, transitions to and from conventional cigarettes and dual use will be reported. Regulatory implications of the research for possible FDA regulation of these products will also be discussed.

IX. *Novel approaches to examining the intertwining epidemics of HIV and drug abuse:*

*From decision-making to viral load*

Chair: Matthew W. Johnson and Steven Shoptaw

Drug abuse and HIV infection are complex, intertwined epidemics. Both the epidemiology of HIV transmission and our scientific understanding of the behavioral and biological factors that underlie HIV infection and related outcomes have evolved over time. These changes have prompted the development of new research methodologies in effort to more fully understand the causal factors that underlie the relationship between drug use and HIV infection. This symposium brings together four independent research teams to discuss novel methods of examining HIV risk behavior among drug users. Topics include: 1) laboratory investigations of sexual decision making after acute administration of alcohol, cocaine, and methamphetamine, 2) a laboratory examination of relationships between measures of risk-taking, real-life HIV risk behavior, and HIV infection among cocaine users 3), using crowdsourcing technology to examine sexual decision-making, substance abuse, and HIV infection among a difficult-to-reach population of men who have sex with men (MSM), and 4), individual and partner-level correlates

## SYMPOSIA

of stimulant use, antiretroviral therapy (ART) adherence, and viral load among MSM. This program spans from basic rigorous laboratory studies to population-level assessment, providing a unique opportunity for integration of laboratory science and clinical research.

### **Tuesday, June 17**

#### *X. CB2 functions in the brain and the periphery*

Chairs: Toby K. Eisenstein and Vishnutt Purohit

New discoveries are showing that the CB2 receptor has a multitude of functions. It was originally recognized that this receptor is abundantly expressed in the immune system and only sparsely in the brain. Recent discoveries suggest that CB2 receptors are present in neurons. Exploration of its functions is revealing that CB2 does not produce the same psychoactive effects as ligation of CB1, but it does modulate effects of neuronal processes involved in addiction. Further, it has a role in neuropathic pain. Newer evidence indicates that the CB2 receptor is expressed on endothelial cells of the blood-brain barrier, and CB2 agonists alter the BBB permeability. In the immune system, CB2-selective agonists are emerging as a powerful class of immunosuppressive compounds. This symposium presents new developments in this rapidly emerging field and explores the potential role of CB2 receptor activation in the treatment of pain, drug addiction, inflammation, and preservation of BBB integrity.

#### *XI. Trajectories of heroin use: Insights from longitudinal studies*

Chairs: Linda Cottler and Christina Marel

Longitudinal naturalistic studies of heroin dependence provide the unique opportunity to examine predictors of remission, criminality, mortality, psychopathology and long-term treatment outcomes. Indeed, although there has been much research examining heroin dependence from cross-sectional perspectives, the comparably few longitudinal cohort studies allow long-term trajectories of heroin use, abstinence and other comorbid disorders to be examined. Long-term patterns and trajectories of heroin use have important implications for treatment responses, clinical practice and policy. This symposium examines long-term trajectories of heroin use across three countries: USA, Ireland and Australia, and discusses the implications for clinical practice and policy. From Australia, the 11-year follow-up of ATOS will be completed in December 2013, on a sample of 615 treatment and non-treatment seeking heroin users who were recruited into the study in 2001. Over 66% of the cohort has been interviewed to date, and we have accounted for over 88% (including those who are deceased, refusals, and incarcerated). ATOS trajectories data will be presented for the first time, with a particular focus on the relationship of heroin use trajectories, PTSD and depression, and how these disorders affect patterns of heroin use and abstinence. Longitudinal findings from the ROSIE study in Ireland, and from the US, studies on recovery from heroin addiction, based on 33-year findings. Gender differences in 30-year trajectories of heroin and other drug use will also be reported.

## SYMPOSIA

**Wednesday, June 18**

*XII. Bill Woolverton's greatest hits: Drugs, choices, and consequences*

Chairs: James K. Rowlett and Michael A. Nader

Considerable progress in the understanding of drug abuse has been made through the use of animal models. This symposium describes animal research homologous to the human condition and highlights the profound insights by one of CPDD's long-time members, Bill Woolverton, who died recently after a brief illness. In honor of Bill's legacy, the speakers are his postdoctoral mentor and former postdoctoral mentees. Bill was passionate about the concept of reinforcing efficacy (or strength) and the choice to take drugs as a determinant of persistent drug use. The efficacy/strength of drugs as reinforcers "pulls" behavior away from other reinforcers, so that the abuser engages in choice for drugs over essentially everything else. A better understanding of these concepts would enhance our ability to develop treatments for drug abuse and other disorders involving dysfunctional consumption. The aims of this symposium are to provide CPDD members with an understanding of the concept of reinforcing efficacy and its impact in medication development, to describe how factors such as environmental context, cost, pharmacology, and social context influence drug choice, to learn about recent advances in delay discounting, in which the extent to which a subject chooses a reinforcer of lower magnitude with no delay over a reinforcer of larger magnitude with a delay provides an analogue of the concept of "impulsive choice", and how punishers of drug choice have clinical potential. Finally, the discussion will allow opportunity for lively discourse and reflection on Bill's substantial legacy to drug abuse research.

*XIII. Environmental and physiological factors predisposing susceptibility to drug abuse*

Chairs: Ellen M. Unterwald and Sari Izenwasser

Many factors influence an individual's susceptibility to substance use disorders. Findings from preclinical and clinical studies will be presented that implicate environmental and physiological factors that impact the vulnerability to drug abuse. Data will be shown demonstrating that diet-induced obesity increases cocaine reward in males, whereas females have increased reward when a high-fat diet is removed. High-fat diets also produce sex-related differences in dopaminergic transmission and hormones involved in feeding. Another presentation will address altered dopaminergic function and reward sensitivity in a rodent model of PTSD. In this model, PTSD causes dysregulation of reward circuits as reflected by anhedonia and reduced reward function, and is accompanied by alterations in the dopamine system. Investigation of adolescent methylphenidate and atomoxetine treatments on adult cocaine self-administration and DAT/NET function in an ADHD model will be presented. Rats with an ADHD phenotype show enhanced cocaine self-administration after adolescent methylphenidate, but not atomoxetine. Although both medications acutely enhance DA and NE in prefrontal cortex, DAT and NET function are altered in opposing ways. How dopamine markers (DAT and D2 receptor availability) measured in early adolescence can predict vulnerability to development of cocaine abuse and relapse in nonhuman primates will be presented. Clinical and translational implications of these studies, including possible targets for the development of therapeutic interventions and prevention efforts will be discussed, as will potential translational studies bridging between these findings and their clinical impact. Collectively, these studies identify specific factors that affect susceptibility to substance use disorders, elucidate underlying mechanisms and suggest avenues of translational importance.

## SYMPOSIA

**Thursday, June 19**

*XIV. Medications for drug addictions: Sex differences in outcomes in animal and human laboratory studies and in clinical trials*

Chairs: Cora Lee Wetherington and Ivan Montoya

There are no FDA-approved medications to treat cocaine and marijuana addiction and treatment medications for nicotine and alcohol addiction often have lower success rates in women than men. This translational symposium will feature data from animal models, human laboratory and clinical trial research demonstrating promise of several medications to treat cocaine, marijuana, nicotine and alcohol addiction. Speakers will review extant studies and highlight their recent findings and differential outcomes and mechanisms in males and females. Mice data showing that guanfacine, an alpha2-adrenergic autoreceptor agonist, has differential anti-depressant-like effects in males and females, and that simultaneously targeting noradrenergic and cholinergic systems could be especially useful in smoking cessation treatment, particularly those with depressive symptoms will be presented. Human laboratory and clinical outcomes demonstrating that guanfacine preferentially targets drug craving and stress reactivity in women versus men across separate samples of cocaine and tobacco dependent adults will also be discussed. Human and animal model data suggesting possible use of progesterone to treat cocaine addiction, including new rodent data showing that progesterone's effectiveness in reducing drug seeking is enhanced by exercise will be reviewed, in addition to animal studies investigating oxytocin and noradrenergic drugs as potential medications for cocaine addiction, and human laboratory research investigating oxytocin for treatment of marijuana and cocaine dependence, including fMRI and stress data. The discussant will synthesize the findings and discuss issues regarding sex differences in outcomes of medications being investigated to treat substance use disorders.

*XV. Demystifying medicinal chemistry and drug design*

Chairs: Andrew Coop and Thomas E. Prisinzano

An educational symposium for all members of CPDD focused on the approaches, techniques, and interdisciplinary nature of medicinal chemistry and drug design as applied to treatments for drug dependence. The vision of the symposium is to provide an overview of medicinal chemistry, accessible to all members of the College, with the aim of improving communication and reducing barriers caused by "cultural" misunderstandings. The ultimate goal is to foster collaborative endeavors towards the development of new medications for the treatment of substance abuse and dependence. The overview and discussant by two senior leaders in the field will be complemented by three junior independent researchers demonstrating the application of principles to their own research programs. In addition to providing an educational experience for all at CPDD, this provides a unique opportunity to introduce three junior independent medicinal chemists to the CPDD and NIDA community, and ensure this important component of the CPDD interdisciplinary community continues to grow and prosper.

## WORKSHOPS

**Sunday, June 15**

*I. The epidemiology of nonmedical use of prescription opioids and opioid use disorders in the USA: Recent trends, longitudinal patterns, and transitions to heroin and injection drug use*

*Chairs: Silvia S. Martins and Sean E. McCabe*

Nonmedical use of prescription opioids (NMUPO) and prescription opioid (PO) disorder is a national public health crisis in the USA as well as in other countries. This workshop brings together leaders in the field of NMUPO who will present recent findings on a) NMUPO and opioid use disorder secondary to NMUPO in adolescents and young adults based upon data from the 2002-2011 U.S. National Survey on Drug Use and Health (NSDUH); b) longitudinal patterns of NMUPO based on four waves of U.S. regional (Secondary Student Life Survey) and national samples (Monitoring the Future data) of middle and high school students; c) the risk of transition to heroin use among 396 U.S. young adult NMUPO users in the community followed for 36 months (data from Ohio); d) patterns of injection drug use and other risk behaviors among a longitudinal cohort of 500 rural Appalachian NMUPO followed since 2008; and e) the overlap of alcohol use disorders and opioid dependence using data from the two waves U.S. National Epidemiologic Study on Alcohol and Related Conditions (NESARC). By the end of this session participants will be able to better understand the prescription opioid epidemic as well as longitudinal patterns of NMUPO, prevalence and trends on opioid use disorders, the transition from NMUPO to heroin and injection drug use and the association of NMUPO with other risk behaviors. The presented findings have implications for both prevention and treatment.

*II. Integration of addiction care into medical settings: The state of the science*

*Chairs: Richard Saitz and Jeffrey Samet*

To address barriers to addiction treatment, integration of care into medical settings is advocated and being disseminated. Few studies address integration in medical settings. This workshop will discuss 1) identification of drug use in primary care by using results of alcohol screening, highlighting characteristics and predictors of drug use among those who screen positive for alcohol misuse and implications for improving identification of drug use; 2) results of a cohort analysis in primary care, the aim of which was to determine the effects of reduction of drug use (versus abstinence and no change), which showed that among cocaine and opioid users but not marijuana users, abstinence, but not use reductions, was associated with fewer drug use consequences; 3) a large study of variability in opioid prescribing in urban community health centers and a safety-net hospital that determined the effects of prescribing practices and a nurse care manager on outcomes (risk for opioid misuse (e.g. early refills) and guideline concordant care (e.g. opioid agreements, urine drug testing); 4) results of a randomized trial for opioid dependence, comparing referral, to brief intervention (BI) with referral to specialized care, or BI with initiation of buprenorphine and referral to a primary care maintenance program. The state of the science for integration of addiction treatment in medical settings, including results of two large randomized trials—screening and brief intervention for drug use, and chronic care management for addiction in primary care, will be reviewed.

## WORKSHOPS

**Sunday, June 15**

*III. Go/No-Go decisions in medication development: Why some compounds should NOT go forward and how do we identify them*

*Chair: Jane B. Acri*

Marketed drugs in the US and Europe are sometimes discovered to have adverse side effects after they have gone through the rigorous safety and efficacy testing required for approval. Sometimes the adverse effects were missed in early stages of development because they did not occur in preclinical testing, or they were not apparent until the compound had been taken by sufficiently large numbers of individuals to show rare, but serious side effects. Because the possible manifestation of toxic side effects might result in life-threatening risks to the patient population as well as a huge loss of investment, it is important to assess a compound's potential to produce adverse effects at all stages in the development process. This workshop will highlight evaluation procedures used to assist in lead selection during the Structure Activity Relationship (SAR) stage by eliminating compounds with carcinogenic potential and cardiovascular risks, using examples from the NIDA Medication Development Program. For compounds that pass early safety hurdles, we will discuss late stage *in vivo* tests designed to identify those compounds that may exacerbate cardiovascular effects of cocaine, or that might have the potential to produce severe negative mood states. The procedures, and examples, both from the literature and from recent failures in NIDA's medication candidate pipeline will be presented and discussed.

*IV. The 20th Annual Contingency Management Working Group*

*Chairs: Steven Meredith and Kelly Dunn*

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the dissemination and discussion of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide-range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 20th annual meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input, and providing opportunities for junior and senior researchers to interact.

*V. Epidemiology and public health research methods for minorities and under-represented minorities (Co-Sponsored by CPDD International Programs Committee)*

*Chairs: James Anthony and Jan Copeland*

This year, the annual workshop is co-sponsored by the CPDD International Programs Committee. As in the past, the focus is on methods issues pertinent to epidemiology, biostatistics, and public health research generally. There will be a talk about adaptive designs for clinical research with a special focus on smartphone interventions. Thereafter, focus will shift to methodological challenges in minority health disparities and equity research.

## WORKSHOPS

**Monday, June 16**

*VI. Knowledge translation in addiction sciences: Why and how to share research knowledge beyond the academic community*

*Chair: Doris Payer and Marc Kaufman*

Evidence suggests that despite the wealth of important research information produced in the health sciences, there is a gap between what is known within academic circles and what is practiced outside of these circles by knowledge users (e.g., clinicians, policy-makers, educators, healthcare administrators, community leaders, patients, or the public). There is increasing acknowledgement among scientists and funding agencies that more can be done to bridge this “know-do gap,” resulting in increasing investment in the practice of Knowledge Translation (KT), i.e., the pro-active dissemination of research knowledge to facilitate real-world implementation. This practice seems especially important in the field of addictions, where clinical success rates, policy decisions, and even public opinion stand to benefit greatly from scientific support. In turn, an interest in KT can increase funding success for scientists, and help researchers understand the real-world differences their work can make. This workshop, organized by members of the CPDD “Education, Outreach, & Public Policy” and “Media” committees, aims to raise awareness about KT among addiction scientists and encourage adoption of KT strategies in their research. Workshop presentations will explain the importance and benefits of KT to researchers and to the field, present theoretical models, strategies, and tools for actual practice, and share the experiences of individuals already actively engaged in some of this work.

*VII: High risk and understudied: Assessing abuse liability in opioid-dependent subjects*

*Chairs: Sandra D. Comer and Kerri A. Schoedel*

Literature reviews and FDA draft guidance on the assessment of drug abuse potential and abuse-deterrent formulations describe methodology for evaluating abuse potential clinically in recreational drug users. Both FDA guidance documents indicate that subjects should not be those diagnosed with dependence, in treatment for substance use disorders, or in the case of the opioids, physically dependent. However, opioid-dependent individuals represent a population at very high risk for abusing, misusing and tampering with prescription opioids, as well as using these drugs by alternative routes, such as intranasal or intravenous administration. Because of their high-risk behavior, opioid-dependent individuals may also be disproportionately represented in negative medical and societal outcomes of abuse, such as emergency department visits. Hence, these subjects represent both an ‘at-risk’ population, as well as a relatively understudied one. Therefore, assessment of opioid-dependent subjects, along with recreational drug users, may provide a more comprehensive picture with improved predictive validity for translating outcomes to the post-market setting. The aim of this workshop is to provide an overview and critical discussion of methods of evaluating the abuse liability of opioids in opioid-dependent subject models. Specific methodological issues, such as the use of detoxification and/or maintenance drugs in non-treatment-seeking subjects or patients in treatment (methadone-, buprenorphine-maintained), subject management, appropriate measures/endpoints, and ethical concerns, will be discussed. The strengths and challenges associated with these subject populations will be contrasted with studies performed in recreational drug users.



## WORKSHOPS

**Monday, June 16**

*VIII. Eating disorders, addictions and substance use disorders: Research, clinical and treatment aspects*

*Chairs: Timothy D. Brewerton and Therese K. Killeen*

Patients with eating disorders (EDs), particularly those with bulimic symptoms, have high rates of substance use disorders (SUD), and conversely, patients with SUD have higher rates of EDs. EDs often involve the abuse of substances as well as the compulsive engagement in maladaptive behaviors (dieting, exercising, binge eating, vomiting) that are addictive in nature. Substances are used to promote vomiting (emetics), retard absorption (lipase inhibitors), promote elimination (laxatives, diuretics), and suppress appetite (stimulants, caffeine, alcohol, nicotine, herbs). Highly palatable foods have been found to act much like substances of abuse in the brains of both animals and humans. Specifically, high concentrations of refined sugar, fat, salt, and caffeine have been reported to have addictive properties. Animal and human experiments confirm that both food ingestion and drug use cause dopamine release in brain areas that mediate pleasure and emotion, and the amount of dopamine release correlates with the sense of subjective reward or experience of pleasure from both food and drug use. Similar patterns of brain activation as seen on fMRI in response to food and drug cues have also been found. In addition, food stimulates the opiate system and there are striking similarities in use and withdrawal patterns of sugar and of classic drugs of abuse. Furthermore, there often appear to be reciprocal relationships among food and other substances. Taken together, these observations support the conclusion that food, ED behaviors and classic addictive substances compete for the same brain pathways and may serve the same purposes psychologically.

*IX. Advances in adolescent recovery research*

*Chairs: Michael L. Dennis and John F. Kelly*

Over 90% of people with substance use disorders (SUD) started using under age 18 and met diagnostic criteria by age 21. Intervention in the first 9 years of use is associated with cutting the years of use before achieving a year of abstinence by over 57%. But only 8% of adolescent with SUD enter treatment and over half of those stay less than 90 days, are discharged negatively, and relapse within 90 days. In addition to improving access and treatment effectiveness, a comprehensive solution also requires a better understanding of adolescent recovery and how it can be managed better (which is the focus of this workshop). The workshop will describe 1) the role of 12-step mutual-help organizations in youth recovery and then examine their benefits, moderators, and mechanisms; evolution of the recovery school movement and its role as an aftercare pathway to maintain recovery; how smartphones can be used to manage adolescent recovery through increased self-monitoring, immediate access to interventions, and predicting the risk of relapse.

## WORKSHOPS

**Tuesday, June 17**

*X. The use of GIS & GPS technology in addiction research*

*Chair: C. Debra Furr-Holden and Kenzie Preston*

There is a growing body of evidence that place matters with respect to opportunities to use drugs, decisions about what drugs to use, and success in recovery from addiction and drug dependence. Geographic Information Systems (GIS) provide a valuable framework and a set of analytic tools for understanding and empirically clarifying how the environment influences the addiction process. Global Positioning System (GPS) technology has also advanced such that we are able to continuously monitor where people are and combine this data with added information from electronic diary entries to understand the interaction between place, self-reported stress, drug cravings, intentions to use drugs, and actual drug use. Combined, these methods open new avenues for research that offers great promise for drug prevention, treatment intervention, and recovery from addiction. The workshop will discuss the use of both GIS- & GPS-based technology in understanding the addiction process. Specifically, recent advancement in GIS methods will be explored including the use of remote sensing to classify environmental risk for substance use, application of geospatial analytic techniques and tools within a GIS framework, and multi-level modeling with geographic data. In addition, ongoing studies that use GPS-based technology to understand how place influences drug cravings, decisions about drug use, and success in drug treatment will be discussed.

*XI. Improving the writing of emerging investigators in addiction science:*

*Innovative training, evaluation methods, and resources*

*Chairs: James L. Sorensen and Joseph Guydish*

The addiction research field needs increasingly productive investigators who create high-quality scientific reports. At the 2013 meeting we presented a workshop focusing on how emerging researchers can publish their manuscripts. This year we focus on training methods and resources to improve the writing of emerging investigators. Presenters are investigators spanning both preclinical and clinical research, and include three current editors of addiction research journals. All presenters suggest both conceptual and practical guidelines. While the workshop is aimed at assisting those providing training to young investigators, both junior and senior colleagues can benefit and provide their perspective. In this interactive workshop, one third of the time is reserved for audience questions, comments, and discussion. The workshop spans both manuscript and proposal writing, with learning levels from fellows to faculty. The first presenter emphasizes that you really can't succeed as a researcher if you can't write well (and quickly); she explains how her training program integrates publication issues into a Professional Development seminar that is followed by participation in an ongoing Writers' Workgroup. The second presenter describes an innovative Writers' Task Force that focuses junior investigators on completing manuscripts; since the seminar's inception in 1992, a total of 207 papers have been supported, 73% of these have been submitted for publication, and 65% have been published to date. The third presenter, a scientist and journal editor, describes an innovative editorial internship program that has developed editorial skills among developing investigators. The fourth presenter, a clinical laboratory researcher, describes training to help new investigators develop high-quality manuscripts.

## WORKSHOPS

**Tuesday, June 17**

*XII: Update on the Abuse-Deterrent Science Meeting on the FDA draft  
Guidance for industry on abuse-deterrent opioids –evaluation and labeling  
Chairs: Beatriz Rocha and Cynthia Arons*

This workshop is sponsored by CPDD's Committee on Industry, Academia, and Government Relations. The FDA issued a draft Guidance on Evaluation and Labeling of Abuse-Deterrent Opioids in January 2013. It outlined four Categories of testing of opioid formulations that are designed to deter abuse (three pre-approval, one post-marketing). The draft then discussed four tiers of labeling language, ranging from claims that the drug formulation incorporates physiochemical barriers to abuse to claims that the product has actually reduced abuse in the real world setting. The FDA expressed an interest in encouraging and stimulating scientific input from non-governmental experts on the draft Guidance. In response to the interest expressed by the FDA, a two-day meeting was held in the fall of 2013 where over 200 participants from FDA, industry, and academia discussed and deliberated study-design considerations, data interpretation, and potential criteria for each section of the draft Guidance, as well as how to apply the principles to an ANDA referencing a listed drug that had some approved abuse-deterrence labeling. This workshop will summarize and synthesize the key points of the 2013 meeting from the perspectives of academia, industry, and government; update the audience with new developments in this emerging science; present a moderated panel discussion amongst the speakers; and provide for audience interaction with the speakers.

*XIII. Addiction treatment research vs. usual care:  
What are the foreseeable risks?  
Chair: Andrew Saxon*

The Office for Human Research Protections (OHRP), part of the US Department of Health and Human Services, is seeking advice from all stakeholders on how to assess the risks to people in randomized studies that involve existing treatments. Addiction treatment trials that include 'standard of care' (or "treatment as usual") are conducted in community health care settings (i.e. hospitals, primary care, treatment clinics). Such trials are being done currently and are likely to become more widespread. Researchers, clinicians, and bioethicists have differing opinions regarding how best to protect participants; some may insist that all risks, including those of usual care, be included in the informed consent process, even though patients with a particular condition would be taking one or the other treatment anyway. How best to assess and present these risks is a complex issue. The main questions include: What are the treatment-as-usual risks? Are they more than minimal risk? How does one assess risks of combined research and usual treatments? (especially with potentially vulnerable populations such as those with substance use and addiction). These issues will be addressed by a panel of experts in addiction treatment, clinical research, and bioethics, including membership on institutional review boards (IRB). Panelists will attempt to shed some light and provide recommendations that will assist clinical investigators designing and conducting future addiction treatment clinical trials.

## **Acknowledgements and Advertisements**

The following organizations have financially supported the work  
of the CPDD organization during the past year

**Collegium Pharmaceutical, Inc.**

**Grunenthal USA, Inc**

**NIDA (National Institute on Drug Abuse)**

**The Harris Family Foundation**

**Vince & Associates Clinical Research**

Funding for this conference was made possible (in part) by  
Grant Agreement # R13 DA 013192 from NIDA.

The views expressed in written conference materials or publications and by  
speakers and moderators do not necessarily reflect the official policies of the  
Department of Health and Human Services; nor does mention of trade names,  
commercial practices, or organizations imply endorsement by the U.S.  
Government

